<XBRL>
<?xml version="1.0" encoding="UTF-8"?><!--EDGARizerX:  Instance document generated by EDGARizerX, version 3.7.2.0--><xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:asi="http://regeneron.com/20120217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:regn="http://regeneron.com/20111231" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31">
  <link:schemaRef xlink:type="simple" xlink:href="regn-20111231.xsd"/>
  <context id="c00000">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="c00001">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00002">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00003">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00004">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00005">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00006">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00007">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00008">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00009">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithSanofiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00010">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithSanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:AfliberceptAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithSanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:AntibodyCollaborationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithSanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:VelocigeneAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithBayerHealthcareLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">regn:LicenseAgreementWithAstellasPharmaIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">regn:FurnitureComputerAndOfficeEquipmentAndOtherMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsHeldUnderCapitalLeasesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00022">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">regn:NewLaboratoryAndOfficeFacilitiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00023">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">regn:CollaborationAgreementWithSanofiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00024">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">regn:CollaborationAgreementWithBayerHealthcareLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00025">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:NonsoftwareLicenseArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00026">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">regn:OtherDeferredRevenueAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00027">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">regn:ExecutiveStockPurchasePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00028">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00029">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00030">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxis">regn:USGovernmentGuaranteedCorporateBondsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00031">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00032">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00033">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00034">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00035">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00036">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00037">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00038">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00039">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00041">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00042">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00043">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00044">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00045">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00046">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00047">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:NameOfLeaseAxis">regn:TarrytownLeaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00048">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:FacilityLeaseObligationsAxis">regn:FacilitiesBuildingsAndBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00049">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:FacilityLeaseObligationsAxis">regn:FacilitiesBuildingCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00050">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ResearchCollaborationAndLicensingAgreementsAxis">regn:LicenseAgreementWithGenentechMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00051">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ResearchCollaborationAndLicensingAgreementsAxis">regn:CellectisAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00052">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00053">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxis">regn:LongTermIncentivePlan2000Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00054">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00055">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxis">regn:NonPerformanceBasedStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00056">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxis">regn:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00057">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00058">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">regn:USFederalAndNewYorkStateMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00059">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:LicenseAgreementWithGenentechMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c00060">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00061">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00062">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00063">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00064">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00065">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00066">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00067">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00068">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithSanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:AfliberceptAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00069">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithSanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:AntibodyCollaborationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00070">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithBayerHealthcareLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00071">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">regn:LicenseAgreementWithAstellasPharmaIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00072">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00073">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00074">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00075">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00076">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">regn:FurnitureComputerAndOfficeEquipmentAndOtherMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00077">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00078">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsHeldUnderCapitalLeasesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00079">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">regn:NewLaboratoryAndOfficeFacilitiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00080">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">regn:CollaborationAgreementWithSanofiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00081">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">regn:CollaborationAgreementWithBayerHealthcareLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00082">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:NonsoftwareLicenseArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00083">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">regn:OtherDeferredRevenueAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00084">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00085">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00086">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxis">regn:USGovernmentGuaranteedCorporateBondsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00087">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00088">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00089">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00090">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00091">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00092">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00093">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfAvailableForSaleSecuritiesMajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00095">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00096">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00097">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00098">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00099">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00100">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00101">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:NameOfLeaseAxis">regn:TarrytownLeaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00102">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:FacilityLeaseObligationsAxis">regn:FacilitiesBuildingsAndBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00103">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:FacilityLeaseObligationsAxis">regn:FacilitiesBuildingCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00104">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ResearchCollaborationAndLicensingAgreementsAxis">regn:CellectisAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00105">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00106">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="c00108">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="c00109">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="c00110">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="c00111">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="c00112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="c00113">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="c00114">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithSanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:AntibodyCollaborationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="c00115">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="c00116">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="c00117">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-03-31</endDate>
    </period>
  </context>
  <context id="c00118">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-03-31</endDate>
    </period>
  </context>
  <context id="c00119">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-03-31</endDate>
    </period>
  </context>
  <context id="c00120">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <startDate>2011-04-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="c00121">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <startDate>2010-04-01</startDate>
      <endDate>2010-06-30</endDate>
    </period>
  </context>
  <context id="c00122">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <startDate>2011-07-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="c00123">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <startDate>2010-07-01</startDate>
      <endDate>2010-09-30</endDate>
    </period>
  </context>
  <context id="c00124">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00125">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00126">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00127">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00128">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00130">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00131">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00132">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00133">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithSanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:AfliberceptAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00135">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithSanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:AntibodyCollaborationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00136">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithBayerHealthcareLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00137">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:GrantFromNationalInstitutesOfHealthMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00138">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">regn:LicenseAgreementWithAstellasPharmaIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00139">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">regn:LicenseAgreementWithAstrazenecaUkLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00140">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00141">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00142">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00143">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00144">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00145">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00146">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00147">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00148">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:NameOfLeaseAxis">regn:TarrytownLeaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00149">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ResearchCollaborationAndLicensingAgreementsAxis">regn:AgreementsWithRoyaltyProvisionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00150">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ResearchCollaborationAndLicensingAgreementsAxis">regn:CellectisAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00151">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00152">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00153">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxis">regn:PhantomStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00154">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxis">regn:NonPerformanceBasedStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00155">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxis">regn:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00156">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00157">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">regn:NetOperatingLossCarryforwardAndTaxCreditCarryforwardsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00158">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">regn:USFederalAndNewYorkStateMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00159">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00160">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithSanofiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00161">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:LicenseAgreementWithGenentechMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00162">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:FacilityLeaseObligationsAxis">regn:FacilitiesBuildingCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00163">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:FacilityLeaseObligationsAxis">regn:FacilitiesBuildingsAndBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00164">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00165">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00166">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00167">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00168">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00169">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00170">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00171">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithSanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:AfliberceptAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00172">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithSanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:AntibodyCollaborationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00173">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithBayerHealthcareLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00174">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:GrantFromNationalInstitutesOfHealthMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00175">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">regn:LicenseAgreementWithAstellasPharmaIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00176">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">regn:LicenseAgreementWithAstrazenecaUkLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00177">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00178">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00179">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00180">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00181">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00182">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00183">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:FacilityLeaseObligationsAxis">regn:FacilitiesBuildingCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00184">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:FacilityLeaseObligationsAxis">regn:FacilitiesBuildingsAndBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00185">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ResearchCollaborationAndLicensingAgreementsAxis">regn:AgreementsWithRoyaltyProvisionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00186">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ResearchCollaborationAndLicensingAgreementsAxis">regn:CellectisAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00187">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00188">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxis">regn:NonPerformanceBasedStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00189">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxis">regn:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00190">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00191">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">regn:NetOperatingLossCarryforwardAndTaxCreditCarryforwardsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00192">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithSanofiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00193">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">regn:LicenseAgreementWithAstellasPharmaIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="c00194">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">regn:LicenseAgreementWithAstrazenecaUkLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="c00195">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00196">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00197">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00198">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00199">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00200">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00201">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00202">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithSanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:AfliberceptAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00203">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithSanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:AntibodyCollaborationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00204">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithBayerHealthcareLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00205">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:GrantFromNationalInstitutesOfHealthMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00206">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">regn:LicenseAgreementWithAstellasPharmaIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00207">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">regn:LicenseAgreementWithAstrazenecaUkLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00208">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00209">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00210">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00211">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00212">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00213">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00214">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:FacilityLeaseObligationsAxis">regn:FacilitiesBuildingsAndBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00215">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ResearchCollaborationAndLicensingAgreementsAxis">regn:AgreementsWithRoyaltyProvisionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00216">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ResearchCollaborationAndLicensingAgreementsAxis">regn:CellectisAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00217">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00218">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxis">regn:NonPerformanceBasedStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00219">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxis">regn:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00220">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00221">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithSanofiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00222">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="c00223">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="c00224">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="c00225">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="c00226">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="c00227">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="c00228">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <instant>2012-02-10</instant>
    </period>
  </context>
  <context id="c00229">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-02-10</instant>
    </period>
  </context>
  <context id="c00230">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithSanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:AfliberceptAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-01-31</endDate>
    </period>
  </context>
  <context id="c00231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithSanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:AfliberceptAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-01-31</endDate>
    </period>
  </context>
  <context id="c00232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithSanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:AfliberceptAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2003-01-01</startDate>
      <endDate>2003-01-31</endDate>
    </period>
  </context>
  <context id="c00233">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2003-01-01</startDate>
      <endDate>2003-01-31</endDate>
    </period>
  </context>
  <context id="c00234">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithSanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:AntibodyCollaborationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-12-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="c00235">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-12-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="c00236">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-11-01</startDate>
      <endDate>2009-11-30</endDate>
    </period>
  </context>
  <context id="c00237">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithSanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:AntibodyCollaborationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-11-01</startDate>
      <endDate>2007-11-30</endDate>
    </period>
  </context>
  <context id="c00238">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithSanofiMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:AntibodyCollaborationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-11-30</instant>
    </period>
  </context>
  <context id="c00239">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-11-30</instant>
    </period>
  </context>
  <context id="c00240">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithBayerHealthcareLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-01-31</endDate>
    </period>
  </context>
  <context id="c00241">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithBayerHealthcareLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-12-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00242">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithBayerHealthcareLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-07-01</startDate>
      <endDate>2009-07-31</endDate>
    </period>
  </context>
  <context id="c00243">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithBayerHealthcareLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-08-01</startDate>
      <endDate>2007-08-31</endDate>
    </period>
  </context>
  <context id="c00244">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithBayerHealthcareLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-10-01</startDate>
      <endDate>2006-10-31</endDate>
    </period>
  </context>
  <context id="c00245">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:CollaborationAgreementWithBayerHealthcareLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-10-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00246">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">regn:GrantFromNationalInstitutesOfHealthMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-09-01</startDate>
      <endDate>2006-09-30</endDate>
    </period>
  </context>
  <context id="c00247">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">regn:LicenseAgreementWithAstellasPharmaIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-03-01</startDate>
      <endDate>2007-03-31</endDate>
    </period>
  </context>
  <context id="c00248">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">regn:LicenseAgreementWithAstellasPharmaIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="c00249">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">regn:LicenseAgreementWithAstrazenecaUkLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="c00250">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">regn:LicenseAgreementWithAstellasPharmaIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-08-01</startDate>
      <endDate>2010-08-31</endDate>
    </period>
  </context>
  <context id="c00251">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <startDate>2010-08-01</startDate>
      <endDate>2010-08-31</endDate>
    </period>
  </context>
  <context id="c00252">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">regn:LicenseAgreementWithAstrazenecaUkLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-02-01</startDate>
      <endDate>2011-02-28</endDate>
    </period>
  </context>
  <context id="c00253">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">regn:LicenseAgreementWithAstrazenecaUkLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-02-01</startDate>
      <endDate>2007-02-28</endDate>
    </period>
  </context>
  <context id="c00254">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">regn:ExecutiveStockPurchasePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>1989-01-01</startDate>
      <endDate>1990-12-31</endDate>
    </period>
  </context>
  <context id="c00255">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">regn:ExecutiveStockPurchasePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>1989-12-31</instant>
    </period>
  </context>
  <context id="c00256">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <startDate>2011-10-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00257">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <startDate>2010-10-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00258">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-10-01</startDate>
      <endDate>2011-10-17</endDate>
    </period>
  </context>
  <context id="c00259">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <startDate>2011-10-01</startDate>
      <endDate>2011-10-31</endDate>
    </period>
  </context>
  <context id="c00260">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-10-01</startDate>
      <endDate>2011-10-31</endDate>
    </period>
  </context>
  <context id="c00261">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-10-17</instant>
    </period>
  </context>
  <context id="c00262">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ResearchCollaborationAndLicensingAgreementsAxis">regn:LicenseAgreementWithGenentechMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-12-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c00263">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:ResearchCollaborationAndLicensingAgreementsAxis">regn:CellectisAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-07-01</startDate>
      <endDate>2008-07-31</endDate>
    </period>
  </context>
  <context id="c00264">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-10-01</startDate>
      <endDate>2010-10-31</endDate>
    </period>
  </context>
  <context id="c00265">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <startDate>2010-10-01</startDate>
      <endDate>2010-10-31</endDate>
    </period>
  </context>
  <context id="c00266">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameAxis">regn:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-12-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="c00267">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="regn:FacilityLeaseObligationsAxis">regn:FacilitiesBuildingsAndBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00268">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-10-31</instant>
    </period>
  </context>
  <context id="c00269">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">regn:WarrantTransactionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-10-31</instant>
    </period>
  </context>
  <unit id="u000">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="u001">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="u002">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="u003">
    <measure>regn:PerShare</measure>
  </unit>
  <unit id="u004">
    <measure>regn:Percent</measure>
  </unit>
  <unit id="u005">
    <measure>regn:Decimal</measure>
  </unit>
  <unit id="u006">
    <measure>regn:Integer</measure>
  </unit>
  <!--Per Share Data-->
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Per Share Data&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;Net income (loss) per share, basic and diluted, is computed on the basis of the net income (loss) for the period divided by the weighted average number of shares of Common Stock and Class A Stock outstanding during the period.&amp;#160;&amp;#160;Basic net income (loss) per share excludes restricted stock awards until vested.&amp;#160;&amp;#160;Diluted net income per share is based upon the weighted average number of shares of Common Stock and Class A Stock outstanding, and of common stock equivalents outstanding when dilutive.&amp;#160;&amp;#160;Common stock equivalents include: (i) outstanding stock options and restricted stock awards under the Company's Long-Term Incentive Plans, which are included under the "treasury stock method" when dilutive, (ii) Common Stock to be issued upon the assumed conversion of the Company's convertible senior notes, which are included under the "if-converted method" when dilutive, and (iii) Common Stock to be issued upon the exercise of outstanding warrants, which are included under the "treasury stock method" when dilutive.&amp;#160;&amp;#160;The computation of diluted net loss per share for the years ended December 31, 2011, 2010, and 2009 does not include common stock equivalents, since such inclusion would be antidilutive.&lt;/font&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <!--Imputed interest rate applicable to the facility lease obligation (in hundredths)- Facilities Building C [Member]-->
  <regn:ImputedInterestRateApplicableToFacilityLeaseObligation contextRef="c00162" unitRef="u004" decimals="2">0.09</regn:ImputedInterestRateApplicableToFacilityLeaseObligation>
  <!--Imputed interest rate applicable to the facility lease obligation (in hundredths)- Facilities Buildings A and B [Member]-->
  <regn:ImputedInterestRateApplicableToFacilityLeaseObligation contextRef="c00163" unitRef="u004" decimals="2">0.11</regn:ImputedInterestRateApplicableToFacilityLeaseObligation>
  <!--Income tax expense (benefit) in connection with the net tax effect of unrealized gain on 'available for sale' marketable securities + Income tax expense (benefit) in connection with the net tax effect of unrealized gain on 'available for sale' marketable securities-->
  <us-gaap:AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss contextRef="c00124" unitRef="u000" decimals="-5">-400000</us-gaap:AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss>
  <!--Income tax expense (benefit) in connection with the net tax effect of unrealized gain on 'available for sale' marketable securities + Income tax expense (benefit) in connection with the net tax effect of unrealized gain on 'available for sale' marketable securities-->
  <us-gaap:AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss contextRef="c00195" unitRef="u000" decimals="-5">-700000</us-gaap:AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss>
  <!--Number of options expected to vest upon achieving certain development milestones (in shares)- Performance-Based Stock Options [Member]-->
  <regn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestUponAchievingDevelopmentMilestones contextRef="c00056" unitRef="u001" decimals="0">1992000</regn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestUponAchievingDevelopmentMilestones>
  <!--Expired, weighted-average exercise price (in dollars per share)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="c00054" unitRef="u002" decimals="2">13.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
  <!--Maximum term of awards (in years)- Stock Options [Member]-->
  <regn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpiration contextRef="c00152">10Y</regn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpiration>
  <!--2016- Cellectis Agreement [Member]-->
  <regn:FutureExpenseOfAdvancePaymentYearFive contextRef="c00150" unitRef="u000" decimals="-5">900000</regn:FutureExpenseOfAdvancePaymentYearFive>
  <!--Cumulative sales range, minimum- License Agreement With Genentech [Member]-->
  <regn:CumulativeSalesRangeMinimum contextRef="c00262" unitRef="u000" decimals="-6">400000000</regn:CumulativeSalesRangeMinimum>
  <!--Cumulative sales range, minimum- License Agreement With Genentech [Member]-->
  <regn:CumulativeSalesRangeMinimum contextRef="c00161" unitRef="u000" decimals="-6">400000000</regn:CumulativeSalesRangeMinimum>
  <!--Rental charges for utilities, real estate taxes, and operating expense + Rental charges for utilities, real estate taxes, and operating expense + Rental charges for utilities, real estate taxes, and operating expense-->
  <regn:RentalChargesForUtilitiesRealEstateTaxesAndOperatingExpense contextRef="c00124" unitRef="u000" decimals="-5">9300000</regn:RentalChargesForUtilitiesRealEstateTaxesAndOperatingExpense>
  <!--Rental charges for utilities, real estate taxes, and operating expense + Rental charges for utilities, real estate taxes, and operating expense + Rental charges for utilities, real estate taxes, and operating expense-->
  <regn:RentalChargesForUtilitiesRealEstateTaxesAndOperatingExpense contextRef="c00164" unitRef="u000" decimals="-5">10300000</regn:RentalChargesForUtilitiesRealEstateTaxesAndOperatingExpense>
  <!--Rental charges for utilities, real estate taxes, and operating expense + Rental charges for utilities, real estate taxes, and operating expense + Rental charges for utilities, real estate taxes, and operating expense-->
  <regn:RentalChargesForUtilitiesRealEstateTaxesAndOperatingExpense contextRef="c00195" unitRef="u000" decimals="-5">8400000</regn:RentalChargesForUtilitiesRealEstateTaxesAndOperatingExpense>
  <!--2015-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="c00001" unitRef="u000" decimals="-3">7583000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <!--2015- Building [Member]-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="c00046" unitRef="u000" decimals="-3">7583000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <!--Initial conversion rate- Convertible Debt [Member]-->
  <us-gaap:DebtInstrumentConvertibleConversionRatio contextRef="c00258" unitRef="u005" decimals="4">11.9021</us-gaap:DebtInstrumentConvertibleConversionRatio>
  <!--Contractual coupon interest rate- Convertible Debt [Member]-->
  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c00146" unitRef="u000" decimals="-3">1455000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <!--Unrealized (Losses) - Maturities after five years through ten years- Unrestricted [Member]- Mortgage-Backed Securities [Member] + Unrealized (Losses) - Maturities after five years through ten years- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsGrossUnrealizedLoss contextRef="c00033" unitRef="u000" decimals="-3">77000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsGrossUnrealizedLoss>
  <!--Unrealized (Losses) - Maturities after five years through ten years- Unrestricted [Member]- Mortgage-Backed Securities [Member] + Unrealized (Losses) - Maturities after five years through ten years- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsGrossUnrealizedLoss contextRef="c00089" unitRef="u000" decimals="-3">41000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsGrossUnrealizedLoss>
  <!--Unrealized (Losses) - Maturities after five years through ten years- Unrestricted [Member] + Unrealized (Losses) - Maturities after five years through ten years- Unrestricted [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsGrossUnrealizedLoss contextRef="c00034" unitRef="u000" decimals="-3">77000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsGrossUnrealizedLoss>
  <!--Unrealized (Losses) - Maturities after five years through ten years- Unrestricted [Member] + Unrealized (Losses) - Maturities after five years through ten years- Unrestricted [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsGrossUnrealizedLoss contextRef="c00090" unitRef="u000" decimals="-3">41000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsGrossUnrealizedLoss>
  <!--Amortized Cost Basis - Maturities after one year through five years- Unrestricted [Member]- U S Government Obligations [Member] + Amortized Cost Basis - Maturities after one year through five years- Unrestricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="c00029" unitRef="u000" decimals="-3">272433000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
  <!--Amortized Cost Basis - Maturities after one year through five years- Unrestricted [Member]- U S Government Obligations [Member] + Amortized Cost Basis - Maturities after one year through five years- Unrestricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="c00085" unitRef="u000" decimals="-3">352345000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
  <!--Amortized Cost Basis - Maturities after one year through five years- Unrestricted [Member]- Mortgage-Backed Securities [Member] + Amortized Cost Basis - Maturities after one year through five years- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="c00033" unitRef="u000" decimals="-3">104000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
  <!--Amortized Cost Basis - Maturities after one year through five years- Unrestricted [Member]- Mortgage-Backed Securities [Member] + Amortized Cost Basis - Maturities after one year through five years- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="c00089" unitRef="u000" decimals="-3">110000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
  <!--Amortized Cost Basis - Maturities after one year through five years- Unrestricted [Member] + Amortized Cost Basis - Maturities after one year through five years- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="c00034" unitRef="u000" decimals="-3">272537000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
  <!--Amortized Cost Basis - Maturities after one year through five years- Unrestricted [Member] + Amortized Cost Basis - Maturities after one year through five years- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="c00090" unitRef="u000" decimals="-3">367977000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
  <!--Amortized Cost Basis - Maturities after one year through five years- Restricted [Member]- U S Government Obligations [Member] + Amortized Cost Basis - Maturities after one year through five years- Restricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="c00035" unitRef="u000" decimals="-3">2572000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
  <!--Amortized Cost Basis - Maturities after one year through five years- Restricted [Member]- U S Government Obligations [Member] + Amortized Cost Basis - Maturities after one year through five years- Restricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="c00091" unitRef="u000" decimals="-3">4135000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
  <!--Amortized Cost Basis - Maturities after one year through five years- Unrestricted [Member]- U S Government Guaranteed Corporate Bonds [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="c00086" unitRef="u000" decimals="-3">15522000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
  <!--Change in accounting estimate, deferred revenue - lower net loss per share (in dollars per share)- Arcalyst Net Product Sales Member- Product Concentration Risk [Member]-->
  <regn:ChangeInAccountingEstimateDeferredRevenueLowerNetLossPerShare contextRef="c00177" unitRef="u002" decimals="2">-0.06</regn:ChangeInAccountingEstimateDeferredRevenueLowerNetLossPerShare>
  <!--Percentage Of Prompt Pay Discount The Compay Accrues-->
  <regn:PercentageOfPromptPayDiscountCompayAccrues contextRef="c00001" unitRef="u004" decimals="2">1.00</regn:PercentageOfPromptPayDiscountCompayAccrues>
  <!--Percentage of Shared Phase 3 Trial Costs to be reimbursed due to profitability of agreement- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:PercentageOfTrialCostsToBeReimbursedDueToProfitabilityOfAgreement contextRef="c00135" unitRef="u004" decimals="2">0.30</regn:PercentageOfTrialCostsToBeReimbursedDueToProfitabilityOfAgreement>
  <!--Balance between amount funded and annual funding maximum- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:BalanceBetweenAmountFundedAndAnnualFundingMaximum contextRef="c00069" unitRef="u000" decimals="-5">22300000</regn:BalanceBetweenAmountFundedAndAnnualFundingMaximum>
  <!--Royalty based on percentage of annual sales in Japan (in hundredths)- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member]-->
  <regn:RoyaltyBasedOnPercentageOfAnnualSalesInJapan contextRef="c00134" unitRef="u004" decimals="2">0.35</regn:RoyaltyBasedOnPercentageOfAnnualSalesInJapan>
  <!--Amount of non-refundable payment received for collaboration agreement- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member] + Amount of non-refundable payment received for collaboration agreement- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member] + Amount of non-refundable payment received for collaboration agreement- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member]-->
  <regn:AmountOfNonRefundablePaymentReceivedForCollaborationAgreement contextRef="c00232" unitRef="u000" decimals="-5">80000000</regn:AmountOfNonRefundablePaymentReceivedForCollaborationAgreement>
  <!--Amount of non-refundable payment received for collaboration agreement- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member] + Amount of non-refundable payment received for collaboration agreement- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member] + Amount of non-refundable payment received for collaboration agreement- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member]-->
  <regn:AmountOfNonRefundablePaymentReceivedForCollaborationAgreement contextRef="c00231" unitRef="u000" decimals="-5">25000000</regn:AmountOfNonRefundablePaymentReceivedForCollaborationAgreement>
  <!--Amount of non-refundable payment received for collaboration agreement- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member] + Amount of non-refundable payment received for collaboration agreement- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member] + Amount of non-refundable payment received for collaboration agreement- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member]-->
  <regn:AmountOfNonRefundablePaymentReceivedForCollaborationAgreement contextRef="c00230" unitRef="u000" decimals="-5">25000000</regn:AmountOfNonRefundablePaymentReceivedForCollaborationAgreement>
  <!--Amount of non-refundable payment received for collaboration agreement- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:AmountOfNonRefundablePaymentReceivedForCollaborationAgreement contextRef="c00237" unitRef="u000" decimals="-6">85000000</regn:AmountOfNonRefundablePaymentReceivedForCollaborationAgreement>
  <!--Amount of non-refundable payment received for collaboration agreement- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <regn:AmountOfNonRefundablePaymentReceivedForCollaborationAgreement contextRef="c00244" unitRef="u000" decimals="-5">75000000</regn:AmountOfNonRefundablePaymentReceivedForCollaborationAgreement>
  <!--Proceeds in connection with facility lease obligation-->
  <regn:ProceedsFromFacilityLeaseObligations contextRef="c00124" unitRef="u000" decimals="-3">0</regn:ProceedsFromFacilityLeaseObligations>
  <!--Proceeds in connection with facility lease obligation-->
  <regn:ProceedsFromFacilityLeaseObligations contextRef="c00164" unitRef="u000" decimals="-3">47544000</regn:ProceedsFromFacilityLeaseObligations>
  <!--Proceeds in connection with facility lease obligation-->
  <regn:ProceedsFromFacilityLeaseObligations contextRef="c00195" unitRef="u000" decimals="-3">23640000</regn:ProceedsFromFacilityLeaseObligations>
  <!--Equity component of convertible senior notes, net of issuance costs - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="c00126" unitRef="u000" decimals="-3">120623000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
  <!--Equity component of convertible senior notes, net of issuance costs - Total Stockholders' Equity-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="c00259" unitRef="u000" decimals="-3">120623000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
  <!--Conversion of Class A Stock to Common Stock - Total Stockholders' Equity + Conversion of Class A Stock to Common Stock - Total Stockholders' Equity + Conversion of Class A Stock to Common Stock - Total Stockholders' Equity-->
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c00195" unitRef="u000" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <!--Conversion of Class A Stock to Common Stock - Total Stockholders' Equity + Conversion of Class A Stock to Common Stock - Total Stockholders' Equity + Conversion of Class A Stock to Common Stock - Total Stockholders' Equity-->
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c00164" unitRef="u000" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <!--Conversion of Class A Stock to Common Stock - Total Stockholders' Equity + Conversion of Class A Stock to Common Stock - Total Stockholders' Equity + Conversion of Class A Stock to Common Stock - Total Stockholders' Equity-->
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c00124" unitRef="u000" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <!--Net loss per share, basic and diluted + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c00124" unitRef="u002" decimals="2">-2.45</us-gaap:EarningsPerShareBasicAndDiluted>
  <!--Net loss per share, basic and diluted + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c00164" unitRef="u002" decimals="2">-1.26</us-gaap:EarningsPerShareBasicAndDiluted>
  <!--Net loss per share, basic and diluted + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c00195" unitRef="u002" decimals="2">-0.85</us-gaap:EarningsPerShareBasicAndDiluted>
  <!--Net loss per share, basic and diluted + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c00117" unitRef="u002" decimals="2">-0.49</us-gaap:EarningsPerShareBasicAndDiluted>
  <!--Net loss per share, basic and diluted + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c00120" unitRef="u002" decimals="2">-0.69</us-gaap:EarningsPerShareBasicAndDiluted>
  <!--Net loss per share, basic and diluted + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c00122" unitRef="u002" decimals="2">-0.68</us-gaap:EarningsPerShareBasicAndDiluted>
  <!--Net loss per share, basic and diluted + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c00256" unitRef="u002" decimals="2">-0.58</us-gaap:EarningsPerShareBasicAndDiluted>
  <!--Net loss per share, basic and diluted + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c00119" unitRef="u002" decimals="2">-0.38</us-gaap:EarningsPerShareBasicAndDiluted>
  <!--Net loss per share, basic and diluted + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c00121" unitRef="u002" decimals="2">-0.31</us-gaap:EarningsPerShareBasicAndDiluted>
  <!--Net loss per share, basic and diluted + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c00123" unitRef="u002" decimals="2">-0.41</us-gaap:EarningsPerShareBasicAndDiluted>
  <!--Net loss per share, basic and diluted + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share) + Net loss per share, basic and diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c00257" unitRef="u002" decimals="2">-0.17</us-gaap:EarningsPerShareBasicAndDiluted>
  <!--Net loss before income tax benefit-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c00124" unitRef="u000" decimals="-3">-222892000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <!--Net loss before income tax benefit-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c00164" unitRef="u000" decimals="-3">-104468000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <!--Net loss before income tax benefit-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c00195" unitRef="u000" decimals="-3">-71952000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <!--Total expenses-->
  <us-gaap:CostsAndExpenses contextRef="c00124" unitRef="u000" decimals="-3">650983000</us-gaap:CostsAndExpenses>
  <!--Total expenses-->
  <us-gaap:CostsAndExpenses contextRef="c00164" unitRef="u000" decimals="-3">556546000</us-gaap:CostsAndExpenses>
  <!--Total expenses-->
  <us-gaap:CostsAndExpenses contextRef="c00195" unitRef="u000" decimals="-3">453371000</us-gaap:CostsAndExpenses>
  <!--Preferred stock-->
  <us-gaap:PreferredStockValue contextRef="c00001" unitRef="u000" decimals="-3">0</us-gaap:PreferredStockValue>
  <!--Preferred stock-->
  <us-gaap:PreferredStockValue contextRef="c00060" unitRef="u000" decimals="-3">0</us-gaap:PreferredStockValue>
  <!--Deferred revenue from Sanofi-->
  <regn:DeferredRevenueFromRelatedPartyNoncurrent contextRef="c00001" unitRef="u000" decimals="-3">86017000</regn:DeferredRevenueFromRelatedPartyNoncurrent>
  <!--Deferred revenue from Sanofi-->
  <regn:DeferredRevenueFromRelatedPartyNoncurrent contextRef="c00060" unitRef="u000" decimals="-3">97081000</regn:DeferredRevenueFromRelatedPartyNoncurrent>
  <!--Net Loss Per Share Data-->
  <us-gaap:EarningsPerShareTextBlock contextRef="c00124">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;19.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Net Loss Per Share Data&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company&amp;#8217;s basic net loss per share amounts have been computed by dividing net loss by the weighted average number of Common and Class A shares outstanding.&amp;#160;&amp;#160;Net loss per share is presented on a combined basis, inclusive of Common Stock and Class A Stock outstanding, as each class of stock has equivalent economic rights.&amp;#160;&amp;#160;In 2011, 2010, and 2009, the Company reported net losses; therefore, no common stock equivalents were included in the computation of diluted net loss per share since such inclusion would have been antidilutive.&amp;#160;&amp;#160;The calculations of basic and diluted net loss per share are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="37%" colspan="3"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Net loss (Numerator)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$(221,760)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$(104,468)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$(67,830)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%" align="left"&gt;&lt;div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Weighted-average shares, in thousands (Denominator)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;90,610&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;82,926&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;79,782&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Basic and diluted net loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$(2.45)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$(1.26)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$(0.85)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Shares issuable upon the exercise of options and warrants, vesting of restricted stock awards, and conversion of convertible senior notes, which have been excluded from the diluted per share amounts because their effect would have been antidilutive, include the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Options:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Weighted average number, in thousands&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;20,942&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;21,428&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;20,040&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Weighted average exercise price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$21.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$18.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$17.66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Restricted Stock:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Weighted average number, in thousands&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;526&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Convertible Senior Notes:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Weighted average number, in thousands&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;939&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Warrants:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Weighted average number, in thousands&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;939&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <!--Executive Stock Purchase Plan-->
  <regn:ExecutiveStockPurchasePlanTextBlock contextRef="c00124">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;15.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Executive Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In 1989, the Company adopted an Executive Stock Purchase Plan (the &amp;#8220;Plan&amp;#8221;) under which 1,027,500 shares of Class A Stock were reserved for restricted stock awards.&amp;#160;&amp;#160;The Plan provides for the compensation committee of the board of directors to award employees, directors, consultants, and other individuals (&amp;#8220;Plan participants&amp;#8221;) who render service to the Company the right to purchase Class A Stock at a price set by the compensation committee.&amp;#160;&amp;#160;The Plan provides for the vesting of shares as determined by the compensation committee and, should the Company's relationship with a Plan participant terminate before all shares are vested, unvested shares will be repurchased by the Company at a price per share equal to the original amount paid by the Plan participant.&amp;#160;&amp;#160;During 1989 and 1990, a total of 983,254 shares were issued, all of which vested as of December 31, 1999.&amp;#160;&amp;#160;As of December 31, 2011, there were 44,246 shares available for future grants under the Plan.&lt;/font&gt;&lt;/div&gt;</regn:ExecutiveStockPurchasePlanTextBlock>
  <!--Marketable Securities-->
  <us-gaap:MarketableSecuritiesTextBlock contextRef="c00124">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;6.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Marketable Securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Marketable securities at December 31, 2011 and 2010 consisted of debt securities, as detailed below, and equity securities.&amp;#160;&amp;#160;The aggregate fair value of the equity securities was $3.0 million and $3.6 million at December 31, 2011 and 2010, respectively, and the aggregate cost basis was $4.0 million at both December 31, 2011 and 2010.&amp;#160;&amp;#160;The Company also held restricted marketable securities at both December 31, 2011 and December 31, 2010, which consisted of debt securities, as detailed below, that collateralize letters of credit and lease obligations.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The following tables summarize the amortized cost basis of debt securities included in marketable securities, the aggregate fair value of those securities, and gross unrealized gains and losses on those securities at December 31, 2011 and 2010.&amp;#160;&amp;#160;The Company classifies its debt securities, other than mortgage-backed securities, based on their contractual maturity dates.&amp;#160;&amp;#160;Maturities of mortgage-backed securities have been estimated based primarily on repayment characteristics and experience of the senior tranches that the Company holds.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;Fair&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="31%" colspan="3"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;At December 31, 2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Cost Basis&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;Gains&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;(Losses)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;Net&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Unrestricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Maturities within one year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$12,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$12,067&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government guaranteed corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;15,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;15,316&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government guaranteed collateralized mortgage obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Municipal bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;15,314&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;15,326&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;13&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(1)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;12&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;43,225&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;43,331&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;108&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(2)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;106&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Maturities after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;272,433&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;272,752&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;400&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(81)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;104&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;28&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;___&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(76)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(76)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;272,537&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;272,780&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;400&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(157)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;243&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Maturities after five years through ten years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;164&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;87&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;___&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(77)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(77)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;315,926&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;316,198&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;508&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(236)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;272&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Restricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Maturities within one year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;3,347&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;3,357&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Maturities after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;2,572&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;2,583&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;11&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;___&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;11&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;5,919&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;5,940&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;21&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;___&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;21&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$321,845&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$322,138&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$529&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$(236)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$293&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br /&gt;&lt;div style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;&lt;div&gt;&lt;div style="WIDTH: 100%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="PAGE-BREAK-AFTER: always; WIDTH: 100%"&gt;&lt;div style="TEXT-ALIGN: center; WIDTH: 100%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-ALIGN: center; WIDTH: 100%"&gt;&lt;hr style="COLOR: black" size="2" noshade="noshade" /&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="WIDTH: 100%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br /&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;Fair&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="31%" colspan="3"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;At December 31, 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Cost Basis&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;Gains&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;(Losses)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;Net&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Unrestricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Maturities within one year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$83,635&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$83,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$(5)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government guaranteed corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;48,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;48,531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;358&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;358&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;U.S. government guaranteed&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;collateralized mortgage obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2,027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2,131&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;104&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;104&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Municipal bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;1,597&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;1,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;875&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;847&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;___&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(28)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(28)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;136,307&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;136,796&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;522&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(33)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;489&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Maturities after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;352,345&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;350,683&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;64&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1,726)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1,662)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government guaranteed corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;15,522&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;15,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(45)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(45)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;110&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;38&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;___&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(72)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(72)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;367,977&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;366,198&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;64&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(1,843)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(1,779)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Maturities after five years through ten years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;284&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;243&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;___&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(41)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(41)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;504,568&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;503,237&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;586&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(1.917)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(1,331)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Restricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Maturities within one year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2,922&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2,921&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Maturities after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;4,135&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;4,118&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;___&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(17)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(17)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;7,057&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;7,039&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;___&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(18)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(18)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$511,625&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$510,276&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$586&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$(1,935)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$(1,349)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br /&gt;&lt;div style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;&lt;div&gt;&lt;div style="WIDTH: 100%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="PAGE-BREAK-AFTER: always; WIDTH: 100%"&gt;&lt;div style="TEXT-ALIGN: center; WIDTH: 100%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-ALIGN: center; WIDTH: 100%"&gt;&lt;hr style="COLOR: black" size="2" noshade="noshade" /&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="WIDTH: 100%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br /&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;At December 31, 2011 and 2010, marketable securities included an additional unrealized loss of $1.0 million and $0.4 million, respectively, related to one equity security in the Company&amp;#8217;s marketable securities portfolio.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The following table shows the fair value of the Company&amp;#8217;s marketable securities that have unrealized losses and that are deemed to be only temporarily impaired, aggregated by investment category and length of time that the individual securities have been in a continuous unrealized loss position, at December 31, 2011 and 2010.&amp;#160;&amp;#160;The debt securities listed at December 31, 2011, excluding mortgage-backed securities, mature at various dates through December 2014.&amp;#160;&amp;#160;The mortgage-backed securities listed at December 31, 2011 mature at various dates through April 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="19%" colspan="2"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Less than 12 Months&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="19%" colspan="2"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;12 Months or Greater&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="20%" colspan="2"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Total&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="26%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;At December 31, 2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Fair Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Unrealized &lt;font style="DISPLAY: inline"&gt;Loss&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Fair Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Unrealized &lt;font style="DISPLAY: inline"&gt;Loss&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Fair Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Unrealized &lt;font style="DISPLAY: inline"&gt;Loss&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Unrestricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$103,529&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$(81)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$103,529&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$(81)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%" align="left"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government guaranteed&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;collateralized mortgage&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Municipal bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;4,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;4,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Equity security&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;3,019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1,025)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;3,019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1,025)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;_____&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;____&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$116&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$(152)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;116&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(152)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$111,774&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$(1,108)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$116&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$(152)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$111,890&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$(1,260)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;At December 31, 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Unrestricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$340,444&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$(1,731)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$340,444&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$(1,731)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government guaranteed&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;19,005&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(45)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;19,005&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(45)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Equity security&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;3,612&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(433)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;3,612&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(433)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;_____&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;____&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$1,128&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$(141)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;1,128&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(141)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;363,061&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(2,209)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;1,128&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(141)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;364,189&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(2,350)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Restricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;6,154&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(18)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;____&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;____&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;6,154&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(18)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;6,154&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(18)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;____&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;____&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;6,154&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(18)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$369,215&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$(2,227)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$1,128&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$(141)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$370,343&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$(2,368)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Realized gains and losses are included as a component of investment income.&amp;#160;&amp;#160;For the years ended December 31, 2011, 2010, and 2009, total realized gains and losses on sales of marketable securities were not material.&amp;#160;&amp;#160;In computing realized gains and losses, the Company computes the cost of its investments on a specific identification basis.&amp;#160;&amp;#160;Such cost includes the direct costs to acquire the security, adjusted for the amortization of any discount or premium.&lt;/font&gt;&lt;/div&gt;&lt;br /&gt;&lt;div style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;&lt;div&gt;&lt;div style="WIDTH: 100%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="PAGE-BREAK-AFTER: always; WIDTH: 100%"&gt;&lt;div style="TEXT-ALIGN: center; WIDTH: 100%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-ALIGN: center; WIDTH: 100%"&gt;&lt;hr style="COLOR: black" size="2" noshade="noshade" /&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="WIDTH: 100%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br /&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company&amp;#8217;s assets that are measured at fair value on a recurring basis&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;,&lt;/font&gt; at December 31, 2011 and 2010, were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="41%" colspan="3"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Fair Value Measurements at Reporting Date Using&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="16%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Fair Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Quoted Prices in Active Markets for Identical Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;(Level 1)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="16%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Significant Other Observable Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;(Level 2)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Significant Unobservable Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;(Level 3)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;At December 31, 2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Unrestricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Available-for-sale marketable securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$284,819&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$284,819&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government guaranteed corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;15,316&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;15,316&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government guaranteed collateralized mortgage obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Municipal bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;15,326&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;15,326&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Equity security&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;3,019&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$3,019&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;_______&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;319,217&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;3,019&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;316,198&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Restricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Available-for-sale marketable securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%"&gt;&lt;div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;5,940&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;_____&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="16%"&gt;&lt;div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;5,940&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$325,157&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$3,019&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$322,138&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;At December 31, 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Unrestricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Available-for-sale marketable securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$434,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$434,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government guaranteed corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;64,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;64,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government guaranteed collateralized mortgage obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2,131&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2,131&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Municipal bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;1,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;1,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;1,128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;1,128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Equity security&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;3,612&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$3,612&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;_______&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;506,849&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;3,612&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;503,237&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Restricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Available-for-sale marketable securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;7,039&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;_____&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="16%"&gt;&lt;div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;7,039&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$513,888&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$3,612&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$510,276&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Marketable securities included in Level 2 were valued using a market approach utilizing prices and other relevant information, such as interest rates, yield curves, prepayment speeds, loss severities, credit risks, and default rates, generated by market transactions involving identical or comparable assets.&amp;#160;&amp;#160;The Company considers market liquidity in determining the fair value for these securities.&amp;#160;&amp;#160;During the year ended December 31, 2010, deterioration in the credit quality of a marketable security subjected the Company to the risk of not being able to recover the carrying value of these securities.&amp;#160;&amp;#160;As a result, the Company recognized a $0.1 million impairment charge related to its Level 2 marketable securities in 2010, which the Company considered to be other-than-temporarily impaired.&amp;#160;&amp;#160;The Company did not record any charges for other-than-temporary impairment of its Level 2 marketable securities in 2011 and 2009.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company held one Level 3 marketable security, which had a fair value of $0 at December 31, 2011 and 2010.&amp;#160;&amp;#160;This Level 3 security was valued using information provided by the Company&amp;#8217;s investment advisors and other sources, including quoted bid prices which took into consideration the securities&amp;#8217; lack of liquidity.&amp;#160;&amp;#160;In 2009, the Company recorded a charge of $0.1 million for other-than-temporary impairment of this Level 3 marketable security; therefore, as of December 31, 2009, the fair value of this security had been written down to zero.&amp;#160;&amp;#160;There were no purchases, sales, or maturities of Level 3 marketable securities and no unrealized gains or losses related to Level 3 marketable securities for the years ended December 31, 2011 and 2010.&amp;#160;&amp;#160;There were no transfers of marketable securities between Levels 1, 2, or 3 classifications during the years ended December 31, 2011 and 2010.&lt;/font&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
  <!--Income Taxes-->
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns.&amp;#160;&amp;#160;Under this method, deferred tax liabilities and assets are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts ("temporary differences") at enacted tax rates in effect for the years in which the differences are expected to reverse.&amp;#160;&amp;#160;A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets will not be realized.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Uncertain tax positions are accounted for in accordance with FASB authoritative guidance, which prescribes a comprehensive model for the manner in which a company should recognize, measure, present, and disclose in its financial statements all material uncertain tax positions that the company has taken or expects to take on a tax return.&amp;#160;&amp;#160;Those positions, for which management's assessment is that there is more than a 50% probability of sustaining the position upon challenge by a taxing authority based upon its technical merits, are subjected to certain measurement criteria.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company's policy is to recognize interest and penalties related to income tax matters in income tax expense.&lt;/font&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <!--Accounts Receivable - Trade-->
  <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c00124">&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Accounts Receivable - Trade&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company&amp;#8217;s trade accounts receivable represents amounts due from its distributors and specialty pharmacies (collectively, the Company&amp;#8217;s &amp;#8220;customers&amp;#8221;), which are all located in the United States.&amp;#160;&amp;#160;The Company monitors the financial performance and credit worthiness of its large customers so that it can properly assess and respond to changes in their credit profile.&amp;#160;&amp;#160;The Company provides reserves against trade receivables for estimated losses that may result from a customer&amp;#8217;s inability to pay.&amp;#160;&amp;#160;Amounts determined to be uncollectible are written-off against the reserve.&amp;#160;&amp;#160;As of December 31, 2011 and 2010, there were no reserves against trade accounts receivable.&amp;#160;&amp;#160;In addition, during the years ended December 31, 2011, 2010 and 2009, no trade accounts receivable were written-off.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
  <!--Maximum amount of milestone payments that may be received relating to marketing approvals in the U.S. or European Union- Collaboration Agreement with Sanofi [Member]-->
  <regn:MaximumAmountOfSubstantiveMilestonePaymentsThatMayBeReceivedInUSOrEuropeanUnion contextRef="c00160" unitRef="u000" decimals="-6">360000000</regn:MaximumAmountOfSubstantiveMilestonePaymentsThatMayBeReceivedInUSOrEuropeanUnion>
  <!--Potential compensation cost to be recognized if vesting is probable- Performance-Based Stock Options [Member]-->
  <regn:EmployeeServiceShareBasedCompensationNonvestedOptionsPotentialCompensationCost contextRef="c00056" unitRef="u000" decimals="-5">10200000</regn:EmployeeServiceShareBasedCompensationNonvestedOptionsPotentialCompensationCost>
  <!--Cumulative sales range, maximum- License Agreement With Genentech [Member]-->
  <regn:CumulativeSalesRangeMaximum contextRef="c00262" unitRef="u000" decimals="-6">3000000000</regn:CumulativeSalesRangeMaximum>
  <!--Cumulative sales range, maximum- License Agreement With Genentech [Member]-->
  <regn:CumulativeSalesRangeMaximum contextRef="c00161" unitRef="u000" decimals="-6">3000000000</regn:CumulativeSalesRangeMaximum>
  <!--2012- Facilities Buildings A and B [Member]-->
  <regn:FacilityLeasesFutureMinimumPaymentsDueCurrent contextRef="c00048" unitRef="u000" decimals="-3">12847000</regn:FacilityLeasesFutureMinimumPaymentsDueCurrent>
  <!--2012- Facilities Building C [Member]-->
  <regn:FacilityLeasesFutureMinimumPaymentsDueCurrent contextRef="c00049" unitRef="u000" decimals="-3">2825000</regn:FacilityLeasesFutureMinimumPaymentsDueCurrent>
  <!--2012-->
  <regn:FacilityLeasesFutureMinimumPaymentsDueCurrent contextRef="c00001" unitRef="u000" decimals="-3">15672000</regn:FacilityLeasesFutureMinimumPaymentsDueCurrent>
  <!--Interest expense in connection with facility lease obligation- Facilities Buildings A and B [Member] + Interest expense in connection with facility lease obligation- Facilities Buildings A and B [Member]-->
  <regn:InterestExpenseInConnectionWithFacilityLeaseObligation contextRef="c00184" unitRef="u000" decimals="-5">9100000</regn:InterestExpenseInConnectionWithFacilityLeaseObligation>
  <!--Interest expense in connection with facility lease obligation- Facilities Buildings A and B [Member] + Interest expense in connection with facility lease obligation- Facilities Buildings A and B [Member]-->
  <regn:InterestExpenseInConnectionWithFacilityLeaseObligation contextRef="c00214" unitRef="u000" decimals="-5">2300000</regn:InterestExpenseInConnectionWithFacilityLeaseObligation>
  <!--Interest expense in connection with facility lease obligation-->
  <regn:InterestExpenseInConnectionWithFacilityLeaseObligation contextRef="c00124" unitRef="u000" decimals="-5">15600000</regn:InterestExpenseInConnectionWithFacilityLeaseObligation>
  <!--Purchase of convertible note hedges- Call Option [Member]-->
  <regn:PurchaseOfConvertibleNoteHedges contextRef="c00260" unitRef="u000" decimals="-5">117500000</regn:PurchaseOfConvertibleNoteHedges>
  <!--InventoryWriteDown-->
  <us-gaap:InventoryWriteDown contextRef="c00124" unitRef="u000" decimals="-5">500000</us-gaap:InventoryWriteDown>
  <!--Fair Value - Maturities after one year through five years- Unrestricted [Member]- U S Government Obligations [Member] + Fair Value - Maturities after one year through five years- Unrestricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c00029" unitRef="u000" decimals="-3">272752000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
  <!--Fair Value - Maturities after one year through five years- Unrestricted [Member]- U S Government Obligations [Member] + Fair Value - Maturities after one year through five years- Unrestricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c00085" unitRef="u000" decimals="-3">350683000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
  <!--Fair Value - Maturities after one year through five years- Unrestricted [Member]- Mortgage-Backed Securities [Member] + Fair Value - Maturities after one year through five years- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c00033" unitRef="u000" decimals="-3">28000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
  <!--Fair Value - Maturities after one year through five years- Unrestricted [Member]- Mortgage-Backed Securities [Member] + Fair Value - Maturities after one year through five years- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c00089" unitRef="u000" decimals="-3">38000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
  <!--Fair Value - Maturities after one year through five years- Unrestricted [Member] + Fair Value - Maturities after one year through five years- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c00034" unitRef="u000" decimals="-3">272780000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
  <!--Fair Value - Maturities after one year through five years- Unrestricted [Member] + Fair Value - Maturities after one year through five years- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c00090" unitRef="u000" decimals="-3">366198000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
  <!--Fair Value - Maturities after one year through five years- Restricted [Member]- U S Government Obligations [Member] + Fair Value - Maturities after one year through five years- Restricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c00035" unitRef="u000" decimals="-3">2583000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
  <!--Fair Value - Maturities after one year through five years- Restricted [Member]- U S Government Obligations [Member] + Fair Value - Maturities after one year through five years- Restricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c00091" unitRef="u000" decimals="-3">4118000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
  <!--Fair Value - Maturities after one year through five years- Unrestricted [Member]- U S Government Guaranteed Corporate Bonds [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c00086" unitRef="u000" decimals="-3">15477000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
  <!--Other accrued expenses and liabilities + Other accrued expenses and liabilities-->
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c00001" unitRef="u000" decimals="-3">14134000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <!--Other accrued expenses and liabilities + Other accrued expenses and liabilities-->
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c00060" unitRef="u000" decimals="-3">6441000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <!--Shared Pre-Launch Commercialization Expenses With Collaborator- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member]-->
  <regn:SharedPreLaunchCommercializationExpensesWithCollaborator contextRef="c00134" unitRef="u000" decimals="-5">9300000</regn:SharedPreLaunchCommercializationExpensesWithCollaborator>
  <!--Minimum amount of research funding- Grant from National Institutes of Health [Member]-->
  <regn:MinimumAmountOfResearchFunding contextRef="c00246" unitRef="u000" decimals="-5">25300000</regn:MinimumAmountOfResearchFunding>
  <!--Percentage of Shared Phase 3 Trial Costs borne by collaborating party (in hundredths)- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:PercentageOfTrialCostsBorneByCollaboratingParty contextRef="c00135" unitRef="u004" decimals="2">0.80</regn:PercentageOfTrialCostsBorneByCollaboratingParty>
  <!--Percentage of development expenses to be reimbursed due to profitability of agreement (in hundredths)- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member]-->
  <regn:PercentageOfDevelopmentExpensesToBeReimbursedDueToProfitabilityOfCollaborationAgreement contextRef="c00134" unitRef="u004" decimals="2">0.50</regn:PercentageOfDevelopmentExpensesToBeReimbursedDueToProfitabilityOfCollaborationAgreement>
  <!--Percentage of development expenses to be reimbursed due to profitability of agreement (in hundredths)- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:PercentageOfDevelopmentExpensesToBeReimbursedDueToProfitabilityOfCollaborationAgreement contextRef="c00135" unitRef="u004" decimals="2">0.50</regn:PercentageOfDevelopmentExpensesToBeReimbursedDueToProfitabilityOfCollaborationAgreement>
  <!--Percentage of development expenses to be reimbursed due to profitability of agreement (in hundredths)- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <regn:PercentageOfDevelopmentExpensesToBeReimbursedDueToProfitabilityOfCollaborationAgreement contextRef="c00136" unitRef="u004" decimals="2">0.50</regn:PercentageOfDevelopmentExpensesToBeReimbursedDueToProfitabilityOfCollaborationAgreement>
  <!--Payments in connection with capital lease obligation-->
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="c00124" unitRef="u000" decimals="-3">993000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <!--Payments in connection with capital lease obligation-->
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="c00164" unitRef="u000" decimals="-3">104000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <!--Payments in connection with capital lease obligation-->
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="c00195" unitRef="u000" decimals="-3">0</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <!--Increase in accounts payable, accrued expenses, and other liabilities-->
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c00124" unitRef="u000" decimals="-3">50016000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <!--Increase in accounts payable, accrued expenses, and other liabilities-->
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c00164" unitRef="u000" decimals="-3">7605000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <!--Increase in accounts payable, accrued expenses, and other liabilities-->
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c00195" unitRef="u000" decimals="-3">12577000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <!--Issuance of Common Stock in a public offering, net of issuance costs - Common Stock Amount- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c00165" unitRef="u000" decimals="-3">6000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <!--Issuance of Common Stock in a public offering, net of issuance costs - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c00166" unitRef="u000" decimals="-3">174822000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <!--Issuance of Common Stock in a public offering, net of issuance costs - Total Stockholders' Equity-->
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c00164" unitRef="u000" decimals="-3">174828000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <!--Total other income (expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c00124" unitRef="u000" decimals="-3">-17733000</us-gaap:NonoperatingIncomeExpense>
  <!--Total other income (expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c00164" unitRef="u000" decimals="-3">-6996000</us-gaap:NonoperatingIncomeExpense>
  <!--Total other income (expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c00195" unitRef="u000" decimals="-3">2151000</us-gaap:NonoperatingIncomeExpense>
  <!--Total liabilities and stockholders' equity-->
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c00001" unitRef="u000" decimals="-3">1323583000</us-gaap:LiabilitiesAndStockholdersEquity>
  <!--Total liabilities and stockholders' equity-->
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c00060" unitRef="u000" decimals="-3">1089432000</us-gaap:LiabilitiesAndStockholdersEquity>
  <!--Accumulated other comprehensive loss-->
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c00001" unitRef="u000" decimals="-3">-1862000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <!--Accumulated other comprehensive loss-->
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c00060" unitRef="u000" decimals="-3">-2491000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <!--Accounts payable and accrued expenses-->
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c00001" unitRef="u000" decimals="-3">95625000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <!--Accounts payable and accrued expenses-->
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c00060" unitRef="u000" decimals="-3">53658000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <!--Other assets-->
  <us-gaap:OtherAssetsNoncurrent contextRef="c00001" unitRef="u000" decimals="-3">19145000</us-gaap:OtherAssetsNoncurrent>
  <!--Other assets-->
  <us-gaap:OtherAssetsNoncurrent contextRef="c00060" unitRef="u000" decimals="-3">6789000</us-gaap:OtherAssetsNoncurrent>
  <!--Marketable securities-->
  <us-gaap:MarketableSecuritiesNoncurrent contextRef="c00001" unitRef="u000" decimals="-3">275887000</us-gaap:MarketableSecuritiesNoncurrent>
  <!--Marketable securities-->
  <us-gaap:MarketableSecuritiesNoncurrent contextRef="c00060" unitRef="u000" decimals="-3">370053000</us-gaap:MarketableSecuritiesNoncurrent>
  <!--Prepaid expenses and other current assets-->
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c00001" unitRef="u000" decimals="-3">22898000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <!--Prepaid expenses and other current assets-->
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c00060" unitRef="u000" decimals="-3">26337000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <!--Net Carrying Amount of the Liability Component of Convertible Notes-->
  <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The net carrying amount of the liability component of the Notes as of December 31, 2011 consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="46%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Total convertible senior notes - par&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 16.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$400,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Unamortized discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 16.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;124,981&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 16.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$275,019&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
  <!--Company-incurred expenses associated with Sanofi collaborations- Collaboration Agreement with Sanofi [Member] + Company-incurred expenses associated with Sanofi collaborations- Collaboration Agreement with Sanofi [Member] + Company-incurred expenses associated with Sanofi collaborations- Collaboration Agreement with Sanofi [Member]-->
  <regn:CompanyIncurredExpensesAssociatedWithSanofiCollaborations contextRef="c00160" unitRef="u000" decimals="-5">381200000</regn:CompanyIncurredExpensesAssociatedWithSanofiCollaborations>
  <!--Company-incurred expenses associated with Sanofi collaborations- Collaboration Agreement with Sanofi [Member] + Company-incurred expenses associated with Sanofi collaborations- Collaboration Agreement with Sanofi [Member] + Company-incurred expenses associated with Sanofi collaborations- Collaboration Agreement with Sanofi [Member]-->
  <regn:CompanyIncurredExpensesAssociatedWithSanofiCollaborations contextRef="c00192" unitRef="u000" decimals="-5">282400000</regn:CompanyIncurredExpensesAssociatedWithSanofiCollaborations>
  <!--Company-incurred expenses associated with Sanofi collaborations- Collaboration Agreement with Sanofi [Member] + Company-incurred expenses associated with Sanofi collaborations- Collaboration Agreement with Sanofi [Member] + Company-incurred expenses associated with Sanofi collaborations- Collaboration Agreement with Sanofi [Member]-->
  <regn:CompanyIncurredExpensesAssociatedWithSanofiCollaborations contextRef="c00221" unitRef="u000" decimals="-5">209400000</regn:CompanyIncurredExpensesAssociatedWithSanofiCollaborations>
  <!--Net operating loss carry-forwards related to exercises of Nonqualified Stock Options and disqualifying dispositions of Incentive Stock Options- U S Federal and New York State [Member]-->
  <regn:NetOperatingLossCarryForwardsExercisesOfNonqualifiedStockOptionsAndDisqualifyingDispositionsOfIncentiveStockOptions contextRef="c00058" unitRef="u000" decimals="-5">96200000</regn:NetOperatingLossCarryForwardsExercisesOfNonqualifiedStockOptionsAndDisqualifyingDispositionsOfIncentiveStockOptions>
  <!--Unused net operating loss carry-forwards- U S Federal and New York State [Member]-->
  <us-gaap:OperatingLossCarryforwards contextRef="c00058" unitRef="u000" decimals="-5">800200000</us-gaap:OperatingLossCarryforwards>
  <!--Capitalized research and development costs + Capitalized research and development costs-->
  <regn:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="c00001" unitRef="u000" decimals="-3">31371000</regn:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
  <!--Capitalized research and development costs + Capitalized research and development costs-->
  <regn:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="c00060" unitRef="u000" decimals="-3">38865000</regn:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
  <!--Income tax expense (benefit) resulting from provision in Worker, Homeownership, and Business Assistance Act of 2009-->
  <regn:IncomeTaxExpenseBenefitResultingFromProvisionInWorkerHomeownershipAndBusinessAssistanceActOf2009 contextRef="c00195" unitRef="u000" decimals="-5">-2700000</regn:IncomeTaxExpenseBenefitResultingFromProvisionInWorkerHomeownershipAndBusinessAssistanceActOf2009>
  <!--Non-cash stock-based compensation expense- Non-Performance Based Stock Options [Member] + Non-cash stock-based compensation expense- Non-Performance Based Stock Options [Member] + Non-cash stock-based compensation expense- Non-Performance Based Stock Options [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c00154" unitRef="u000" decimals="-5">39200000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Non-cash stock-based compensation expense- Non-Performance Based Stock Options [Member] + Non-cash stock-based compensation expense- Non-Performance Based Stock Options [Member] + Non-cash stock-based compensation expense- Non-Performance Based Stock Options [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c00188" unitRef="u000" decimals="-5">29400000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Non-cash stock-based compensation expense- Non-Performance Based Stock Options [Member] + Non-cash stock-based compensation expense- Non-Performance Based Stock Options [Member] + Non-cash stock-based compensation expense- Non-Performance Based Stock Options [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c00218" unitRef="u000" decimals="-5">27400000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Non-cash stock-based compensation expense- Performance-Based Stock Options [Member] + Non-cash stock-based compensation expense- Performance-Based Stock Options [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c00155" unitRef="u000" decimals="-5">11700000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Non-cash stock-based compensation expense- Performance-Based Stock Options [Member] + Non-cash stock-based compensation expense- Performance-Based Stock Options [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c00189" unitRef="u000" decimals="-5">8100000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Non-cash stock-based compensation expense- Restricted Stock [Member] + Non-cash stock-based compensation expense- Restricted Stock [Member] + Non-cash stock-based compensation expense- Restricted Stock [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c00156" unitRef="u000" decimals="-5">5700000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Non-cash stock-based compensation expense- Restricted Stock [Member] + Non-cash stock-based compensation expense- Restricted Stock [Member] + Non-cash stock-based compensation expense- Restricted Stock [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c00190" unitRef="u000" decimals="-5">2400000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Non-cash stock-based compensation expense- Restricted Stock [Member] + Non-cash stock-based compensation expense- Restricted Stock [Member] + Non-cash stock-based compensation expense- Restricted Stock [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c00220" unitRef="u000" decimals="-5">2200000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Granted, weighted-average exercise price (in dollars per share)- Stock Options [Member] + Granted, weighted-average exercise price (in dollars per share)- Stock Options [Member] + Granted, weighted-average exercise price (in dollars per share)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c00054" unitRef="u002" decimals="2">51.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <!--Granted, weighted-average exercise price (in dollars per share)- Stock Options [Member] + Granted, weighted-average exercise price (in dollars per share)- Stock Options [Member] + Granted, weighted-average exercise price (in dollars per share)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c00105" unitRef="u002" decimals="2">29.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <!--Granted, weighted-average exercise price (in dollars per share)- Stock Options [Member] + Granted, weighted-average exercise price (in dollars per share)- Stock Options [Member] + Granted, weighted-average exercise price (in dollars per share)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c00115" unitRef="u002" decimals="2">20.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <!--Granted (in shares)- Stock Options [Member] + Granted (in shares)- Stock Options [Member] + Granted (in shares)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c00152" unitRef="u001" decimals="0">4286640</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <!--Granted (in shares)- Stock Options [Member] + Granted (in shares)- Stock Options [Member] + Granted (in shares)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c00187" unitRef="u001" decimals="0">4319856</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <!--Granted (in shares)- Stock Options [Member] + Granted (in shares)- Stock Options [Member] + Granted (in shares)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c00217" unitRef="u001" decimals="0">3490560</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <!--Non-refundable advance payment made under license agreement- Cellectis Agreement [Member]-->
  <regn:NonRefundableAdvancePaymentMadeUnderLicenseAgreement contextRef="c00263" unitRef="u000" decimals="-5">12500000</regn:NonRefundableAdvancePaymentMadeUnderLicenseAgreement>
  <!--Total- Equipment [Member]-->
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDue contextRef="c00020" unitRef="u000" decimals="-3">2778000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
  <!--Other-than-temporary impairment charge- Fair Value, Inputs, Level 2 [Member]-->
  <us-gaap:MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmount contextRef="c00180" unitRef="u000" decimals="-5">100000</us-gaap:MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmount>
  <!--Other-than-temporary impairment charge- Fair Value, Inputs, Level 3 [Member]-->
  <us-gaap:MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmount contextRef="c00211" unitRef="u000" decimals="-5">100000</us-gaap:MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmount>
  <!--Strike price of the warrant transaction (in dollars per share)- Warrant Transactions [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="c00269" unitRef="u002" decimals="2">103.41</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <!--Principal amount- Convertible Debt [Member]-->
  <us-gaap:DebtInstrumentFaceAmount contextRef="c00268" unitRef="u000" decimals="-6">400000000</us-gaap:DebtInstrumentFaceAmount>
  <!--Total interest expense- Convertible Debt [Member]-->
  <us-gaap:InterestExpenseDebt contextRef="c00146" unitRef="u000" decimals="-3">5399000</us-gaap:InterestExpenseDebt>
  <!--Amortization of discount and note issuance costs- Convertible Debt [Member]-->
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c00146" unitRef="u000" decimals="-3">3944000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <!--Net carrying amount of the liability component- Convertible Debt [Member]-->
  <us-gaap:LongTermDebt contextRef="c00039" unitRef="u000" decimals="-3">275019000</us-gaap:LongTermDebt>
  <!--Unrealized (Losses) - Maturities after one year through five years- Unrestricted [Member]- U S Government Obligations [Member] + Unrealized (Losses) - Maturities after one year through five years- Unrestricted [Member]- U S Government Obligations [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedLoss contextRef="c00029" unitRef="u000" decimals="-3">81000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedLoss>
  <!--Unrealized (Losses) - Maturities after one year through five years- Unrestricted [Member]- U S Government Obligations [Member] + Unrealized (Losses) - Maturities after one year through five years- Unrestricted [Member]- U S Government Obligations [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedLoss contextRef="c00085" unitRef="u000" decimals="-3">1726000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedLoss>
  <!--Unrealized (Losses) - Maturities after one year through five years- Unrestricted [Member]- Mortgage-Backed Securities [Member] + Unrealized (Losses) - Maturities after one year through five years- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedLoss contextRef="c00033" unitRef="u000" decimals="-3">76000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedLoss>
  <!--Unrealized (Losses) - Maturities after one year through five years- Unrestricted [Member]- Mortgage-Backed Securities [Member] + Unrealized (Losses) - Maturities after one year through five years- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedLoss contextRef="c00089" unitRef="u000" decimals="-3">72000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedLoss>
  <!--Unrealized (Losses) - Maturities after one year through five years- Unrestricted [Member] + Unrealized (Losses) - Maturities after one year through five years- Unrestricted [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedLoss contextRef="c00034" unitRef="u000" decimals="-3">157000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedLoss>
  <!--Unrealized (Losses) - Maturities after one year through five years- Unrestricted [Member] + Unrealized (Losses) - Maturities after one year through five years- Unrestricted [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedLoss contextRef="c00090" unitRef="u000" decimals="-3">1843000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedLoss>
  <!--Unrealized (Losses) - Maturities after one year through five years- Unrestricted [Member]- U S Government Guaranteed Corporate Bonds [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedLoss contextRef="c00086" unitRef="u000" decimals="-3">45000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedLoss>
  <!--Unrealized (Losses) - Maturities after one year through five years- Restricted [Member]- U S Government Obligations [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedLoss contextRef="c00091" unitRef="u000" decimals="-3">17000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedLoss>
  <!--Number of annual payments not received due to cancellation of obligation- License Agreement with AstraZeneca UK Limited [Member]-->
  <regn:NumberOfAnnualPaymentsNotReceivedDueToCancellationOfObligation contextRef="c00252" unitRef="u006" decimals="0">2</regn:NumberOfAnnualPaymentsNotReceivedDueToCancellationOfObligation>
  <!--Annual, non-refundable licensing payment received- License Agreement with Astellas Pharma Inc [Member] + Annual, non-refundable licensing payment received- License Agreement with Astellas Pharma Inc [Member] + Annual, non-refundable licensing payment received- License Agreement with Astellas Pharma Inc [Member] + Annual, non-refundable licensing payment received- License Agreement with Astellas Pharma Inc [Member]-->
  <regn:AnnualNonRefundableLicensingPaymentReceived contextRef="c00175" unitRef="u000" decimals="-5">20000000</regn:AnnualNonRefundableLicensingPaymentReceived>
  <!--Annual, non-refundable licensing payment received- License Agreement with Astellas Pharma Inc [Member] + Annual, non-refundable licensing payment received- License Agreement with Astellas Pharma Inc [Member] + Annual, non-refundable licensing payment received- License Agreement with Astellas Pharma Inc [Member] + Annual, non-refundable licensing payment received- License Agreement with Astellas Pharma Inc [Member]-->
  <regn:AnnualNonRefundableLicensingPaymentReceived contextRef="c00206" unitRef="u000" decimals="-5">20000000</regn:AnnualNonRefundableLicensingPaymentReceived>
  <!--Annual, non-refundable licensing payment received- License Agreement with Astellas Pharma Inc [Member] + Annual, non-refundable licensing payment received- License Agreement with Astellas Pharma Inc [Member] + Annual, non-refundable licensing payment received- License Agreement with Astellas Pharma Inc [Member] + Annual, non-refundable licensing payment received- License Agreement with Astellas Pharma Inc [Member]-->
  <regn:AnnualNonRefundableLicensingPaymentReceived contextRef="c00193" unitRef="u000" decimals="-5">20000000</regn:AnnualNonRefundableLicensingPaymentReceived>
  <!--Annual, non-refundable licensing payment received- License Agreement with Astellas Pharma Inc [Member] + Annual, non-refundable licensing payment received- License Agreement with Astellas Pharma Inc [Member] + Annual, non-refundable licensing payment received- License Agreement with Astellas Pharma Inc [Member] + Annual, non-refundable licensing payment received- License Agreement with Astellas Pharma Inc [Member]-->
  <regn:AnnualNonRefundableLicensingPaymentReceived contextRef="c00248" unitRef="u000" decimals="-5">20000000</regn:AnnualNonRefundableLicensingPaymentReceived>
  <!--Annual, non-refundable licensing payment received- License Agreement with AstraZeneca UK Limited [Member] + Annual, non-refundable licensing payment received- License Agreement with AstraZeneca UK Limited [Member] + Annual, non-refundable licensing payment received- License Agreement with AstraZeneca UK Limited [Member] + Annual, non-refundable licensing payment received- License Agreement with AstraZeneca UK Limited [Member]-->
  <regn:AnnualNonRefundableLicensingPaymentReceived contextRef="c00176" unitRef="u000" decimals="-5">20000000</regn:AnnualNonRefundableLicensingPaymentReceived>
  <!--Annual, non-refundable licensing payment received- License Agreement with AstraZeneca UK Limited [Member] + Annual, non-refundable licensing payment received- License Agreement with AstraZeneca UK Limited [Member] + Annual, non-refundable licensing payment received- License Agreement with AstraZeneca UK Limited [Member] + Annual, non-refundable licensing payment received- License Agreement with AstraZeneca UK Limited [Member]-->
  <regn:AnnualNonRefundableLicensingPaymentReceived contextRef="c00207" unitRef="u000" decimals="-5">20000000</regn:AnnualNonRefundableLicensingPaymentReceived>
  <!--Annual, non-refundable licensing payment received- License Agreement with AstraZeneca UK Limited [Member] + Annual, non-refundable licensing payment received- License Agreement with AstraZeneca UK Limited [Member] + Annual, non-refundable licensing payment received- License Agreement with AstraZeneca UK Limited [Member] + Annual, non-refundable licensing payment received- License Agreement with AstraZeneca UK Limited [Member]-->
  <regn:AnnualNonRefundableLicensingPaymentReceived contextRef="c00194" unitRef="u000" decimals="-5">20000000</regn:AnnualNonRefundableLicensingPaymentReceived>
  <!--Annual, non-refundable licensing payment received- License Agreement with AstraZeneca UK Limited [Member] + Annual, non-refundable licensing payment received- License Agreement with AstraZeneca UK Limited [Member] + Annual, non-refundable licensing payment received- License Agreement with AstraZeneca UK Limited [Member] + Annual, non-refundable licensing payment received- License Agreement with AstraZeneca UK Limited [Member]-->
  <regn:AnnualNonRefundableLicensingPaymentReceived contextRef="c00249" unitRef="u000" decimals="-5">20000000</regn:AnnualNonRefundableLicensingPaymentReceived>
  <!--Period of notice to opt-out of further development and/or commercialization (in months)- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:PeriodOfNoticeToOptOutOfFurtherDevelopmentAndOrCommercialization contextRef="c00135">12M</regn:PeriodOfNoticeToOptOutOfFurtherDevelopmentAndOrCommercialization>
  <!--Reimbursement of development expenses in accordance with formula until first commercial sale- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member]-->
  <regn:ReimbursementOfDevelopmentExpensesInAccordanceWithFormulaUntilFirstCommercialSale contextRef="c00134" unitRef="u000" decimals="-5">7500000</regn:ReimbursementOfDevelopmentExpensesInAccordanceWithFormulaUntilFirstCommercialSale>
  <!--Proceeds in connection with issuance of convertible notes, net of debt issuance costs-->
  <regn:ProceedsFromConvertibleDebtNetOfIssuanceCosts contextRef="c00124" unitRef="u000" decimals="-3">391107000</regn:ProceedsFromConvertibleDebtNetOfIssuanceCosts>
  <!--Proceeds in connection with issuance of convertible notes, net of debt issuance costs-->
  <regn:ProceedsFromConvertibleDebtNetOfIssuanceCosts contextRef="c00164" unitRef="u000" decimals="-3">0</regn:ProceedsFromConvertibleDebtNetOfIssuanceCosts>
  <!--Proceeds in connection with issuance of convertible notes, net of debt issuance costs-->
  <regn:ProceedsFromConvertibleDebtNetOfIssuanceCosts contextRef="c00195" unitRef="u000" decimals="-3">0</regn:ProceedsFromConvertibleDebtNetOfIssuanceCosts>
  <!--Payments in connection with facility lease obligation-->
  <regn:PaymentsInConnectionWithFacilityLeaseObligations contextRef="c00124" unitRef="u000" decimals="-3">674000</regn:PaymentsInConnectionWithFacilityLeaseObligations>
  <!--Payments in connection with facility lease obligation-->
  <regn:PaymentsInConnectionWithFacilityLeaseObligations contextRef="c00164" unitRef="u000" decimals="-3">924000</regn:PaymentsInConnectionWithFacilityLeaseObligations>
  <!--Payments in connection with facility lease obligation-->
  <regn:PaymentsInConnectionWithFacilityLeaseObligations contextRef="c00195" unitRef="u000" decimals="-3">875000</regn:PaymentsInConnectionWithFacilityLeaseObligations>
  <!--Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss-->
  <us-gaap:NetIncomeLoss contextRef="c00124" unitRef="u000" decimals="-3">-221760000</us-gaap:NetIncomeLoss>
  <!--Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss-->
  <us-gaap:NetIncomeLoss contextRef="c00164" unitRef="u000" decimals="-3">-104468000</us-gaap:NetIncomeLoss>
  <!--Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss-->
  <us-gaap:NetIncomeLoss contextRef="c00195" unitRef="u000" decimals="-3">-67830000</us-gaap:NetIncomeLoss>
  <!--Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss-->
  <us-gaap:NetIncomeLoss contextRef="c00117" unitRef="u000" decimals="-3">-43447000</us-gaap:NetIncomeLoss>
  <!--Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss-->
  <us-gaap:NetIncomeLoss contextRef="c00120" unitRef="u000" decimals="-3">-62505000</us-gaap:NetIncomeLoss>
  <!--Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss-->
  <us-gaap:NetIncomeLoss contextRef="c00122" unitRef="u000" decimals="-3">-62365000</us-gaap:NetIncomeLoss>
  <!--Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss-->
  <us-gaap:NetIncomeLoss contextRef="c00256" unitRef="u000" decimals="-3">-53443000</us-gaap:NetIncomeLoss>
  <!--Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss-->
  <us-gaap:NetIncomeLoss contextRef="c00119" unitRef="u000" decimals="-3">-30522000</us-gaap:NetIncomeLoss>
  <!--Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss-->
  <us-gaap:NetIncomeLoss contextRef="c00121" unitRef="u000" decimals="-3">-25474000</us-gaap:NetIncomeLoss>
  <!--Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss-->
  <us-gaap:NetIncomeLoss contextRef="c00123" unitRef="u000" decimals="-3">-33875000</us-gaap:NetIncomeLoss>
  <!--Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss + Net loss-->
  <us-gaap:NetIncomeLoss contextRef="c00257" unitRef="u000" decimals="-3">-14597000</us-gaap:NetIncomeLoss>
  <!--Net loss, 2009 - Accumulated Deficit- Accumulated Deficit [Member] + Net loss, 2010 - Accumulated Deficit- Accumulated Deficit [Member] + Net loss, 2011 - Accumulated Deficit- Accumulated Deficit [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c00199" unitRef="u000" decimals="-3">-67830000</us-gaap:NetIncomeLoss>
  <!--Net loss, 2009 - Accumulated Deficit- Accumulated Deficit [Member] + Net loss, 2010 - Accumulated Deficit- Accumulated Deficit [Member] + Net loss, 2011 - Accumulated Deficit- Accumulated Deficit [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c00168" unitRef="u000" decimals="-3">-104468000</us-gaap:NetIncomeLoss>
  <!--Net loss, 2009 - Accumulated Deficit- Accumulated Deficit [Member] + Net loss, 2010 - Accumulated Deficit- Accumulated Deficit [Member] + Net loss, 2011 - Accumulated Deficit- Accumulated Deficit [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c00128" unitRef="u000" decimals="-3">-221760000</us-gaap:NetIncomeLoss>
  <!--Net loss, 2009 - Comprehensive Loss- Comprehensive Loss [Member] + Net loss, 2010 - Comprehensive Loss- Comprehensive Loss [Member] + Net loss, 2011 - Comprehensive Loss- Comprehensive Loss [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c00200" unitRef="u000" decimals="-3">-67830000</us-gaap:NetIncomeLoss>
  <!--Net loss, 2009 - Comprehensive Loss- Comprehensive Loss [Member] + Net loss, 2010 - Comprehensive Loss- Comprehensive Loss [Member] + Net loss, 2011 - Comprehensive Loss- Comprehensive Loss [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c00169" unitRef="u000" decimals="-3">-104468000</us-gaap:NetIncomeLoss>
  <!--Net loss, 2009 - Comprehensive Loss- Comprehensive Loss [Member] + Net loss, 2010 - Comprehensive Loss- Comprehensive Loss [Member] + Net loss, 2011 - Comprehensive Loss- Comprehensive Loss [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c00129" unitRef="u000" decimals="-3">-221760000</us-gaap:NetIncomeLoss>
  <!--Investment income-->
  <us-gaap:InvestmentIncomeNonoperating contextRef="c00124" unitRef="u000" decimals="-3">3549000</us-gaap:InvestmentIncomeNonoperating>
  <!--Investment income-->
  <us-gaap:InvestmentIncomeNonoperating contextRef="c00164" unitRef="u000" decimals="-3">2122000</us-gaap:InvestmentIncomeNonoperating>
  <!--Investment income-->
  <us-gaap:InvestmentIncomeNonoperating contextRef="c00195" unitRef="u000" decimals="-3">4488000</us-gaap:InvestmentIncomeNonoperating>
  <!--Selling, general, and admistrative-->
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c00124" unitRef="u000" decimals="-3">117261000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <!--Selling, general, and admistrative-->
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c00164" unitRef="u000" decimals="-3">65201000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <!--Selling, general, and admistrative-->
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c00195" unitRef="u000" decimals="-3">52923000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <!--Class A Stock, shares issued- Class A Stock [Member]-->
  <us-gaap:CommonStockSharesIssued contextRef="c00002" unitRef="u001" decimals="0">2109512</us-gaap:CommonStockSharesIssued>
  <!--Class A Stock, shares issued- Class A Stock [Member]-->
  <us-gaap:CommonStockSharesIssued contextRef="c00061" unitRef="u001" decimals="0">2182036</us-gaap:CommonStockSharesIssued>
  <!--Common Stock, shares issued-->
  <us-gaap:CommonStockSharesIssued contextRef="c00001" unitRef="u001" decimals="0">90692071</us-gaap:CommonStockSharesIssued>
  <!--Common Stock, shares issued-->
  <us-gaap:CommonStockSharesIssued contextRef="c00060" unitRef="u001" decimals="0">87238301</us-gaap:CommonStockSharesIssued>
  <!--Document Type-->
  <dei:DocumentType contextRef="c00124">10-K</dei:DocumentType>
  <!--Total liabilities-->
  <us-gaap:Liabilities contextRef="c00001" unitRef="u000" decimals="-3">837851000</us-gaap:Liabilities>
  <!--Total liabilities-->
  <us-gaap:Liabilities contextRef="c00060" unitRef="u000" decimals="-3">561617000</us-gaap:Liabilities>
  <!--Facility lease obligations-->
  <regn:FacilityLeaseObligationsNoncurrent contextRef="c00001" unitRef="u000" decimals="-3">159508000</regn:FacilityLeaseObligationsNoncurrent>
  <!--Facility lease obligations-->
  <regn:FacilityLeaseObligationsNoncurrent contextRef="c00060" unitRef="u000" decimals="-3">159355000</regn:FacilityLeaseObligationsNoncurrent>
  <!--Deferred revenue - other-->
  <regn:DeferredRevenueOtherNoncurrent contextRef="c00001" unitRef="u000" decimals="-3">162593000</regn:DeferredRevenueOtherNoncurrent>
  <!--Deferred revenue - other-->
  <regn:DeferredRevenueOtherNoncurrent contextRef="c00060" unitRef="u000" decimals="-3">188775000</regn:DeferredRevenueOtherNoncurrent>
  <!--Long-Term Incentive Plans-->
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c00124">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;14.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Long-Term Incentive Plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;During 2000, the Company established the Regeneron Pharmaceuticals, Inc. 2000 Long-Term Incentive Plan which, as amended and restated (the &amp;#8220;2000 Incentive Plan&amp;#8221;), provides for the issuance of up to 41,307,016 shares of Common Stock in respect of awards.&amp;#160;&amp;#160;Employees of the Company, including officers, and nonemployees, including consultants and nonemployee members of the Company&amp;#8217;s board of directors, (collectively, &amp;#8220;Participants&amp;#8221;) may receive awards as determined by a committee of independent directors (&amp;#8220;Committee&amp;#8221;).&amp;#160;&amp;#160;The awards that may be made under the 2000 Incentive Plan include: (a) Incentive Stock Options (&amp;#8220;ISOs&amp;#8221;) and Nonqualified Stock Options, (b) shares of Restricted Stock, (c) shares of Phantom Stock, (d) Stock Bonuses, and (e) Other Awards.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Stock Option awards grant Participants the right to purchase shares of Common Stock at prices determined by the Committee; however, in the case of an ISO, the option exercise price will not be less than the fair market value of a share of Common Stock on the date the Option is granted.&amp;#160;&amp;#160;Options vest over a period of time determined by the Committee, generally on a pro rata basis over a three to five year period.&amp;#160;&amp;#160;The Committee also determines the expiration date of each Option; however, no ISO is exercisable more than ten years after the date of grant.&amp;#160;&amp;#160;The maximum term of options that have been awarded under the 2000 Incentive Plan is ten years.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Restricted Stock awards grant Participants shares of restricted Common Stock or allow Participants to purchase such shares at a price determined by the Committee.&amp;#160;&amp;#160;Such shares are nontransferable for a period determined by the Committee (&amp;#8220;vesting period&amp;#8221;).&amp;#160;&amp;#160;Should employment terminate, as defined by the 2000 Incentive Plan, the ownership of the Restricted Stock, which has not vested, will be transferred to the Company, except under defined circumstances with Committee approval, in consideration of amounts, if any, paid by the Participant to acquire such shares.&amp;#160;&amp;#160;In addition, if the Company requires a return of the Restricted Shares, it also has the right to require a return of all dividends paid on such shares.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Phantom Stock awards provide the Participant the right to receive, within 30 days of the date on which the share vests, an amount, in cash and/or shares of the Company&amp;#8217;s Common Stock as determined by the Committee, equal to the sum of the fair market value of a share of Common Stock on the date such share of Phantom Stock vests and the aggregate amount of cash dividends paid with respect to a share of Common Stock during the period from the grant date of the share of Phantom Stock to the date on which the share vests.&amp;#160;&amp;#160;Stock Bonus awards are bonuses payable in shares of Common Stock which are granted at the discretion of the Committee.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Other Awards are other forms of awards which are valued based on the Company&amp;#8217;s Common Stock.&amp;#160;&amp;#160;Subject to the provisions of the 2000 Incentive Plan, the terms and provisions of such Other Awards are determined solely on the authority of the Committee.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The 2000 Incentive Plan contains provisions that allow for the Committee to provide for the immediate vesting of awards upon a change in control of the Company, as defined in the plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;As of December 31, 2011, there were 10,244,318 shares available for future grants under the 2000 Incentive Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 4.5pt"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="WIDTH: 18pt"&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;a.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Stock Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Transactions involving stock option awards during 2011 under the 2000 Incentive Plan is summarized in the table below.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="36%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;Stock Options:&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Number of &lt;font style="DISPLAY: inline"&gt;Shares&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Exercise Price&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Weighted-Average Remaining Contractual Term (in &lt;font style="DISPLAY: inline"&gt;years)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Intrinsic Value (in &lt;font style="DISPLAY: inline"&gt;thousands)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="36%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Outstanding at December 31, 2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;23,362,248&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$19.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="36%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;2011:&lt;/font&gt;&amp;#160;&amp;#160;&amp;#160;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;4,286,640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$51.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="36%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(247,898)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$28.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="36%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(551,456)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$13.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="36%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;font style="DISPLAY: inline"&gt;(4,523,173)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$18.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="36%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Outstanding at December 31, 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;22,326,361&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$26.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 18.55pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;6.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$663,376&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="36%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="36%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Vested and expected to vest at December 31, 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;21,755,141&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$26.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 18.55pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;6.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$653,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="36%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="36%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Exercisable at December 31, 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;11,963,345&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$18.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 18.55pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;5.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$451,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;The Company satisfies stock option exercises with newly issued shares of the Company&amp;#8217;s Common Stock.&amp;#160;&amp;#160;The total intrinsic value of stock options exercised during 2011, 2010, and 2009 was $49.2 million, $21.4 million, and $13.2 million,&amp;#160;&amp;#160;&amp;#160;&amp;#160;respectively.&amp;#160;&amp;#160;The intrinsic value represents the amount by which the market price of the underlying stock exceeds the exercise price of an option.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;br /&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company grants stock options with exercise prices that are equal to or greater than the average market price of the Company&amp;#8217;s Common Stock on the date of grant (&amp;#8220;Market Price&amp;#8221;).&amp;#160;&amp;#160;The table below summarizes the weighted-average exercise prices and weighted-average grant-date fair values of options issued during the years ended December 31, 2011, 2010, and 2009.&amp;#160;&amp;#160;The fair value of each option granted under the 2000 Incentive Plan during 2011, 2010, and 2009 was estimated on the date of grant using the Black-Scholes option-pricing model.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="15%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Number of &lt;font style="DISPLAY: inline"&gt;Options Granted&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Weighted-Average Exercise &lt;font style="DISPLAY: inline"&gt;Price&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Weighted-Average Fair &lt;font style="DISPLAY: inline"&gt;Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;2011:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Exercise price equal to Market Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;4,286,640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$51.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$23.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;2010:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Exercise price equal to Market Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;4,319,856&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$29.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$13.36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;2009:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Exercise price equal to Market Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;3,490,560&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$20.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$10.89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;For the years ended December 31, 2011, 2010, and 2009, the Company recognized $39.2 million, $29.4 million, and $27.4 million, respectively, of non-cash stock-based compensation expense related to non-performance based stock option awards.&amp;#160;&amp;#160;As of December 31, 2011, there was $93.6 million of stock-based compensation cost related to outstanding non-performance based stock options, net of estimated forfeitures, which had not yet been recognized.&amp;#160;&amp;#160;The Company expects to recognize this compensation cost over a weighted-average period of 1.9 years.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In addition, there were 2,195,429 performance-based options which were outstanding and unvested as of December 31, 2011 of which, subject to the optionee satisfying certain service conditions, 203,429 options that were issued in 2005 would vest upon achieving certain defined sales targets for the Company&amp;#8217;s products and 1,992,000 options that were issued in 2011, 2010, and 2009 would vest upon achieving certain development milestones for the Company&amp;#8217;s product candidates.&amp;#160;&amp;#160;In light of the Company&amp;#8217;s receipt of marketing approval for EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; for the treatment of wet AMD in November 2011, and the status of the Company&amp;#8217;s development programs at December 31, 2011, the Company estimates that all of the remaining performance-based options issued in 2005, 2009, and 2010 will vest and approximately 50% of the performance-based options issued in 2011 will vest.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;For the years ended December 31, 2011 and 2010, the Company recognized $11.7 million and $8.1 million, respectively, of non-cash stock-based compensation expense related to these performance options.&amp;#160;&amp;#160;As of December 31, 2011 there was $17.4 million of stock-based compensation cost which had not yet been recognized related to the performance&amp;#8211;based options that the Company currently estimates will vest.&amp;#160;&amp;#160;The Company expects to recognize this compensation cost over a weighted-average period of 2.5 years.&amp;#160;&amp;#160;In addition, potential compensation cost of $10.2 million related to the performance options issued in 2011, whose performance conditions (based on current facts and circumstances) are not currently considered by the Company to be probable of attainment, will begin to be recognized only if and when the Company estimates that it is probable that these options will vest.&amp;#160;&amp;#160;The Company&amp;#8217;s estimates of the number of performance-based options that will vest will be revised, if necessary, in subsequent periods.&amp;#160;&amp;#160;Changes in these estimates may materially affect the amount of stock-based compensation recognized in future periods related to performance-based options.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;Fair value Assumptions:&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The following table summarizes the weighted average values of the assumptions used in computing the fair value of option grants during 2011, 2010, and 2009.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;br /&gt;&amp;#160;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="15%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="15%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="15%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;48%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;47%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;54%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Expected lives from grant date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;6.1 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;5.6 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;5.9 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;1.31%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2.11%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2.87%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Expected volatility has been estimated based on actual movements in the Company&amp;#8217;s stock price over the most recent historical periods equivalent to the options&amp;#8217; expected lives.&amp;#160;&amp;#160;Expected lives are principally based on the Company&amp;#8217;s historical exercise experience with previously issued employee and board of directors&amp;#8217; option grants.&amp;#160;&amp;#160;The expected dividend yield is zero as the Company has never paid dividends and does not currently anticipate paying any in the foreseeable future.&amp;#160;&amp;#160;The risk-free interest rates are based on quoted U.S. Treasury rates for securities with maturities approximating the options&amp;#8217; expected lives.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 4.5pt"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="WIDTH: 18pt"&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;b.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Restricted Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;A summary of the Company&amp;#8217;s activity related to Restricted Stock awards for the year ended December 31, 2011 is summarized below:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="41%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;Restricted Stock:&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Number of &lt;font style="DISPLAY: inline"&gt;Shares&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Grant Date Fair &lt;font style="DISPLAY: inline"&gt;Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="41%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Outstanding at December 31, 2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;845,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 29.65pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$25.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="41%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;2011:&lt;/font&gt;&amp;#160;&amp;#160;&amp;#160;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;16,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 29.65pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$58.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="41%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Released&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="middle" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(110,001)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 29.65pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$30.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="41%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Outstanding at December 31, 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;751,499&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 29.65pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$25.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company recognized non-cash stock-based employee compensation expense from Restricted Stock awards of $5.7 million, $2.4 million, and $2.2 million in 2011, 2010, and 2009, respectively.&amp;#160;&amp;#160;As of December 31, 2011, there were 751,499 unvested shares of Restricted Stock outstanding and $9.8 million of stock-based compensation cost related to these unvested shares which had not yet been recognized.&amp;#160;&amp;#160;The Company expects to recognize this compensation cost over a weighted-average period of 1.4 years.&lt;/font&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <!--Deferred Tax Assets-->
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The tax effect of temporary differences, net operating loss carry-forwards, and research and experimental and other tax credit carry-forwards as of December 31, 2011 and 2010 is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="48%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="48%" colspan="2"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="4%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="44%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Net operating loss carry-forward&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$282,480&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$243,893&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="4%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="44%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Fixed assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;14,847&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;13,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="4%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="44%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;120,490&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;70,443&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="4%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="44%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;47,092&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;39,120&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="4%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="44%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Research and experimental and other tax credit carry-forwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;67,734&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;45,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="4%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="44%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Capitalized research and development costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;31,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;38,865&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="4%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="44%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;15,956&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;10,863&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="48%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;579,790&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;462,372&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="48%" colspan="2"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="4%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="44%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Convertible senior notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;(1,428)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="48%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="48%" colspan="2"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Net deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;578,542&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="48%" colspan="2"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;(578,542)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(462,372)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="4%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="44%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;--&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;--&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <!--Commitments Under Capital Leases-->
  <us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The estimated future minimum noncancelable lease commitments under capital leases were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="29%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;December 31,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Equipment&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$1,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;1,254&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;130&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Total minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2,778&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Less: amount representing interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(272)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$2,506&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock>
  <!--Deferred Revenue-->
  <us-gaap:DeferredRevenueByArrangementDisclosureTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Deferred revenue as of December 31, 2011 and 2010 consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="44%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Current portion:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Received from Sanofi (see Note 3a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="9%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$20,011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$19,506&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Received from Bayer HealthCare (see Note 3b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="9%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,907&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;9,884&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Received for technology license agreements (see Note 4)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="9%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;23,572&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;25,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;150&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;325&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$51,640&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$54,723&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Long-term portion:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Received from Sanofi (see Note 3a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="9%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$86,017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$97,081&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Received from Bayer HealthCare (see Note 3b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="9%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;34,456&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;37,067&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Received for technology license agreements (see Note 4)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;128,137&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;151,708&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$248,610&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$285,856&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredRevenueByArrangementDisclosureTextBlock>
  <!--Deferred tax assets, gross + Deferred tax assets, gross-->
  <us-gaap:DeferredTaxAssetsGross contextRef="c00060" unitRef="u000" decimals="-3">462372000</us-gaap:DeferredTaxAssetsGross>
  <!--Deferred tax assets, gross + Deferred tax assets, gross-->
  <us-gaap:DeferredTaxAssetsGross contextRef="c00001" unitRef="u000" decimals="-3">579970000</us-gaap:DeferredTaxAssetsGross>
  <!--Weighted average period for recognition of total unrecognized compensation expense (in years)- Non-Performance Based Stock Options [Member]-->
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition contextRef="c00154" unitRef="u006" decimals="1">1.9</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition>
  <!--Weighted average period for recognition of total unrecognized compensation expense (in years)- Performance-Based Stock Options [Member]-->
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition contextRef="c00155" unitRef="u006" decimals="1">2.5</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition>
  <!--Weighted average period for recognition of total unrecognized compensation expense (in years)- Restricted Stock [Member]-->
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition contextRef="c00156" unitRef="u005" decimals="1">1.4</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition>
  <!--Royalty payment percentage of cumulative sales within cumulative sales range (in hundredths)- License Agreement With Genentech [Member]-->
  <regn:RoyaltyPaymentPercentageOfCumulativeSalesWithinRange contextRef="c00262" unitRef="u004" decimals="4">0.0475</regn:RoyaltyPaymentPercentageOfCumulativeSalesWithinRange>
  <!--Royalty payment percentage of cumulative sales within cumulative sales range (in hundredths)- License Agreement With Genentech [Member]-->
  <regn:RoyaltyPaymentPercentageOfCumulativeSalesWithinRange contextRef="c00161" unitRef="u004" decimals="4">0.0475</regn:RoyaltyPaymentPercentageOfCumulativeSalesWithinRange>
  <!--2015- Cellectis Agreement [Member]-->
  <regn:FutureExpenseOfAdvancePaymentYearFour contextRef="c00150" unitRef="u000" decimals="-5">900000</regn:FutureExpenseOfAdvancePaymentYearFour>
  <!--Unamortized balance of advance payment- Cellectis Agreement [Member] + Unamortized balance of advance payment- Cellectis Agreement [Member]-->
  <regn:UnamortizedBalanceOfAdvancePayment contextRef="c00051" unitRef="u000" decimals="-5">5700000</regn:UnamortizedBalanceOfAdvancePayment>
  <!--Unamortized balance of advance payment- Cellectis Agreement [Member] + Unamortized balance of advance payment- Cellectis Agreement [Member]-->
  <regn:UnamortizedBalanceOfAdvancePayment contextRef="c00104" unitRef="u000" decimals="-5">6600000</regn:UnamortizedBalanceOfAdvancePayment>
  <!--Unrealized Gains - Total- Unrestricted [Member] + Unrealized Gains - Total- Unrestricted [Member]-->
  <us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGain contextRef="c00034" unitRef="u000" decimals="-3">508000</us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGain>
  <!--Unrealized Gains - Total- Unrestricted [Member] + Unrealized Gains - Total- Unrestricted [Member]-->
  <us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGain contextRef="c00090" unitRef="u000" decimals="-3">586000</us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGain>
  <!--Unrealized Gains - Total- Restricted [Member]-->
  <us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGain contextRef="c00036" unitRef="u000" decimals="-3">21000</us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGain>
  <!--Unrealized Gains - Total- Debt Securities [Member] + Unrealized Gains - Total- Debt Securities [Member]-->
  <us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGain contextRef="c00037" unitRef="u000" decimals="-3">529000</us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGain>
  <!--Unrealized Gains - Total- Debt Securities [Member] + Unrealized Gains - Total- Debt Securities [Member]-->
  <us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGain contextRef="c00093" unitRef="u000" decimals="-3">586000</us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGain>
  <!--Unrealized Net - Maturities within one year- Unrestricted [Member]- U S Government Obligations [Member] + Unrealized Net - Maturities within one year- Unrestricted [Member]- U S Government Obligations [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet contextRef="c00029" unitRef="u000" decimals="-3">42000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet>
  <!--Unrealized Net - Maturities within one year- Unrestricted [Member]- U S Government Obligations [Member] + Unrealized Net - Maturities within one year- Unrestricted [Member]- U S Government Obligations [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet contextRef="c00085" unitRef="u000" decimals="-3">49000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet>
  <!--Unrealized Net - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Corporate Bonds [Member] + Unrealized Net - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Corporate Bonds [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet contextRef="c00030" unitRef="u000" decimals="-3">53000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet>
  <!--Unrealized Net - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Corporate Bonds [Member] + Unrealized Net - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Corporate Bonds [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet contextRef="c00086" unitRef="u000" decimals="-3">358000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet>
  <!--Unrealized Net - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Collateralized Mortgage Obligations [Member] + Unrealized Net - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Collateralized Mortgage Obligations [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet contextRef="c00031" unitRef="u000" decimals="-3">-1000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet>
  <!--Unrealized Net - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Collateralized Mortgage Obligations [Member] + Unrealized Net - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Collateralized Mortgage Obligations [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet contextRef="c00087" unitRef="u000" decimals="-3">104000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet>
  <!--Unrealized Net - Maturities within one year- Unrestricted [Member]- Municipal Bonds [Member] + Unrealized Net - Maturities within one year- Unrestricted [Member]- Municipal Bonds [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet contextRef="c00032" unitRef="u000" decimals="-3">12000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet>
  <!--Unrealized Net - Maturities within one year- Unrestricted [Member]- Municipal Bonds [Member] + Unrealized Net - Maturities within one year- Unrestricted [Member]- Municipal Bonds [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet contextRef="c00088" unitRef="u000" decimals="-3">6000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet>
  <!--Unrealized Net - Maturities within one year- Unrestricted [Member] + Unrealized Net - Maturities within one year- Unrestricted [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet contextRef="c00034" unitRef="u000" decimals="-3">106000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet>
  <!--Unrealized Net - Maturities within one year- Unrestricted [Member] + Unrealized Net - Maturities within one year- Unrestricted [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet contextRef="c00090" unitRef="u000" decimals="-3">489000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet>
  <!--Unrealized Net - Maturities within one year- Restricted [Member]- U S Government Obligations [Member] + Unrealized Net - Maturities within one year- Restricted [Member]- U S Government Obligations [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet contextRef="c00035" unitRef="u000" decimals="-3">10000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet>
  <!--Unrealized Net - Maturities within one year- Restricted [Member]- U S Government Obligations [Member] + Unrealized Net - Maturities within one year- Restricted [Member]- U S Government Obligations [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet contextRef="c00091" unitRef="u000" decimals="-3">-1000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet>
  <!--Unrealized Net - Maturities within one year- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet contextRef="c00089" unitRef="u000" decimals="-3">-28000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearUnrealizedGainsLossesNet>
  <!--Accrued capital expenditures + Accrued capital expenditures + Accrued capital expenditures-->
  <regn:AccruedCapitalExpenditures contextRef="c00001" unitRef="u000" decimals="-5">6200000</regn:AccruedCapitalExpenditures>
  <!--Accrued capital expenditures + Accrued capital expenditures + Accrued capital expenditures-->
  <regn:AccruedCapitalExpenditures contextRef="c00060" unitRef="u000" decimals="-5">10700000</regn:AccruedCapitalExpenditures>
  <!--Accrued capital expenditures + Accrued capital expenditures + Accrued capital expenditures-->
  <regn:AccruedCapitalExpenditures contextRef="c00112" unitRef="u000" decimals="-5">9800000</regn:AccruedCapitalExpenditures>
  <!--Weighted average exercise price (in dollars per share)- Stock Options [Member] + Weighted average exercise price (in dollars per share)- Stock Options [Member] + Weighted average exercise price (in dollars per share)- Stock Options [Member]-->
  <regn:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareWeightedAverageExercisePrice contextRef="c00142" unitRef="u002" decimals="2">21.21</regn:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareWeightedAverageExercisePrice>
  <!--Weighted average exercise price (in dollars per share)- Stock Options [Member] + Weighted average exercise price (in dollars per share)- Stock Options [Member] + Weighted average exercise price (in dollars per share)- Stock Options [Member]-->
  <regn:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareWeightedAverageExercisePrice contextRef="c00178" unitRef="u002" decimals="2">18.80</regn:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareWeightedAverageExercisePrice>
  <!--Weighted average exercise price (in dollars per share)- Stock Options [Member] + Weighted average exercise price (in dollars per share)- Stock Options [Member] + Weighted average exercise price (in dollars per share)- Stock Options [Member]-->
  <regn:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareWeightedAverageExercisePrice contextRef="c00209" unitRef="u002" decimals="2">17.66</regn:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareWeightedAverageExercisePrice>
  <!--Employer contribution expense to 401(k) Savings Plan + Employer contribution expense to 401(k) Savings Plan + Employer contribution expense to 401(k) Savings Plan-->
  <us-gaap:DefinedContributionPlanCostRecognized contextRef="c00124" unitRef="u000" decimals="-5">4100000</us-gaap:DefinedContributionPlanCostRecognized>
  <!--Employer contribution expense to 401(k) Savings Plan + Employer contribution expense to 401(k) Savings Plan + Employer contribution expense to 401(k) Savings Plan-->
  <us-gaap:DefinedContributionPlanCostRecognized contextRef="c00164" unitRef="u000" decimals="-5">3200000</us-gaap:DefinedContributionPlanCostRecognized>
  <!--Employer contribution expense to 401(k) Savings Plan + Employer contribution expense to 401(k) Savings Plan + Employer contribution expense to 401(k) Savings Plan-->
  <us-gaap:DefinedContributionPlanCostRecognized contextRef="c00195" unitRef="u000" decimals="-5">2600000</us-gaap:DefinedContributionPlanCostRecognized>
  <!--Net product sales, excluding deferred sales recognized as revenue- Arcalyst Net Product Sales Member- Product Concentration Risk [Member]-->
  <regn:SalesRevenueProductLineExcludingDeferredSalesRecognized contextRef="c00177" unitRef="u000" decimals="-5">20500000</regn:SalesRevenueProductLineExcludingDeferredSalesRecognized>
  <!--Inventories included in prepaid expenses and other current assets-->
  <us-gaap:InventoryGross contextRef="c00001" unitRef="u000" decimals="-5">3500000</us-gaap:InventoryGross>
  <!--Future payment to be made to the Company under the terms of the amended licensing agreement- License Agreement with Astellas Pharma Inc [Member]-->
  <regn:FuturePaymentToBeMadeUnderTermsOfAmendedLicensingAgreement contextRef="c00071" unitRef="u000" decimals="-5">130000000</regn:FuturePaymentToBeMadeUnderTermsOfAmendedLicensingAgreement>
  <!--Period of funding (in years)- Grant from National Institutes of Health [Member]-->
  <regn:PeriodOfFunding contextRef="c00246">5Y</regn:PeriodOfFunding>
  <!--Minimum payments expected to be received under the agreement- Collaboration Agreement with Sanofi [Member]- VelociGene Agreement [Member]-->
  <regn:MinimumPaymentsExpectedToBeReceivedUnderAgreement contextRef="c00012" unitRef="u000" decimals="-5">21500000</regn:MinimumPaymentsExpectedToBeReceivedUnderAgreement>
  <!--Ending share of profits outside the United States, based on sales, for collaborating party (in hundredths)- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty contextRef="c00135" unitRef="u004" decimals="2">0.55</regn:EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty>
  <!--Collaboration development revenue- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member] + Collaboration development revenue- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member] + Collaboration development revenue- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member]-->
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="c00134" unitRef="u000" decimals="-5">17500000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <!--Collaboration development revenue- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member] + Collaboration development revenue- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member] + Collaboration development revenue- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member]-->
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="c00171" unitRef="u000" decimals="-5">26400000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <!--Collaboration development revenue- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member] + Collaboration development revenue- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member] + Collaboration development revenue- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member]-->
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="c00202" unitRef="u000" decimals="-5">36500000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <!--Collaboration development revenue- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member] + Collaboration development revenue- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member] + Collaboration development revenue- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="c00135" unitRef="u000" decimals="-5">309100000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <!--Collaboration development revenue- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member] + Collaboration development revenue- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member] + Collaboration development revenue- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="c00172" unitRef="u000" decimals="-5">284900000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <!--Collaboration development revenue- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member] + Collaboration development revenue- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member] + Collaboration development revenue- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="c00203" unitRef="u000" decimals="-5">210700000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <!--Collaboration development revenue- Collaboration Agreement with Bayer HealthCare LLC [Member] + Collaboration development revenue- Collaboration Agreement with Bayer HealthCare LLC [Member] + Collaboration development revenue- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="c00136" unitRef="u000" decimals="-5">43100000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <!--Collaboration development revenue- Collaboration Agreement with Bayer HealthCare LLC [Member] + Collaboration development revenue- Collaboration Agreement with Bayer HealthCare LLC [Member] + Collaboration development revenue- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="c00204" unitRef="u000" decimals="-5">67300000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <!--Collaboration development revenue- Collaboration Agreement with Bayer HealthCare LLC [Member] + Collaboration development revenue- Collaboration Agreement with Bayer HealthCare LLC [Member] + Collaboration development revenue- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="c00173" unitRef="u000" decimals="-5">75400000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <!--Other non-cash charges and expenses, net-->
  <us-gaap:OtherNoncashIncomeExpense contextRef="c00124" unitRef="u000" decimals="-3">-10366000</us-gaap:OtherNoncashIncomeExpense>
  <!--Other non-cash charges and expenses, net-->
  <us-gaap:OtherNoncashIncomeExpense contextRef="c00164" unitRef="u000" decimals="-3">-3171000</us-gaap:OtherNoncashIncomeExpense>
  <!--Other non-cash charges and expenses, net-->
  <us-gaap:OtherNoncashIncomeExpense contextRef="c00195" unitRef="u000" decimals="-3">-2238000</us-gaap:OtherNoncashIncomeExpense>
  <!--Non-cash compensation expense-->
  <us-gaap:ShareBasedCompensation contextRef="c00124" unitRef="u000" decimals="-3">56094000</us-gaap:ShareBasedCompensation>
  <!--Non-cash compensation expense-->
  <us-gaap:ShareBasedCompensation contextRef="c00164" unitRef="u000" decimals="-3">39897000</us-gaap:ShareBasedCompensation>
  <!--Non-cash compensation expense-->
  <us-gaap:ShareBasedCompensation contextRef="c00195" unitRef="u000" decimals="-3">31259000</us-gaap:ShareBasedCompensation>
  <!--Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Shares- Common Stock [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Shares- Common Stock [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Shares- Common Stock [Member]-->
  <regn:StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesTendered contextRef="c00196" unitRef="u001" decimals="-3">1134000</regn:StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesTendered>
  <!--Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Shares- Common Stock [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Shares- Common Stock [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Shares- Common Stock [Member]-->
  <regn:StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesTendered contextRef="c00165" unitRef="u001" decimals="-3">1533000</regn:StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesTendered>
  <!--Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Shares- Common Stock [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Shares- Common Stock [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Shares- Common Stock [Member]-->
  <regn:StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesTendered contextRef="c00125" unitRef="u001" decimals="-3">3324000</regn:StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesTendered>
  <!--Other collaboration revenue-->
  <regn:OtherCollaborationRevenue contextRef="c00124" unitRef="u000" decimals="-3">43072000</regn:OtherCollaborationRevenue>
  <!--Other collaboration revenue-->
  <regn:OtherCollaborationRevenue contextRef="c00164" unitRef="u000" decimals="-3">75393000</regn:OtherCollaborationRevenue>
  <!--Other collaboration revenue-->
  <regn:OtherCollaborationRevenue contextRef="c00195" unitRef="u000" decimals="-3">67317000</regn:OtherCollaborationRevenue>
  <!--Sanofi collaboration revenue-->
  <us-gaap:RelatedPartyTransactionRevenuesFromTransactionsWithRelatedParty contextRef="c00124" unitRef="u000" decimals="-3">326609000</us-gaap:RelatedPartyTransactionRevenuesFromTransactionsWithRelatedParty>
  <!--Sanofi collaboration revenue-->
  <us-gaap:RelatedPartyTransactionRevenuesFromTransactionsWithRelatedParty contextRef="c00164" unitRef="u000" decimals="-3">311332000</us-gaap:RelatedPartyTransactionRevenuesFromTransactionsWithRelatedParty>
  <!--Sanofi collaboration revenue-->
  <us-gaap:RelatedPartyTransactionRevenuesFromTransactionsWithRelatedParty contextRef="c00195" unitRef="u000" decimals="-3">247140000</us-gaap:RelatedPartyTransactionRevenuesFromTransactionsWithRelatedParty>
  <!--Document Period End Date-->
  <dei:DocumentPeriodEndDate contextRef="c00124">2011-12-31</dei:DocumentPeriodEndDate>
  <!--Entity Common Stock, Shares Outstanding-->
  <dei:EntityCommonStockSharesOutstanding contextRef="c00228" unitRef="u001" decimals="0">91779465</dei:EntityCommonStockSharesOutstanding>
  <!--Entity Class A Stock, Shares Outstanding- Class A Stock [Member]-->
  <dei:EntityCommonStockSharesOutstanding contextRef="c00229" unitRef="u001" decimals="0">2109512</dei:EntityCommonStockSharesOutstanding>
  <!--Entity Public Float-->
  <dei:EntityPublicFloat contextRef="c00000" unitRef="u000" decimals="0">4913223000</dei:EntityPublicFloat>
  <!--Restricted cash and marketable securities-->
  <us-gaap:RestrictedCashAndInvestmentsNoncurrent contextRef="c00001" unitRef="u000" decimals="-3">7721000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
  <!--Restricted cash and marketable securities-->
  <us-gaap:RestrictedCashAndInvestmentsNoncurrent contextRef="c00060" unitRef="u000" decimals="-3">7518000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
  <!--Accrued contribution expense to 401(k) Savings Plan + Accrued contribution expense to 401(k) Savings Plan-->
  <us-gaap:OtherPostretirementBenefitsPayableCurrentAndNoncurrent contextRef="c00001" unitRef="u000" decimals="-5">3600000</us-gaap:OtherPostretirementBenefitsPayableCurrentAndNoncurrent>
  <!--Accrued contribution expense to 401(k) Savings Plan + Accrued contribution expense to 401(k) Savings Plan-->
  <us-gaap:OtherPostretirementBenefitsPayableCurrentAndNoncurrent contextRef="c00060" unitRef="u000" decimals="-5">2900000</us-gaap:OtherPostretirementBenefitsPayableCurrentAndNoncurrent>
  <!--Income Taxes-->
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c00124">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;17.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;For the year ended December 31, 2011, the Company incurred a net loss for tax purposes and recognized a full valuation allowance against deferred taxes.&amp;#160;&amp;#160;In 2011, the Company recognized a $1.1 million income tax benefit, consisting of (i) $0.7 million related to tax legislation that allowed the Company to claim a refund for a portion of its unused pre-2006 research tax credits and (ii) $0.4 million in connection with the net tax effect of the change in the Company&amp;#8217;s unrealized gain (loss) on &amp;#8220;available for sale&amp;#8221; marketable securities, which is included in other comprehensive income (loss).&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;For the year ended December 31, 2010, the Company incurred a net loss for tax purposes and recognized a full valuation allowance against deferred taxes.&amp;#160;&amp;#160;No provision or benefit for income taxes was recognized by the Company in 2010.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;For the year ended December 31, 2009, the Company incurred a net loss for tax purposes and recognized a full valuation allowance against deferred taxes.&amp;#160;&amp;#160;In 2009, the Company recognized a $4.1 million income tax benefit, consisting of (i) $2.7 million resulting from tax legislation that allowed the Company to claim a refund of U.S. federal alternative minimum tax (&amp;#8220;AMT&amp;#8221;) that the Company paid in connection with its 2007 U.S. federal income tax return, (ii) $0.7 million resulting from tax legislation that allowed the Company to claim a refund for a portion of its unused pre-2006 research tax credits on its 2009 U.S. federal income tax return, and (iii) $0.7 million in connection with the net tax effect of the Company&amp;#8217;s unrealized gain on &amp;#8220;available-for-sale&amp;#8221; marketable securities, which is included in other comprehensive income in 2009.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The tax effect of temporary differences, net operating loss carry-forwards, and research and experimental and other tax credit carry-forwards as of December 31, 2011 and 2010 is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="48%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="48%" colspan="2"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="4%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="44%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Net operating loss carry-forward&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$282,480&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$243,893&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="4%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="44%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Fixed assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;14,847&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;13,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="4%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="44%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;120,490&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;70,443&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="4%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="44%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;47,092&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;39,120&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="4%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="44%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Research and experimental and other tax credit carry-forwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;67,734&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;45,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="4%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="44%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Capitalized research and development costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;31,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;38,865&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="4%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="44%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;15,956&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;10,863&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="48%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;579,790&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;462,372&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="48%" colspan="2"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="4%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="44%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Convertible senior notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;(1,428)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="48%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="48%" colspan="2"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Net deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;578,542&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="48%" colspan="2"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;(578,542)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(462,372)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="4%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="44%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;--&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;--&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company&amp;#8217;s valuation allowance increased by $116.2 million in 2011, due primarily to increases in the Company&amp;#8217;s net operating loss carry-forward and tax credit carry-forwards and the full recognition of the $165.0 million up-front payment received from Astellas in 2010 as taxable income in 2011.&amp;#160;&amp;#160;The Company&amp;#8217;s valuation allowance increased by $63.0 million in 2010, due primarily to increases in the net operating loss carry-forward and tax credit carry-forwards.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company is primarily subject to U.S. federal and New York State income taxes. The difference between the Company&amp;#8217;s effective income tax rate and the U.S federal statutory rate of 35% is primarily attributable to an increase in the deferred tax valuation allowance.&amp;#160;&amp;#160;In 2011 and early 2012, U.S. federal tax authorities concluded examinations of the Company&amp;#8217;s 2007, 2008, and 2009 federal income tax returns.&amp;#160;&amp;#160;The Company&amp;#8217;s 2010 federal income tax return is currently being examined by the U.S. federal tax authorities.&amp;#160;&amp;#160;In addition, tax years subsequent to 2007 remain open to examination by New York State tax authorities.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;As of December 31, 2011 and 2010, the Company had no accruals for interest or penalties related to income tax matters.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;As of December 31, 2011, the Company had available for tax purposes unused net operating loss carry-forwards of $800.2 million which will expire in various years from 2018 to 2031 and included $96.2 million of net operating loss carry-forwards related to exercises of Nonqualified Stock Options and disqualifying dispositions of Incentive Stock Options, the tax benefit from which, if realized, will be credited to additional paid-in capital. The Company's research and experimental and other tax credit carry-forwards expire in various years from 2012 to 2031.&amp;#160;&amp;#160;Under the Internal Revenue Code and similar state provisions, substantial changes in the Company&amp;#8217;s ownership have resulted in an annual limitation on the amount of net operating loss and tax credit carry-forwards that can be utilized in future years to offset future taxable income.&amp;#160;&amp;#160;This annual limitation may result in the expiration of net operating losses and tax credit carry-forwards before utilization.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The following table summarizes the gross amounts of unrecognized tax benefits at the beginning and end of 2011 and 2010:&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="38%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="3%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="11%"&gt;&lt;div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="38%" align="left"&gt;&lt;div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Balance as of January 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="3%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$12,819&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="38%" align="left"&gt;&lt;div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Gross increases related to current year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="3%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2,192&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;3,550&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="38%" align="left"&gt;&lt;div style="TEXT-INDENT: -27pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Gross increases related to prior year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="3%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;9,269&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="38%" align="left"&gt;&lt;div style="TEXT-INDENT: -27pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Gross decreases due to settlements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="3%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(9,415)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;_____&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="38%" align="left"&gt;&lt;div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Balance as of December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="3%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$5,596&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$12,819&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In 2011, the gross decrease in unrecognized tax benefits related to prior year tax positions was primarily due to the conclusion of examinations of the Company&amp;#8217;s 2007, 2008, and 2009 federal income tax returns by U.S. federal tax authorities.&amp;#160;&amp;#160;In 2010, the gross increases in unrecognized tax benefits related to prior year tax positions was primarily due to the Company&amp;#8217;s calculations of certain pre-2010 tax credits.&amp;#160;&amp;#160;Due to the amounts of the Company&amp;#8217;s net operating loss carry-forward and tax credit carry-forwards, the Company has not accrued interest or penalties related to these unrecognized tax benefits.&amp;#160;&amp;#160;In addition, unrecognized tax benefits at December 31, 2011 and 2010, if recognized, would not affect the Company&amp;#8217;s effective tax rate since the adjustments to deferred tax assets would be fully offset by adjustments to the Company&amp;#8217;s valuation allowance.&amp;#160;&amp;#160;For the year ended December 31, 2009, income tax positions that were deemed uncertain under the recognition thresholds and measurement attributes prescribed in FASB authoritative guidance were not material.&lt;/font&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <!--Research and Development Expenses-->
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c00124">&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, materials, supplies, depreciation on and maintenance of research equipment, costs related to research collaboration and licensing agreements, the cost of services provided by outside contractors, including services related to the Company's clinical trials, clinical trial expenses, the full cost of manufacturing drug for use in research, preclinical development, and clinical trials, amounts that the Company is obligated to reimburse to collaborators for research and development expenses that they incur, and the allocable portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, and general support services.&amp;#160;&amp;#160;All costs associated with research and development are expensed.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors.&amp;#160;&amp;#160;The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as contract research organizations ("CROs"), independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies.&amp;#160;&amp;#160;For each clinical trial that the Company conducts, certain clinical trial costs are expensed immediately, while others are expensed over time based on the expected total number of patients in the trial, the rate at which patients enter the trial, and/or the period over which clinical investigators or CROs are expected to provide services.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Clinical activities which relate principally to clinical sites and other administrative functions to manage the Company's clinical trials are performed primarily by CROs.&amp;#160;&amp;#160;CROs typically perform most of the start-up activities for the Company's trials, including document preparation, site identification, screening and preparation, pre-study visits, training, and program management.&amp;#160;&amp;#160;On a budgeted basis, these start-up costs are typically&amp;#160;10% to&amp;#160;20% of the total contract value.&amp;#160;&amp;#160;On an actual basis, this percentage range can be significantly wider, as many of the Company's contracts with CROs are either expanded or reduced in scope compared to the original budget, while start-up costs for the particular trial may not change materially.&amp;#160;&amp;#160;These start-up costs usually occur within a few months after the contract has been executed and are event driven in nature. The remaining activities and related costs, such as patient monitoring and administration, generally occur ratably throughout the life of the individual contract or study. In the event of early termination of a clinical trial, the Company accrues and recognizes expenses in an amount based on its estimate of the remaining non-cancelable obligations associated with the winding down of the clinical trial and/or penalties.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;For clinical study sites, where payments are made periodically on a per-patient basis to the institutions performing the clinical study, the Company accrues expense on an estimated cost-per-patient basis, based on subject enrollment and activity in each quarter.&amp;#160;&amp;#160;The amount of clinical study expense recognized in a quarter may vary from period to period based on the duration and progress of the study, the activities to be performed by the sites each quarter, the required level of patient enrollment, the rate at which patients actually enroll in and drop-out of the clinical study, and the number of sites involved in the study.&amp;#160;&amp;#160;Clinical trials that bear the greatest risk of change in estimates are typically those that have a significant number of sites, require a large number of patients, have complex patient screening requirements, and span multiple years.&amp;#160;&amp;#160;During the course of a trial, the Company adjusts its rate of clinical expense recognition if actual results differ from the Company's estimates.&amp;#160;&amp;#160;The Company's estimates and assumptions for clinical expense recognition could differ significantly from its actual results, which could cause material increases or decreases in research and development expenses in future periods when the actual results become known&lt;/font&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <!--Fair Value and Unrealized Losses of Marketable Securities-->
  <us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The following table shows the fair value of the Company's marketable securities that have unrealized losses and that are deemed to be only temporarily impaired, aggregated by investment category and length of time that the individual securities have been in a continuous unrealized loss position, at December 31, 2011 and 2010.&amp;#160;&amp;#160;The debt securities listed at December 31, 2011, excluding mortgage-backed securities, mature at various dates through December 2014.&amp;#160;&amp;#160;The mortgage-backed securities listed at December 31, 2011 mature at various dates through April 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="19%" colspan="2"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Less than 12 Months&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="19%" colspan="2"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;12 Months or Greater&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="20%" colspan="2"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Total&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="26%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;At December 31, 2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Fair Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Unrealized &lt;font style="DISPLAY: inline"&gt;Loss&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Fair Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Unrealized &lt;font style="DISPLAY: inline"&gt;Loss&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Fair Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Unrealized &lt;font style="DISPLAY: inline"&gt;Loss&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Unrestricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$103,529&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$(81)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$103,529&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$(81)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%" align="left"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government guaranteed&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;collateralized mortgage&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Municipal bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;4,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;4,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Equity security&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;3,019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1,025)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;3,019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1,025)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;_____&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;____&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$116&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$(152)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;116&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(152)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$111,774&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$(1,108)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$116&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$(152)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$111,890&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$(1,260)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;At December 31, 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Unrestricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$340,444&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$(1,731)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$340,444&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$(1,731)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government guaranteed&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;19,005&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(45)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;19,005&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(45)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Equity security&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;3,612&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(433)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;3,612&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(433)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;_____&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;____&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$1,128&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$(141)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;1,128&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(141)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;363,061&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(2,209)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;1,128&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(141)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;364,189&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(2,350)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Restricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;6,154&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(18)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;____&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;____&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;6,154&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(18)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;6,154&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(18)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;____&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;____&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;6,154&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(18)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$369,215&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$(2,227)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$1,128&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$(141)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$370,343&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$(2,368)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
  <!--Advance payment received due to amended licensing agreement-->
  <regn:AdvancePaymentReceivedDueToAmendedLicensingAgreement contextRef="c00251" unitRef="u000" decimals="-5">165000000</regn:AdvancePaymentReceivedDueToAmendedLicensingAgreement>
  <!--Expired (in shares)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c00152" unitRef="u001" decimals="0">551456</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
  <!--Maximum percentage of outstanding shares that may be acquired, under 'standstill' provisions (in hundredths)- Sanofi [Member] + Maximum percentage of outstanding shares that may be acquired, under 'standstill' provisions (in hundredths)- Sanofi [Member]-->
  <regn:MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions contextRef="c00239" unitRef="u004" decimals="2">0.25</regn:MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions>
  <!--Maximum percentage of outstanding shares that may be acquired, under 'standstill' provisions (in hundredths)- Sanofi [Member] + Maximum percentage of outstanding shares that may be acquired, under 'standstill' provisions (in hundredths)- Sanofi [Member]-->
  <regn:MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions contextRef="c00052" unitRef="u004" decimals="2">0.30</regn:MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions>
  <!--2012- Equipment [Member]-->
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent contextRef="c00020" unitRef="u000" decimals="-3">1394000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent>
  <!--Carrying amount of Equity Component- Convertible Debt [Member]-->
  <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent contextRef="c00261" unitRef="u000" decimals="-5">120900000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
  <!--Total shares upon conversion (in shares)- Convertible Debt [Member]-->
  <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments contextRef="c00258" unitRef="u006" decimals="0">4760840</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
  <!--Interest rate, stated percentage (in hundredths)- Convertible Debt [Member]-->
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c00261" unitRef="u004" decimals="5">0.01875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <!--Municipal bonds- Unrestricted [Member] + Municipal bonds- Unrestricted [Member]-->
  <regn:MunicipalBondsFairValueDisclosure contextRef="c00034" unitRef="u000" decimals="-3">15326000</regn:MunicipalBondsFairValueDisclosure>
  <!--Municipal bonds- Unrestricted [Member] + Municipal bonds- Unrestricted [Member]-->
  <regn:MunicipalBondsFairValueDisclosure contextRef="c00090" unitRef="u000" decimals="-3">1603000</regn:MunicipalBondsFairValueDisclosure>
  <!--Municipal bonds- Unrestricted [Member]- Fair Value, Inputs, Level 2 [Member] + Municipal bonds- Unrestricted [Member]- Fair Value, Inputs, Level 2 [Member]-->
  <regn:MunicipalBondsFairValueDisclosure contextRef="c00041" unitRef="u000" decimals="-3">15326000</regn:MunicipalBondsFairValueDisclosure>
  <!--Municipal bonds- Unrestricted [Member]- Fair Value, Inputs, Level 2 [Member] + Municipal bonds- Unrestricted [Member]- Fair Value, Inputs, Level 2 [Member]-->
  <regn:MunicipalBondsFairValueDisclosure contextRef="c00096" unitRef="u000" decimals="-3">1603000</regn:MunicipalBondsFairValueDisclosure>
  <!--Capitalized and deferred interest-->
  <us-gaap:InterestCostsCapitalized contextRef="c00164" unitRef="u000" decimals="-5">3700000</us-gaap:InterestCostsCapitalized>
  <!--Accrued property, plant, and equipment costs + Accrued property, plant, and equipment costs-->
  <regn:AccruedPropertyPlantAndEquipmentExpendituresCurrent contextRef="c00001" unitRef="u000" decimals="-3">1070000</regn:AccruedPropertyPlantAndEquipmentExpendituresCurrent>
  <!--Accrued property, plant, and equipment costs + Accrued property, plant, and equipment costs-->
  <regn:AccruedPropertyPlantAndEquipmentExpendituresCurrent contextRef="c00060" unitRef="u000" decimals="-3">7622000</regn:AccruedPropertyPlantAndEquipmentExpendituresCurrent>
  <!--Inventories included in other assets-->
  <us-gaap:InventoryNoncurrent contextRef="c00001" unitRef="u000" decimals="-5">10100000</us-gaap:InventoryNoncurrent>
  <!--Total inventories + Total inventories-->
  <regn:InventoryCurrentAndNoncurrent contextRef="c00001" unitRef="u000" decimals="-3">13556000</regn:InventoryCurrentAndNoncurrent>
  <!--Total inventories + Total inventories-->
  <regn:InventoryCurrentAndNoncurrent contextRef="c00060" unitRef="u000" decimals="-3">1423000</regn:InventoryCurrentAndNoncurrent>
  <!--Period over which annual payment is recognized as revenue (in months)- License Agreement with AstraZeneca UK Limited [Member] + Period over which annual payment is recognized as revenue (in months)- License Agreement with AstraZeneca UK Limited [Member] + Period over which annual payment is recognized as revenue (in months)- License Agreement with AstraZeneca UK Limited [Member] + Period over which annual payment is recognized as revenue (in months)- License Agreement with AstraZeneca UK Limited [Member]-->
  <regn:PeriodOverWhichAnnualPaymentIsRecognizedAsRevenue contextRef="c00176">12M</regn:PeriodOverWhichAnnualPaymentIsRecognizedAsRevenue>
  <!--Period over which annual payment is recognized as revenue (in months)- License Agreement with AstraZeneca UK Limited [Member] + Period over which annual payment is recognized as revenue (in months)- License Agreement with AstraZeneca UK Limited [Member] + Period over which annual payment is recognized as revenue (in months)- License Agreement with AstraZeneca UK Limited [Member] + Period over which annual payment is recognized as revenue (in months)- License Agreement with AstraZeneca UK Limited [Member]-->
  <regn:PeriodOverWhichAnnualPaymentIsRecognizedAsRevenue contextRef="c00207">12M</regn:PeriodOverWhichAnnualPaymentIsRecognizedAsRevenue>
  <!--Period over which annual payment is recognized as revenue (in months)- License Agreement with AstraZeneca UK Limited [Member] + Period over which annual payment is recognized as revenue (in months)- License Agreement with AstraZeneca UK Limited [Member] + Period over which annual payment is recognized as revenue (in months)- License Agreement with AstraZeneca UK Limited [Member] + Period over which annual payment is recognized as revenue (in months)- License Agreement with AstraZeneca UK Limited [Member]-->
  <regn:PeriodOverWhichAnnualPaymentIsRecognizedAsRevenue contextRef="c00194">12M</regn:PeriodOverWhichAnnualPaymentIsRecognizedAsRevenue>
  <!--Period over which annual payment is recognized as revenue (in months)- License Agreement with AstraZeneca UK Limited [Member] + Period over which annual payment is recognized as revenue (in months)- License Agreement with AstraZeneca UK Limited [Member] + Period over which annual payment is recognized as revenue (in months)- License Agreement with AstraZeneca UK Limited [Member] + Period over which annual payment is recognized as revenue (in months)- License Agreement with AstraZeneca UK Limited [Member]-->
  <regn:PeriodOverWhichAnnualPaymentIsRecognizedAsRevenue contextRef="c00249">12M</regn:PeriodOverWhichAnnualPaymentIsRecognizedAsRevenue>
  <!--Annual funding maximum of research activities through 2017 per amended agreement- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:AnnualFundingMaximumOfResearchActivitiesPerAmendedAgreement contextRef="c00238" unitRef="u000" decimals="-6">160000000</regn:AnnualFundingMaximumOfResearchActivitiesPerAmendedAgreement>
  <!--Cash and cash equivalents at beginning of period + Cash and cash equivalents at end of period-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c00060" unitRef="u000" decimals="-3">112572000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and cash equivalents at beginning of period + Cash and cash equivalents at end of period-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c00112" unitRef="u000" decimals="-3">207075000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and cash equivalents at beginning of period + Cash and cash equivalents at end of period-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c00227" unitRef="u000" decimals="-3">247796000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and cash equivalents at beginning of period + Cash and cash equivalents at end of period-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c00001" unitRef="u000" decimals="-3">483610000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Increase in accounts receivable-->
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c00124" unitRef="u000" decimals="-3">21118000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <!--Increase in accounts receivable-->
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c00164" unitRef="u000" decimals="-3">17518000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <!--Increase in accounts receivable-->
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c00195" unitRef="u000" decimals="-3">30494000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <!--Change in net unrealized gain (loss) on marketable securities, net of tax effect + Change in net unrealized gain (loss) on marketable securities, net of tax effect-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax contextRef="c00195" unitRef="u000" decimals="-5">700000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
  <!--Change in net unrealized gain (loss) on marketable securities, net of tax effect + Change in net unrealized gain (loss) on marketable securities, net of tax effect-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax contextRef="c00124" unitRef="u000" decimals="-5">400000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
  <!--Purchase of convertible note hedges - Total Stockholders' Equity-->
  <regn:AdjustmentToAdditionalPaidInCapitalCostOfConvertibleNoteHedge contextRef="c00124" unitRef="u000" decimals="-3">117500000</regn:AdjustmentToAdditionalPaidInCapitalCostOfConvertibleNoteHedge>
  <!--Purchase of convertible note hedges - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <regn:AdjustmentToAdditionalPaidInCapitalCostOfConvertibleNoteHedge contextRef="c00126" unitRef="u000" decimals="-3">117500000</regn:AdjustmentToAdditionalPaidInCapitalCostOfConvertibleNoteHedge>
  <!--Restricted Common Stock tendered upon vesting in connection with employee tax obligations - Total Stockholders' Equity-->
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c00124" unitRef="u000" decimals="-3">2638000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
  <!--Restricted Common Stock tendered upon vesting in connection with employee tax obligations - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c00126" unitRef="u000" decimals="-3">2638000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
  <!--Accumulated deficit-->
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c00001" unitRef="u000" decimals="-3">-1267323000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Accumulated deficit-->
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c00060" unitRef="u000" decimals="-3">-1045563000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Commitments and contingencies-->
  <us-gaap:CommitmentsAndContingencies contextRef="c00001" unitRef="u000" xsi:nil="true"/>
  <!--Commitments and contingencies-->
  <us-gaap:CommitmentsAndContingencies contextRef="c00060" unitRef="u000" xsi:nil="true"/>
  <!--Other long term liabilities-->
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="c00001" unitRef="u000" decimals="-3">6443000</us-gaap:OtherLiabilitiesNoncurrent>
  <!--Other long term liabilities-->
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="c00060" unitRef="u000" decimals="-3">7350000</us-gaap:OtherLiabilitiesNoncurrent>
  <!--Total current liabilities-->
  <us-gaap:LiabilitiesCurrent contextRef="c00001" unitRef="u000" decimals="-3">148271000</us-gaap:LiabilitiesCurrent>
  <!--Total current liabilities-->
  <us-gaap:LiabilitiesCurrent contextRef="c00060" unitRef="u000" decimals="-3">109056000</us-gaap:LiabilitiesCurrent>
  <!--Statement of Cash Flows-->
  <us-gaap:CashFlowSupplementalDisclosuresTextBlock contextRef="c00124">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;20.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Statement of Cash Flows&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Supplemental disclosure of noncash investing and financing activities:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Included in accounts payable and accrued expenses at December 31, 2011, 2010, and 2009 were $6.2 million, $10.7 million, and $9.8 million of accrued capital expenditures, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Pursuant to the application of FASB authoritative guidance to the Company&amp;#8217;s lease of office and laboratory facilities in Tarrytown, New York (see Note 12a), the Company recognized a facility lease obligation of $0.2 million and $31.7 million during 2010 and 2009, respectively, in connection with capitalizing, on the Company&amp;#8217;s books, the landlord&amp;#8217;s costs of constructing new facilities that the Company has leased.&amp;#160;&amp;#160;The Company did not recognize any such facility lease obligations during 2011.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Included in facility lease obligations and property, plant, and equipment at December 31, 2010 was $3.7 million of capitalized and deferred interest for the year ended December 31, 2010, as the related facilities being leased by the Company were under construction and lease payments on these facilities did not commence until January 2011.&amp;#160;&amp;#160;For the years ended December 31, 2011 and 2009, the Company did not capitalize any interest.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company incurred capital lease obligations of $0.7 and $2.9 million during 2011 and 2010 in connection with acquisitions of new equipment.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Included in marketable securities at December 31, 2011, 2010, and 2009 were $0.7 million, $1.4 million, and $0.6 million of accrued interest income, respectively.&lt;/font&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
  <!--Legal Matters-->
  <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="c00124">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;18.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Legal Matters&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;From time to time, the Company is a party to legal proceedings in the course of the Company&amp;#8217;s business.&amp;#160;&amp;#160;The Company does not expect any such current ordinary course legal proceedings to have a material adverse effect on the Company&amp;#8217;s business or financial condition.&amp;#160;&amp;#160;Costs associated with the Company&amp;#8217;s involvement in legal proceedings are expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Genentech Patent Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;The Company is aware of issued patents and pending patent applications owned by Genentech that claim certain chimeric VEGF receptors.&amp;#160;&amp;#160;The Company does not believe that ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt;&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt; or EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt;&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt; infringe any valid claim in these patents or patent applications.&amp;#160;&amp;#160;The Company is involved in five patent litigations with Genentech, two in the United States and three in Europe.&amp;#160;&amp;#160;In November 2010, the Company commenced a lawsuit against Genentech in the U.S. District Court for the Southern District of New York (the &amp;#8220;Court&amp;#8221;), seeking a declaratory judgment that no activities relating to the Company&amp;#8217;s VEGF Trap infringe any valid claim of certain Genentech patents referred to as the Davis-Smyth patents (the &amp;#8220;First Davis-Smyth Case&amp;#8221;).&amp;#160;&amp;#160;&amp;#160;Genentech answered the complaint and asserted counterclaims that the Company&amp;#8217;s prior or planned activities relating to VEGF Trap have infringed or will infringe claims of four of the five Davis-Smyth patents and requested a judgment against the Company for damages, including for willful infringement, and other relief as the Court deems appropriate.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On December 31, 2011, the Company entered into a Non-Exclusive License and Partial Settlement Agreement with Genentech that covers making, using, and selling EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; in the United States for the prevention and treatment of human eye diseases and disorders in the United States.&amp;#160;&amp;#160;Under the Genentech Agreement, the Company received a non-exclusive license to the Davis-Smyth patents, and certain other technology patents owned or co-owned by Genentech.&amp;#160;&amp;#160;The Genentech Agreement does not cover any non-U.S. patent rights or non-U.S. patent disputes, and does not cover any use of aflibercept other than for prevention and treatment of human eye diseases and disorders in the United States.&amp;#160;&amp;#160;The First Davis-Smyth Case is continuing with respect to matters not covered by the Genentech Agreement.&amp;#160;&amp;#160;The Genentech Agreement provides for the Company to make payments to Genentech based on U.S. sales of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; through May 7, 2016, the date the Davis-Smyth patents expire.&amp;#160;&amp;#160;The Company will make a lump-sum payment of $60 million once cumulative U.S. sales of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; reach $400 million.&amp;#160;&amp;#160;The Company will also pay royalties of 4.75% on cumulative U.S. sales of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; between $400 million and $3 billion and 5.5% on any cumulative U.S. sales of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; over $3 billion.&amp;#160;&amp;#160;As a result of the Genentech Agreement, on January 17, 2012 Genentech filed a second amended answer and counterclaim in the First Davis-Smyth Case, in which it amended its counterclaims alleging infringement of four of the five Davis-Smyth patents.&amp;#160; On December 23, 2011, Genentech initiated a related case in the Court against Regeneron and Sanofi alleging infringement of four of the five Davis-Smyth Patents by activities relating to VEGF Trap (but excluding EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt;) (the &amp;#8220;Second Davis-Smyth Case&amp;#8221;).&amp;#160; As in the First Davis-Smyth Case, in the new complaint Genentech requests a judgment against the Company for damages, including for willful infringement, and other relief as the Court deems appropriate.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company believes Genentech's claims in the First Davis Smyth Case and the Second Davis Smyth Case are without merit and intend to continue to defend against all of Genentech&amp;#8217;s remaining claims vigorously.&amp;#160; As this litigation is at an early stage, at this time the Company is not able to predict the probability of the outcome or an estimate of loss, if any, related to these matters.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company has initiated patent-related actions against Genentech in Germany, the United Kingdom, and Italy, and may initiate other actions in other countries outside the United States, which could have similar or other adverse outcomes that would materially harm its business and which, irrespective of the outcomes, may also entail significant costs and expenses.&lt;/font&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
  <!--Employee Savings Plan-->
  <regn:EmployeeSavingsPlanTextBlock contextRef="c00124">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;16.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Employee Savings Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In 1993, the Company adopted the provisions of the Regeneron Pharmaceuticals, Inc. 401(k) Savings Plan (the &amp;#8220;Savings Plan&amp;#8221;).&amp;#160;&amp;#160;The terms of the Savings Plan provide for employees who have met defined service requirements to participate in the Savings Plan by electing to contribute to the Savings Plan a percentage of their compensation to be set aside to pay their future retirement benefits, as defined.&amp;#160;&amp;#160;The Savings Plan, as amended and restated, provides for the Company to make discretionary contributions (&amp;#8220;Contribution&amp;#8221;), as defined.&amp;#160;&amp;#160;The Company recognized $4.1 million, $3.2 million, and $2.6 million of Contribution expense in 2011, 2010, and 2009, respectively.&amp;#160;&amp;#160;At December 31, 2011 and 2010, accrued Contribution expense totaled $3.6 million and $2.9 million, respectively.&amp;#160;&amp;#160;During the first quarter of 2012 and 2011, the Company contributed 63,937 and 91,761 shares, respectively, of Common Stock to the Savings Plan in satisfaction of these obligations.&lt;/font&gt;&lt;/div&gt;</regn:EmployeeSavingsPlanTextBlock>
  <!--Accounts Payable and Accrued Expenses-->
  <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c00124">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;9.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Accounts Payable and Accrued Expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Accounts payable and accrued expenses as of December 31, 2011 and 2010 consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="46%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="15%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Accounts payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$27,736&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$15,589&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Accrued payroll and related costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;42,835&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;12,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Accrued clinical trial expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;9,850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;9,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Accrued property, plant, and equipment costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;1,070&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Other accrued expenses and liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;14,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;6,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Payable to Bayer HealthCare&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;_____&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;2,254&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$95,625&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$53,658&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
  <!--Technology Licensing Agreements-->
  <regn:TechnologyLicensingAgreementsTextBlock contextRef="c00124">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;4.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Technology Licensing Agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In March 2007, the Company entered into a six-year, non-exclusive license agreement with Astellas Pharma Inc. to allow Astellas to utilize the Company&amp;#8217;s &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;VelocImmune&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;&amp;#160;&lt;/font&gt;technology in its internal research programs to discover human monoclonal antibodies.&amp;#160;&amp;#160;Under the terms of the agreement, Astellas made a $20.0 million annual, non-refundable payment to the Company in each of 2010, 2009, 2008, and 2007.&amp;#160;&amp;#160;In July 2010, the license agreement with Astellas was amended and extended through June 2023.&amp;#160;&amp;#160;Under the terms of the amended agreement, Astellas made a $165.0 million up-front payment to the Company in August 2010, which was deferred upon receipt and will be recognized as revenue ratably over the seven-year period beginning in mid-2011.&amp;#160;&amp;#160;In addition, Astellas will make a $130.0 million second payment to the Company in June 2018 unless the license agreement has been terminated prior to that date.&amp;#160;&amp;#160;Astellas has the right to terminate the agreement at any time by providing 90 days&amp;#8217; advance written notice.&amp;#160;&amp;#160;Under certain limited circumstances, such as a material breach of the agreement by the Company, Astellas may terminate the agreement and receive a refund of a portion of its up-front payment or, if such termination occurs after June 2018, a portion of its second payment, to the Company under the July 2010 amendment to the agreement.&amp;#160;&amp;#160;The Company is entitled to receive a mid-single digit royalty on any future sales of antibody products discovered by Astellas using the Company&amp;#8217;s &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;VelocImmune&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; technology.&amp;#160;&amp;#160;In connection with the Astellas license agreement, for each of the years ended December 31, 2011, 2010, and 2009, the Company recognized $22.0 million, $20.0 million, and $20.0 million of technology licensing revenue, respectively.&amp;#160;&amp;#160;In addition, deferred revenue at December 31, 2011 and 2010 was $151.7 million and $173.7 million, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In February 2007, the Company entered into a six-year, non-exclusive license agreement with AstraZeneca UK Limited to allow AstraZeneca to utilize the Company&amp;#8217;s &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;VelocImmune&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; technology in its internal research programs to discover human monoclonal antibodies.&amp;#160;&amp;#160;Under the terms of the agreement, AstraZeneca made a $20.0 million annual, non-refundable payment to the Company in each of 2010, 2009, 2008, and 2007.&amp;#160;&amp;#160;Each annual payment was deferred and recognized as revenue ratably over approximately the ensuing twelve-month period.&amp;#160;&amp;#160;In November 2010, as permitted by the agreement, MedImmune Limited (as successor by novation from AstraZeneca) gave written notice of voluntary termination of the agreement, effective in February 2011, thereby canceling its obligation to make either of the final two annual payments.&amp;#160;&amp;#160;Regeneron remains entitled to receive mid-single digit royalties on any future sales of antibody products discovered by MedImmune/AstraZeneca using the &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;VelocImmune&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; technology.&amp;#160;&amp;#160;In connection with the AstraZeneca license agreement, for the years ended December 31, 2011, 2010, and 2009, the Company recognized $2.9 million, $20.0 million, and $20.0 million, respectively, of technology licensing revenue.&lt;/font&gt;&lt;/div&gt;</regn:TechnologyLicensingAgreementsTextBlock>
  <!--Revenue Recognition, Technology Licensing-->
  <us-gaap:RevenueRecognitionServicesLicensingFees contextRef="c00124">&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;b. &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;VelocImmune&lt;/font&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174; &lt;/font&gt;Technology Licensing&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company enters into non-exclusive license agreements with third parties that allow the third party to utilize the Company&amp;#8217;s &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;VelocImmune&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; technology in its internal research programs.&amp;#160;&amp;#160;The terms of these agreements include up-front payments and entitle the Company to receive royalties on any future sales of products discovered by the third party using the Company&amp;#8217;s &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;VelocImmune&lt;/font&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;&amp;#160;&lt;/font&gt;technology.&amp;#160;&amp;#160;Up-front payments under these agreements, where continuing involvement is required of the Company, are deferred and recognized ratably over their respective license periods.&lt;/font&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionServicesLicensingFees>
  <!--Inventories-->
  <regn:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Inventories as of December 31, 2011 and December 31, 2010 consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="46%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$1,608&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$592&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;10,806&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;699&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;1,142&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;132&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$13,556&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$1,423&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</regn:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock>
  <!--Expenses under the collaboration payable to collaborating party- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member]-->
  <us-gaap:DueToRelatedPartiesCurrent contextRef="c00010" unitRef="u000" decimals="-5">3700000</us-gaap:DueToRelatedPartiesCurrent>
  <!--Maximum number of product candidates for which milestone payments may be received relating to marketing approvals in the U.S. or European Union- Collaboration Agreement with Sanofi [Member]-->
  <regn:MaximumNumberOfProductCandidatesForWhichSubstantiveMilestonePaymentsMayBeReceivedInUSOrEuropeanUnion contextRef="c00160" unitRef="u006" decimals="0">8</regn:MaximumNumberOfProductCandidatesForWhichSubstantiveMilestonePaymentsMayBeReceivedInUSOrEuropeanUnion>
  <!--Gross increases related to prior year tax positions-->
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c00164" unitRef="u000" decimals="-3">9269000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
  <!--Number of unvested options (in shares)- Performance-Based Stock Options [Member]-->
  <regn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedNumber contextRef="c00056" unitRef="u001" decimals="0">2195429</regn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedNumber>
  <!--Number of unvested options (in shares)- Restricted Stock [Member]-->
  <regn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedNumber contextRef="c00057" unitRef="u001" decimals="0">751499</regn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedNumber>
  <!--Vested and expected to vest, end of period, intrinsic value- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c00054" unitRef="u000" decimals="-3">653990000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <!--Outstanding, end of period, intrinsic value- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c00054" unitRef="u000" decimals="-3">663376000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <!--Outstanding, beginning of period (in shares)- Stock Options [Member] + Outstanding, beginning of period (in shares)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c00105" unitRef="u001" decimals="0">23362248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <!--Outstanding, beginning of period (in shares)- Stock Options [Member] + Outstanding, beginning of period (in shares)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c00054" unitRef="u001" decimals="0">22326361</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <!--2014- Cellectis Agreement [Member]-->
  <regn:FutureExpenseOfAdvancePaymentYearThree contextRef="c00150" unitRef="u000" decimals="-5">900000</regn:FutureExpenseOfAdvancePaymentYearThree>
  <!--Marketable debt securities collateral + Marketable debt securities collateral-->
  <regn:MarketableDebtSecuritiesCollateral contextRef="c00001" unitRef="u000" decimals="-5">3300000</regn:MarketableDebtSecuritiesCollateral>
  <!--Marketable debt securities collateral + Marketable debt securities collateral-->
  <regn:MarketableDebtSecuritiesCollateral contextRef="c00060" unitRef="u000" decimals="-5">3500000</regn:MarketableDebtSecuritiesCollateral>
  <!--Unrealized (Losses) - Total- Unrestricted [Member] + Unrealized (Losses) - Total- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLosses1 contextRef="c00034" unitRef="u000" decimals="-3">236000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLosses1>
  <!--Unrealized (Losses) - Total- Unrestricted [Member] + Unrealized (Losses) - Total- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLosses1 contextRef="c00090" unitRef="u000" decimals="-3">1917000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLosses1>
  <!--Unrealized (Losses) - Total- Debt Securities [Member] + Unrealized (Losses) - Total- Debt Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLosses1 contextRef="c00037" unitRef="u000" decimals="-3">236000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLosses1>
  <!--Unrealized (Losses) - Total- Debt Securities [Member] + Unrealized (Losses) - Total- Debt Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLosses1 contextRef="c00093" unitRef="u000" decimals="-3">1935000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLosses1>
  <!--Unrealized (Losses) - Total- Restricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLosses1 contextRef="c00092" unitRef="u000" decimals="-3">18000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLosses1>
  <!--Available-for-sale Securities, Gross Unrealized Losses- Equity Securities [Member] + Available-for-sale Securities, Gross Unrealized Losses- Equity Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLosses1 contextRef="c00028" unitRef="u000" decimals="-5">1000000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLosses1>
  <!--Available-for-sale Securities, Gross Unrealized Losses- Equity Securities [Member] + Available-for-sale Securities, Gross Unrealized Losses- Equity Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLosses1 contextRef="c00084" unitRef="u000" decimals="-5">400000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLosses1>
  <!--Number of shares issued (in shares)- Executive Stock Purchase Plan [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c00254" unitRef="u001" decimals="0">983254</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <!--Accrued clinical trial expense + Accrued clinical trial expense-->
  <regn:AccruedClinicalTrialExpenseCurrent contextRef="c00001" unitRef="u000" decimals="-3">9850000</regn:AccruedClinicalTrialExpenseCurrent>
  <!--Accrued clinical trial expense + Accrued clinical trial expense-->
  <regn:AccruedClinicalTrialExpenseCurrent contextRef="c00060" unitRef="u000" decimals="-3">9727000</regn:AccruedClinicalTrialExpenseCurrent>
  <!--Costs incurred by the landlord to construct new laboratory and office facilities- New Laboratory and Office Facilities [Member] + Costs incurred by the landlord to construct new laboratory and office facilities- New Laboratory and Office Facilities [Member]-->
  <regn:CostsIncurredByLandlordToConstructNewLaboratoryAndOfficeFacilities contextRef="c00022" unitRef="u000" decimals="-5">86200000</regn:CostsIncurredByLandlordToConstructNewLaboratoryAndOfficeFacilities>
  <!--Costs incurred by the landlord to construct new laboratory and office facilities- New Laboratory and Office Facilities [Member] + Costs incurred by the landlord to construct new laboratory and office facilities- New Laboratory and Office Facilities [Member]-->
  <regn:CostsIncurredByLandlordToConstructNewLaboratoryAndOfficeFacilities contextRef="c00079" unitRef="u000" decimals="-5">86200000</regn:CostsIncurredByLandlordToConstructNewLaboratoryAndOfficeFacilities>
  <!--Recognition period for advance payment (in years)- License Agreement with Astellas Pharma Inc [Member]-->
  <regn:RecognitionPeriodForAdvancePayment contextRef="c00250">7Y</regn:RecognitionPeriodForAdvancePayment>
  <!--Conditions for commencement of sales milestone payments- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:ConditionsForCommencementOfSalesMilestonePayments contextRef="c00135">only if and after aggregate annual sales outside the United States exceed $1.0 billion on a rolling 12-month basis</regn:ConditionsForCommencementOfSalesMilestonePayments>
  <!--Ending share of profits outside the United States, based on sales, for Company (in hundredths)- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany contextRef="c00135" unitRef="u004" decimals="2">0.45</regn:EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany>
  <!--Number of years of first commercial sale of the product (in years)- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member]-->
  <regn:NumberOfYearsOfFirstCommercialSaleUnderCollaborationAgreement contextRef="c00134">2Y  </regn:NumberOfYearsOfFirstCommercialSaleUnderCollaborationAgreement>
  <!--Net proceeds in connection with issuances of Common Stock-->
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c00124" unitRef="u000" decimals="-3">18509000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <!--Net proceeds in connection with issuances of Common Stock-->
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c00164" unitRef="u000" decimals="-3">196790000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <!--Net proceeds in connection with issuances of Common Stock-->
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c00195" unitRef="u000" decimals="-3">8598000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <!--Purchases of marketable securities-->
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c00124" unitRef="u000" decimals="-3">240391000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <!--Purchases of marketable securities-->
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c00164" unitRef="u000" decimals="-3">605124000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <!--Purchases of marketable securities-->
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c00195" unitRef="u000" decimals="-3">199997000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <!--Change in net unrealized gain (loss) on marketable securities - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Change in net unrealized gain (loss) on marketable securities - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Change in net unrealized gain (loss) on marketable securities - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member]-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c00201" unitRef="u000" decimals="-3">1158000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Change in net unrealized gain (loss) on marketable securities - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Change in net unrealized gain (loss) on marketable securities - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Change in net unrealized gain (loss) on marketable securities - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member]-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c00170" unitRef="u000" decimals="-3">-3535000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Change in net unrealized gain (loss) on marketable securities - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Change in net unrealized gain (loss) on marketable securities - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Change in net unrealized gain (loss) on marketable securities - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member]-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c00130" unitRef="u000" decimals="-3">629000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Change in net unrealized gain (loss) on marketable securities - Total Stockholders' Equity + Change in net unrealized gain (loss) on marketable securities - Total Stockholders' Equity + Change in net unrealized gain (loss) on marketable securities - Total Stockholders' Equity-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c00195" unitRef="u000" decimals="-3">1158000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Change in net unrealized gain (loss) on marketable securities - Total Stockholders' Equity + Change in net unrealized gain (loss) on marketable securities - Total Stockholders' Equity + Change in net unrealized gain (loss) on marketable securities - Total Stockholders' Equity-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c00164" unitRef="u000" decimals="-3">-3535000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Change in net unrealized gain (loss) on marketable securities - Total Stockholders' Equity + Change in net unrealized gain (loss) on marketable securities - Total Stockholders' Equity + Change in net unrealized gain (loss) on marketable securities - Total Stockholders' Equity-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c00124" unitRef="u000" decimals="-3">629000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Change in net unrealized gain (loss) on marketable securities - Comprehensive Loss- Comprehensive Loss [Member] + Change in net unrealized gain (loss) on marketable securities - Comprehensive Loss- Comprehensive Loss [Member] + Change in net unrealized gain (loss) on marketable securities - Comprehensive Loss- Comprehensive Loss [Member]-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c00200" unitRef="u000" decimals="-3">1158000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Change in net unrealized gain (loss) on marketable securities - Comprehensive Loss- Comprehensive Loss [Member] + Change in net unrealized gain (loss) on marketable securities - Comprehensive Loss- Comprehensive Loss [Member] + Change in net unrealized gain (loss) on marketable securities - Comprehensive Loss- Comprehensive Loss [Member]-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c00169" unitRef="u000" decimals="-3">-3535000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Change in net unrealized gain (loss) on marketable securities - Comprehensive Loss- Comprehensive Loss [Member] + Change in net unrealized gain (loss) on marketable securities - Comprehensive Loss- Comprehensive Loss [Member] + Change in net unrealized gain (loss) on marketable securities - Comprehensive Loss- Comprehensive Loss [Member]-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c00129" unitRef="u000" decimals="-3">629000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Interest expense-->
  <us-gaap:InterestExpense contextRef="c00124" unitRef="u000" decimals="-3">21282000</us-gaap:InterestExpense>
  <!--Interest expense-->
  <us-gaap:InterestExpense contextRef="c00164" unitRef="u000" decimals="-3">9118000</us-gaap:InterestExpense>
  <!--Interest expense-->
  <us-gaap:InterestExpense contextRef="c00195" unitRef="u000" decimals="-3">2337000</us-gaap:InterestExpense>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c00124" unitRef="u000" decimals="-3">529506000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c00164" unitRef="u000" decimals="-3">489252000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c00195" unitRef="u000" decimals="-3">398762000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Total revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues-->
  <us-gaap:Revenues contextRef="c00124" unitRef="u000" decimals="-3">445824000</us-gaap:Revenues>
  <!--Total revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues-->
  <us-gaap:Revenues contextRef="c00164" unitRef="u000" decimals="-3">459074000</us-gaap:Revenues>
  <!--Total revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues-->
  <us-gaap:Revenues contextRef="c00195" unitRef="u000" decimals="-3">379268000</us-gaap:Revenues>
  <!--Total revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues-->
  <us-gaap:Revenues contextRef="c00117" unitRef="u000" decimals="-3">112204000</us-gaap:Revenues>
  <!--Total revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues-->
  <us-gaap:Revenues contextRef="c00120" unitRef="u000" decimals="-3">107810000</us-gaap:Revenues>
  <!--Total revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues-->
  <us-gaap:Revenues contextRef="c00122" unitRef="u000" decimals="-3">102833000</us-gaap:Revenues>
  <!--Total revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues-->
  <us-gaap:Revenues contextRef="c00256" unitRef="u000" decimals="-3">122977000</us-gaap:Revenues>
  <!--Total revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues-->
  <us-gaap:Revenues contextRef="c00119" unitRef="u000" decimals="-3">103534000</us-gaap:Revenues>
  <!--Total revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues-->
  <us-gaap:Revenues contextRef="c00121" unitRef="u000" decimals="-3">115886000</us-gaap:Revenues>
  <!--Total revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues-->
  <us-gaap:Revenues contextRef="c00123" unitRef="u000" decimals="-3">105979000</us-gaap:Revenues>
  <!--Total revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues + Revenues-->
  <us-gaap:Revenues contextRef="c00257" unitRef="u000" decimals="-3">133675000</us-gaap:Revenues>
  <!--Preferred stock, shares authorized-->
  <us-gaap:PreferredStockSharesAuthorized contextRef="c00001" unitRef="u001" decimals="0">30000000</us-gaap:PreferredStockSharesAuthorized>
  <!--Preferred stock, shares authorized-->
  <us-gaap:PreferredStockSharesAuthorized contextRef="c00060" unitRef="u001" decimals="0">30000000</us-gaap:PreferredStockSharesAuthorized>
  <!--Convertible senior notes-->
  <us-gaap:ConvertibleLongTermNotesPayable contextRef="c00001" unitRef="u000" decimals="-3">275019000</us-gaap:ConvertibleLongTermNotesPayable>
  <!--Convertible senior notes-->
  <us-gaap:ConvertibleLongTermNotesPayable contextRef="c00060" unitRef="u000" decimals="-3">0</us-gaap:ConvertibleLongTermNotesPayable>
  <!--Deferred Revenue-->
  <us-gaap:DeferredRevenueDisclosureTextBlock contextRef="c00124">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;10.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Deferred Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 36pt"&gt;&lt;/font&gt;Deferred revenue as of December 31, 2011 and 2010 consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="44%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Current portion:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Received from Sanofi (see Note 3a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="9%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$20,011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$19,506&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Received from Bayer HealthCare (see Note 3b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="9%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,907&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;9,884&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Received for technology license agreements (see Note 4)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="9%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;23,572&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;25,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;150&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;325&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$51,640&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$54,723&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Long-term portion:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Received from Sanofi (see Note 3a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="9%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$86,017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$97,081&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Received from Bayer HealthCare (see Note 3b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="9%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;34,456&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;37,067&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Received for technology license agreements (see Note 4)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;128,137&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;151,708&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$248,610&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$285,856&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredRevenueDisclosureTextBlock>
  <!--Comprehensive Income (Loss)-->
  <us-gaap:StockholdersEquityPolicyTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Comprehensive Income (Loss)&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Comprehensive income (loss) of the Company includes net income (loss) adjusted for the change in net unrealized gain or loss on marketable securities, net of any tax effect.&amp;#160;&amp;#160;Comprehensive income (loss) for the years ended December 31, 2011, 2010, and 2009 have been included in the Statements of Stockholders' Equity.&lt;/font&gt;&lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
  <!--Activity Related to Restricted Stock Awards-->
  <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;A summary of the Company's activity related to Restricted Stock awards for the year ended December 31, 2011 is summarized below:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="41%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;Restricted Stock:&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Number of &lt;font style="DISPLAY: inline"&gt;Shares&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Grant Date Fair &lt;font style="DISPLAY: inline"&gt;Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="41%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Outstanding at December 31, 2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;845,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 29.65pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$25.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="41%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;2011:&lt;/font&gt;&amp;#160;&amp;#160;&amp;#160;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;16,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 29.65pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$58.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="41%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Released&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="middle" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(110,001)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 29.65pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$30.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="41%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Outstanding at December 31, 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;751,499&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 29.65pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$25.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
  <!--Number of shares of Common Stock purchased (in shares)- Collaboration Agreement with Sanofi [Member]-->
  <regn:NumberOfSharesOfCommonStockPurchasedInShares contextRef="c00009" unitRef="u001" decimals="0">15816953</regn:NumberOfSharesOfCommonStockPurchasedInShares>
  <!--2012- Cellectis Agreement [Member]-->
  <regn:FutureExpenseOfAdvancePaymentYearOne contextRef="c00150" unitRef="u000" decimals="-5">1000000</regn:FutureExpenseOfAdvancePaymentYearOne>
  <!--2016- Facilities Buildings A and B [Member]-->
  <regn:FacilityLeasesFutureMinimumPaymentsDueDueInFiveYears contextRef="c00048" unitRef="u000" decimals="-3">13864000</regn:FacilityLeasesFutureMinimumPaymentsDueDueInFiveYears>
  <!--2016- Facilities Building C [Member]-->
  <regn:FacilityLeasesFutureMinimumPaymentsDueDueInFiveYears contextRef="c00049" unitRef="u000" decimals="-3">4740000</regn:FacilityLeasesFutureMinimumPaymentsDueDueInFiveYears>
  <!--2016-->
  <regn:FacilityLeasesFutureMinimumPaymentsDueDueInFiveYears contextRef="c00001" unitRef="u000" decimals="-3">18604000</regn:FacilityLeasesFutureMinimumPaymentsDueDueInFiveYears>
  <!--Less: amount representing interest- Equipment [Member]-->
  <us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments contextRef="c00020" unitRef="u000" decimals="-3">272000</us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments>
  <!--2014-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="c00001" unitRef="u000" decimals="-3">7463000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <!--2014- Equipment [Member]-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="c00020" unitRef="u000" decimals="-3">35000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <!--2014- Building [Member]-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="c00046" unitRef="u000" decimals="-3">7428000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <!--Fair value of the outstanding Notes-->
  <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c00001" unitRef="u000" decimals="-5">375500000</us-gaap:ConvertibleDebtFairValueDisclosures>
  <!--Mortgage-backed securities- Unrestricted [Member] + Mortgage-backed securities- Unrestricted [Member]-->
  <regn:MortgageBackedSecuritiesFairValueDisclosure contextRef="c00034" unitRef="u000" decimals="-3">115000</regn:MortgageBackedSecuritiesFairValueDisclosure>
  <!--Mortgage-backed securities- Unrestricted [Member] + Mortgage-backed securities- Unrestricted [Member]-->
  <regn:MortgageBackedSecuritiesFairValueDisclosure contextRef="c00090" unitRef="u000" decimals="-3">1128000</regn:MortgageBackedSecuritiesFairValueDisclosure>
  <!--Mortgage-backed securities- Unrestricted [Member]- Fair Value, Inputs, Level 2 [Member] + Mortgage-backed securities- Unrestricted [Member]- Fair Value, Inputs, Level 2 [Member]-->
  <regn:MortgageBackedSecuritiesFairValueDisclosure contextRef="c00041" unitRef="u000" decimals="-3">115000</regn:MortgageBackedSecuritiesFairValueDisclosure>
  <!--Mortgage-backed securities- Unrestricted [Member]- Fair Value, Inputs, Level 2 [Member] + Mortgage-backed securities- Unrestricted [Member]- Fair Value, Inputs, Level 2 [Member]-->
  <regn:MortgageBackedSecuritiesFairValueDisclosure contextRef="c00096" unitRef="u000" decimals="-3">1128000</regn:MortgageBackedSecuritiesFairValueDisclosure>
  <!--Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses- Unrestricted [Member]- U S Government Obligations [Member] + Unrealized Loss - Less than 12 Months- Unrestricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses1 contextRef="c00029" unitRef="u000" decimals="-3">81000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses1>
  <!--Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses- Unrestricted [Member]- U S Government Obligations [Member] + Unrealized Loss - Less than 12 Months- Unrestricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses1 contextRef="c00085" unitRef="u000" decimals="-3">1731000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses1>
  <!--Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses- Unrestricted [Member]- U S Government Guaranteed Collateralized Mortgage Obligations [Member] + Unrealized Loss - Less than 12 Months- Unrestricted [Member]- U S Government Guaranteed Collateralized Mortgage Obligations [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses1 contextRef="c00031" unitRef="u000" decimals="-3">1000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses1>
  <!--Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses- Unrestricted [Member]- U S Government Guaranteed Collateralized Mortgage Obligations [Member] + Unrealized Loss - Less than 12 Months- Unrestricted [Member]- U S Government Guaranteed Collateralized Mortgage Obligations [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses1 contextRef="c00087" unitRef="u000" decimals="-3">45000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses1>
  <!--Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses- Unrestricted [Member]- Municipal Bonds [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses1 contextRef="c00032" unitRef="u000" decimals="-3">1000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses1>
  <!--Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses- Equity Securities [Member] + Unrealized Loss - Less than 12 Months- Equity Securities [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses1 contextRef="c00028" unitRef="u000" decimals="-3">1025000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses1>
  <!--Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses- Equity Securities [Member] + Unrealized Loss - Less than 12 Months- Equity Securities [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses1 contextRef="c00084" unitRef="u000" decimals="-3">433000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses1>
  <!--Unrealized Loss - Less than 12 Months + Unrealized Loss - Less than 12 Months-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses1 contextRef="c00001" unitRef="u000" decimals="-3">1108000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses1>
  <!--Unrealized Loss - Less than 12 Months + Unrealized Loss - Less than 12 Months-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses1 contextRef="c00060" unitRef="u000" decimals="-3">2227000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses1>
  <!--Unrealized Loss - Less than 12 Months- Unrestricted [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses1 contextRef="c00090" unitRef="u000" decimals="-3">2209000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses1>
  <!--Unrealized Loss - Less than 12 Months- Restricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses1 contextRef="c00091" unitRef="u000" decimals="-3">18000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses1>
  <!--Unrealized Loss - Less than 12 Months- Restricted [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses1 contextRef="c00092" unitRef="u000" decimals="-3">18000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses1>
  <!--Fair Value - Maturities within one year- Unrestricted [Member]- U S Government Obligations [Member] + Fair Value - Maturities within one year- Unrestricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c00029" unitRef="u000" decimals="-3">12067000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <!--Fair Value - Maturities within one year- Unrestricted [Member]- U S Government Obligations [Member] + Fair Value - Maturities within one year- Unrestricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c00085" unitRef="u000" decimals="-3">83684000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <!--Fair Value - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Corporate Bonds [Member] + Fair Value - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Corporate Bonds [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c00030" unitRef="u000" decimals="-3">15316000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <!--Fair Value - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Corporate Bonds [Member] + Fair Value - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Corporate Bonds [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c00086" unitRef="u000" decimals="-3">48531000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <!--Fair Value - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Collateralized Mortgage Obligations [Member] + Fair Value - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Collateralized Mortgage Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c00031" unitRef="u000" decimals="-3">622000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <!--Fair Value - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Collateralized Mortgage Obligations [Member] + Fair Value - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Collateralized Mortgage Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c00087" unitRef="u000" decimals="-3">2131000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <!--Fair Value - Maturities within one year- Unrestricted [Member]- Municipal Bonds [Member] + Fair Value - Maturities within one year- Unrestricted [Member]- Municipal Bonds [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c00032" unitRef="u000" decimals="-3">15326000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <!--Fair Value - Maturities within one year- Unrestricted [Member]- Municipal Bonds [Member] + Fair Value - Maturities within one year- Unrestricted [Member]- Municipal Bonds [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c00088" unitRef="u000" decimals="-3">1603000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <!--Fair Value - Maturities within one year- Unrestricted [Member] + Fair Value - Maturities within one year- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c00034" unitRef="u000" decimals="-3">43331000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <!--Fair Value - Maturities within one year- Unrestricted [Member] + Fair Value - Maturities within one year- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c00090" unitRef="u000" decimals="-3">136796000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <!--Fair Value - Maturities within one year- Restricted [Member]- U S Government Obligations [Member] + Fair Value - Maturities within one year- Restricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c00035" unitRef="u000" decimals="-3">3357000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <!--Fair Value - Maturities within one year- Restricted [Member]- U S Government Obligations [Member] + Fair Value - Maturities within one year- Restricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c00091" unitRef="u000" decimals="-3">2921000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <!--Fair Value - Maturities within one year- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c00089" unitRef="u000" decimals="-3">847000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <!--Additional research and development expenses obligated to reimburse- Collaboration Agreement with Bayer HealthCare LLC [Member] + Additional research and development expenses obligated to reimburse- Collaboration Agreement with Bayer HealthCare LLC [Member] + Additional research and development expenses obligated to reimburse- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <regn:AdditionalResearchAndDevelopmentExpensesObligatedToReimburse contextRef="c00136" unitRef="u000" decimals="-5">47800000</regn:AdditionalResearchAndDevelopmentExpensesObligatedToReimburse>
  <!--Additional research and development expenses obligated to reimburse- Collaboration Agreement with Bayer HealthCare LLC [Member] + Additional research and development expenses obligated to reimburse- Collaboration Agreement with Bayer HealthCare LLC [Member] + Additional research and development expenses obligated to reimburse- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <regn:AdditionalResearchAndDevelopmentExpensesObligatedToReimburse contextRef="c00173" unitRef="u000" decimals="-5">48900000</regn:AdditionalResearchAndDevelopmentExpensesObligatedToReimburse>
  <!--Additional research and development expenses obligated to reimburse- Collaboration Agreement with Bayer HealthCare LLC [Member] + Additional research and development expenses obligated to reimburse- Collaboration Agreement with Bayer HealthCare LLC [Member] + Additional research and development expenses obligated to reimburse- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <regn:AdditionalResearchAndDevelopmentExpensesObligatedToReimburse contextRef="c00204" unitRef="u000" decimals="-5">37700000</regn:AdditionalResearchAndDevelopmentExpensesObligatedToReimburse>
  <!--Number of therapeutic antibodies currently under development- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:NumberOfTherapeuticAntibodiesCurrentlyUnderDevelopment contextRef="c00011" unitRef="u006" decimals="0">7</regn:NumberOfTherapeuticAntibodiesCurrentlyUnderDevelopment>
  <!--Option to extend (in years)- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:OptionToExtend contextRef="c00135">3Y</regn:OptionToExtend>
  <!--Minimum advance notice required to terminate collaboration agreement- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member]-->
  <regn:MinimumAdvanceNoticeRequiredToTerminateCollaborationAgreement contextRef="c00134">12M</regn:MinimumAdvanceNoticeRequiredToTerminateCollaborationAgreement>
  <!--Minimum advance notice required to terminate collaboration agreement- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:MinimumAdvanceNoticeRequiredToTerminateCollaborationAgreement contextRef="c00135">3M</regn:MinimumAdvanceNoticeRequiredToTerminateCollaborationAgreement>
  <!--Minimum advance notice required to terminate collaboration agreement- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <regn:MinimumAdvanceNoticeRequiredToTerminateCollaborationAgreement contextRef="c00136">six months or twelve months</regn:MinimumAdvanceNoticeRequiredToTerminateCollaborationAgreement>
  <!--(Increase) decrease in restricted cash and marketable securities-->
  <us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments contextRef="c00124" unitRef="u000" decimals="-3">277000</us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments>
  <!--(Increase) decrease in restricted cash and marketable securities-->
  <us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments contextRef="c00164" unitRef="u000" decimals="-3">5941000</us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments>
  <!--(Increase) decrease in restricted cash and marketable securities-->
  <us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments contextRef="c00195" unitRef="u000" decimals="-3">-50000</us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments>
  <!--Issuance of restricted Common Stock under Long-Term Incentive Plan - Total Stockholders' Equity + Issuance of restricted Common Stock under Long-Term Incentive Plan - Total Stockholders' Equity-->
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c00164" unitRef="u000" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <!--Issuance of restricted Common Stock under Long-Term Incentive Plan - Total Stockholders' Equity + Issuance of restricted Common Stock under Long-Term Incentive Plan - Total Stockholders' Equity-->
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c00124" unitRef="u000" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <!--Class A Stock, par value- Class A Stock [Member]-->
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c00002" unitRef="u003" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <!--Class A Stock, par value- Class A Stock [Member]-->
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c00061" unitRef="u003" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <!--Common Stock, par value-->
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c00001" unitRef="u003" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <!--Common Stock, par value-->
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c00060" unitRef="u003" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <!--Investment Income-->
  <us-gaap:RevenueRecognitionInterest contextRef="c00124">&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Investment Income&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Interest income, which is included in investment income, is recognized as earned.&lt;/font&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionInterest>
  <!--U.S federal statutory income tax rate (in hundredths)-->
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c00124" unitRef="u004" decimals="2">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <!--Deferred compensation + Deferred compensation-->
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="c00001" unitRef="u000" decimals="-3">47092000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
  <!--Deferred compensation + Deferred compensation-->
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="c00060" unitRef="u000" decimals="-3">39120000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
  <!--Fixed assets + Fixed assets-->
  <regn:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c00001" unitRef="u000" decimals="-3">14847000</regn:DeferredTaxAssetsPropertyPlantAndEquipment>
  <!--Fixed assets + Fixed assets-->
  <regn:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c00060" unitRef="u000" decimals="-3">13600000</regn:DeferredTaxAssetsPropertyPlantAndEquipment>
  <!--Exercisable, end of period, weighted-average remaining contractual term (in years)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm contextRef="c00152" unitRef="u006" decimals="2">5.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm>
  <!--Percentage of outstanding shares or voting rights under the amended investor agreement (in hundredths)- Sanofi [Member]-->
  <regn:PercentageOfOutstandingSharesOrVotingRightsUnderAmendedInvestorAgreement contextRef="c00239" unitRef="u004" decimals="2">0.10</regn:PercentageOfOutstandingSharesOrVotingRightsUnderAmendedInvestorAgreement>
  <!--Rent expense- Building [Member] + Rent expense- Building [Member] + Rent expense- Building [Member]-->
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="c00147" unitRef="u000" decimals="-3">7191000</us-gaap:OperatingLeasesRentExpenseNet>
  <!--Rent expense- Building [Member] + Rent expense- Building [Member] + Rent expense- Building [Member]-->
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="c00181" unitRef="u000" decimals="-3">7301000</us-gaap:OperatingLeasesRentExpenseNet>
  <!--Rent expense- Building [Member] + Rent expense- Building [Member] + Rent expense- Building [Member]-->
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="c00212" unitRef="u000" decimals="-3">7722000</us-gaap:OperatingLeasesRentExpenseNet>
  <!--Rent expense- Equipment [Member] + Rent expense- Equipment [Member] + Rent expense- Equipment [Member]-->
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="c00132" unitRef="u000" decimals="-3">599000</us-gaap:OperatingLeasesRentExpenseNet>
  <!--Rent expense- Equipment [Member] + Rent expense- Equipment [Member] + Rent expense- Equipment [Member]-->
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="c00182" unitRef="u000" decimals="-3">335000</us-gaap:OperatingLeasesRentExpenseNet>
  <!--Rent expense- Equipment [Member] + Rent expense- Equipment [Member] + Rent expense- Equipment [Member]-->
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="c00213" unitRef="u000" decimals="-3">395000</us-gaap:OperatingLeasesRentExpenseNet>
  <!--Rent expense + Rent expense + Rent expense-->
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="c00124" unitRef="u000" decimals="-3">7790000</us-gaap:OperatingLeasesRentExpenseNet>
  <!--Rent expense + Rent expense + Rent expense-->
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="c00164" unitRef="u000" decimals="-3">7636000</us-gaap:OperatingLeasesRentExpenseNet>
  <!--Rent expense + Rent expense + Rent expense-->
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="c00195" unitRef="u000" decimals="-3">8117000</us-gaap:OperatingLeasesRentExpenseNet>
  <!--Total-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="c00001" unitRef="u000" decimals="-3">97237000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <!--Total- Building [Member]-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="c00046" unitRef="u000" decimals="-3">95756000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <!--Total- Equipment [Member]-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="c00020" unitRef="u000" decimals="-3">1481000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <!--Estimated fair value of the Liability Component- Convertible Debt [Member]-->
  <regn:DebtInstrumentConvertibleFairValueOfLiabilityComponent contextRef="c00261" unitRef="u000" decimals="-5">271100000</regn:DebtInstrumentConvertibleFairValueOfLiabilityComponent>
  <!--U.S. government guaranteed corporate bonds- Unrestricted [Member] + U.S. government guaranteed corporate bonds- Unrestricted [Member]-->
  <regn:USGovernmentGuaranteedCorporateBondsFairValueDisclosure contextRef="c00034" unitRef="u000" decimals="-3">15316000</regn:USGovernmentGuaranteedCorporateBondsFairValueDisclosure>
  <!--U.S. government guaranteed corporate bonds- Unrestricted [Member] + U.S. government guaranteed corporate bonds- Unrestricted [Member]-->
  <regn:USGovernmentGuaranteedCorporateBondsFairValueDisclosure contextRef="c00090" unitRef="u000" decimals="-3">64008000</regn:USGovernmentGuaranteedCorporateBondsFairValueDisclosure>
  <!--U.S. government guaranteed corporate bonds- Unrestricted [Member]- Fair Value, Inputs, Level 2 [Member] + U.S. government guaranteed corporate bonds- Unrestricted [Member]- Fair Value, Inputs, Level 2 [Member]-->
  <regn:USGovernmentGuaranteedCorporateBondsFairValueDisclosure contextRef="c00041" unitRef="u000" decimals="-3">15316000</regn:USGovernmentGuaranteedCorporateBondsFairValueDisclosure>
  <!--U.S. government guaranteed corporate bonds- Unrestricted [Member]- Fair Value, Inputs, Level 2 [Member] + U.S. government guaranteed corporate bonds- Unrestricted [Member]- Fair Value, Inputs, Level 2 [Member]-->
  <regn:USGovernmentGuaranteedCorporateBondsFairValueDisclosure contextRef="c00096" unitRef="u000" decimals="-3">64008000</regn:USGovernmentGuaranteedCorporateBondsFairValueDisclosure>
  <!--Unrealized Loss - 12 Months or Greater- Unrestricted [Member]- Mortgage-Backed Securities [Member] + Unrealized Loss - 12 Months or Greater- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses1 contextRef="c00033" unitRef="u000" decimals="-3">152000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses1>
  <!--Unrealized Loss - 12 Months or Greater- Unrestricted [Member]- Mortgage-Backed Securities [Member] + Unrealized Loss - 12 Months or Greater- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses1 contextRef="c00089" unitRef="u000" decimals="-3">141000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses1>
  <!--Unrealized Loss - 12 Months or Greater + Unrealized Loss - 12 Months or Greater-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses1 contextRef="c00001" unitRef="u000" decimals="-3">152000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses1>
  <!--Unrealized Loss - 12 Months or Greater + Unrealized Loss - 12 Months or Greater-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses1 contextRef="c00060" unitRef="u000" decimals="-3">141000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses1>
  <!--Unrealized Loss - 12 Months or Greater- Unrestricted [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses1 contextRef="c00090" unitRef="u000" decimals="-3">141000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses1>
  <!--Unrealized Net - Maturities after one year through five years- Unrestricted [Member]- Mortgage-Backed Securities [Member] + Unrealized Net - Maturities after one year through five years- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsUnrealizedGainsLossesNet contextRef="c00033" unitRef="u000" decimals="-3">-76000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsUnrealizedGainsLossesNet>
  <!--Unrealized Net - Maturities after one year through five years- Unrestricted [Member]- Mortgage-Backed Securities [Member] + Unrealized Net - Maturities after one year through five years- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsUnrealizedGainsLossesNet contextRef="c00089" unitRef="u000" decimals="-3">-72000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsUnrealizedGainsLossesNet>
  <!--Unrealized Net - Maturities after one year through five years- Unrestricted [Member]- U S Government Obligations [Member] + Unrealized Net - Maturities after one year through five years- Unrestricted [Member]- U S Government Obligations [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsUnrealizedGainsLossesNet contextRef="c00029" unitRef="u000" decimals="-3">319000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsUnrealizedGainsLossesNet>
  <!--Unrealized Net - Maturities after one year through five years- Unrestricted [Member]- U S Government Obligations [Member] + Unrealized Net - Maturities after one year through five years- Unrestricted [Member]- U S Government Obligations [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsUnrealizedGainsLossesNet contextRef="c00085" unitRef="u000" decimals="-3">-1662000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsUnrealizedGainsLossesNet>
  <!--Unrealized Net - Maturities after one year through five years- Unrestricted [Member] + Unrealized Net - Maturities after one year through five years- Unrestricted [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsUnrealizedGainsLossesNet contextRef="c00034" unitRef="u000" decimals="-3">243000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsUnrealizedGainsLossesNet>
  <!--Unrealized Net - Maturities after one year through five years- Unrestricted [Member] + Unrealized Net - Maturities after one year through five years- Unrestricted [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsUnrealizedGainsLossesNet contextRef="c00090" unitRef="u000" decimals="-3">-1779000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsUnrealizedGainsLossesNet>
  <!--Unrealized Net - Maturities after one year through five years- Restricted [Member]- U S Government Obligations [Member] + Unrealized Net - Maturities after one year through five years- Restricted [Member]- U S Government Obligations [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsUnrealizedGainsLossesNet contextRef="c00035" unitRef="u000" decimals="-3">11000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsUnrealizedGainsLossesNet>
  <!--Unrealized Net - Maturities after one year through five years- Restricted [Member]- U S Government Obligations [Member] + Unrealized Net - Maturities after one year through five years- Restricted [Member]- U S Government Obligations [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsUnrealizedGainsLossesNet contextRef="c00091" unitRef="u000" decimals="-3">-17000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsUnrealizedGainsLossesNet>
  <!--Unrealized Net - Maturities after one year through five years- Unrestricted [Member]- U S Government Guaranteed Corporate Bonds [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsUnrealizedGainsLossesNet contextRef="c00086" unitRef="u000" decimals="-3">-45000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsUnrealizedGainsLossesNet>
  <!--Unrealized Gains - Maturities after one year through five years- Unrestricted [Member]- U S Government Obligations [Member] + Unrealized Gains - Maturities after one year through five years- Unrestricted [Member]- U S Government Obligations [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedGains contextRef="c00029" unitRef="u000" decimals="-3">400000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedGains>
  <!--Unrealized Gains - Maturities after one year through five years- Unrestricted [Member]- U S Government Obligations [Member] + Unrealized Gains - Maturities after one year through five years- Unrestricted [Member]- U S Government Obligations [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedGains contextRef="c00085" unitRef="u000" decimals="-3">64000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedGains>
  <!--Unrealized Gains - Maturities after one year through five years- Unrestricted [Member] + Unrealized Gains - Maturities after one year through five years- Unrestricted [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedGains contextRef="c00034" unitRef="u000" decimals="-3">400000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedGains>
  <!--Unrealized Gains - Maturities after one year through five years- Unrestricted [Member] + Unrealized Gains - Maturities after one year through five years- Unrestricted [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedGains contextRef="c00090" unitRef="u000" decimals="-3">64000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedGains>
  <!--Unrealized Gains - Maturities after one year through five years- Restricted [Member]- U S Government Obligations [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedGains contextRef="c00035" unitRef="u000" decimals="-3">11000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsGrossUnrealizedGains>
  <!--Accounts payable + Accounts payable-->
  <us-gaap:AccountsPayableTradeCurrent contextRef="c00001" unitRef="u000" decimals="-3">27736000</us-gaap:AccountsPayableTradeCurrent>
  <!--Accounts payable + Accounts payable-->
  <us-gaap:AccountsPayableTradeCurrent contextRef="c00060" unitRef="u000" decimals="-3">15589000</us-gaap:AccountsPayableTradeCurrent>
  <!--Raw materials + Raw materials-->
  <us-gaap:InventoryRawMaterials contextRef="c00001" unitRef="u000" decimals="-3">1608000</us-gaap:InventoryRawMaterials>
  <!--Raw materials + Raw materials-->
  <us-gaap:InventoryRawMaterials contextRef="c00060" unitRef="u000" decimals="-3">592000</us-gaap:InventoryRawMaterials>
  <!--Starting specified levels of annual sales at which sales milestone payments may be received- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <regn:StartingSpecifiedLevelsOfAnnualSalesAtWhichSalesMilestonePaymentsMayBeReceived contextRef="c00136" unitRef="u000" decimals="-6">200000000</regn:StartingSpecifiedLevelsOfAnnualSalesAtWhichSalesMilestonePaymentsMayBeReceived>
  <!--Number of substantive milestone payments earned- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <regn:NumberOfSubstantiveMilestonePaymentsEarned contextRef="c00245" unitRef="u006" decimals="0">2</regn:NumberOfSubstantiveMilestonePaymentsEarned>
  <!--Sales or maturities of marketable securities-->
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c00124" unitRef="u000" decimals="-3">426356000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <!--Sales or maturities of marketable securities-->
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c00164" unitRef="u000" decimals="-3">273723000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <!--Sales or maturities of marketable securities-->
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c00195" unitRef="u000" decimals="-3">295117000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <!--Facility lease obligations, current portion-->
  <regn:FacilityLeaseObligationsCurrent contextRef="c00001" unitRef="u000" decimals="-3">1006000</regn:FacilityLeaseObligationsCurrent>
  <!--Facility lease obligations, current portion-->
  <regn:FacilityLeaseObligationsCurrent contextRef="c00060" unitRef="u000" decimals="-3">675000</regn:FacilityLeaseObligationsCurrent>
  <!--Inventory-->
  <us-gaap:InventoryDisclosureTextBlock contextRef="c00124">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;7.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Inventories as of December 31, 2011 and December 31, 2010 consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="46%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$1,608&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$592&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;10,806&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;699&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;1,142&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;132&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$13,556&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$1,423&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;At December 31, 2011, $3.5 million of inventories were included in prepaid expenses and other current assets and $10.1 million of inventories were included in other assets.&amp;#160;&amp;#160;At December 31, 2010, inventories were included in prepaid expenses and other current assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In 2011, cost of goods sold included inventory write-downs of $0.5 million.&amp;#160;&amp;#160;In 2010, there were no inventory write-downs included in cost of goods sold.&lt;/font&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <!--Operating Leases-->
  <us-gaap:LeasePolicyTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Operating Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On certain of its operating lease agreements, the Company may receive rent holidays and other incentives.&amp;#160;&amp;#160;The Company recognizes operating lease costs on a straight-line basis without regard to deferred payment terms, such as rent holidays, that defer the commencement date of required payments.&amp;#160;&amp;#160;In addition, lease incentives that the Company receives are treated as a reduction of rent expense over the term of the related agreements.&lt;/font&gt;&lt;/div&gt;</us-gaap:LeasePolicyTextBlock>
  <!--Fair Value, Assets Measured on a Recurring Basis-->
  <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company's assets that are measured at fair value on a recurring basis&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;,&lt;/font&gt; at December 31, 2011 and 2010, were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="41%" colspan="3"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Fair Value Measurements at Reporting Date Using&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="16%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Fair Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Quoted Prices in Active Markets for Identical Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;(Level 1)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="16%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Significant Other Observable Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;(Level 2)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Significant Unobservable Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;(Level 3)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;At December 31, 2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Unrestricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Available-for-sale marketable securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$284,819&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$284,819&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government guaranteed corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;15,316&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;15,316&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government guaranteed collateralized mortgage obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Municipal bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;15,326&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;15,326&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Equity security&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;3,019&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$3,019&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;_______&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;319,217&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;3,019&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;316,198&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Restricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Available-for-sale marketable securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%"&gt;&lt;div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;5,940&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;_____&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="16%"&gt;&lt;div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;5,940&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$325,157&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$3,019&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$322,138&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;At December 31, 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Unrestricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Available-for-sale marketable securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$434,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$434,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government guaranteed corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;64,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;64,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government guaranteed collateralized mortgage obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2,131&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2,131&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Municipal bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;1,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;1,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;1,128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;1,128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Equity security&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;3,612&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$3,612&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;_______&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;506,849&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;3,612&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;503,237&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Restricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Available-for-sale marketable securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;7,039&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;_____&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="16%"&gt;&lt;div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;7,039&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$513,888&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$3,612&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$510,276&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
  <!--Maximum amount of milestone payments that may be received relating to marketing approvals in Japan- Collaboration Agreement with Sanofi [Member]-->
  <regn:MaximumAmountOfSubstantiveMilestonePaymentsThatMayBeReceivedInJapan contextRef="c00160" unitRef="u000" decimals="-6">40000000</regn:MaximumAmountOfSubstantiveMilestonePaymentsThatMayBeReceivedInJapan>
  <!--Balance, as of January 1 + Balance, as of January 1-->
  <us-gaap:UnrecognizedTaxBenefits contextRef="c00060" unitRef="u000" decimals="-3">12819000</us-gaap:UnrecognizedTaxBenefits>
  <!--Balance, as of January 1 + Balance, as of January 1-->
  <us-gaap:UnrecognizedTaxBenefits contextRef="c00001" unitRef="u000" decimals="-3">5596000</us-gaap:UnrecognizedTaxBenefits>
  <!--Royalty rate, minimum (in hundredths)- Agreements with Royalty Provisions [Member]-->
  <regn:RoyaltyRateMinimum contextRef="c00149" unitRef="u004" decimals="4">0.0025</regn:RoyaltyRateMinimum>
  <!--Cash and marketable debt securities collateral- Tarrytown Lease [Member] + Cash and marketable debt securities collateral- Tarrytown Lease [Member]-->
  <regn:CashAndMarketableDebtSecuritiesCollateral contextRef="c00047" unitRef="u000" decimals="-5">3600000</regn:CashAndMarketableDebtSecuritiesCollateral>
  <!--Cash and marketable debt securities collateral- Tarrytown Lease [Member] + Cash and marketable debt securities collateral- Tarrytown Lease [Member]-->
  <regn:CashAndMarketableDebtSecuritiesCollateral contextRef="c00101" unitRef="u000" decimals="-5">3600000</regn:CashAndMarketableDebtSecuritiesCollateral>
  <!--Percentage of principal value that holders can require the Company to repurchase (in hundredths)- Convertible Debt [Member]-->
  <regn:DebtInstrumentPercentageOfPrincipalValueThatHoldersCanRequireCompanyToRepurchase contextRef="c00261" unitRef="u004" decimals="2">1.00</regn:DebtInstrumentPercentageOfPrincipalValueThatHoldersCanRequireCompanyToRepurchase>
  <!--Terms of conversion feature- Convertible Debt [Member]-->
  <us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature contextRef="c00258">A holder of the Notes may surrender their Notes at their option any time prior to the close of business on the business day immediately preceding July 1, 2016, only under the following circumstances: (i) during any calendar quarter commencing after the calendar quarter ending on December 31, 2011 (and only during such calendar quarter), if the last reported sale price of the Company's Common Stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (ii) during the five business day period after any ten consecutive trading day period (the "measurement period") in which the trading price, as defined, of the Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company's Common Stock and the conversion rate on each such trading day; (iii) if the Company elects to issue to all or substantially all holders of its Common Stock any right, options or warrants (other than pursuant to a rights plan) entitling them for a period of not more than 60 calendar days after the record date for such issuance, to subscribe for or purchase shares of the Company's Common Stock, at a price per share less than the average of the last reported sales prices of the Company's Common Stock for the ten consecutive day period ending on, and including, the trading day immediately preceding the declaration date for such issuance; (iv) upon specified distributions to the Company's shareholders; or (v) upon the occurrence of specified corporate transactions, such as a fundamental change (i.e., a change in control), or the Company's Common Stock ceasing to be listed on at least one U.S. national securities exchange. On or after July 1, 2016, holders may convert their Notes at the conversion rate at any time prior to the close of business on the second scheduled trading day immediately preceding the maturity date irrespective of the foregoing conditions.</us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature>
  <!--Initial conversion price (in dollars per share)- Convertible Debt [Member]-->
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="c00261" unitRef="u002" decimals="2">84.02</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <!--Total convertible senior notes - par- Convertible Debt [Member]-->
  <us-gaap:DebtInstrumentCarryingAmount contextRef="c00039" unitRef="u000" decimals="-3">400000000</us-gaap:DebtInstrumentCarryingAmount>
  <!--Equity security- Unrestricted [Member] + Equity security- Unrestricted [Member]-->
  <regn:EquitySecurityFairValueDisclosure contextRef="c00034" unitRef="u000" decimals="-3">3019000</regn:EquitySecurityFairValueDisclosure>
  <!--Equity security- Unrestricted [Member] + Equity security- Unrestricted [Member]-->
  <regn:EquitySecurityFairValueDisclosure contextRef="c00090" unitRef="u000" decimals="-3">3612000</regn:EquitySecurityFairValueDisclosure>
  <!--Equity security- Unrestricted [Member]- Fair Value, Inputs, Level 1 [Member] + Equity security- Unrestricted [Member]- Fair Value, Inputs, Level 1 [Member]-->
  <regn:EquitySecurityFairValueDisclosure contextRef="c00040" unitRef="u000" decimals="-3">3019000</regn:EquitySecurityFairValueDisclosure>
  <!--Equity security- Unrestricted [Member]- Fair Value, Inputs, Level 1 [Member] + Equity security- Unrestricted [Member]- Fair Value, Inputs, Level 1 [Member]-->
  <regn:EquitySecurityFairValueDisclosure contextRef="c00095" unitRef="u000" decimals="-3">3612000</regn:EquitySecurityFairValueDisclosure>
  <!--Unrealized Net - Maturities after five years through ten years- Unrestricted [Member]- Mortgage-Backed Securities [Member] + Unrealized Net - Maturities after five years through ten years- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsUnrealizedGainsLossesNet contextRef="c00033" unitRef="u000" decimals="-3">-77000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsUnrealizedGainsLossesNet>
  <!--Unrealized Net - Maturities after five years through ten years- Unrestricted [Member]- Mortgage-Backed Securities [Member] + Unrealized Net - Maturities after five years through ten years- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsUnrealizedGainsLossesNet contextRef="c00089" unitRef="u000" decimals="-3">-41000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsUnrealizedGainsLossesNet>
  <!--Unrealized Net - Maturities after five years through ten years- Unrestricted [Member] + Unrealized Net - Maturities after five years through ten years- Unrestricted [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsUnrealizedGainsLossesNet contextRef="c00034" unitRef="u000" decimals="-3">-77000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsUnrealizedGainsLossesNet>
  <!--Unrealized Net - Maturities after five years through ten years- Unrestricted [Member] + Unrealized Net - Maturities after five years through ten years- Unrestricted [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsUnrealizedGainsLossesNet contextRef="c00090" unitRef="u000" decimals="-3">-41000</regn:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsUnrealizedGainsLossesNet>
  <!--Fair Value - Maturities after five years through ten years- Unrestricted [Member]- Mortgage-Backed Securities [Member] + Fair Value - Maturities after five years through ten years- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue contextRef="c00033" unitRef="u000" decimals="-3">87000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
  <!--Fair Value - Maturities after five years through ten years- Unrestricted [Member]- Mortgage-Backed Securities [Member] + Fair Value - Maturities after five years through ten years- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue contextRef="c00089" unitRef="u000" decimals="-3">243000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
  <!--Fair Value - Maturities after five years through ten years- Unrestricted [Member] + Fair Value - Maturities after five years through ten years- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue contextRef="c00034" unitRef="u000" decimals="-3">87000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
  <!--Fair Value - Maturities after five years through ten years- Unrestricted [Member] + Fair Value - Maturities after five years through ten years- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue contextRef="c00090" unitRef="u000" decimals="-3">243000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
  <!--Unrealized (Losses) - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Collateralized Mortgage Obligations [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss contextRef="c00031" unitRef="u000" decimals="-3">1000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss>
  <!--Unrealized (Losses) - Maturities within one year- Unrestricted [Member]- Municipal Bonds [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss contextRef="c00032" unitRef="u000" decimals="-3">1000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss>
  <!--Unrealized (Losses) - Maturities within one year- Unrestricted [Member] + Unrealized (Losses) - Maturities within one year- Unrestricted [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss contextRef="c00034" unitRef="u000" decimals="-3">2000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss>
  <!--Unrealized (Losses) - Maturities within one year- Unrestricted [Member] + Unrealized (Losses) - Maturities within one year- Unrestricted [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss contextRef="c00090" unitRef="u000" decimals="-3">33000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss>
  <!--Unrealized (Losses) - Maturities within one year- Unrestricted [Member]- U S Government Obligations [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss contextRef="c00085" unitRef="u000" decimals="-3">5000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss>
  <!--Unrealized (Losses) - Maturities within one year- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss contextRef="c00089" unitRef="u000" decimals="-3">28000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss>
  <!--Unrealized (Losses) - Maturities within one year- Restricted [Member]- U S Government Obligations [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss contextRef="c00091" unitRef="u000" decimals="-3">1000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss>
  <!--Accrued interest income + Accrued interest income + Accrued interest income-->
  <us-gaap:AccruedInvestmentIncomeReceivable contextRef="c00001" unitRef="u000" decimals="-5">700000</us-gaap:AccruedInvestmentIncomeReceivable>
  <!--Accrued interest income + Accrued interest income + Accrued interest income-->
  <us-gaap:AccruedInvestmentIncomeReceivable contextRef="c00060" unitRef="u000" decimals="-5">1400000</us-gaap:AccruedInvestmentIncomeReceivable>
  <!--Accrued interest income + Accrued interest income + Accrued interest income-->
  <us-gaap:AccruedInvestmentIncomeReceivable contextRef="c00112" unitRef="u000" decimals="-5">600000</us-gaap:AccruedInvestmentIncomeReceivable>
  <!--Capital lease obligations + Capital lease obligations-->
  <us-gaap:CapitalLeaseObligationsIncurred contextRef="c00124" unitRef="u000" decimals="-5">700000</us-gaap:CapitalLeaseObligationsIncurred>
  <!--Capital lease obligations + Capital lease obligations-->
  <us-gaap:CapitalLeaseObligationsIncurred contextRef="c00164" unitRef="u000" decimals="-5">2900000</us-gaap:CapitalLeaseObligationsIncurred>
  <!--Deferred revenue, current- Collaboration Agreement with Sanofi [Member] + Deferred revenue, current- Collaboration Agreement with Sanofi [Member]-->
  <us-gaap:DeferredRevenueCurrent contextRef="c00023" unitRef="u000" decimals="-3">20011000</us-gaap:DeferredRevenueCurrent>
  <!--Deferred revenue, current- Collaboration Agreement with Sanofi [Member] + Deferred revenue, current- Collaboration Agreement with Sanofi [Member]-->
  <us-gaap:DeferredRevenueCurrent contextRef="c00080" unitRef="u000" decimals="-3">19506000</us-gaap:DeferredRevenueCurrent>
  <!--Deferred revenue, current- Collaboration Agreement with Bayer HealthCare LLC [Member] + Deferred revenue, current- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <us-gaap:DeferredRevenueCurrent contextRef="c00024" unitRef="u000" decimals="-3">7907000</us-gaap:DeferredRevenueCurrent>
  <!--Deferred revenue, current- Collaboration Agreement with Bayer HealthCare LLC [Member] + Deferred revenue, current- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <us-gaap:DeferredRevenueCurrent contextRef="c00081" unitRef="u000" decimals="-3">9884000</us-gaap:DeferredRevenueCurrent>
  <!--Deferred revenue, current- Technology License Agreements [Member] + Deferred revenue, current- Technology License Agreements [Member]-->
  <us-gaap:DeferredRevenueCurrent contextRef="c00025" unitRef="u000" decimals="-3">23572000</us-gaap:DeferredRevenueCurrent>
  <!--Deferred revenue, current- Technology License Agreements [Member] + Deferred revenue, current- Technology License Agreements [Member]-->
  <us-gaap:DeferredRevenueCurrent contextRef="c00082" unitRef="u000" decimals="-3">25008000</us-gaap:DeferredRevenueCurrent>
  <!--Deferred revenue, current- Other Deferred Revenue Agreements [Member] + Deferred revenue, current- Other Deferred Revenue Agreements [Member]-->
  <us-gaap:DeferredRevenueCurrent contextRef="c00026" unitRef="u000" decimals="-3">150000</us-gaap:DeferredRevenueCurrent>
  <!--Deferred revenue, current- Other Deferred Revenue Agreements [Member] + Deferred revenue, current- Other Deferred Revenue Agreements [Member]-->
  <us-gaap:DeferredRevenueCurrent contextRef="c00083" unitRef="u000" decimals="-3">325000</us-gaap:DeferredRevenueCurrent>
  <!--Deferred revenue, current + Deferred revenue, current-->
  <us-gaap:DeferredRevenueCurrent contextRef="c00001" unitRef="u000" decimals="-3">51640000</us-gaap:DeferredRevenueCurrent>
  <!--Deferred revenue, current + Deferred revenue, current-->
  <us-gaap:DeferredRevenueCurrent contextRef="c00060" unitRef="u000" decimals="-3">54723000</us-gaap:DeferredRevenueCurrent>
  <!--Deferred net product sales recognized as revenue- Arcalyst Net Product Sales Member- Product Concentration Risk [Member]-->
  <us-gaap:RecognitionOfDeferredRevenue contextRef="c00118" unitRef="u000" decimals="-5">4800000</us-gaap:RecognitionOfDeferredRevenue>
  <!--Change in accounting estimate, decrease in depreciation expense-->
  <regn:ChangeInAccountingEstimateDecreaseInDepreciationExpense contextRef="c00164" unitRef="u000" decimals="-5">4000000</regn:ChangeInAccountingEstimateDecreaseInDepreciationExpense>
  <!--Amount of milestone payment received- Collaboration Agreement with Bayer HealthCare LLC [Member] + Amount of milestone payment received- Collaboration Agreement with Bayer HealthCare LLC [Member] + Amount of milestone payment received- Collaboration Agreement with Bayer HealthCare LLC [Member] + Amount of milestone payment received- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="c00243" unitRef="u000" decimals="-5">20000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <!--Amount of milestone payment received- Collaboration Agreement with Bayer HealthCare LLC [Member] + Amount of milestone payment received- Collaboration Agreement with Bayer HealthCare LLC [Member] + Amount of milestone payment received- Collaboration Agreement with Bayer HealthCare LLC [Member] + Amount of milestone payment received- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="c00242" unitRef="u000" decimals="-5">20000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <!--Amount of milestone payment received- Collaboration Agreement with Bayer HealthCare LLC [Member] + Amount of milestone payment received- Collaboration Agreement with Bayer HealthCare LLC [Member] + Amount of milestone payment received- Collaboration Agreement with Bayer HealthCare LLC [Member] + Amount of milestone payment received- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="c00241" unitRef="u000" decimals="-5">10000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <!--Amount of milestone payment received- Collaboration Agreement with Bayer HealthCare LLC [Member] + Amount of milestone payment received- Collaboration Agreement with Bayer HealthCare LLC [Member] + Amount of milestone payment received- Collaboration Agreement with Bayer HealthCare LLC [Member] + Amount of milestone payment received- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="c00240" unitRef="u000" decimals="-5">10000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <!--Adjusted maximum amount of annual funding per amended agreement- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:AdjustedMaximumAmountOfAnnualFundingPerAmendedAgreement contextRef="c00114" unitRef="u000" decimals="-6">120000000</regn:AdjustedMaximumAmountOfAnnualFundingPerAmendedAgreement>
  <!--Number of newly issued, unregistered shares of Common Stock purchased (in shares)- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member]-->
  <regn:NumberOfNewlyIssuedUnregisteredSharesOfCommonStockPurchased contextRef="c00232" unitRef="u001" decimals="0">2799552</regn:NumberOfNewlyIssuedUnregisteredSharesOfCommonStockPurchased>
  <!--Number of newly issued, unregistered shares of Common Stock purchased (in shares)- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:NumberOfNewlyIssuedUnregisteredSharesOfCommonStockPurchased contextRef="c00234" unitRef="u001" decimals="-3">12000000</regn:NumberOfNewlyIssuedUnregisteredSharesOfCommonStockPurchased>
  <!--Number of newly issued, unregistered shares of Common Stock purchased (in shares)- Sanofi [Member] + Number of newly issued, unregistered shares of Common Stock purchased (in shares)- Sanofi [Member] + Number of newly issued, unregistered shares of Common Stock purchased (in shares)- Sanofi [Member]-->
  <regn:NumberOfNewlyIssuedUnregisteredSharesOfCommonStockPurchased contextRef="c00233" unitRef="u001" decimals="0">2799552</regn:NumberOfNewlyIssuedUnregisteredSharesOfCommonStockPurchased>
  <!--Number of newly issued, unregistered shares of Common Stock purchased (in shares)- Sanofi [Member] + Number of newly issued, unregistered shares of Common Stock purchased (in shares)- Sanofi [Member] + Number of newly issued, unregistered shares of Common Stock purchased (in shares)- Sanofi [Member]-->
  <regn:NumberOfNewlyIssuedUnregisteredSharesOfCommonStockPurchased contextRef="c00264" unitRef="u001" decimals="0">1017401</regn:NumberOfNewlyIssuedUnregisteredSharesOfCommonStockPurchased>
  <!--Number of newly issued, unregistered shares of Common Stock purchased (in shares)- Sanofi [Member] + Number of newly issued, unregistered shares of Common Stock purchased (in shares)- Sanofi [Member] + Number of newly issued, unregistered shares of Common Stock purchased (in shares)- Sanofi [Member]-->
  <regn:NumberOfNewlyIssuedUnregisteredSharesOfCommonStockPurchased contextRef="c00235" unitRef="u001" decimals="0">12000000</regn:NumberOfNewlyIssuedUnregisteredSharesOfCommonStockPurchased>
  <!--Net cash provided by financing activities-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c00124" unitRef="u000" decimals="-3">384249000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <!--Net cash provided by financing activities-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c00164" unitRef="u000" decimals="-3">243306000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <!--Net cash provided by financing activities-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c00195" unitRef="u000" decimals="-3">31363000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <!--Current Fiscal Year End Date-->
  <dei:CurrentFiscalYearEndDate contextRef="c00124">--12-31</dei:CurrentFiscalYearEndDate>
  <!--Entity Well-known Seasoned Issuer-->
  <dei:EntityWellKnownSeasonedIssuer contextRef="c00124">Yes</dei:EntityWellKnownSeasonedIssuer>
  <!--Accounts receivable from Sanofi-->
  <us-gaap:DueFromRelatedPartiesCurrent contextRef="c00001" unitRef="u000" decimals="-3">74781000</us-gaap:DueFromRelatedPartiesCurrent>
  <!--Accounts receivable from Sanofi-->
  <us-gaap:DueFromRelatedPartiesCurrent contextRef="c00060" unitRef="u000" decimals="-3">79603000</us-gaap:DueFromRelatedPartiesCurrent>
  <!--Amounts receivable from collaboration agreements- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member] + Amounts receivable from collaboration agreements- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <us-gaap:DueFromRelatedPartiesCurrent contextRef="c00011" unitRef="u000" decimals="-5">78500000</us-gaap:DueFromRelatedPartiesCurrent>
  <!--Amounts receivable from collaboration agreements- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member] + Amounts receivable from collaboration agreements- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <us-gaap:DueFromRelatedPartiesCurrent contextRef="c00069" unitRef="u000" decimals="-5">75700000</us-gaap:DueFromRelatedPartiesCurrent>
  <!--Amounts receivable from collaboration agreements- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member]-->
  <us-gaap:DueFromRelatedPartiesCurrent contextRef="c00068" unitRef="u000" decimals="-5">3900000</us-gaap:DueFromRelatedPartiesCurrent>
  <!--Amounts receivable from collaboration agreements- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <us-gaap:DueFromRelatedPartiesCurrent contextRef="c00013" unitRef="u000" decimals="-5">4500000</us-gaap:DueFromRelatedPartiesCurrent>
  <!--Collaboration and Contract Research Agreements-->
  <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="c00124">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;3.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Collaboration and Contract Research Agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company has entered into various agreements related to its activities to develop and commercialize product candidates and utilize its technology platforms.&amp;#160;&amp;#160;Significant agreements of this kind are described below.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;br /&gt;&amp;#160;&lt;/div&gt;&lt;div&gt;&lt;table border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 18pt"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;a.&amp;#160;&amp;#160;&amp;#160;Sanofi&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;As described in Note 13, Sanofi has purchased a total of 15,816,953 shares of the Company&amp;#8217;s Common Stock, principally in connection with the companies&amp;#8217; ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174; &lt;/font&gt;and antibody collaborations described below.&amp;#160;&amp;#160;Total Company-incurred expenses associated with these Sanofi collaborations, which include reimbursable and non-reimbursable amounts and an allocable portion of general and administrative costs, were $318.2 million in 2011, $282.4 million in 2010, and $209.4 million in 2009.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;ZALTRAP&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174; &lt;/font&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;( aflibercept)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In September 2003, the Company entered into a collaboration agreement (the &amp;#8220;ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174; &lt;/font&gt;Agreement&amp;#8221;) with Aventis Pharmaceuticals Inc. (predecessor to Sanofi U.S.), to jointly develop and commercialize ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt;.&amp;#160;&amp;#160;In connection with this agreement, Sanofi made a non-refundable up-front payment of $80.0 million and purchased 2,799,552 newly issued unregistered shares of the Company&amp;#8217;s Common Stock for $45.0 million.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In January 2005, the Company and Sanofi amended the ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; Agreement to exclude intraocular delivery of aflibercept to the eye (&amp;#8220;Intraocular Delivery&amp;#8221;) from joint development under the agreement, and product rights to aflibercept in Intraocular Delivery reverted to Regeneron.&amp;#160;&amp;#160;In connection with this amendment, Sanofi made a $25.0 million non-refundable payment to Regeneron (the &amp;#8220;Intraocular Termination Payment&amp;#8221;).&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In December 2005, the Company and Sanofi amended the ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; Agreement to expand the territory in which the companies are collaborating on the development of ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; to include Japan.&amp;#160;&amp;#160;In connection with this amendment, Sanofi agreed to make a $25.0 million non-refundable up-front payment to the Company, which was received in January 2006.&amp;#160;&amp;#160;Under the ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; Agreement, as amended, the Company and Sanofi will share co-promotion rights and profits on sales, if any, of ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; outside of Japan, for disease indications included in the companies&amp;#8217; collaboration.&amp;#160;&amp;#160;The Company is entitled to a royalty of approximately 35% on annual sales of ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; in Japan, subject to certain potential adjustments.&amp;#160;&amp;#160;The Company may also receive up to $400 million in substantive milestone payments upon receipt of specified marketing approvals, including up to $360 million in milestone payments related to the receipt of marketing approvals for up to eight ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; oncology and other indications in the United States or the European Union and up to $40 million related to the receipt of marketing approvals for up to five ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; oncology indications in Japan.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Under the ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-WEIGHT: bold"&gt;&amp;#174;&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;&amp;#160;&lt;/font&gt;Agreement, as amended, agreed upon worldwide development expenses incurred by both companies during the term of the agreement will be funded by Sanofi.&amp;#160;&amp;#160;If the collaboration becomes profitable, Regeneron will be obligated to reimburse Sanofi for 50% of these development expenses, or half of $763.4 million as of December 31, 2011, in accordance with a formula based on the amount of development expenses and Regeneron&amp;#8217;s share of the collaboration profits and Japan royalties, or at a faster rate at Regeneron&amp;#8217;s option.&amp;#160;&amp;#160;Regeneron has the option to conduct additional pre-Phase III studies at its own expense.&amp;#160;&amp;#160;In connection with the January 2005 amendment to the ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-WEIGHT: bold"&gt;&amp;#174;&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;&amp;#160;&lt;/font&gt;Agreement, the Intraocular Termination Payment of $25.0 million will also be subject to 50% reimbursement by Regeneron to Sanofi if the collaboration becomes profitable.&amp;#160;&amp;#160;In addition, if the first commercial sale of an aflibercept product in Intraocular Delivery predates the first commercial sale of a ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; product under the collaboration by two years, Regeneron will begin reimbursing Sanofi for up to $7.5 million of ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; development expenses in accordance with a formula until the first commercial ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; sale under the collaboration occurs.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Sanofi has the right to terminate the agreement without cause with at least twelve months advance notice.&amp;#160;&amp;#160;Upon termination of the agreement for any reason, Regeneron&amp;#8217;s obligation to reimburse Sanofi, for 50% of ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; development expenses will terminate, and the Company will retain all rights to ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In accordance with the Company&amp;#8217;s revenue recognition policy described in Note 2, the up-front payments received in September 2003 and January 2006, of $80.0 million and $25.0 million, respectively, and reimbursement of Regeneron-incurred development expenses, are being recognized as collaboration revenue over the related performance period.&amp;#160;&amp;#160;In addition, in 2011, the Company and Sanofi began equally sharing ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174; &lt;/font&gt;pre-launch commercialization expenses under the ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-WEIGHT: bold"&gt;&amp;#174;&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#160;&lt;/font&gt;Agreement.&amp;#160;&amp;#160;The Company&amp;#8217;s share of these expenses was $9.3 million in 2011, which reduced collaboration revenue in connection with the ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-WEIGHT: bold"&gt;&amp;#174;&lt;/font&gt; Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company recognized $17.5 million, $26.4 million, and $36.5 million of collaboration revenue in 2011, 2010, and 2009, respectively, in connection with the ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-WEIGHT: bold"&gt;&amp;#174;&lt;/font&gt; Agreement, as amended.&amp;#160;&amp;#160;In connection with the ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; Agreement, (i) at December 31, 2011, there was a net payable of $3.7 million to Sanofi, (ii) at December 31, 2010, amounts receivable from Sanofi were $3.9 million, and (iii) deferred revenue at December 31, 2011 and 2010 was $22.9 million and $32.6 million, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;Antibodies&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In November 2007, the Company entered into a global, strategic collaboration (the &amp;#8220;Antibody Collaboration&amp;#8221;) with Sanofi to discover, develop, and commercialize fully human monoclonal antibodies&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;.&amp;#160;&amp;#160;&lt;/font&gt;In connection with the collaboration, in December 2007, Sanofi purchased 12 million newly issued, unregistered shares of the Company&amp;#8217;s Common Stock for $312.0 million (see Note 13).&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Antibody Collaboration is governed by a Discovery and Preclinical Development Agreement (the &amp;#8220;Discovery Agreement&amp;#8221;) and a License and Collaboration Agreement (the &amp;#8220;License Agreement&amp;#8221;).&amp;#160;&amp;#160;In connection with the execution of the Discovery Agreement in 2007, the Company received a non-refundable up-front payment of $85.0 million from Sanofi.&amp;#160;&amp;#160;In addition, under the Discovery Agreement, Sanofi is funding the Company&amp;#8217;s research to identify and validate potential drug discovery targets and develop fully human monoclonal antibodies against these targets.&amp;#160;&amp;#160;In November 2009, the Company and Sanofi amended these collaboration agreements to expand and extend the Antibody Collaboration.&amp;#160;&amp;#160;Pursuant to the Discovery Agreement, as amended, Sanofi agreed to fund up to $160 million per year of the Company&amp;#8217;s research activities in 2010 through 2017, subject to a one-time option for Sanofi to adjust the maximum reimbursement amount down to $120 million per year commencing in 2014 if over the prior two years certain specified criteria were not satisfied.&amp;#160;&amp;#160;In 2010, as the Company scaled up its capacity to conduct antibody discovery activities, Sanofi funded $137.7 million of the Company&amp;#8217;s preclinical research under the amended Discovery Agreement.&amp;#160;&amp;#160;The balance between that amount and $160 million, or $22.3 million, has been added to the funding otherwise available to the Company in 2011-2012 under the amended Discovery Agreement.&amp;#160;&amp;#160;The amended Discovery Agreement will expire on December 31, 2017; however, Sanofi has an option to extend the agreement for up to an additional three years for further antibody development and preclinical activities.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;For each drug candidate identified under the Discovery Agreement, Sanofi has the option to license rights to the candidate under the License Agreement.&amp;#160;&amp;#160;If it elects to do so, Sanofi will co-develop the drug candidate with the Company through product approval.&amp;#160;&amp;#160;Under certain defined circumstances, upon exercising its option to license rights to particular candidates, Sanofi must make a $10 million substantive milestone payment to the Company.&amp;#160;&amp;#160;If Sanofi does not exercise its option to license rights to a particular drug candidate under the License Agreement, the Company retains the exclusive right to develop and commercialize such drug candidate, and Sanofi will receive a royalty on sales, if any.&amp;#160;&amp;#160;The Company and Sanofi are currently co-developing seven therapeutic antibodies under the License Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Under the License Agreement, agreed upon worldwide development expenses incurred by both companies during the term of the agreement are funded by Sanofi, except that following receipt of the first positive Phase 3 trial results for a co-developed drug candidate, subsequent Phase 3 trial-related costs for that drug candidate (&amp;#8220;Shared Phase 3 Trial Costs&amp;#8221;) are shared 80% by Sanofi and 20% by Regeneron.&amp;#160;&amp;#160;If the Antibody Collaboration becomes profitable, Regeneron will be obligated to reimburse Sanofi for 50% of development expenses that were fully funded by Sanofi (or half of $582.3 million as of December 31, 2011) and 30% of Shared Phase 3 Trial Costs, in accordance with a defined formula based on the amounts of these expenses and the Company&amp;#8217;s share of collaboration profits from commercialization of collaboration products.&amp;#160;&amp;#160;However, the Company is not required to apply more than 10% of its share of the profits from the antibody collaboration in any calendar quarter to reimburse Sanofi for these development costs.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Sanofi will lead commercialization activities for products developed under the License Agreement, subject to the Company&amp;#8217;s right to co-promote such products.&amp;#160;&amp;#160;The parties will equally share profits and losses from sales within the United States.&amp;#160;&amp;#160;The parties will share profits outside the United States on a sliding scale based on sales starting at 65% (Sanofi)/35% (Regeneron) and ending at 55% (Sanofi)/45% (Regeneron), and losses outside the United States at 55% (Sanofi)/45% (Regeneron).&amp;#160;&amp;#160;In addition to profit sharing, the Company is entitled to receive up to $250 million in sales milestone payments, with milestone payments commencing only if and after aggregate annual sales outside the United States exceed $1.0 billion on a rolling 12-month basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Regeneron is obligated to use commercially reasonable efforts to supply clinical requirements of each drug candidate under the Antibody Collaboration until commercial supplies of that drug candidate are being manufactured.&amp;#160;&amp;#160;In connection with the November 2009 amendment of the collaboration&amp;#8217;s Discovery Agreement, Sanofi is funding up to $30 million of agreed-upon costs incurred by the Company to expand its manufacturing capacity at the Company&amp;#8217;s Rensselaer, New York facilities, of which $28.2 million has been received or is receivable at December 31, 2011.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;With respect to each antibody product which enters development under the License Agreement, Sanofi or the Company may, by giving twelve months notice, opt-out of further development and/or commercialization of the product, in which event the other party retains exclusive rights to continue the development and/or commercialization of the product.&amp;#160;&amp;#160;The Company may also opt-out of the further development of an antibody product if it gives notice to Sanofi within thirty days of the date that Sanofi enters joint development of such antibody product under the License Agreement.&amp;#160;&amp;#160;Each of the Discovery Agreement and the License Agreement contains other termination provisions, including for material breach by the other party.&amp;#160;&amp;#160;Prior to December 31, 2017, Sanofi has the right to terminate the amended Discovery Agreement without cause with at least three months advance written notice; however, except under defined circumstances, Sanofi would be obligated to immediately pay to the Company the full amount of unpaid research funding during the remaining term of the research agreement through December 31, 2017.&amp;#160;&amp;#160;Upon termination of the collaboration in its entirety, the Company&amp;#8217;s obligation to reimburse Sanofi for development costs out of any future profits from collaboration products will terminate.&amp;#160;&amp;#160;Upon expiration of the amended Discovery Agreement, Sanofi has an option to license the Company&amp;#8217;s &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;VelocImmune&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; technology for agreed upon consideration.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In connection with the Antibody Collaboration, in August 2008, the Company entered into a separate agreement with Sanofi to use Regeneron's proprietary &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;VelociGene&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; technology platform to supply Sanofi with genetically modified mammalian models of gene function and disease (the &amp;#8220;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;VelociGene&lt;/font&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; Agreement&amp;#8221;)&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;.&lt;/font&gt;&amp;#160;&amp;#160;The &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;VelociGene&lt;/font&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; Agreement provides for minimum annual order quantities for the term of the agreement, which extends through December 2012, for which the Company expects to receive payments totaling a minimum of $21.5 million.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In accordance with the Company&amp;#8217;s revenue recognition policy described in Note 2, the (i) $85.0 million up-front payment received in December 2007, (ii) reimbursement of Regeneron-incurred expenses under the Discovery and License Agreements, (iii) $21.5 million of aggregate minimum payments under the &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;VelociGene&lt;/font&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; Agreement, and (iv) reimbursement of agreed-upon costs to expand the Company&amp;#8217;s manufacturing capacity are being recognized as collaboration revenue over the related performance period.&amp;#160;&amp;#160;In connection with the amendments to expand and extend the Company&amp;#8217;s antibody collaboration with Sanofi, during the fourth quarter of 2009, the Company extended its estimated performance period related to the $85.0 million up-front payment received from Sanofi under the Discovery Agreement and the $21.5 million of aggregate minimum payments under the &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;VelociGene&lt;/font&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; Agreement.&amp;#160;&amp;#160;The effect of this change in estimate resulted in the recognition of $5.3 million less in collaboration revenue in both 2011 and 2010, compared to 2009.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In connection with the Antibody Collaboration, the Company recognized $309.1 million, $284.9 million, and $210.7 million of collaboration revenue in 2011, 2010, and 2009, respectively.&amp;#160;&amp;#160;In addition, at December 31, 2011 and 2010, amounts receivable from Sanofi totaled $78.5 million and $75.7 million and deferred revenue was $83.1 million and $84.0 million, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 18pt" align="right"&gt;&lt;div&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;b.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Bayer HealthCare LLC&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In October 2006, the Company entered into a license and collaboration agreement with Bayer HealthCare for the global development and commercialization outside the United States of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt;.&amp;#160;&amp;#160;Under the terms of the agreement, Bayer HealthCare made a non-refundable up-front payment to the Company of $75.0 million.&amp;#160;&amp;#160;In August 2007, the Company received a $20.0 million milestone payment from Bayer HealthCare following dosing of the first patient in a Phase 3 study of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; in the neovascular form of wet AMD.&amp;#160;&amp;#160;In July 2009, the Company received a $20.0 million substantive milestone payment from Bayer HealthCare following dosing of the first patient in a Phase 3 study of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; in central retinal vein occlusion (&amp;#8220;CRVO&amp;#8221;).&amp;#160;&amp;#160;In the fourth quarter of 2010, the Company earned two $10.0 million substantive milestone payments (for a total of $20.0 million) from Bayer HealthCare for achieving positive 52-week results in the Phase 3 study of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; in wet AMD and positive 6-month results in the Phase 3 study of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; in CRVO.&amp;#160;&amp;#160;One of these $10.0 million payments was received in December 2010 and the other $10.0 million payment was received in January 2011.&amp;#160;&amp;#160;The Company is eligible to receive up to $50 million in future substantive milestone payments related to marketing approvals of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; in major market countries outside the United States.&amp;#160;&amp;#160;The Company is also eligible to receive up to $135 million in sales milestone payments when and if total annual sales of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; outside the United States achieve certain specified levels starting at $200 million.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company will share equally with Bayer HealthCare in any future profits arising from the commercialization of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; outside the United States.&amp;#160;&amp;#160;If EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; is granted marketing authorization in a major market country outside the United States and the collaboration becomes profitable, the Company will be obligated to reimburse Bayer HealthCare out of its share of the collaboration profits for 50% of the agreed upon development expenses that Bayer HealthCare has incurred (or half of $370.9 million as of December 31, 2011) in accordance with a formula based on the amount of development expenses that Bayer HealthCare has incurred and the Company&amp;#8217;s share of the collaboration profits, or at a faster rate at the Company&amp;#8217;s option.&amp;#160;&amp;#160;Within the United States, the Company is responsible for commercialization of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; and retains exclusive rights to any profits from such commercialization in the United States.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Starting in 2009, all agreed upon EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; development expenses incurred by the Company and Bayer HealthCare, under a global development plan, are being shared equally.&amp;#160;&amp;#160;The Company is also obligated to use commercially reasonable efforts to supply clinical and commercial product requirements.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Bayer HealthCare has the right to terminate the Bayer Agreement without cause with at least six months or twelve months advance notice depending on defined circumstances at the time of termination.&amp;#160;&amp;#160;In the event of termination of the agreement for any reason, the Company retains all rights to EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The $75.0 million up-front licensing payment and the $20.0 million milestone payment received in August 2007 from Bayer HealthCare are being recognized as collaboration revenue over the related estimated performance period in accordance with the Company&amp;#8217;s revenue recognition policy as described in Note 2.&amp;#160;&amp;#160;&amp;#160;&amp;#160;In periods when the Company recognizes EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; development expenses that the Company incurs under the collaboration, the Company also recognizes, as collaboration revenue, the portion of those EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; development expenses that is reimbursable from Bayer HealthCare.&amp;#160;&amp;#160;In periods when Bayer HealthCare incurs agreed upon EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; development expenses that benefit the collaboration and Regeneron, the Company also recognizes, as additional research and development expense, the portion of Bayer HealthCare&amp;#8217;s EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; development expenses that the Company is obligated to reimburse.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company recognized $43.1 million, $75.4 million, and $67.3 million of collaboration revenue from Bayer HealthCare in 2011, 2010, and 2009, respectively.&amp;#160;&amp;#160;In both 2010 and 2009, collaboration revenue from Bayer HealthCare included $20.0 million in milestone payments, as described above, which, for the purpose of revenue recognition, were considered substantive.&amp;#160;&amp;#160;In addition, in 2011, 2010, and 2009, the Company recognized as additional research and development expense $47.8 million, $48.9 million, and $37.7 million, respectively, of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; development expenses that the Company was obligated to reimburse to Bayer HealthCare.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In connection with cost-sharing of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; expenses under the collaboration, $4.5 million was receivable from Bayer HealthCare at December 31, 2011 and $2.3 million was payable to Bayer HealthCare at December 31, 2010.&amp;#160;&amp;#160;In addition, at December 31, 2011 and 2010, deferred revenue from the Company&amp;#8217;s collaboration with Bayer HealthCare was $42.4 million and $47.0 million, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;br /&gt;&amp;#160;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 18pt" align="right"&gt;&lt;div&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;c.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;National Institute of Health&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;br /&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In September 2006, the Company was awarded a grant from the National Institutes of Health (&amp;#8220;NIH&amp;#8221;) as part of the NIH&amp;#8217;s Knockout Mouse Project.&amp;#160;&amp;#160;As amended, the NIH grant provided a minimum of $25.3 million in funding over a five-year period, including $1.5 million in funding to optimize certain existing technology, subject to compliance with its terms and annual funding approvals, for the Company&amp;#8217;s use of its &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;VelociGene&lt;/font&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;&amp;#160;&lt;/font&gt;technology to generate a collection of targeting vectors and targeted mouse embryonic stem cells which can be used to produce knockout mice.&amp;#160;&amp;#160;The Company records revenue in connection with the NIH grant using a proportional performance model as it incurs expenses related to the grant, subject to the grant&amp;#8217;s terms and annual funding approvals.&amp;#160;&amp;#160;In 2011, 2010, and 2009, the Company recognized contract research revenue of $3.6 million, $4.6 million, and $5.5 million, respectively, from the NIH Grant.&amp;#160;&amp;#160;As of the end of 2011, no further revenue will be recognized by the Company in connection with this NIH Grant.&lt;/font&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
  <!--Patents-->
  <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c00124">&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Patents&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;As a result of the Company's research and development efforts, the Company obtains and applies for patents to protect proprietary technology and inventions.&amp;#160;&amp;#160;All costs associated with patents for product candidates under development are expensed as incurred.&amp;#160;Patent costs related to commercial products are capitalized and amortized over the shorter of their estimated useful life or the remaining patent term.&amp;#160;&amp;#160;To date, the Company has no capitalized patent costs.&lt;/font&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
  <!--Accounting for the Impairment of Long-Lived Assets-->
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Accounting for the Impairment of Long-Lived Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company periodically assesses the recoverability of long-lived assets, such as property, plant, and equipment, and evaluates such assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&amp;#160;&amp;#160;Asset impairment is determined to exist if estimated future undiscounted cash flows are less than the carrying amount.&amp;#160;&amp;#160;For all periods presented, no impairment losses were recorded.&lt;/font&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <!--Summarized Quarterly Financial Data-->
  <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Summarized quarterly financial data for the years ended December 31, 2011 and 2010 are set forth in the following tables.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;First Quarter&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;March 31, 2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Second Quarter Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;June 30, 2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Third Quarter Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;September 30, 2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="17%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Fourth Quarter&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;December 31, 2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="64%" colspan="4"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;(Unaudited)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;$112,204&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$107,810&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$102,833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="17%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$122,977&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;(43,447)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;(62,505)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;(62,365)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="17%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;(53,443)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Net loss per share, basic and diluted:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;$(0.49)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;$(0.69)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;$(0.68)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="17%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;$(0.58)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;First Quarter&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;March 31, 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Second Quarter Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;June 30, 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Third Quarter Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;September 30, 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="17%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Fourth Quarter&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;December 31, 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="64%" colspan="4"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;(Unaudited)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;$103,534&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$115,886&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$105,979&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="17%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$133,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;(30,522)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;(25,474)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;(33,875)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="17%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;(14,597)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Net loss per share, basic and diluted:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;$(0.38)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;$(0.31)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;$(0.41)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="17%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;$(0.17)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
  <!--Basic and Diluted Net Loss Per Share-->
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The calculations of basic and diluted net loss per share are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="37%" colspan="3"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Net loss (Numerator)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$(221,760)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$(104,468)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$(67,830)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%" align="left"&gt;&lt;div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Weighted-average shares, in thousands (Denominator)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;90,610&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;82,926&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;79,782&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Basic and diluted net loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$(2.45)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$(1.26)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$(0.85)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <!--Convertible senior notes-->
  <us-gaap:DeferredTaxLiabilitiesFinancingArrangements contextRef="c00001" unitRef="u000" decimals="-3">1428000</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
  <!--Granted (in shares)- Restricted Stock [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c00156" unitRef="u001" decimals="0">16500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <!--Outstanding, beginning of period (in shares)- Restricted Stock [Member] + Outstanding, beginning of period (in shares)- Restricted Stock [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c00106" unitRef="u001" decimals="0">845000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <!--Outstanding, beginning of period (in shares)- Restricted Stock [Member] + Outstanding, beginning of period (in shares)- Restricted Stock [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c00057" unitRef="u001" decimals="0">751499</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <!--Outstanding, end of period, weighted-average remaining contractual term (in years)- Stock Options [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c00054" unitRef="u006" decimals="2">6.90</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1>
  <!--Exercised, weighted-average exercise price (in dollars per share)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c00054" unitRef="u002" decimals="2">18.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <!--Exercisable, end of period (in shares)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c00054" unitRef="u001" decimals="0">11963345</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <!--Description of period of 'standstill' provisions- Sanofi [Member]-->
  <regn:DescriptionOfPeriodOfStandstillProvisions contextRef="c00236">Until the later of the fifth anniversaries of the expiration or earlier termination of the License and Collaboration Agreement</regn:DescriptionOfPeriodOfStandstillProvisions>
  <!--Royalty rate, maximum (in hundredths)- Agreements with Royalty Provisions [Member]-->
  <regn:RoyaltyRateMaximum contextRef="c00149" unitRef="u004" decimals="3">0.165</regn:RoyaltyRateMaximum>
  <!--Royalty expense- Agreements with Royalty Provisions [Member] + Royalty expense- Agreements with Royalty Provisions [Member] + Royalty expense- Agreements with Royalty Provisions [Member]-->
  <us-gaap:RoyaltyExpense contextRef="c00149" unitRef="u000" decimals="-5">3200000</us-gaap:RoyaltyExpense>
  <!--Royalty expense- Agreements with Royalty Provisions [Member] + Royalty expense- Agreements with Royalty Provisions [Member] + Royalty expense- Agreements with Royalty Provisions [Member]-->
  <us-gaap:RoyaltyExpense contextRef="c00185" unitRef="u000" decimals="-5">1700000</us-gaap:RoyaltyExpense>
  <!--Royalty expense- Agreements with Royalty Provisions [Member] + Royalty expense- Agreements with Royalty Provisions [Member] + Royalty expense- Agreements with Royalty Provisions [Member]-->
  <us-gaap:RoyaltyExpense contextRef="c00215" unitRef="u000" decimals="-5">1500000</us-gaap:RoyaltyExpense>
  <!--Total- Equipment [Member]-->
  <us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments contextRef="c00020" unitRef="u000" decimals="-3">2506000</us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments>
  <!--2012-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="c00001" unitRef="u000" decimals="-3">7260000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <!--2012- Equipment [Member]-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="c00020" unitRef="u000" decimals="-3">1188000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <!--2012- Building [Member]-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="c00046" unitRef="u000" decimals="-3">6072000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <!--Number of marketable securities held- Fair Value, Inputs, Level 3 [Member] + Number of marketable securities held- Fair Value, Inputs, Level 3 [Member]-->
  <regn:NumberOfMarketableSecuritiesHeld contextRef="c00045" unitRef="u006" decimals="0">1</regn:NumberOfMarketableSecuritiesHeld>
  <!--Number of marketable securities held- Fair Value, Inputs, Level 3 [Member] + Number of marketable securities held- Fair Value, Inputs, Level 3 [Member]-->
  <regn:NumberOfMarketableSecuritiesHeld contextRef="c00100" unitRef="u006" decimals="0">1</regn:NumberOfMarketableSecuritiesHeld>
  <!--Gross proceeds from the issuance of the Notes- Convertible Debt [Member]-->
  <regn:GrossProceedsFromIssuanceOfNotes contextRef="c00258" unitRef="u000" decimals="-5">392000000</regn:GrossProceedsFromIssuanceOfNotes>
  <!--U.S. government obligations- Unrestricted [Member] + U.S. government obligations- Unrestricted [Member]-->
  <regn:USGovernmentObligationsFairValueDisclosure contextRef="c00034" unitRef="u000" decimals="-3">284819000</regn:USGovernmentObligationsFairValueDisclosure>
  <!--U.S. government obligations- Unrestricted [Member] + U.S. government obligations- Unrestricted [Member]-->
  <regn:USGovernmentObligationsFairValueDisclosure contextRef="c00090" unitRef="u000" decimals="-3">434367000</regn:USGovernmentObligationsFairValueDisclosure>
  <!--U.S. government obligations- Restricted [Member] + U.S. government obligations- Restricted [Member]-->
  <regn:USGovernmentObligationsFairValueDisclosure contextRef="c00036" unitRef="u000" decimals="-3">5940000</regn:USGovernmentObligationsFairValueDisclosure>
  <!--U.S. government obligations- Restricted [Member] + U.S. government obligations- Restricted [Member]-->
  <regn:USGovernmentObligationsFairValueDisclosure contextRef="c00092" unitRef="u000" decimals="-3">7039000</regn:USGovernmentObligationsFairValueDisclosure>
  <!--U.S. government obligations- Unrestricted [Member]- Fair Value, Inputs, Level 2 [Member] + U.S. government obligations- Unrestricted [Member]- Fair Value, Inputs, Level 2 [Member]-->
  <regn:USGovernmentObligationsFairValueDisclosure contextRef="c00041" unitRef="u000" decimals="-3">284819000</regn:USGovernmentObligationsFairValueDisclosure>
  <!--U.S. government obligations- Unrestricted [Member]- Fair Value, Inputs, Level 2 [Member] + U.S. government obligations- Unrestricted [Member]- Fair Value, Inputs, Level 2 [Member]-->
  <regn:USGovernmentObligationsFairValueDisclosure contextRef="c00096" unitRef="u000" decimals="-3">434367000</regn:USGovernmentObligationsFairValueDisclosure>
  <!--U.S. government obligations- Restricted [Member]- Fair Value, Inputs, Level 2 [Member] + U.S. government obligations- Restricted [Member]- Fair Value, Inputs, Level 2 [Member]-->
  <regn:USGovernmentObligationsFairValueDisclosure contextRef="c00044" unitRef="u000" decimals="-3">5940000</regn:USGovernmentObligationsFairValueDisclosure>
  <!--U.S. government obligations- Restricted [Member]- Fair Value, Inputs, Level 2 [Member] + U.S. government obligations- Restricted [Member]- Fair Value, Inputs, Level 2 [Member]-->
  <regn:USGovernmentObligationsFairValueDisclosure contextRef="c00097" unitRef="u000" decimals="-3">7039000</regn:USGovernmentObligationsFairValueDisclosure>
  <!--Fair Value - 12 Months or Greater- Unrestricted [Member]- Mortgage-Backed Securities [Member] + Fair Value - 12 Months or Greater- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue contextRef="c00033" unitRef="u000" decimals="-3">116000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
  <!--Fair Value - 12 Months or Greater- Unrestricted [Member]- Mortgage-Backed Securities [Member] + Fair Value - 12 Months or Greater- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue contextRef="c00089" unitRef="u000" decimals="-3">1128000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
  <!--Fair Value - 12 Months or Greater + Fair Value - 12 Months or Greater-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue contextRef="c00001" unitRef="u000" decimals="-3">116000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
  <!--Fair Value - 12 Months or Greater + Fair Value - 12 Months or Greater-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue contextRef="c00060" unitRef="u000" decimals="-3">1128000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
  <!--Fair Value - Total- Unrestricted [Member]- U S Government Guaranteed Corporate Bonds [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue contextRef="c00086" unitRef="u000" decimals="-3">19005000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
  <!--Fair Value - 12 Months or Greater- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue contextRef="c00090" unitRef="u000" decimals="-3">1128000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
  <!--Fair value of equity securities- Equity Securities [Member] + Fair value of equity securities- Equity Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesEquitySecurities contextRef="c00084" unitRef="u000" decimals="-5">3600000</us-gaap:AvailableForSaleSecuritiesEquitySecurities>
  <!--Fair value of equity securities- Equity Securities [Member] + Fair value of equity securities- Equity Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesEquitySecurities contextRef="c00028" unitRef="u000" decimals="-5">3000000</us-gaap:AvailableForSaleSecuritiesEquitySecurities>
  <!--Accrued payroll and related costs + Accrued payroll and related costs-->
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c00001" unitRef="u000" decimals="-3">42835000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <!--Accrued payroll and related costs + Accrued payroll and related costs-->
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c00060" unitRef="u000" decimals="-3">12025000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <!--Amount of milestone payments earned- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <regn:AmountOfMilestonePaymentsEarned contextRef="c00245" unitRef="u000" decimals="-5">20000000</regn:AmountOfMilestonePaymentsEarned>
  <!--Expenses under the collaboration payable to collaborating party- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <regn:PayableToBayerHealthcare contextRef="c00070" unitRef="u000" decimals="-5">2300000</regn:PayableToBayerHealthcare>
  <!--Period of notice to opt-out of further development upon entering of joint development product (in days)- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:PeriodOfNoticeToOptOutOfFurtherDevelopmentUponEnteringOfJointDevelopmentProduct contextRef="c00135">30D   </regn:PeriodOfNoticeToOptOutOfFurtherDevelopmentUponEnteringOfJointDevelopmentProduct>
  <!--Development expenses incurred to date- Collaboration Agreement with Sanofi [Member]-->
  <regn:DevelopmentExpensesIncurredToDate contextRef="c00009" unitRef="u000" decimals="-5">763400000</regn:DevelopmentExpensesIncurredToDate>
  <!--Development expenses incurred to date- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:DevelopmentExpensesIncurredToDate contextRef="c00011" unitRef="u000" decimals="-5">582300000</regn:DevelopmentExpensesIncurredToDate>
  <!--Development expenses incurred to date- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <regn:DevelopmentExpensesIncurredToDate contextRef="c00013" unitRef="u000" decimals="-5">370900000</regn:DevelopmentExpensesIncurredToDate>
  <!--Useful life, minimum (in years)- Building and Building Improvements [Member]-->
  <us-gaap:PropertyPlantAndEquipmentUsefulLifeMinimum contextRef="c00131" unitRef="u005" decimals="0">10</us-gaap:PropertyPlantAndEquipmentUsefulLifeMinimum>
  <!--Useful life, minimum (in years)- Equipment [Member]-->
  <us-gaap:PropertyPlantAndEquipmentUsefulLifeMinimum contextRef="c00132" unitRef="u005" decimals="0">3</us-gaap:PropertyPlantAndEquipmentUsefulLifeMinimum>
  <!--Depreciation and amortization-->
  <regn:DepreciationAndAmortizationLessAmountsCapitalized contextRef="c00124" unitRef="u000" decimals="-3">31082000</regn:DepreciationAndAmortizationLessAmountsCapitalized>
  <!--Depreciation and amortization-->
  <regn:DepreciationAndAmortizationLessAmountsCapitalized contextRef="c00164" unitRef="u000" decimals="-3">19687000</regn:DepreciationAndAmortizationLessAmountsCapitalized>
  <!--Depreciation and amortization-->
  <regn:DepreciationAndAmortizationLessAmountsCapitalized contextRef="c00195" unitRef="u000" decimals="-3">14247000</regn:DepreciationAndAmortizationLessAmountsCapitalized>
  <!--Document Fiscal Period Focus-->
  <dei:DocumentFiscalPeriodFocus contextRef="c00124">FY</dei:DocumentFiscalPeriodFocus>
  <!--Additional paid-in capital-->
  <us-gaap:AdditionalPaidInCapital contextRef="c00001" unitRef="u000" decimals="-3">1754824000</us-gaap:AdditionalPaidInCapital>
  <!--Additional paid-in capital-->
  <us-gaap:AdditionalPaidInCapital contextRef="c00060" unitRef="u000" decimals="-3">1575780000</us-gaap:AdditionalPaidInCapital>
  <!--Unaudited Quarterly Results-->
  <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="c00124">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;21.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Unaudited Quarterly Results&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Summarized quarterly financial data for the years ended December 31, 2011 and 2010 are set forth in the following tables.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;First Quarter&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;March 31, 2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Second Quarter Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;June 30, 2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Third Quarter Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;September 30, 2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="17%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Fourth Quarter&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;December 31, 2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="64%" colspan="4"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;(Unaudited)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;$112,204&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$107,810&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$102,833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="17%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$122,977&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;(43,447)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;(62,505)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;(62,365)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="17%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;(53,443)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Net loss per share, basic and diluted:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;$(0.49)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;$(0.69)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;$(0.68)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="17%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;$(0.58)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;First Quarter&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;March 31, 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Second Quarter Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;June 30, 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Third Quarter Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;September 30, 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="17%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Fourth Quarter&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;December 31, 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="64%" colspan="4"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;(Unaudited)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;$103,534&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$115,886&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$105,979&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="17%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$133,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;(30,522)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;(25,474)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;(33,875)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="17%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;(14,597)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Net loss per share, basic and diluted:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;$(0.38)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;$(0.31)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;$(0.41)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="17%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;$(0.17)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <!--Revenue Recognition, Product Revenue-->
  <us-gaap:RevenueRecognitionSalesOfGoods contextRef="c00124">&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;c. Product Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;Product sales consist of U.S. sales of the Company&amp;#8217;s two marketed products, EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; and ARCALYST&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt;.&amp;#160;&amp;#160;Revenue from product sales is recognized when persuasive evidence of an arrangement exists, title to product and associated risk of loss have passed to the customer, the price is fixed or determinable, collection from the customer is reasonably assured, the Company has no further performance obligations, and returns can be reasonably estimated.&amp;#160;&amp;#160;The Company&amp;#8217;s written contracts with its customers stipulate product is shipped freight on board destination (FOB destination).&amp;#160;&amp;#160;The Company records revenue from product sales upon delivery to its customers.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;The Company sells EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#160;&lt;/font&gt;in the United States to three distributors and several specialty pharmacies.&amp;#160;&amp;#160;The Company sells ARCALYST&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; in the United States to two specialty pharmacies.&amp;#160;&amp;#160;Under these distribution models, the distributors and specialty pharmacies generally take physical delivery of product.&amp;#160;&amp;#160;For EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt;, the distributors and specialty pharmacies generally sell the product directly to healthcare providers; whereas for ARCALYST&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt;, the specialty pharmacies sell the product directly to patients.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;Revenue from product sales are recorded net of applicable provisions for prompt pay discounts, rebates and chargebacks under governmental programs (including Medicaid), product returns, distribution-related fees, and other sales-related deductions.&amp;#160;&amp;#160;Calculating these provisions involves estimates and judgments.&amp;#160;&amp;#160;The Company reviews its estimates of rebates, chargebacks, and other applicable provisions each period and records any necessary adjustments in the current period&amp;#8217;s net product sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Prompt Pay Discounts: &lt;/font&gt;No prompt pay discounts are currently offered to the Company&amp;#8217;s customers on sales of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt;.&amp;#160;&amp;#160;In connection with sales of ARCALYST&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt;, the Company offers discounts to its customers for prompt payments.&amp;#160;&amp;#160;The Company estimates these discounts based on customer terms and historical experience, and expects that its customers will always take advantage of this discount.&amp;#160;&amp;#160;Therefore, the Company accrues 100% of the prompt pay discount that is based on the gross amount of each ARCALYST&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#160;&lt;/font&gt;invoice, at the time of sale.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;The Company&amp;#8217;s accrual for prompt pay discounts was not material at December 31, 2011 and 2010.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Government Rebates and Chargebacks:&amp;#160;&amp;#160;&lt;/font&gt;The Company estimates reductions to product sales for Medicaid and Veterans&amp;#8217; Administration (VA) programs, and for certain other qualifying federal and state government programs.&amp;#160;&amp;#160;Based upon the Company&amp;#8217;s contracts with government agencies, statutorily-defined discounts applicable to government-funded programs, historical experience, and, in the case of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt;, estimated payer mix based on third-party market research data, the Company estimates and records an allowance for rebates and chargebacks.&amp;#160;&amp;#160;The Company&amp;#8217;s liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, and invoices received for claims from prior quarters that have not been paid.&amp;#160;&amp;#160;The Company&amp;#8217;s reserves related to discounted pricing offered to VA,&amp;#160;&amp;#160;Public Health Services (PHS), and other institutions (collectively, &amp;#8220;qualified healthcare providers&amp;#8221;) represent the Company&amp;#8217;s estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices the Company charges to its customers (i.e., distributors and specialty pharmacies).&amp;#160;&amp;#160;The Company&amp;#8217;s customers charge the Company for the difference between what they pay for the products and the ultimate selling price to the qualified healthcare providers.&amp;#160;&amp;#160;The Company&amp;#8217;s reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;The Company&amp;#8217;s government rebate and chargeback accruals were $0.6 million at December 31, 2011, which was based on a percentage of gross sales.&amp;#160;&amp;#160;Government rebate and chargeback accruals were not material at December 31, 2010.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Product Returns:&amp;#160;&amp;#160;&lt;/font&gt;Consistent with industry practice, the Company offers its customers a limited right to return product purchased directly from the Company, which is principally based upon the product&amp;#8217;s expiration date.&amp;#160;&amp;#160;The Company will accept returns for three months prior to and up to six months after the product expiration date.&amp;#160;&amp;#160;Product returned is generally not resalable given the nature of the Company&amp;#8217;s products and method of administration.&amp;#160;&amp;#160;The Company develops estimates for product returns based upon historical experience, inventory levels in the distribution channel, and other relevant factors.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;The Company has developed estimates for EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; product returns, based on several factors, including (i) the Company&amp;#8217;s historical experience to date, and the Company&amp;#8217;s expectation, that its customers will not stock significant supplies of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; due to contractual limitations and other mitigating circumstances, (ii) historical industry information regarding product return rates for similar specialty products, and (iii) the shelf life of the product.&amp;#160;&amp;#160;Estimates for ARCALYST&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; product returns have been developed based primarily on historical returns experience; to date, actual ARCALYST&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; product returns have been negligible.&amp;#160;&amp;#160;The Company monitors product supply levels in the distribution channel, as well as sales by its customers of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; to healthcare providers and ARCALYST&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; to patients using product-specific data provided by its customers.&amp;#160;&amp;#160;If necessary, the Company&amp;#8217;s estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;The Company&amp;#8217;s product returns accruals were not material at December 31, 2011 and 2010.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Distribution-Related Fees:&amp;#160;&amp;#160;&lt;/font&gt;The Company has written contracts with its customers that include terms for distribution-related fees.&amp;#160;&amp;#160;The Company estimates and records distribution and related fees due to its customers based on a percentage of gross sales.&amp;#160;&amp;#160;The Company&amp;#8217;s accrual for distribution-related fees was $1.5 million at December 31, 2011.&amp;#160;&amp;#160;&amp;#160;The Company&amp;#8217;s accrual for distribution-related fees at December 31, 2010 was not material.&lt;/font&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionSalesOfGoods>
  <!--Revenue Recognition, Collaboration Revenue-->
  <us-gaap:RevenueRecognitionLongTermContracts contextRef="c00124">&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;a. Collaboration Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company earns collaboration revenue in connection with collaboration agreements to develop and commercialize product candidates and utilize the Company&amp;#8217;s technology platforms.&amp;#160;&amp;#160;The terms of these agreements typically include non-refundable up-front licensing payments, research progress (milestone) payments, and payments for development activities.&amp;#160;&amp;#160;Non-refundable up-front license payments, where continuing involvement is required of the Company, are deferred and recognized over the related performance period.&amp;#160;&amp;#160;The Company estimates its performance period based on the specific terms of each agreement, and adjusts the performance periods, if appropriate, based on the applicable facts and circumstances.&amp;#160;&amp;#160;&amp;#160;Although the Company did not enter into, or materially modify, any collaboration arrangements with multiple-deliverables during the year ended December 31, 2011, any future arrangements with multiple deliverables will be divided into separate units of accounting if the deliverables in the arrangement meet certain criteria, including whether the delivered item or items has value to the collaborator on a standalone basis.&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold"&gt;&amp;#160;&lt;/font&gt;Payments which are based on achieving a specific performance milestone, involving a degree of risk, are recognized as revenue when the milestone is achieved and the related payment is due and non-refundable, provided there is no future service obligation associated with that milestone.&amp;#160; Substantive performance milestones typically consist of significant achievements in the development life-cycle of the related product candidate, such as completion of clinical trials, filing for approval with regulatory agencies, and receipt of approvals by regulatory agencies.&amp;#160;&amp;#160;In determining whether a payment is deemed to be a substantive performance milestone, the Company takes into consideration (i) the enhancement in value to the related development product candidate, (ii) the Company&amp;#8217;s performance and relative level of effort required to achieve the milestone, (iii) whether the milestone relates solely to past performance, and (iv) whether the milestone payment is considered reasonable relative to all of the deliverables and payment terms.&amp;#160; Payments for achieving milestones which are not considered substantive are deferred and recognized over the related performance period.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;a id="p25-2" name="p25-2"&gt;&lt;!--EFPlaceholder--&gt;&lt;/a&gt;&lt;a id="p25-2-a" name="p25-2-a"&gt;&lt;!--EFPlaceholder--&gt;&lt;/a&gt;&lt;a id="p25-2-a-1" name="p25-2-a-1"&gt;&lt;!--EFPlaceholder--&gt;&lt;/a&gt;&lt;a id="p25-2-a-2" name="p25-2-a-2"&gt;&lt;!--EFPlaceholder--&gt;&lt;/a&gt;&lt;a id="p25-2-b" name="p25-2-b"&gt;&lt;!--EFPlaceholder--&gt;&lt;/a&gt;&lt;a id="p25-2-c" name="p25-2-c"&gt;&lt;!--EFPlaceholder--&gt;&lt;/a&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company enters into collaboration agreements that include varying arrangements regarding which parties perform and bear the costs of research and development activities.&amp;#160;&amp;#160;The Company may&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;&amp;#160;&lt;/font&gt;share the costs of research and development activities with a collaborator, such as in the Company&amp;#8217;s EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-WEIGHT: bold"&gt;&amp;#210;&lt;/font&gt; collaboration with Bayer HealthCare LLC, or the Company may be reimbursed for all or a significant portion of the costs of the Company&amp;#8217;s research and development activities, such as in the Company&amp;#8217;s ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-WEIGHT: bold"&gt;&amp;#174;&lt;/font&gt; (aflibercept) and antibody collaborations with Sanofi.&amp;#160;&amp;#160;The Company records its internal and third-party development costs associated with these collaborations as research and development expenses.&amp;#160;&amp;#160;When the Company is entitled to reimbursement of all or a portion of the research and development expenses that it incurs under a collaboration, the Company records those reimbursable amounts as collaboration revenue proportionately as the Company recognizes its expenses.&amp;#160;&amp;#160;If the collaboration is a cost-sharing arrangement in which both the Company and its collaborator perform development work and share costs, in periods when the Company&amp;#8217;s collaborator incurs development expenses that benefit the collaboration and Regeneron, the Company also recognizes, as additional research and development expense, the portion of the collaborator&amp;#8217;s development expenses that the Company is obligated to reimburse.&amp;#160;&amp;#160;In certain cases, the Company may also share the costs of pre-launch commercialization activities with its collaborators.&amp;#160;&amp;#160;The Company records its share of these costs as a reduction of collaboration revenue.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In connection with non-refundable licensing payments, the Company&amp;#8217;s performance period estimates are principally based on projections of the scope, progress, and results of its research and development activities.&amp;#160;&amp;#160;Due to the variability in the scope of activities and length of time necessary to develop a drug product, changes to development plans as programs progress, and uncertainty in the ultimate requirements to obtain governmental approval for commercialization, revisions to performance period estimates are likely to occur periodically, and could result in material changes to the amount of revenue recognized each year in the future.&amp;#160;&amp;#160;In addition, estimated performance periods may change if development programs encounter delays, or the Company and its collaborators decide to expand or contract the clinical plans for a drug candidate in various disease indications.&amp;#160;&amp;#160;Also, if a collaborator terminates an agreement in accordance with the terms of the agreement, the Company would recognize any unamortized remainder of an up-front or previously deferred payment at the time of the termination.&lt;/font&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionLongTermContracts>
  <!--Rent Expense Under Operating Leases-->
  <us-gaap:ScheduleOfRentExpenseTableTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Rent expense under operating leases was:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="29%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Year Ending December 31,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Facilities&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;Equipment&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Total&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$7,191&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 18.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$599&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 18.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$7,790&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,301&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 18.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;335&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 18.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2009&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,722&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 18.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 18.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;8,117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRentExpenseTableTextBlock>
  <!--Interest Expense Associated with Convertible Notes-->
  <regn:InterestExpenseAssociatedWithConvertibleNotesTableTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Total interest expense associated with the Notes consisted of the following for the year ended December 31, 2011:&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="46%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Contractual coupon interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 16.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$1,455&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Amortization of discount and note issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 16.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;3,944&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 16.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$5,399&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</regn:InterestExpenseAssociatedWithConvertibleNotesTableTextBlock>
  <!--Total- Facilities Buildings A and B [Member]-->
  <regn:FacilityLeasesFutureMinimumPaymentsDue contextRef="c00048" unitRef="u000" decimals="-3">179786000</regn:FacilityLeasesFutureMinimumPaymentsDue>
  <!--Total- Facilities Building C [Member]-->
  <regn:FacilityLeasesFutureMinimumPaymentsDue contextRef="c00049" unitRef="u000" decimals="-3">60938000</regn:FacilityLeasesFutureMinimumPaymentsDue>
  <!--Total-->
  <regn:FacilityLeasesFutureMinimumPaymentsDue contextRef="c00001" unitRef="u000" decimals="-3">240724000</regn:FacilityLeasesFutureMinimumPaymentsDue>
  <!--Deferred revenue, noncurrent- Collaboration Agreement with Sanofi [Member] + Deferred revenue, noncurrent- Collaboration Agreement with Sanofi [Member]-->
  <us-gaap:DeferredRevenueNoncurrent contextRef="c00023" unitRef="u000" decimals="-3">86017000</us-gaap:DeferredRevenueNoncurrent>
  <!--Deferred revenue, noncurrent- Collaboration Agreement with Sanofi [Member] + Deferred revenue, noncurrent- Collaboration Agreement with Sanofi [Member]-->
  <us-gaap:DeferredRevenueNoncurrent contextRef="c00080" unitRef="u000" decimals="-3">97081000</us-gaap:DeferredRevenueNoncurrent>
  <!--Deferred revenue, noncurrent- Collaboration Agreement with Bayer HealthCare LLC [Member] + Deferred revenue, noncurrent- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <us-gaap:DeferredRevenueNoncurrent contextRef="c00024" unitRef="u000" decimals="-3">34456000</us-gaap:DeferredRevenueNoncurrent>
  <!--Deferred revenue, noncurrent- Collaboration Agreement with Bayer HealthCare LLC [Member] + Deferred revenue, noncurrent- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <us-gaap:DeferredRevenueNoncurrent contextRef="c00081" unitRef="u000" decimals="-3">37067000</us-gaap:DeferredRevenueNoncurrent>
  <!--Deferred revenue, noncurrent- Technology License Agreements [Member] + Deferred revenue, noncurrent- Technology License Agreements [Member]-->
  <us-gaap:DeferredRevenueNoncurrent contextRef="c00025" unitRef="u000" decimals="-3">128137000</us-gaap:DeferredRevenueNoncurrent>
  <!--Deferred revenue, noncurrent- Technology License Agreements [Member] + Deferred revenue, noncurrent- Technology License Agreements [Member]-->
  <us-gaap:DeferredRevenueNoncurrent contextRef="c00082" unitRef="u000" decimals="-3">151708000</us-gaap:DeferredRevenueNoncurrent>
  <!--Deferred revenue, noncurrent + Deferred revenue, noncurrent-->
  <us-gaap:DeferredRevenueNoncurrent contextRef="c00001" unitRef="u000" decimals="-3">248610000</us-gaap:DeferredRevenueNoncurrent>
  <!--Deferred revenue, noncurrent + Deferred revenue, noncurrent-->
  <us-gaap:DeferredRevenueNoncurrent contextRef="c00060" unitRef="u000" decimals="-3">285856000</us-gaap:DeferredRevenueNoncurrent>
  <!--Payable to Bayer HealthCare + Payable to Bayer HealthCare-->
  <regn:AccountsPayableToHealthcareCompanyCurrent contextRef="c00001" unitRef="u000" decimals="-3">0</regn:AccountsPayableToHealthcareCompanyCurrent>
  <!--Payable to Bayer HealthCare + Payable to Bayer HealthCare-->
  <regn:AccountsPayableToHealthcareCompanyCurrent contextRef="c00060" unitRef="u000" decimals="-3">2254000</regn:AccountsPayableToHealthcareCompanyCurrent>
  <!--Depreciation and amortization expense + Depreciation and amortization expense + Depreciation and amortization expense-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c00124" unitRef="u000" decimals="-5">31100000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Depreciation and amortization expense + Depreciation and amortization expense + Depreciation and amortization expense-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c00164" unitRef="u000" decimals="-5">19700000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Depreciation and amortization expense + Depreciation and amortization expense + Depreciation and amortization expense-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c00195" unitRef="u000" decimals="-5">14200000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Deferred revenue- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member] + Deferred revenue- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member]-->
  <us-gaap:DeferredRevenue contextRef="c00010" unitRef="u000" decimals="-5">22900000</us-gaap:DeferredRevenue>
  <!--Deferred revenue- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member] + Deferred revenue- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member]-->
  <us-gaap:DeferredRevenue contextRef="c00068" unitRef="u000" decimals="-5">32600000</us-gaap:DeferredRevenue>
  <!--Deferred revenue- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member] + Deferred revenue- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <us-gaap:DeferredRevenue contextRef="c00011" unitRef="u000" decimals="-5">83100000</us-gaap:DeferredRevenue>
  <!--Deferred revenue- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member] + Deferred revenue- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <us-gaap:DeferredRevenue contextRef="c00069" unitRef="u000" decimals="-5">84000000</us-gaap:DeferredRevenue>
  <!--Deferred revenue- Collaboration Agreement with Bayer HealthCare LLC [Member] + Deferred revenue- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <us-gaap:DeferredRevenue contextRef="c00013" unitRef="u000" decimals="-5">42400000</us-gaap:DeferredRevenue>
  <!--Deferred revenue- Collaboration Agreement with Bayer HealthCare LLC [Member] + Deferred revenue- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <us-gaap:DeferredRevenue contextRef="c00070" unitRef="u000" decimals="-5">47000000</us-gaap:DeferredRevenue>
  <!--Deferred revenue- License Agreement with Astellas Pharma Inc [Member] + Deferred revenue- License Agreement with Astellas Pharma Inc [Member]-->
  <us-gaap:DeferredRevenue contextRef="c00014" unitRef="u000" decimals="-5">151700000</us-gaap:DeferredRevenue>
  <!--Deferred revenue- License Agreement with Astellas Pharma Inc [Member] + Deferred revenue- License Agreement with Astellas Pharma Inc [Member]-->
  <us-gaap:DeferredRevenue contextRef="c00071" unitRef="u000" decimals="-5">173700000</us-gaap:DeferredRevenue>
  <!--Useful life, maximum (in years)- Building and Building Improvements [Member]-->
  <us-gaap:PropertyPlantAndEquipmentUsefulLifeMaximum contextRef="c00131" unitRef="u005" decimals="0">40</us-gaap:PropertyPlantAndEquipmentUsefulLifeMaximum>
  <!--Useful life, maximum (in years)- Equipment [Member]-->
  <us-gaap:PropertyPlantAndEquipmentUsefulLifeMaximum contextRef="c00132" unitRef="u005" decimals="0">10</us-gaap:PropertyPlantAndEquipmentUsefulLifeMaximum>
  <!--Useful life, maximum (in years)- Furniture and Fixtures [Member]-->
  <us-gaap:PropertyPlantAndEquipmentUsefulLifeMaximum contextRef="c00133" unitRef="u005" decimals="0">5</us-gaap:PropertyPlantAndEquipmentUsefulLifeMaximum>
  <!--Cash paid for interest-->
  <us-gaap:InterestPaidNet contextRef="c00124" unitRef="u000" decimals="-3">14725000</us-gaap:InterestPaidNet>
  <!--Cash paid for interest-->
  <us-gaap:InterestPaidNet contextRef="c00164" unitRef="u000" decimals="-3">12737000</us-gaap:InterestPaidNet>
  <!--Cash paid for interest-->
  <us-gaap:InterestPaidNet contextRef="c00195" unitRef="u000" decimals="-3">2525000</us-gaap:InterestPaidNet>
  <!--Total adjustments-->
  <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="c00124" unitRef="u000" decimals="-3">80078000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
  <!--Total adjustments-->
  <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="c00164" unitRef="u000" decimals="-3">203690000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
  <!--Total adjustments-->
  <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="c00195" unitRef="u000" decimals="-3">-2106000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
  <!--Decrease (increase) in prepaid expenses and other assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c00124" unitRef="u000" decimals="-3">6033000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Decrease (increase) in prepaid expenses and other assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c00164" unitRef="u000" decimals="-3">7303000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Decrease (increase) in prepaid expenses and other assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c00195" unitRef="u000" decimals="-3">4436000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Contract research and other-->
  <us-gaap:ContractsRevenue contextRef="c00124" unitRef="u000" decimals="-3">6599000</us-gaap:ContractsRevenue>
  <!--Contract research and other-->
  <us-gaap:ContractsRevenue contextRef="c00164" unitRef="u000" decimals="-3">6945000</us-gaap:ContractsRevenue>
  <!--Contract research and other-->
  <us-gaap:ContractsRevenue contextRef="c00195" unitRef="u000" decimals="-3">6434000</us-gaap:ContractsRevenue>
  <!--Contract research revenue- Grant from National Institutes of Health [Member] + Contract research revenue- Grant from National Institutes of Health [Member] + Contract research revenue- Grant from National Institutes of Health [Member]-->
  <us-gaap:ContractsRevenue contextRef="c00137" unitRef="u000" decimals="-5">3600000</us-gaap:ContractsRevenue>
  <!--Contract research revenue- Grant from National Institutes of Health [Member] + Contract research revenue- Grant from National Institutes of Health [Member] + Contract research revenue- Grant from National Institutes of Health [Member]-->
  <us-gaap:ContractsRevenue contextRef="c00174" unitRef="u000" decimals="-5">4600000</us-gaap:ContractsRevenue>
  <!--Contract research revenue- Grant from National Institutes of Health [Member] + Contract research revenue- Grant from National Institutes of Health [Member] + Contract research revenue- Grant from National Institutes of Health [Member]-->
  <us-gaap:ContractsRevenue contextRef="c00205" unitRef="u000" decimals="-5">5500000</us-gaap:ContractsRevenue>
  <!--Preferred stock, shares outstanding-->
  <us-gaap:PreferredStockSharesOutstanding contextRef="c00001" unitRef="u001" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
  <!--Preferred stock, shares outstanding-->
  <us-gaap:PreferredStockSharesOutstanding contextRef="c00060" unitRef="u001" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
  <!--Preferred stock, shares issued-->
  <us-gaap:PreferredStockSharesIssued contextRef="c00001" unitRef="u001" decimals="0">0</us-gaap:PreferredStockSharesIssued>
  <!--Preferred stock, shares issued-->
  <us-gaap:PreferredStockSharesIssued contextRef="c00060" unitRef="u001" decimals="0">0</us-gaap:PreferredStockSharesIssued>
  <!--Entity Registrant Name-->
  <dei:EntityRegistrantName contextRef="c00124">REGENERON PHARMACEUTICALS INC</dei:EntityRegistrantName>
  <!--Total stockholders' equity + Balance, December 31, 2008 - Total Stockholders' Equity + Balance, December 31, 2009 - Total Stockholders' Equity-->
  <us-gaap:StockholdersEquity contextRef="c00001" unitRef="u000" decimals="-3">485732000</us-gaap:StockholdersEquity>
  <!--Total stockholders' equity + Balance, December 31, 2008 - Total Stockholders' Equity + Balance, December 31, 2009 - Total Stockholders' Equity-->
  <us-gaap:StockholdersEquity contextRef="c00060" unitRef="u000" decimals="-3">527815000</us-gaap:StockholdersEquity>
  <!--Total stockholders' equity + Balance, December 31, 2008 - Total Stockholders' Equity + Balance, December 31, 2009 - Total Stockholders' Equity-->
  <us-gaap:StockholdersEquity contextRef="c00227" unitRef="u000" decimals="-3">421514000</us-gaap:StockholdersEquity>
  <!--Total stockholders' equity + Balance, December 31, 2008 - Total Stockholders' Equity + Balance, December 31, 2009 - Total Stockholders' Equity-->
  <us-gaap:StockholdersEquity contextRef="c00112" unitRef="u000" decimals="-3">396762000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2008 - Class A Stock Amount- Class A Stock [Member] + Balance, December 31, 2009 - Class A Stock Amount- Class A Stock [Member] + Balance, December 31, 2010 - Class A Stock Amount- Class A Stock [Member] + Balance, December 31, 2011 - Class A Stock Amount- Class A Stock [Member]-->
  <us-gaap:StockholdersEquity contextRef="c00222" unitRef="u000" decimals="-3">2000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2008 - Class A Stock Amount- Class A Stock [Member] + Balance, December 31, 2009 - Class A Stock Amount- Class A Stock [Member] + Balance, December 31, 2010 - Class A Stock Amount- Class A Stock [Member] + Balance, December 31, 2011 - Class A Stock Amount- Class A Stock [Member]-->
  <us-gaap:StockholdersEquity contextRef="c00107" unitRef="u000" decimals="-3">2000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2008 - Class A Stock Amount- Class A Stock [Member] + Balance, December 31, 2009 - Class A Stock Amount- Class A Stock [Member] + Balance, December 31, 2010 - Class A Stock Amount- Class A Stock [Member] + Balance, December 31, 2011 - Class A Stock Amount- Class A Stock [Member]-->
  <us-gaap:StockholdersEquity contextRef="c00062" unitRef="u000" decimals="-3">2000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2008 - Class A Stock Amount- Class A Stock [Member] + Balance, December 31, 2009 - Class A Stock Amount- Class A Stock [Member] + Balance, December 31, 2010 - Class A Stock Amount- Class A Stock [Member] + Balance, December 31, 2011 - Class A Stock Amount- Class A Stock [Member]-->
  <us-gaap:StockholdersEquity contextRef="c00003" unitRef="u000" decimals="-3">2000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2008 - Common Stock Amount- Common Stock [Member] + Balance, December 31, 2009 - Common Stock Amount- Common Stock [Member] + Balance, December 31, 2010 - Common Stock Amount- Common Stock [Member] + Balance, December 31, 2011 - Common Stock Amount- Common Stock [Member]-->
  <us-gaap:StockholdersEquity contextRef="c00223" unitRef="u000" decimals="-3">78000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2008 - Common Stock Amount- Common Stock [Member] + Balance, December 31, 2009 - Common Stock Amount- Common Stock [Member] + Balance, December 31, 2010 - Common Stock Amount- Common Stock [Member] + Balance, December 31, 2011 - Common Stock Amount- Common Stock [Member]-->
  <us-gaap:StockholdersEquity contextRef="c00108" unitRef="u000" decimals="-3">79000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2008 - Common Stock Amount- Common Stock [Member] + Balance, December 31, 2009 - Common Stock Amount- Common Stock [Member] + Balance, December 31, 2010 - Common Stock Amount- Common Stock [Member] + Balance, December 31, 2011 - Common Stock Amount- Common Stock [Member]-->
  <us-gaap:StockholdersEquity contextRef="c00063" unitRef="u000" decimals="-3">87000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2008 - Common Stock Amount- Common Stock [Member] + Balance, December 31, 2009 - Common Stock Amount- Common Stock [Member] + Balance, December 31, 2010 - Common Stock Amount- Common Stock [Member] + Balance, December 31, 2011 - Common Stock Amount- Common Stock [Member]-->
  <us-gaap:StockholdersEquity contextRef="c00004" unitRef="u000" decimals="-3">91000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2008 - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Balance, December 31, 2009 - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Balance, December 31, 2010 - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Balance, December 31, 2011 - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:StockholdersEquity contextRef="c00224" unitRef="u000" decimals="-3">1294813000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2008 - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Balance, December 31, 2009 - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Balance, December 31, 2010 - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Balance, December 31, 2011 - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:StockholdersEquity contextRef="c00109" unitRef="u000" decimals="-3">1336732000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2008 - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Balance, December 31, 2009 - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Balance, December 31, 2010 - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Balance, December 31, 2011 - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:StockholdersEquity contextRef="c00064" unitRef="u000" decimals="-3">1575780000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2008 - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Balance, December 31, 2009 - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Balance, December 31, 2010 - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Balance, December 31, 2011 - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:StockholdersEquity contextRef="c00005" unitRef="u000" decimals="-3">1754824000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2008 - Accumulated Deficit- Accumulated Deficit [Member] + Balance, December 31, 2009 - Accumulated Deficit- Accumulated Deficit [Member] + Balance, December 31, 2010 - Accumulated Deficit- Accumulated Deficit [Member] + Balance, December 31, 2011 - Accumulated Deficit- Accumulated Deficit [Member]-->
  <us-gaap:StockholdersEquity contextRef="c00225" unitRef="u000" decimals="-3">-873265000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2008 - Accumulated Deficit- Accumulated Deficit [Member] + Balance, December 31, 2009 - Accumulated Deficit- Accumulated Deficit [Member] + Balance, December 31, 2010 - Accumulated Deficit- Accumulated Deficit [Member] + Balance, December 31, 2011 - Accumulated Deficit- Accumulated Deficit [Member]-->
  <us-gaap:StockholdersEquity contextRef="c00110" unitRef="u000" decimals="-3">-941095000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2008 - Accumulated Deficit- Accumulated Deficit [Member] + Balance, December 31, 2009 - Accumulated Deficit- Accumulated Deficit [Member] + Balance, December 31, 2010 - Accumulated Deficit- Accumulated Deficit [Member] + Balance, December 31, 2011 - Accumulated Deficit- Accumulated Deficit [Member]-->
  <us-gaap:StockholdersEquity contextRef="c00065" unitRef="u000" decimals="-3">-1045563000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2008 - Accumulated Deficit- Accumulated Deficit [Member] + Balance, December 31, 2009 - Accumulated Deficit- Accumulated Deficit [Member] + Balance, December 31, 2010 - Accumulated Deficit- Accumulated Deficit [Member] + Balance, December 31, 2011 - Accumulated Deficit- Accumulated Deficit [Member]-->
  <us-gaap:StockholdersEquity contextRef="c00006" unitRef="u000" decimals="-3">-1267323000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2008 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Balance, December 31, 2009 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Balance, December 31, 2010 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Balance, December 31, 2011 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member]-->
  <us-gaap:StockholdersEquity contextRef="c00226" unitRef="u000" decimals="-3">-114000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2008 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Balance, December 31, 2009 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Balance, December 31, 2010 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Balance, December 31, 2011 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member]-->
  <us-gaap:StockholdersEquity contextRef="c00111" unitRef="u000" decimals="-3">1044000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2008 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Balance, December 31, 2009 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Balance, December 31, 2010 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Balance, December 31, 2011 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member]-->
  <us-gaap:StockholdersEquity contextRef="c00066" unitRef="u000" decimals="-3">-2491000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2008 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Balance, December 31, 2009 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Balance, December 31, 2010 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Balance, December 31, 2011 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member]-->
  <us-gaap:StockholdersEquity contextRef="c00007" unitRef="u000" decimals="-3">-1862000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2009 - Comprehensive Loss- Comprehensive Loss [Member] + Balance, December 31, 2010 - Comprehensive Loss- Comprehensive Loss [Member] + Balance, December 31, 2011 - Comprehensive Loss- Comprehensive Loss [Member]-->
  <us-gaap:StockholdersEquity contextRef="c00113" unitRef="u000" decimals="-3">-66672000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2009 - Comprehensive Loss- Comprehensive Loss [Member] + Balance, December 31, 2010 - Comprehensive Loss- Comprehensive Loss [Member] + Balance, December 31, 2011 - Comprehensive Loss- Comprehensive Loss [Member]-->
  <us-gaap:StockholdersEquity contextRef="c00067" unitRef="u000" decimals="-3">-108003000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2009 - Comprehensive Loss- Comprehensive Loss [Member] + Balance, December 31, 2010 - Comprehensive Loss- Comprehensive Loss [Member] + Balance, December 31, 2011 - Comprehensive Loss- Comprehensive Loss [Member]-->
  <us-gaap:StockholdersEquity contextRef="c00008" unitRef="u000" decimals="-3">-221131000</us-gaap:StockholdersEquity>
  <!--Class A Stock- Class A Stock [Member]-->
  <us-gaap:CommonStockValue contextRef="c00002" unitRef="u000" decimals="-3">2000</us-gaap:CommonStockValue>
  <!--Class A Stock- Class A Stock [Member]-->
  <us-gaap:CommonStockValue contextRef="c00061" unitRef="u000" decimals="-3">2000</us-gaap:CommonStockValue>
  <!--Common Stock-->
  <us-gaap:CommonStockValue contextRef="c00001" unitRef="u000" decimals="-3">91000</us-gaap:CommonStockValue>
  <!--Common Stock-->
  <us-gaap:CommonStockValue contextRef="c00060" unitRef="u000" decimals="-3">87000</us-gaap:CommonStockValue>
  <!--Property, plant, and equipment, at cost, net of accumulated depreciation and amortization-->
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="c00001" unitRef="u000" decimals="-3">367955000</us-gaap:PropertyPlantAndEquipmentNet>
  <!--Property, plant, and equipment, at cost, net of accumulated depreciation and amortization-->
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="c00060" unitRef="u000" decimals="-3">347450000</us-gaap:PropertyPlantAndEquipmentNet>
  <!--Property, Plant, and Equipment-->
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c00124">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;8.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Property, Plant, and Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 36pt"&gt;&lt;/font&gt;Property, plant, and equipment as of December 31, 2011 and 2010 consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="39%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.25pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="39%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;$2,117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;$2,117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="39%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Building and improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;322,753&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;242,035&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="39%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;4,479&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;4,063&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="39%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Construction-in-progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;10,880&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;70,356&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="39%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Laboratory and other equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;156,397&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;137,951&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="39%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Furniture, computer and office equipment, and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;29,468&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;22,235&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="39%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;526,094&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;478,757&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="39%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Less, accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(158,139)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(131,307)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="39%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$367,955&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$347,450&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Depreciation and amortization expense on property, plant, and equipment amounted to $31.1 million, $19.7 million, and $14.2 million for the years ended December 31, 2011, 2010, and 2009, respectively.&amp;#160;&amp;#160;Effective in the first quarter of 2010, the estimated useful lives of certain capitalized laboratory and other equipment, which is a component of property, plant, and equipment, were extended.&amp;#160;&amp;#160;The effect of this change in estimate was to lower depreciation expense by $4.0 million and to lower the Company&amp;#8217;s net loss per share by $0.05 for the year ended December 31, 2010.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Included in property, plant, and equipment at December 31, 2011 and December 31 2010 was $3.6 million and $2.8 million, respectively, of leased equipment under capital leases, and related accumulated amortization was $0.5 million and $0.1 million at December 31, 2011 and December 31, 2010, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Property, plant, and equipment at both December 31, 2011 and 2010 includes $86.2 million of costs incurred by the Company&amp;#8217;s landlord to construct new laboratory and office facilities in Tarrytown, New York in connection with the Company&amp;#8217;s December 2006 lease, as amended, of these facilities.&amp;#160;&amp;#160;See Note 12a.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company capitalized interest costs of $6.4 million in 2010.&amp;#160;&amp;#160;The Company did not capitalize any interest costs in 2011.&lt;/font&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <!--Organization and Business-->
  <us-gaap:NatureOfOperations contextRef="c00124">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;1.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Organization and Business&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Regeneron Pharmaceuticals, Inc. (the &amp;#8220;Company&amp;#8221; or &amp;#8220;Regeneron&amp;#8221;) was incorporated in January 1988 in the State of New York.&amp;#160;&amp;#160;The Company is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.&amp;#160;&amp;#160;In 2008, the Company received marketing approval from the U.S. Food and Drug Administration (&amp;#8220;FDA&amp;#8221;) for the Company&amp;#8217;s first commercial drug product, ARCALYST&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; (rilonacept) Injection for Subcutaneous Use for the treatment of Cryopyrin-Associated Periodic Syndromes (&amp;#8220;CAPS&amp;#8221;).&amp;#160;&amp;#160;In November 2011, the Company received marketing approval from the FDA for EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; (aflibercept) Injection for the treatment of neovascular wet age-related macular degeneration (&amp;#8220;wet AMD&amp;#8221;).&amp;#160;&amp;#160;The Company's facilities are primarily located in New York.&amp;#160;&amp;#160;The Company&amp;#8217;s business is subject to certain risks including, but not limited to, uncertainties relating to conducting pharmaceutical research, obtaining regulatory approvals, commercializing products, and obtaining and enforcing patents.&lt;/font&gt;&lt;/div&gt;&lt;br /&gt;</us-gaap:NatureOfOperations>
  <!--Weighted-Average Values of Assumptions Used in Computing Fair Value of Option Grants-->
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The following table summarizes the weighted average values of the assumptions used in computing the fair value of option grants during 2011, 2010, and 2009.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;br /&gt;&amp;#160;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="15%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="15%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="15%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;48%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;47%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;54%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Expected lives from grant date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;6.1 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;5.6 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;5.9 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;1.31%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2.11%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2.87%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <!--Commitments Under Operating Leases-->
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The estimated future minimum noncancelable lease commitments under operating leases were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="29%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;December 31,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Facilities&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Equipment&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;Total&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$6,072&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 23pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$1,188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$7,260&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,304&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 23pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;258&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,428&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 23pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,463&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,583&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,583&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;59,631&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 23pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;___&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;59,631&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$95,756&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 23pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$1,481&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$97,237&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <!--Property, Plant, and Equipment-->
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Property, plant, and equipment as of December 31, 2011 and 2010 consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="39%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.25pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="39%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;$2,117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;$2,117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="39%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Building and improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;322,753&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;242,035&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="39%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;4,479&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;4,063&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="39%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Construction-in-progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;10,880&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;70,356&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="39%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Laboratory and other equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;156,397&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;137,951&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="39%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Furniture, computer and office equipment, and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;29,468&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;22,235&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="39%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;526,094&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;478,757&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="39%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Less, accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(158,139)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(131,307)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="39%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$367,955&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$347,450&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <!--Increase in valuation allowance- Net Operating Loss Carryforward and Tax Credit Carryforwards [Member] + Increase in valuation allowance- Net Operating Loss Carryforward and Tax Credit Carryforwards [Member]-->
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c00157" unitRef="u000" decimals="-5">116200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <!--Increase in valuation allowance- Net Operating Loss Carryforward and Tax Credit Carryforwards [Member] + Increase in valuation allowance- Net Operating Loss Carryforward and Tax Credit Carryforwards [Member]-->
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c00191" unitRef="u000" decimals="-5">63000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <!--Released (in shares)- Restricted Stock [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c00156" unitRef="u001" decimals="0">110001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <!--Risk-free interest rate (in hundredths)- Stock Options [Member] + Risk-free interest rate (in hundredths)- Stock Options [Member] + Risk-free interest rate (in hundredths)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c00152" unitRef="u004" decimals="4">0.0131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <!--Risk-free interest rate (in hundredths)- Stock Options [Member] + Risk-free interest rate (in hundredths)- Stock Options [Member] + Risk-free interest rate (in hundredths)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c00187" unitRef="u004" decimals="4">0.0211</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <!--Risk-free interest rate (in hundredths)- Stock Options [Member] + Risk-free interest rate (in hundredths)- Stock Options [Member] + Risk-free interest rate (in hundredths)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c00217" unitRef="u004" decimals="4">0.0287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <!--Expected dividend yield (in hundredths)- Stock Options [Member] + Expected dividend yield (in hundredths)- Stock Options [Member] + Expected dividend yield (in hundredths)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c00152" unitRef="u004" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <!--Expected dividend yield (in hundredths)- Stock Options [Member] + Expected dividend yield (in hundredths)- Stock Options [Member] + Expected dividend yield (in hundredths)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c00187" unitRef="u004" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <!--Expected dividend yield (in hundredths)- Stock Options [Member] + Expected dividend yield (in hundredths)- Stock Options [Member] + Expected dividend yield (in hundredths)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c00217" unitRef="u004" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <!--Expected lives from grant date (in years)- Stock Options [Member] + Expected lives from grant date (in years)- Stock Options [Member] + Expected lives from grant date (in years)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm contextRef="c00152" unitRef="u006" decimals="1">6.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm>
  <!--Expected lives from grant date (in years)- Stock Options [Member] + Expected lives from grant date (in years)- Stock Options [Member] + Expected lives from grant date (in years)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm contextRef="c00187" unitRef="u006" decimals="1">5.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm>
  <!--Expected lives from grant date (in years)- Stock Options [Member] + Expected lives from grant date (in years)- Stock Options [Member] + Expected lives from grant date (in years)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm contextRef="c00217" unitRef="u006" decimals="1">5.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm>
  <!--Expected volatility (in hundredths)- Stock Options [Member] + Expected volatility (in hundredths)- Stock Options [Member] + Expected volatility (in hundredths)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c00152" unitRef="u004" decimals="2">0.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <!--Expected volatility (in hundredths)- Stock Options [Member] + Expected volatility (in hundredths)- Stock Options [Member] + Expected volatility (in hundredths)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c00187" unitRef="u004" decimals="2">0.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <!--Expected volatility (in hundredths)- Stock Options [Member] + Expected volatility (in hundredths)- Stock Options [Member] + Expected volatility (in hundredths)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c00217" unitRef="u004" decimals="2">0.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <!--Number of options expected to vest upon achieving sales targets (in shares)- Performance-Based Stock Options [Member]-->
  <regn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestUponAchievingSalesTargets contextRef="c00056" unitRef="u001" decimals="0">203429</regn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestUponAchievingSalesTargets>
  <!--Exercisable, end of period, weighted-average exercise price (in dollars per share)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c00054" unitRef="u002" decimals="2">18.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <!--Exercised (in shares)- Stock Options [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c00152" unitRef="u001" decimals="0">4523173</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <!--Common Stock, voting rights- Class A Stock [Member]-->
  <us-gaap:CommonStockVotingRights contextRef="c00151">ten votes per share</us-gaap:CommonStockVotingRights>
  <!--Common Stock, voting rights-->
  <us-gaap:CommonStockVotingRights contextRef="c00124">one vote per share</us-gaap:CommonStockVotingRights>
  <!--Capitalized costs of constructing the new facility- Facilities Buildings A and B [Member]-->
  <us-gaap:BuildingsAndImprovementsGross contextRef="c00102" unitRef="u000" decimals="-5">58400000</us-gaap:BuildingsAndImprovementsGross>
  <!--Capitalized costs of constructing the new facility- Facilities Building C [Member]-->
  <us-gaap:BuildingsAndImprovementsGross contextRef="c00103" unitRef="u000" decimals="-5">27800000</us-gaap:BuildingsAndImprovementsGross>
  <!--Capital lease obligations + Capital lease obligations-->
  <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="c00001" unitRef="u000" decimals="-5">2500000</us-gaap:CapitalLeaseObligationsNoncurrent>
  <!--Capital lease obligations + Capital lease obligations-->
  <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="c00060" unitRef="u000" decimals="-5">2800000</us-gaap:CapitalLeaseObligationsNoncurrent>
  <!--2016-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="c00001" unitRef="u000" decimals="-3">7738000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <!--2016- Building [Member]-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="c00046" unitRef="u000" decimals="-3">7738000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <!--Increment of principal amount of conversion- Convertible Debt [Member]-->
  <regn:DebtInstrumentConvertibleIncrementOfPrincipalAmountOfConversion contextRef="c00261" unitRef="u000" decimals="0">1000</regn:DebtInstrumentConvertibleIncrementOfPrincipalAmountOfConversion>
  <!--Total available-for-sale marketable securities- Unrestricted [Member] + Total available-for-sale marketable securities- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesFairValueDisclosure contextRef="c00034" unitRef="u000" decimals="-3">319217000</us-gaap:AvailableForSaleSecuritiesFairValueDisclosure>
  <!--Total available-for-sale marketable securities- Unrestricted [Member] + Total available-for-sale marketable securities- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesFairValueDisclosure contextRef="c00090" unitRef="u000" decimals="-3">506849000</us-gaap:AvailableForSaleSecuritiesFairValueDisclosure>
  <!--Total available-for-sale marketable securities- Fair Value, Measurements, Recurring [Member] + Total available-for-sale marketable securities- Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:AvailableForSaleSecuritiesFairValueDisclosure contextRef="c00038" unitRef="u000" decimals="-3">325157000</us-gaap:AvailableForSaleSecuritiesFairValueDisclosure>
  <!--Total available-for-sale marketable securities- Fair Value, Measurements, Recurring [Member] + Total available-for-sale marketable securities- Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:AvailableForSaleSecuritiesFairValueDisclosure contextRef="c00094" unitRef="u000" decimals="-3">513888000</us-gaap:AvailableForSaleSecuritiesFairValueDisclosure>
  <!--Total available-for-sale marketable securities- Unrestricted [Member]- Fair Value, Inputs, Level 1 [Member] + Total available-for-sale marketable securities- Unrestricted [Member]- Fair Value, Inputs, Level 1 [Member]-->
  <us-gaap:AvailableForSaleSecuritiesFairValueDisclosure contextRef="c00040" unitRef="u000" decimals="-3">3019000</us-gaap:AvailableForSaleSecuritiesFairValueDisclosure>
  <!--Total available-for-sale marketable securities- Unrestricted [Member]- Fair Value, Inputs, Level 1 [Member] + Total available-for-sale marketable securities- Unrestricted [Member]- Fair Value, Inputs, Level 1 [Member]-->
  <us-gaap:AvailableForSaleSecuritiesFairValueDisclosure contextRef="c00095" unitRef="u000" decimals="-3">3612000</us-gaap:AvailableForSaleSecuritiesFairValueDisclosure>
  <!--Total available-for-sale marketable securities- Unrestricted [Member]- Fair Value, Inputs, Level 2 [Member] + Total available-for-sale marketable securities- Unrestricted [Member]- Fair Value, Inputs, Level 2 [Member]-->
  <us-gaap:AvailableForSaleSecuritiesFairValueDisclosure contextRef="c00041" unitRef="u000" decimals="-3">316198000</us-gaap:AvailableForSaleSecuritiesFairValueDisclosure>
  <!--Total available-for-sale marketable securities- Unrestricted [Member]- Fair Value, Inputs, Level 2 [Member] + Total available-for-sale marketable securities- Unrestricted [Member]- Fair Value, Inputs, Level 2 [Member]-->
  <us-gaap:AvailableForSaleSecuritiesFairValueDisclosure contextRef="c00096" unitRef="u000" decimals="-3">503237000</us-gaap:AvailableForSaleSecuritiesFairValueDisclosure>
  <!--Total available-for-sale marketable securities- Fair Value, Inputs, Level 1 [Member] + Total available-for-sale marketable securities- Fair Value, Inputs, Level 1 [Member]-->
  <us-gaap:AvailableForSaleSecuritiesFairValueDisclosure contextRef="c00042" unitRef="u000" decimals="-3">3019000</us-gaap:AvailableForSaleSecuritiesFairValueDisclosure>
  <!--Total available-for-sale marketable securities- Fair Value, Inputs, Level 1 [Member] + Total available-for-sale marketable securities- Fair Value, Inputs, Level 1 [Member]-->
  <us-gaap:AvailableForSaleSecuritiesFairValueDisclosure contextRef="c00098" unitRef="u000" decimals="-3">3612000</us-gaap:AvailableForSaleSecuritiesFairValueDisclosure>
  <!--Total available-for-sale marketable securities- Fair Value, Inputs, Level 2 [Member] + Total available-for-sale marketable securities- Fair Value, Inputs, Level 2 [Member]-->
  <us-gaap:AvailableForSaleSecuritiesFairValueDisclosure contextRef="c00043" unitRef="u000" decimals="-3">322138000</us-gaap:AvailableForSaleSecuritiesFairValueDisclosure>
  <!--Total available-for-sale marketable securities- Fair Value, Inputs, Level 2 [Member] + Total available-for-sale marketable securities- Fair Value, Inputs, Level 2 [Member]-->
  <us-gaap:AvailableForSaleSecuritiesFairValueDisclosure contextRef="c00099" unitRef="u000" decimals="-3">510276000</us-gaap:AvailableForSaleSecuritiesFairValueDisclosure>
  <!--Total available-for-sale marketable securities- Fair Value, Inputs, Level 3 [Member] + Total available-for-sale marketable securities- Fair Value, Inputs, Level 3 [Member]-->
  <us-gaap:AvailableForSaleSecuritiesFairValueDisclosure contextRef="c00100" unitRef="u000" decimals="0">0</us-gaap:AvailableForSaleSecuritiesFairValueDisclosure>
  <!--Total available-for-sale marketable securities- Fair Value, Inputs, Level 3 [Member] + Total available-for-sale marketable securities- Fair Value, Inputs, Level 3 [Member]-->
  <us-gaap:AvailableForSaleSecuritiesFairValueDisclosure contextRef="c00045" unitRef="u000" decimals="0">0</us-gaap:AvailableForSaleSecuritiesFairValueDisclosure>
  <!--Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses- Unrestricted [Member]- U S Government Obligations [Member] + Unrealized Loss - Total- Unrestricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1 contextRef="c00029" unitRef="u000" decimals="-3">81000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1>
  <!--Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses- Unrestricted [Member]- U S Government Obligations [Member] + Unrealized Loss - Total- Unrestricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1 contextRef="c00085" unitRef="u000" decimals="-3">1731000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1>
  <!--Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses- Unrestricted [Member]- U S Government Guaranteed Collateralized Mortgage Obligations [Member] + Unrealized Loss - Total- Unrestricted [Member]- U S Government Guaranteed Collateralized Mortgage Obligations [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1 contextRef="c00031" unitRef="u000" decimals="-3">1000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1>
  <!--Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses- Unrestricted [Member]- U S Government Guaranteed Collateralized Mortgage Obligations [Member] + Unrealized Loss - Total- Unrestricted [Member]- U S Government Guaranteed Collateralized Mortgage Obligations [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1 contextRef="c00087" unitRef="u000" decimals="-3">45000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1>
  <!--Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses- Unrestricted [Member]- Municipal Bonds [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1 contextRef="c00032" unitRef="u000" decimals="-3">1000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1>
  <!--Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses- Equity Securities [Member] + Unrealized Loss - Total- Equity Securities [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1 contextRef="c00028" unitRef="u000" decimals="-3">1025000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1>
  <!--Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses- Equity Securities [Member] + Unrealized Loss - Total- Equity Securities [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1 contextRef="c00084" unitRef="u000" decimals="-3">433000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1>
  <!--Unrealized Loss - Total- Unrestricted [Member]- Mortgage-Backed Securities [Member] + Unrealized Loss - Total- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1 contextRef="c00033" unitRef="u000" decimals="-3">152000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1>
  <!--Unrealized Loss - Total- Unrestricted [Member]- Mortgage-Backed Securities [Member] + Unrealized Loss - Total- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1 contextRef="c00089" unitRef="u000" decimals="-3">141000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1>
  <!--Unrealized Loss - Total + Unrealized Loss - Total-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1 contextRef="c00001" unitRef="u000" decimals="-3">1260000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1>
  <!--Unrealized Loss - Total + Unrealized Loss - Total-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1 contextRef="c00060" unitRef="u000" decimals="-3">2368000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1>
  <!--Unrealized Loss - Total- Unrestricted [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1 contextRef="c00090" unitRef="u000" decimals="-3">2350000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1>
  <!--Unrealized Loss - Total- Restricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1 contextRef="c00091" unitRef="u000" decimals="-3">18000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1>
  <!--Unrealized Loss - Total- Restricted [Member]-->
  <us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1 contextRef="c00092" unitRef="u000" decimals="-3">18000</us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses1>
  <!--Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value- Unrestricted [Member]- U S Government Obligations [Member] + Fair Value - Total- Unrestricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="c00029" unitRef="u000" decimals="-3">103529000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <!--Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value- Unrestricted [Member]- U S Government Obligations [Member] + Fair Value - Total- Unrestricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="c00085" unitRef="u000" decimals="-3">340444000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <!--Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value- Unrestricted [Member]- U S Government Guaranteed Collateralized Mortgage Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="c00031" unitRef="u000" decimals="-3">623000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <!--Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value- Unrestricted [Member]- Municipal Bonds [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="c00032" unitRef="u000" decimals="-3">4603000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <!--Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value- Equity Securities [Member] + Fair Value - Total- Equity Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="c00028" unitRef="u000" decimals="-3">3019000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <!--Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value- Equity Securities [Member] + Fair Value - Total- Equity Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="c00084" unitRef="u000" decimals="-3">3612000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <!--Fair Value - Total- Unrestricted [Member]- Mortgage-Backed Securities [Member] + Fair Value - Total- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="c00033" unitRef="u000" decimals="-3">116000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <!--Fair Value - Total- Unrestricted [Member]- Mortgage-Backed Securities [Member] + Fair Value - Total- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="c00089" unitRef="u000" decimals="-3">1128000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <!--Fair Value - Total + Fair Value - Total-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="c00001" unitRef="u000" decimals="-3">111890000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <!--Fair Value - Total + Fair Value - Total-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="c00060" unitRef="u000" decimals="-3">370343000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <!--Fair Value - Total- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="c00090" unitRef="u000" decimals="-3">364189000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <!--Fair Value - Total- Restricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="c00091" unitRef="u000" decimals="-3">6154000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <!--Fair Value - Total- Restricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="c00092" unitRef="u000" decimals="-3">6154000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <!--Less, accumulated depreciation and amortization + Less, accumulated depreciation and amortization-->
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c00001" unitRef="u000" decimals="-3">158139000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <!--Less, accumulated depreciation and amortization + Less, accumulated depreciation and amortization-->
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c00060" unitRef="u000" decimals="-3">131307000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <!--Less, accumulated depreciation and amortization- Leased Equipment Under Capital Leases [Member] + Less, accumulated depreciation and amortization- Leased Equipment Under Capital Leases [Member]-->
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c00021" unitRef="u000" decimals="-5">500000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <!--Less, accumulated depreciation and amortization- Leased Equipment Under Capital Leases [Member] + Less, accumulated depreciation and amortization- Leased Equipment Under Capital Leases [Member]-->
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c00078" unitRef="u000" decimals="-5">100000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <!--Finished goods + Finished goods-->
  <us-gaap:InventoryFinishedGoods contextRef="c00001" unitRef="u000" decimals="-3">1142000</us-gaap:InventoryFinishedGoods>
  <!--Finished goods + Finished goods-->
  <us-gaap:InventoryFinishedGoods contextRef="c00060" unitRef="u000" decimals="-3">132000</us-gaap:InventoryFinishedGoods>
  <!--Starting share of profits outside the United States, based on sales, for Company (in hundredths)- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany contextRef="c00135" unitRef="u004" decimals="2">0.35</regn:StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany>
  <!--Starting share of profits outside the United States, based on sales, for collaborating party (in hundredths)- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty contextRef="c00135" unitRef="u004" decimals="2">0.65</regn:StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty>
  <!--Amount of research funded during the period- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:AmountOfResearchFundedDuringPeriod contextRef="c00172" unitRef="u000" decimals="-5">137700000</regn:AmountOfResearchFundedDuringPeriod>
  <!--Cash price of newly issued, unregistered shares of Common Stock purchased- Collaboration Agreement with Sanofi [Member]- Aflibercept Agreement [Member]-->
  <regn:CashPriceOfNewlyIssuedUnregisteredSharesOfCommonStockPurchased contextRef="c00232" unitRef="u000" decimals="-5">45000000</regn:CashPriceOfNewlyIssuedUnregisteredSharesOfCommonStockPurchased>
  <!--Cash price of newly issued, unregistered shares of Common Stock purchased- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:CashPriceOfNewlyIssuedUnregisteredSharesOfCommonStockPurchased contextRef="c00234" unitRef="u000" decimals="-6">312000000</regn:CashPriceOfNewlyIssuedUnregisteredSharesOfCommonStockPurchased>
  <!--Cash price of newly issued, unregistered shares of Common Stock purchased- Sanofi [Member] + Cash price of newly issued, unregistered shares of Common Stock purchased- Sanofi [Member]-->
  <regn:CashPriceOfNewlyIssuedUnregisteredSharesOfCommonStockPurchased contextRef="c00233" unitRef="u000" decimals="-5">45000000</regn:CashPriceOfNewlyIssuedUnregisteredSharesOfCommonStockPurchased>
  <!--Cash price of newly issued, unregistered shares of Common Stock purchased- Sanofi [Member] + Cash price of newly issued, unregistered shares of Common Stock purchased- Sanofi [Member]-->
  <regn:CashPriceOfNewlyIssuedUnregisteredSharesOfCommonStockPurchased contextRef="c00235" unitRef="u000" decimals="-5">312000000</regn:CashPriceOfNewlyIssuedUnregisteredSharesOfCommonStockPurchased>
  <!--Net cash (used in) provided by operating activities-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c00124" unitRef="u000" decimals="-3">-141682000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <!--Net cash (used in) provided by operating activities-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c00164" unitRef="u000" decimals="-3">99222000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <!--Net cash (used in) provided by operating activities-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c00195" unitRef="u000" decimals="-3">-69936000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <!--Issuance of Common Stock in a public offering, net of issuance costs - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c00165" unitRef="u001" decimals="-3">6325000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <!--Issuance of Common Stock in a public offering (in shares)-->
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c00265" unitRef="u001" decimals="-3">6325000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <!--Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Amount- Common Stock [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Amount- Common Stock [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Amount- Common Stock [Member]-->
  <regn:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesTendered contextRef="c00196" unitRef="u000" decimals="-3">1000</regn:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesTendered>
  <!--Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Amount- Common Stock [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Amount- Common Stock [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Amount- Common Stock [Member]-->
  <regn:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesTendered contextRef="c00165" unitRef="u000" decimals="-3">2000</regn:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesTendered>
  <!--Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Amount- Common Stock [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Amount- Common Stock [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Amount- Common Stock [Member]-->
  <regn:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesTendered contextRef="c00125" unitRef="u000" decimals="-3">4000</regn:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesTendered>
  <!--Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <regn:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesTendered contextRef="c00197" unitRef="u000" decimals="-3">9269000</regn:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesTendered>
  <!--Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <regn:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesTendered contextRef="c00166" unitRef="u000" decimals="-3">21462000</regn:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesTendered>
  <!--Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <regn:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesTendered contextRef="c00126" unitRef="u000" decimals="-3">21171000</regn:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesTendered>
  <!--Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Total Stockholders' Equity + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Total Stockholders' Equity + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Total Stockholders' Equity-->
  <regn:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesTendered contextRef="c00195" unitRef="u000" decimals="-3">9270000</regn:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesTendered>
  <!--Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Total Stockholders' Equity + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Total Stockholders' Equity + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Total Stockholders' Equity-->
  <regn:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesTendered contextRef="c00164" unitRef="u000" decimals="-3">21464000</regn:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesTendered>
  <!--Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Total Stockholders' Equity + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Total Stockholders' Equity + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Total Stockholders' Equity-->
  <regn:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesTendered contextRef="c00124" unitRef="u000" decimals="-3">21175000</regn:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesTendered>
  <!--Technology licensing-->
  <us-gaap:LicensesRevenue contextRef="c00124" unitRef="u000" decimals="-3">24858000</us-gaap:LicensesRevenue>
  <!--Technology licensing-->
  <us-gaap:LicensesRevenue contextRef="c00164" unitRef="u000" decimals="-3">40150000</us-gaap:LicensesRevenue>
  <!--Technology licensing-->
  <us-gaap:LicensesRevenue contextRef="c00195" unitRef="u000" decimals="-3">40013000</us-gaap:LicensesRevenue>
  <!--Technology licensing revenue recognized- License Agreement with Astellas Pharma Inc [Member] + Technology licensing revenue recognized- License Agreement with Astellas Pharma Inc [Member] + Technology licensing revenue recognized- License Agreement with Astellas Pharma Inc [Member]-->
  <us-gaap:LicensesRevenue contextRef="c00138" unitRef="u000" decimals="-5">22000000</us-gaap:LicensesRevenue>
  <!--Technology licensing revenue recognized- License Agreement with Astellas Pharma Inc [Member] + Technology licensing revenue recognized- License Agreement with Astellas Pharma Inc [Member] + Technology licensing revenue recognized- License Agreement with Astellas Pharma Inc [Member]-->
  <us-gaap:LicensesRevenue contextRef="c00175" unitRef="u000" decimals="-5">20000000</us-gaap:LicensesRevenue>
  <!--Technology licensing revenue recognized- License Agreement with Astellas Pharma Inc [Member] + Technology licensing revenue recognized- License Agreement with Astellas Pharma Inc [Member] + Technology licensing revenue recognized- License Agreement with Astellas Pharma Inc [Member]-->
  <us-gaap:LicensesRevenue contextRef="c00206" unitRef="u000" decimals="-5">20000000</us-gaap:LicensesRevenue>
  <!--Technology licensing revenue recognized- License Agreement with AstraZeneca UK Limited [Member] + Technology licensing revenue recognized- License Agreement with AstraZeneca UK Limited [Member] + Technology licensing revenue recognized- License Agreement with AstraZeneca UK Limited [Member]-->
  <us-gaap:LicensesRevenue contextRef="c00139" unitRef="u000" decimals="-5">2900000</us-gaap:LicensesRevenue>
  <!--Technology licensing revenue recognized- License Agreement with AstraZeneca UK Limited [Member] + Technology licensing revenue recognized- License Agreement with AstraZeneca UK Limited [Member] + Technology licensing revenue recognized- License Agreement with AstraZeneca UK Limited [Member]-->
  <us-gaap:LicensesRevenue contextRef="c00176" unitRef="u000" decimals="-5">20000000</us-gaap:LicensesRevenue>
  <!--Technology licensing revenue recognized- License Agreement with AstraZeneca UK Limited [Member] + Technology licensing revenue recognized- License Agreement with AstraZeneca UK Limited [Member] + Technology licensing revenue recognized- License Agreement with AstraZeneca UK Limited [Member]-->
  <us-gaap:LicensesRevenue contextRef="c00207" unitRef="u000" decimals="-5">20000000</us-gaap:LicensesRevenue>
  <!--Entity Voluntary Filers-->
  <dei:EntityVoluntaryFilers contextRef="c00124">No</dei:EntityVoluntaryFilers>
  <!--Stockholders Equity-->
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c00124">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;13.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Stockholders&amp;#8217; Equity&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company's Restated Certificate of Incorporation provides for the issuance of up to 40 million shares of Class A Stock, par value $0.001 per share, and 160 million shares of Common Stock, par value $0.001 per share.&amp;#160;&amp;#160;Shares of Class A Stock are convertible, at any time, at the option of the holder into shares of Common Stock on a share-for-share basis.&amp;#160;&amp;#160;&amp;#160;Holders of Class A Stock have rights and privileges identical to Common Stockholders except that each share of Class A is entitled to ten votes per share, while each share of Common Stock is entitled to one vote per share.&amp;#160;&amp;#160;Class A Stock may only be transferred to specified Permitted Transferees, as defined.&amp;#160;&amp;#160;Under the Company&amp;#8217;s Restated Certificate of Incorporation, the Company&amp;#8217;s board of directors is authorized to issue up to 30 million shares of preferred stock, in series, with rights, privileges, and qualifications of each series determined by the board of directors.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In September 2003, Sanofi purchased 2,799,552 newly issued, unregistered shares of the Company&amp;#8217;s Common Stock for $45.0 million.&amp;#160;&amp;#160;See Note 3.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In December 2007, Sanofi purchased 12 million newly issued, unregistered shares of the Company&amp;#8217;s Common Stock for an aggregate cash price of $312.0 million.&amp;#160;&amp;#160;As a condition to the closing of this transaction, Sanofi entered into an investor agreement with the Company, which was amended in November 2009.&amp;#160;&amp;#160;Under the amended investor agreement, Sanofi has three demand rights to require the Company to use all reasonable efforts to conduct a registered underwritten public offering with respect to shares of the Company&amp;#8217;s Common Stock beneficially owned by Sanofi immediately after the closing of the transaction.&amp;#160;&amp;#160;Until the later of the fifth anniversaries of the expiration or earlier termination of the License and Collaboration Agreement, as amended in 2009, under the Company&amp;#8217;s antibody collaboration with Sanofi (see Note 3) and the Company&amp;#8217;s collaboration agreement with Sanofi for the development and commercialization of ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; (see Note 3), Sanofi will be bound by certain &amp;#8220;standstill&amp;#8221; provisions.&amp;#160;&amp;#160;These provisions include an agreement not to acquire more than a specified percentage of the outstanding shares of the Company&amp;#8217;s Class A Stock and Common Stock&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;.&lt;/font&gt;&amp;#160;&amp;#160;The percentage increased from 25% to 30% as of December 20, 2011.&amp;#160;&amp;#160;Under the amended investor agreement, Sanofi has also agreed not to dispose of any shares of the Company&amp;#8217;s Common Stock that were beneficially owned by Sanofi immediately after the closing of the transaction until December 20, 2017, subject to certain limited exceptions.&amp;#160;&amp;#160;Following December 20, 2017, Sanofi will be permitted to sell shares of the Company&amp;#8217;s Common Stock (i) in a registered underwritten public offering undertaken pursuant to the demand registration rights granted to Sanofi and described above, subject to the underwriter's broad distribution of securities sold, (ii) pursuant to Rule 144 under the Securities Act and transactions exempt from registration under the Securities Act, subject to a volume limitation of one million shares of the Company&amp;#8217;s Common Stock every three months and a prohibition on selling to beneficial owners, or persons that would become beneficial owners as a result of such sale, of 5% or more of the outstanding shares of the Company&amp;#8217;s Common Stock, and (iii) into an issuer tender offer, or a tender offer by a third party that is recommended or not opposed by the Company&amp;#8217;s board of directors.&amp;#160;&amp;#160;Sanofi has agreed to vote, and cause its affiliates to vote, all shares of the Company&amp;#8217;s voting securities they are entitled to vote, at Sanofi's election, either as recommended by the Company&amp;#8217;s board of directors or proportionally with the votes cast by the Company&amp;#8217;s other shareholders, except with respect to certain change of control transactions, liquidation or dissolution, stock issuances equal to or exceeding 10% of the then outstanding shares or voting rights of the Company&amp;#8217;s Class A Stock and Common Stock, and new equity compensation plans or amendments if not materially consistent with the Company&amp;#8217;s historical equity compensation practices.&amp;#160;&amp;#160;The rights and restrictions under the investor agreement are subject to termination upon the occurrence of certain events.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In October 2010, the Company completed an underwritten public offering of 6,325,000 shares of Common Stock and received net proceeds of $174.8 million.&amp;#160;&amp;#160;Sanofi purchased 1,017,401 shares of Common Stock in this offering.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In October 2011, the Company completed a private placement of $400.0 million aggregate principal amount of Notes, which are convertible into shares of the Company&amp;#8217;s Common Stock. &amp;#160; In accordance with accounting guidance for debt with conversion and other options, the Company accounted for the liability and equity components of the Notes separately.&amp;#160;&amp;#160;&amp;#160;The equity component of the Notes was $120.6 million, net of issuance costs.&amp;#160;&amp;#160;In connection with the offering of the Notes, the Company entered into convertible note hedge and warrant transactions.&amp;#160;&amp;#160;The Company paid $117.5 million for the convertible note hedge, which was recorded as a reduction to additional paid-in capital.&amp;#160;&amp;#160;The warrant transactions have an initial strike price of approximately $103.41 per share, and may be settled in cash or shares of the Company&amp;#8217;s Common Stock, at the Company&amp;#8217;s option.&amp;#160;&amp;#160;Proceeds received from the warrant transactions totaled $93.8&amp;#160;million and were recorded as additional paid-in capital.&amp;#160;&amp;#160;The warrants expire at various dates during 2017.&amp;#160;&amp;#160;See Note 11.&lt;/font&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <!--Stock-based Compensation-->
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c00124">&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Stock-based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company recognizes stock-based compensation expense for grants of stock option awards and restricted stock under the Company's Long-Term Incentive Plan to employees and non-employee members of the Company's board of directors based on the grant-date fair value of those awards.&amp;#160;&amp;#160;The grant-date fair value of an award is generally recognized as compensation expense over the award's requisite service period.&amp;#160;&amp;#160;In addition, the Company has granted performance-based stock option awards which vest based upon the optionee satisfying certain performance and service conditions as defined in the agreements.&amp;#160;&amp;#160;Potential compensation cost, measured on the grant date, related to these performance options will be recognized only if, and when, the Company estimates that these options will vest, which is based on whether the Company consider the options' performance conditions to be probable of attainment.&amp;#160;&amp;#160;The Company's estimates of the number of performance-based options that will vest will be revised, if necessary, in subsequent periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company uses the Black-Scholes model to compute the estimated fair value of stock option awards.&amp;#160;&amp;#160;Using this model, fair value is calculated based on assumptions with respect to (i) expected volatility of the Company's Common Stock price, (ii) the periods of time over which employees and members of the board of directors are expected to hold their options prior to exercise (expected lives), (iii) expected dividend yield on the Common Stock, and (iv) risk-free interest rates.&amp;#160;&amp;#160;Stock-based compensation expense also includes an estimate, which is made at the time of grant, of the number of awards that are expected to be forfeited.&amp;#160;&amp;#160;This estimate is revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&lt;/font&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <!--Marketable Securities-->
  <us-gaap:MarketableSecuritiesAvailableForSaleSecuritiesPolicy contextRef="c00124">&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Marketable Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company has an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and concentration and diversification.&amp;#160;&amp;#160;The Company has invested its excess cash primarily in direct obligations of the U.S. government and its agencies, other debt securities guaranteed by the U.S. government, and money market funds that invest in U.S. government securities.&amp;#160;&amp;#160;The Company considers its marketable securities to be "available-for-sale," as defined by authoritative guidance issued by the Financial Accounting Standards Board ("FASB").&amp;#160;&amp;#160;These assets are carried at fair value and the unrealized gains and losses are included in accumulated other comprehensive income (loss) as a separate component of stockholders' equity.&amp;#160;&amp;#160;If the decline in the value of a marketable security in the Company's investment portfolio is deemed to be other-than-temporary, the Company writes down the security to its current fair value and recognizes a loss as a charge against income.&amp;#160;&amp;#160;As described under "Use of Estimates" below, the Company reviews its portfolio of marketable securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost are other-than-temporary.&lt;/font&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesAvailableForSaleSecuritiesPolicy>
  <!--Antidilutive Securities-->
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Shares issuable upon the exercise of options and warrants, vesting of restricted stock awards, and conversion of convertible senior notes, which have been excluded from the diluted per share amounts because their effect would have been antidilutive, include the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Options:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Weighted average number, in thousands&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;20,942&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;21,428&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;20,040&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Weighted average exercise price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$21.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$18.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$17.66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Restricted Stock:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Weighted average number, in thousands&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;526&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Convertible Senior Notes:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Weighted average number, in thousands&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;939&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Warrants:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Weighted average number, in thousands&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;939&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <!--Unrecognized Tax Benefits-->
  <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The following table summarizes the gross amounts of unrecognized tax benefits at the beginning and end of 2011 and 2010:&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="38%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="3%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="11%"&gt;&lt;div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="38%" align="left"&gt;&lt;div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Balance as of January 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="3%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$12,819&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="38%" align="left"&gt;&lt;div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Gross increases related to current year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="3%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2,192&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;3,550&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="38%" align="left"&gt;&lt;div style="TEXT-INDENT: -27pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Gross increases related to prior year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="3%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;9,269&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="38%" align="left"&gt;&lt;div style="TEXT-INDENT: -27pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Gross decreases due to settlements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="3%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(9,415)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;_____&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="38%" align="left"&gt;&lt;div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Balance as of December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="3%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$5,596&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$12,819&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
  <!--Marketable Securities, Based on Contractual Maturity Dates-->
  <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The following tables summarize the amortized cost basis of debt securities included in marketable securities, the aggregate fair value of those securities, and gross unrealized gains and losses on those securities at December 31, 2011 and 2010.&amp;#160;&amp;#160;The Company classifies its debt securities, other than mortgage-backed securities, based on their contractual maturity dates.&amp;#160;&amp;#160;Maturities of mortgage-backed securities have been estimated based primarily on repayment characteristics and experience of the senior tranches that the Company holds.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;Fair&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="31%" colspan="3"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;At December 31, 2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Cost Basis&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;Gains&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;(Losses)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;Net&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Unrestricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Maturities within one year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$12,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$12,067&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government guaranteed corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;15,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;15,316&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government guaranteed collateralized mortgage obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Municipal bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;15,314&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;15,326&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;13&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(1)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;12&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;43,225&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;43,331&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;108&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(2)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;106&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Maturities after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;272,433&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;272,752&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;400&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(81)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;104&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;28&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;___&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(76)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(76)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;272,537&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;272,780&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;400&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(157)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;243&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Maturities after five years through ten years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;164&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;87&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;___&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(77)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(77)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;315,926&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;316,198&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;508&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(236)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;272&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Restricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Maturities within one year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;3,347&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;3,357&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Maturities after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;2,572&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;2,583&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;11&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;___&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;11&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;5,919&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;5,940&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;21&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;___&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;21&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$321,845&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$322,138&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$529&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$(236)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$293&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br /&gt;&lt;div style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;&lt;div&gt;&lt;div style="WIDTH: 100%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="PAGE-BREAK-AFTER: always; WIDTH: 100%"&gt;&lt;div style="TEXT-ALIGN: center; WIDTH: 100%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-ALIGN: center; WIDTH: 100%"&gt;&lt;hr style="COLOR: black" size="2" noshade="noshade" /&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="WIDTH: 100%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br /&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;Fair&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="31%" colspan="3"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;At December 31, 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Cost Basis&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;Gains&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;(Losses)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;Net&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Unrestricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Maturities within one year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$83,635&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$83,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$(5)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government guaranteed corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;48,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;48,531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;358&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;358&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;U.S. government guaranteed&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;collateralized mortgage obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2,027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2,131&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;104&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;104&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Municipal bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;1,597&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;1,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;875&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;847&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;___&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(28)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(28)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;136,307&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;136,796&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;522&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(33)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;489&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Maturities after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;352,345&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;350,683&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;64&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1,726)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1,662)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;U.S. government guaranteed corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;15,522&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;15,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(45)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(45)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;110&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;38&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;___&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(72)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(72)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;367,977&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;366,198&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;64&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(1,843)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(1,779)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Maturities after five years through ten years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;284&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;243&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;___&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(41)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(41)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;504,568&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;503,237&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;586&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(1.917)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(1,331)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Restricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Maturities within one year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2,922&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2,921&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Maturities after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;4,135&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;4,118&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;___&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(17)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(17)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;7,057&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;7,039&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;___&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(18)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(18)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="31%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$511,625&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$510,276&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$586&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$(1,935)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="11%" colspan="2" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$(1,349)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br /&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
  <!--Estimated Useful Lives of Property, Plant, and Equipment-->
  <regn:EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The estimated useful lives of property, plant, and equipment are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 72pt"&gt;&lt;/font&gt;Building and improvements&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;10-40 years&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 72pt"&gt;&lt;/font&gt;Laboratory and other equipment&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3-10 years&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 72pt"&gt;&lt;/font&gt;Furniture and fixtures&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;5 years&lt;/font&gt;&lt;/div&gt;</regn:EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock>
  <!--Maximum amount of milestone payments that may be received related to marketing approvals in major market countries outside the U.S.- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <regn:MaximumAmountOfSubstantiveMilestonePaymentsThatMayBeReceivedInMajorMarketCountriesOutsideUS contextRef="c00136" unitRef="u000" decimals="-6">50000000</regn:MaximumAmountOfSubstantiveMilestonePaymentsThatMayBeReceivedInMajorMarketCountriesOutsideUS>
  <!--Tax credit carry-forwards, expiration dates- Research [Member]-->
  <us-gaap:TaxCreditCarryforwardExpirationDates contextRef="c00159">2012 to 2031</us-gaap:TaxCreditCarryforwardExpirationDates>
  <!--Net operating loss carry-forwards, expiration dates- U S Federal and New York State [Member]-->
  <us-gaap:OperatingLossCarryforwardsExpirationDates contextRef="c00158">2018 to 2031</us-gaap:OperatingLossCarryforwardsExpirationDates>
  <!--Valuation allowance + Valuation allowance-->
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c00001" unitRef="u000" decimals="-3">578542000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <!--Valuation allowance + Valuation allowance-->
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c00060" unitRef="u000" decimals="-3">462372000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <!--Royalty payment percentage of cumulative sales over range (in hundredths)- License Agreement With Genentech [Member]-->
  <regn:RoyaltyPaymentPercentageOfCumulativeSalesOverRange contextRef="c00262" unitRef="u004" decimals="3">0.055</regn:RoyaltyPaymentPercentageOfCumulativeSalesOverRange>
  <!--Royalty payment percentage of cumulative sales over range (in hundredths)- License Agreement With Genentech [Member]-->
  <regn:RoyaltyPaymentPercentageOfCumulativeSalesOverRange contextRef="c00161" unitRef="u004" decimals="3">0.055</regn:RoyaltyPaymentPercentageOfCumulativeSalesOverRange>
  <!--2013- Cellectis Agreement [Member]-->
  <regn:FutureExpenseOfAdvancePaymentYearTwo contextRef="c00150" unitRef="u000" decimals="-5">1000000</regn:FutureExpenseOfAdvancePaymentYearTwo>
  <!--Amount of payment to be made upon reaching minimum sales target- License Agreement With Genentech [Member]-->
  <regn:AmountOfPaymentToBeMadeUponReachingMinimumSalesTarget contextRef="c00050" unitRef="u000" decimals="-6">60000000</regn:AmountOfPaymentToBeMadeUponReachingMinimumSalesTarget>
  <!--Amount of payment to be made upon reaching minimum sales target- License Agreement With Genentech [Member]-->
  <regn:AmountOfPaymentToBeMadeUponReachingMinimumSalesTarget contextRef="c00059" unitRef="u000" decimals="-6">60000000</regn:AmountOfPaymentToBeMadeUponReachingMinimumSalesTarget>
  <!--2015- Facilities Buildings A and B [Member]-->
  <regn:FacilityLeasesFutureMinimumPaymentsDueDueInFourYears contextRef="c00048" unitRef="u000" decimals="-3">13600000</regn:FacilityLeasesFutureMinimumPaymentsDueDueInFourYears>
  <!--2015- Facilities Building C [Member]-->
  <regn:FacilityLeasesFutureMinimumPaymentsDueDueInFourYears contextRef="c00049" unitRef="u000" decimals="-3">4614000</regn:FacilityLeasesFutureMinimumPaymentsDueDueInFourYears>
  <!--2015-->
  <regn:FacilityLeasesFutureMinimumPaymentsDueDueInFourYears contextRef="c00001" unitRef="u000" decimals="-3">18214000</regn:FacilityLeasesFutureMinimumPaymentsDueDueInFourYears>
  <!--Reimbursements recognized as additional facility lease obligation- Facilities Buildings A and B [Member]-->
  <regn:ReimbursementsRecognizedAsAdditionalFacilityLeaseObligation contextRef="c00267" unitRef="u000" decimals="-5">56900000</regn:ReimbursementsRecognizedAsAdditionalFacilityLeaseObligation>
  <!--Reimbursements recognized as additional facility lease obligation- Facilities Building C [Member]-->
  <regn:ReimbursementsRecognizedAsAdditionalFacilityLeaseObligation contextRef="c00183" unitRef="u000" decimals="-5">14200000</regn:ReimbursementsRecognizedAsAdditionalFacilityLeaseObligation>
  <!--Issuance costs- Convertible Debt [Member]-->
  <regn:IssuanceCosts contextRef="c00261" unitRef="u000" decimals="-5">900000</regn:IssuanceCosts>
  <!--Fair Value - Total- Unrestricted [Member] + Fair Value - Total- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c00034" unitRef="u000" decimals="-3">316198000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <!--Fair Value - Total- Unrestricted [Member] + Fair Value - Total- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c00090" unitRef="u000" decimals="-3">503237000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <!--Fair Value - Total- Restricted [Member] + Fair Value - Total- Restricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c00036" unitRef="u000" decimals="-3">5940000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <!--Fair Value - Total- Restricted [Member] + Fair Value - Total- Restricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c00092" unitRef="u000" decimals="-3">7039000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <!--Fair Value - Total- Debt Securities [Member] + Fair Value - Total- Debt Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c00037" unitRef="u000" decimals="-3">322138000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <!--Fair Value - Total- Debt Securities [Member] + Fair Value - Total- Debt Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c00093" unitRef="u000" decimals="-3">510276000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <!--Unrealized Gains - Maturities within one year- Unrestricted [Member]- U S Government Obligations [Member] + Unrealized Gains - Maturities within one year- Unrestricted [Member]- U S Government Obligations [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains contextRef="c00029" unitRef="u000" decimals="-3">42000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains>
  <!--Unrealized Gains - Maturities within one year- Unrestricted [Member]- U S Government Obligations [Member] + Unrealized Gains - Maturities within one year- Unrestricted [Member]- U S Government Obligations [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains contextRef="c00085" unitRef="u000" decimals="-3">54000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains>
  <!--Unrealized Gains - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Corporate Bonds [Member] + Unrealized Gains - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Corporate Bonds [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains contextRef="c00030" unitRef="u000" decimals="-3">53000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains>
  <!--Unrealized Gains - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Corporate Bonds [Member] + Unrealized Gains - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Corporate Bonds [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains contextRef="c00086" unitRef="u000" decimals="-3">358000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains>
  <!--Unrealized Gains - Maturities within one year- Unrestricted [Member]- Municipal Bonds [Member] + Unrealized Gains - Maturities within one year- Unrestricted [Member]- Municipal Bonds [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains contextRef="c00032" unitRef="u000" decimals="-3">13000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains>
  <!--Unrealized Gains - Maturities within one year- Unrestricted [Member]- Municipal Bonds [Member] + Unrealized Gains - Maturities within one year- Unrestricted [Member]- Municipal Bonds [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains contextRef="c00088" unitRef="u000" decimals="-3">6000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains>
  <!--Unrealized Gains - Maturities within one year- Unrestricted [Member] + Unrealized Gains - Maturities within one year- Unrestricted [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains contextRef="c00034" unitRef="u000" decimals="-3">108000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains>
  <!--Unrealized Gains - Maturities within one year- Unrestricted [Member] + Unrealized Gains - Maturities within one year- Unrestricted [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains contextRef="c00090" unitRef="u000" decimals="-3">522000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains>
  <!--Unrealized Gains - Maturities within one year- Restricted [Member]- U S Government Obligations [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains contextRef="c00035" unitRef="u000" decimals="-3">10000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains>
  <!--Unrealized Gains - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Collateralized Mortgage Obligations [Member]-->
  <regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains contextRef="c00087" unitRef="u000" decimals="-3">104000</regn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains>
  <!--Amortized Cost Basis - Maturities within one year- Unrestricted [Member]- U S Government Obligations [Member] + Amortized Cost Basis - Maturities within one year- Unrestricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c00029" unitRef="u000" decimals="-3">12025000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
  <!--Amortized Cost Basis - Maturities within one year- Unrestricted [Member]- U S Government Obligations [Member] + Amortized Cost Basis - Maturities within one year- Unrestricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c00085" unitRef="u000" decimals="-3">83635000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
  <!--Amortized Cost Basis - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Corporate Bonds [Member] + Amortized Cost Basis - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Corporate Bonds [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c00030" unitRef="u000" decimals="-3">15263000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
  <!--Amortized Cost Basis - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Corporate Bonds [Member] + Amortized Cost Basis - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Corporate Bonds [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c00086" unitRef="u000" decimals="-3">48173000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
  <!--Amortized Cost Basis - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Collateralized Mortgage Obligations [Member] + Amortized Cost Basis - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Collateralized Mortgage Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c00031" unitRef="u000" decimals="-3">623000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
  <!--Amortized Cost Basis - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Collateralized Mortgage Obligations [Member] + Amortized Cost Basis - Maturities within one year- Unrestricted [Member]- U S Government Guaranteed Collateralized Mortgage Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c00087" unitRef="u000" decimals="-3">2027000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
  <!--Amortized Cost Basis - Maturities within one year- Unrestricted [Member]- Municipal Bonds [Member] + Amortized Cost Basis - Maturities within one year- Unrestricted [Member]- Municipal Bonds [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c00032" unitRef="u000" decimals="-3">15314000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
  <!--Amortized Cost Basis - Maturities within one year- Unrestricted [Member]- Municipal Bonds [Member] + Amortized Cost Basis - Maturities within one year- Unrestricted [Member]- Municipal Bonds [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c00088" unitRef="u000" decimals="-3">1597000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
  <!--Amortized Cost Basis - Maturities within one year- Unrestricted [Member] + Amortized Cost Basis - Maturities within one year- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c00034" unitRef="u000" decimals="-3">43225000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
  <!--Amortized Cost Basis - Maturities within one year- Unrestricted [Member] + Amortized Cost Basis - Maturities within one year- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c00090" unitRef="u000" decimals="-3">136307000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
  <!--Amortized Cost Basis - Maturities within one year- Restricted [Member]- U S Government Obligations [Member] + Amortized Cost Basis - Maturities within one year- Restricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c00035" unitRef="u000" decimals="-3">3347000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
  <!--Amortized Cost Basis - Maturities within one year- Restricted [Member]- U S Government Obligations [Member] + Amortized Cost Basis - Maturities within one year- Restricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c00091" unitRef="u000" decimals="-3">2922000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
  <!--Amortized Cost Basis - Maturities within one year- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c00089" unitRef="u000" decimals="-3">875000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
  <!--Change in accounting estimate, decrease in net loss per share (in dollars per share)-->
  <regn:ChangeInAccountingEstimateDecreaseInNetLossPerShare contextRef="c00164" unitRef="u002" decimals="2">0.05</regn:ChangeInAccountingEstimateDecreaseInNetLossPerShare>
  <!--Percentage of Shared Phase 3 Trial Costs borne by entity (in hundredths)- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:PercentageOfTrialCostsBorneByEntity contextRef="c00135" unitRef="u004" decimals="2">0.20</regn:PercentageOfTrialCostsBorneByEntity>
  <!--Restricted Common Stock tendered upon vesting in connection with employee tax obligations - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c00125" unitRef="u001" decimals="-3">51000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
  <!--Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="c00197" unitRef="u000" decimals="-3">1391000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
  <!--Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="c00166" unitRef="u000" decimals="-3">2867000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
  <!--Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="c00126" unitRef="u000" decimals="-3">6979000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
  <!--Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Total Stockholders' Equity + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Total Stockholders' Equity + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Total Stockholders' Equity-->
  <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="c00195" unitRef="u000" decimals="-3">1391000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
  <!--Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Total Stockholders' Equity + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Total Stockholders' Equity + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Total Stockholders' Equity-->
  <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="c00164" unitRef="u000" decimals="-3">2867000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
  <!--Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Total Stockholders' Equity + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Total Stockholders' Equity + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Total Stockholders' Equity-->
  <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="c00124" unitRef="u000" decimals="-3">6979000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
  <!--Cost of goods sold-->
  <us-gaap:CostOfGoodsSold contextRef="c00124" unitRef="u000" decimals="-3">4216000</us-gaap:CostOfGoodsSold>
  <!--Cost of goods sold-->
  <us-gaap:CostOfGoodsSold contextRef="c00164" unitRef="u000" decimals="-3">2093000</us-gaap:CostOfGoodsSold>
  <!--Cost of goods sold-->
  <us-gaap:CostOfGoodsSold contextRef="c00195" unitRef="u000" decimals="-3">1686000</us-gaap:CostOfGoodsSold>
  <!--Preferred stock, par value-->
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c00001" unitRef="u003" decimals="2">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <!--Preferred stock, par value-->
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c00060" unitRef="u003" decimals="2">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <!--Deferred revenue - other, current portion-->
  <regn:DeferredRevenueOtherCurrent contextRef="c00001" unitRef="u000" decimals="-3">31629000</regn:DeferredRevenueOtherCurrent>
  <!--Deferred revenue - other, current portion-->
  <regn:DeferredRevenueOtherCurrent contextRef="c00060" unitRef="u000" decimals="-3">35217000</regn:DeferredRevenueOtherCurrent>
  <!--Total assets-->
  <us-gaap:Assets contextRef="c00001" unitRef="u000" decimals="-3">1323583000</us-gaap:Assets>
  <!--Total assets-->
  <us-gaap:Assets contextRef="c00060" unitRef="u000" decimals="-3">1089432000</us-gaap:Assets>
  <!--Use of Estimates-->
  <us-gaap:UseOfEstimates contextRef="c00124">&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.&amp;#160;&amp;#160;Actual results could differ from those estimates.&amp;#160;&amp;#160;Estimates which could have a significant impact on the Company&amp;#8217;s financial statements include:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Product rebates, chargebacks, and returns in connection with the recognition of product sales revenue.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Periods over which payments, including non-refundable up-front, license, and milestone payments, are recognized as revenue in connection with collaboration and other agreements to develop and commercialize product candidates and utilize the Company&amp;#8217;s technology platforms.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Periods over which certain clinical trial costs, including costs for clinical activities performed by contract research organizations, are recognized as research and development expenses.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In connection with the recognition of expense, using a blended royalty rate, related to the Company&amp;#8217;s non-exclusive license with Genentech, Inc., the Company&amp;#8217;s estimate of cumulative EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; sales through May 7, 2016 (see Note 12b).&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In connection with stock option awards, (i) the fair value of stock options on their date of grant using the Black-Scholes option-pricing model, based on assumptions with respect to (a) expected volatility of the Company&amp;#8217;s Common Stock price, (b) the periods of time for which employees and members of the Company&amp;#8217;s board of directors are expected to hold their options prior to exercise (expected lives), (c) expected dividend yield on the Company&amp;#8217;s Common Stock, and (d) risk-free interest rates, which are based on quoted U.S. Treasury rates for securities with maturities approximating the options&amp;#8217; expected lives; (ii) the number of stock option awards that are expected to be forfeited; and (iii) with respect to performance-based stock option awards, if and when the options&amp;#8217; performance conditions are considered to be probable of attainment.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company&amp;#8217;s determination of whether marketable securities are other-than-temporarily impaired.&amp;#160;&amp;#160;The Company conducts a review of its portfolio of marketable securities, using both quantitative and qualitative factors, to determine, for securities whose current fair value is less than their cost, whether the decline in fair value below cost is other-than-temporary.&amp;#160;&amp;#160;In making this determination, the Company considers factors such as the length of time and the extent to which fair value has been less than cost, financial condition and near-term prospects of the issuer, recommendations of investment advisors, and forecasts of economic, market, or industry trends.&amp;#160;&amp;#160;This review process also includes an evaluation of the Company&amp;#8217;s ability and intent to hold individual securities until they mature or their full value can be recovered.&amp;#160;&amp;#160;This review is subjective and requires a high degree of judgment.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Useful lives of property, plant, and equipment.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value, which is written-down, as appropriate.&amp;#160;&amp;#160;In addition, capitalization of inventory costs associated with the Company&amp;#8217;s products prior to regulatory approval when, based on management&amp;#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The extent to which deferred tax assets and liabilities are offset by a valuation allowance.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In addition, the Company&amp;#8217;s share of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-WEIGHT: bold"&gt;&amp;#210;&lt;/font&gt; development expenses incurred by Bayer HealthCare, including the Company&amp;#8217;s share of Bayer HealthCare&amp;#8217;s estimated EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-WEIGHT: bold"&gt;&amp;#210;&lt;/font&gt; development expenses for the most recent fiscal quarter, are included in research and development expenses.&amp;#160;&amp;#160;The Bayer HealthCare estimate for the most recent fiscal quarter is adjusted in the subsequent quarter to reflect actual expenses for the quarter.&amp;#160;&amp;#160;Also, the Company&amp;#8217;s share of ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; pre-launch commercialization expenses incurred by Sanofi, including the Company&amp;#8217;s share of Sanofi&amp;#8217;s estimated ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; pre-launch commercialization expenses for the most recent fiscal quarter, are included as a reduction of Sanofi collaboration revenue.&amp;#160;&amp;#160;The Sanofi estimate for the most recent fiscal quarter is adjusted in the subsequent quarter to reflect actual expenses for the quarter.&lt;/font&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <!--Commitments Under Facility Lease Obligations-->
  <regn:CommitmentsUnderFacilityLeaseObligationsTableTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The estimated future minimum noncancelable commitments under these facility lease obligations, as of December 31, 2011, were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="29%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;December 31,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="15%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Buildings A and B&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Building C&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Total&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$12,847&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$2,825&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$15,672&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;13,092&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;4,370&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;17,462&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;13,343&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;4,490&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;17,833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;13,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;4,614&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;18,214&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;13,864&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;4,740&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;18,604&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;113,040&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;39,899&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;152,939&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$179,786&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$60,938&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$240,724&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</regn:CommitmentsUnderFacilityLeaseObligationsTableTextBlock>
  <!--Accounts Payable and Accrued Expenses-->
  <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Accounts payable and accrued expenses as of December 31, 2011 and 2010 consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="46%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="15%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Accounts payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$27,736&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$15,589&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Accrued payroll and related costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;42,835&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;12,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Accrued clinical trial expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;9,850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;9,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Accrued property, plant, and equipment costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;1,070&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Other accrued expenses and liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;14,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;6,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Payable to Bayer HealthCare&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;_____&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;2,254&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$95,625&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="16%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$53,658&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
  <!--Substantive milestone payment to the Company- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:SubstantiveMilestonePaymentToCompany contextRef="c00135" unitRef="u000" decimals="-6">10000000</regn:SubstantiveMilestonePaymentToCompany>
  <!--Gross increases related to current year tax positions + Gross increases related to current year tax positions-->
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c00124" unitRef="u000" decimals="-3">2192000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <!--Gross increases related to current year tax positions + Gross increases related to current year tax positions-->
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c00164" unitRef="u000" decimals="-3">3550000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <!--Forfeited, weighted-average exercise price (in dollars per share)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="c00054" unitRef="u002" decimals="2">28.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <!--Vested and expected to vest, end of period (in shares)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c00054" unitRef="u001" decimals="0">21755141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <!--2013- Facilities Buildings A and B [Member]-->
  <regn:FacilityLeasesFutureMinimumPaymentsDueDueInTwoYears contextRef="c00048" unitRef="u000" decimals="-3">13092000</regn:FacilityLeasesFutureMinimumPaymentsDueDueInTwoYears>
  <!--2013- Facilities Building C [Member]-->
  <regn:FacilityLeasesFutureMinimumPaymentsDueDueInTwoYears contextRef="c00049" unitRef="u000" decimals="-3">4370000</regn:FacilityLeasesFutureMinimumPaymentsDueDueInTwoYears>
  <!--2013-->
  <regn:FacilityLeasesFutureMinimumPaymentsDueDueInTwoYears contextRef="c00001" unitRef="u000" decimals="-3">17462000</regn:FacilityLeasesFutureMinimumPaymentsDueDueInTwoYears>
  <!--Facility lease obligation, including reimbursements- Facilities Buildings A and B [Member] + Facility lease obligation, including reimbursements- Facilities Buildings A and B [Member]-->
  <regn:FacilityLeaseObligationIncludingReimbursements contextRef="c00048" unitRef="u000" decimals="-5">113000000</regn:FacilityLeaseObligationIncludingReimbursements>
  <!--Facility lease obligation, including reimbursements- Facilities Buildings A and B [Member] + Facility lease obligation, including reimbursements- Facilities Buildings A and B [Member]-->
  <regn:FacilityLeaseObligationIncludingReimbursements contextRef="c00102" unitRef="u000" decimals="-5">113700000</regn:FacilityLeaseObligationIncludingReimbursements>
  <!--Facility lease obligation, including reimbursements- Facilities Building C [Member] + Facility lease obligation, including reimbursements- Facilities Building C [Member]-->
  <regn:FacilityLeaseObligationIncludingReimbursements contextRef="c00049" unitRef="u000" decimals="-5">47500000</regn:FacilityLeaseObligationIncludingReimbursements>
  <!--Facility lease obligation, including reimbursements- Facilities Building C [Member] + Facility lease obligation, including reimbursements- Facilities Building C [Member]-->
  <regn:FacilityLeaseObligationIncludingReimbursements contextRef="c00103" unitRef="u000" decimals="-5">46400000</regn:FacilityLeaseObligationIncludingReimbursements>
  <!--2014- Equipment [Member]-->
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears contextRef="c00020" unitRef="u000" decimals="-3">130000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears>
  <!--Unamortized discount- Convertible Debt [Member]-->
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c00039" unitRef="u000" decimals="-3">124981000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <!--Number of shares of Class A Stock reserved for restricted stock awards (in shares)- Executive Stock Purchase Plan [Member]-->
  <us-gaap:EmployeeStockOwnershipPlanESOPSharesInESOP contextRef="c00255" unitRef="u001" decimals="0">1027500</us-gaap:EmployeeStockOwnershipPlanESOPSharesInESOP>
  <!--Number of days of advance written notice to terminate agreement (in days)- License Agreement with Astellas Pharma Inc [Member]-->
  <regn:NumberOfDaysOfAdvanceWrittenNoticeToTerminateAgreement contextRef="c00175">90D</regn:NumberOfDaysOfAdvanceWrittenNoticeToTerminateAgreement>
  <!--Distribution-Related Fees Accruals-->
  <regn:DistributionRelatedFeesAccruals contextRef="c00001" unitRef="u000" decimals="-5">1500000</regn:DistributionRelatedFeesAccruals>
  <!--Maximum amount of sales milestone payments if total sales achieve specific levels- Collaboration Agreement with Bayer HealthCare LLC [Member]-->
  <regn:MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels contextRef="c00136" unitRef="u000" decimals="-6">135000000</regn:MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels>
  <!--Percentage of start-up costs of total contract value, minimum (in hundredths)-->
  <regn:PercentageOfStartUpCostsOfTotalContractValueMinimum contextRef="c00124" unitRef="u004" decimals="2">0.10</regn:PercentageOfStartUpCostsOfTotalContractValueMinimum>
  <!--Net increase (decrease) in cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c00124" unitRef="u000" decimals="-3">371038000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Net increase (decrease) in cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c00164" unitRef="u000" decimals="-3">-94503000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Net increase (decrease) in cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c00195" unitRef="u000" decimals="-3">-40721000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Net cash provided by (used in) investing activities-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c00124" unitRef="u000" decimals="-3">128471000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <!--Net cash provided by (used in) investing activities-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c00164" unitRef="u000" decimals="-3">-437031000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <!--Net cash provided by (used in) investing activities-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c00195" unitRef="u000" decimals="-3">-2148000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <!--Loss from operations-->
  <us-gaap:OperatingIncomeLoss contextRef="c00124" unitRef="u000" decimals="-3">-205159000</us-gaap:OperatingIncomeLoss>
  <!--Loss from operations-->
  <us-gaap:OperatingIncomeLoss contextRef="c00164" unitRef="u000" decimals="-3">-97472000</us-gaap:OperatingIncomeLoss>
  <!--Loss from operations-->
  <us-gaap:OperatingIncomeLoss contextRef="c00195" unitRef="u000" decimals="-3">-74103000</us-gaap:OperatingIncomeLoss>
  <!--Document Fiscal Year Focus-->
  <dei:DocumentFiscalYearFocus contextRef="c00124">2011</dei:DocumentFiscalYearFocus>
  <!--Total current assets-->
  <us-gaap:AssetsCurrent contextRef="c00001" unitRef="u000" decimals="-3">652875000</us-gaap:AssetsCurrent>
  <!--Total current assets-->
  <us-gaap:AssetsCurrent contextRef="c00060" unitRef="u000" decimals="-3">357622000</us-gaap:AssetsCurrent>
  <!--Summary of Significant Accounting Policies-->
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c00124">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;2.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;For purposes of the statement of cash flows and the balance sheet, the Company considers all highly liquid debt instruments with a maturity of three months or less when purchased to be cash equivalents.&amp;#160;&amp;#160;The carrying amount reported in the balance sheet for cash and cash equivalents approximates its fair value.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;/font&gt;&lt;br /&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Marketable Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company has an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and concentration and diversification.&amp;#160;&amp;#160;The Company has invested its excess cash primarily in direct obligations of the U.S. government and its agencies, other debt securities guaranteed by the U.S. government, and money market funds that invest in U.S. government securities.&amp;#160;&amp;#160;The Company considers its marketable securities to be &amp;#8220;available-for-sale,&amp;#8221; as defined by authoritative guidance issued by the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;).&amp;#160;&amp;#160;These assets are carried at fair value and the unrealized gains and losses are included in accumulated other comprehensive income (loss) as a separate component of stockholders&amp;#8217; equity.&amp;#160;&amp;#160;If the decline in the value of a marketable security in the Company&amp;#8217;s investment portfolio is deemed to be other-than-temporary, the Company writes down the security to its current fair value and recognizes a loss as a charge against income.&amp;#160;&amp;#160;As described under &amp;#8220;Use of Estimates&amp;#8221; below, the Company reviews its portfolio of marketable securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost are other-than-temporary.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Accounts Receivable - Trade&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company&amp;#8217;s trade accounts receivable represents amounts due from its distributors and specialty pharmacies (collectively, the Company&amp;#8217;s &amp;#8220;customers&amp;#8221;), which are all located in the United States.&amp;#160;&amp;#160;The Company monitors the financial performance and credit worthiness of its large customers so that it can properly assess and respond to changes in their credit profile.&amp;#160;&amp;#160;The Company provides reserves against trade receivables for estimated losses that may result from a customer&amp;#8217;s inability to pay.&amp;#160;&amp;#160;Amounts determined to be uncollectible are written-off against the reserve.&amp;#160;&amp;#160;As of December 31, 2011 and 2010, there were no reserves against trade accounts receivable.&amp;#160;&amp;#160;In addition, during the years ended December 31, 2011, 2010 and 2009, no trade accounts receivable were written-off.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Inventories are stated at the lower of cost or estimated realizable value.&amp;#160;&amp;#160;The Company determines the cost of inventory using the first-in, first-out, or FIFO, method.&amp;#160;&amp;#160;The Company capitalizes inventory costs associated with the Company&amp;#8217;s products prior to regulatory approval when, based on management&amp;#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development.&amp;#160;&amp;#160;The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value, and writes-down such inventories as appropriate. In addition, the Company&amp;#8217;s products are subject to strict quality control and monitoring which the Company performs throughout the manufacturing process.&amp;#160;&amp;#160;If certain batches or units of product no longer meet quality specifications or become obsolete due to expiration, the Company records a charge to cost of goods sold to write down such unmarketable inventory to its estimated realizable value.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Property, Plant, and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Property, plant, and equipment are stated at cost, net of accumulated depreciation.&amp;#160;&amp;#160;Depreciation is provided on a straight-line basis over the estimated useful lives of the assets.&amp;#160;&amp;#160;Expenditures for maintenance and repairs which do not materially extend the useful lives of the assets are charged to expense as incurred.&amp;#160;&amp;#160;The cost and accumulated depreciation or amortization of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized in operations.&amp;#160;&amp;#160;The estimated useful lives of property, plant, and equipment are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 72pt"&gt;&lt;/font&gt;Building and improvements&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;10-40 years&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 72pt"&gt;&lt;/font&gt;Laboratory and other equipment&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3-10 years&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 72pt"&gt;&lt;/font&gt;Furniture and fixtures&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;5 years&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Leasehold improvements are amortized over the shorter of the estimated useful lives of the assets or the lease term, without assuming renewal features, if any, are exercised.&amp;#160;&amp;#160;Costs of construction of certain long-lived assets include capitalized interest which is amortized over the estimated useful life of the related asset.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;a id="jump_exp_29" name="jump_exp_29"&gt;&lt;!--EFPlaceholder--&gt;&lt;/a&gt;&lt;a id="jump_exp_30" name="jump_exp_30"&gt;&lt;!--EFPlaceholder--&gt;&lt;/a&gt;&lt;a id="jump_exp_31" name="jump_exp_31"&gt;&lt;!--EFPlaceholder--&gt;&lt;/a&gt;&lt;a id="jump_exp_32" name="jump_exp_32"&gt;&lt;!--EFPlaceholder--&gt;&lt;/a&gt;Accounting for the Impairment of Long-Lived Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company periodically assesses the recoverability of long-lived assets, such as property, plant, and equipment, and evaluates such assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&amp;#160;&amp;#160;Asset impairment is determined to exist if estimated future undiscounted cash flows are less than the carrying amount.&amp;#160;&amp;#160;For all periods presented, no impairment losses were recorded.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Patents&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;As a result of the Company&amp;#8217;s research and development efforts, the Company obtains and applies for patents to protect proprietary technology and inventions.&amp;#160;&amp;#160;All costs associated with patents for product candidates under development are expensed as incurred.&amp;#160;Patent costs related to commercial products are capitalized and amortized over the shorter of their estimated useful life or the remaining patent term.&amp;#160;&amp;#160;To date, the Company has no capitalized patent costs.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Operating Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On certain of its operating lease agreements, the Company may receive rent holidays and other incentives.&amp;#160;&amp;#160;The Company recognizes operating lease costs on a straight-line basis without regard to deferred payment terms, such as rent holidays, that defer the commencement date of required payments.&amp;#160;&amp;#160;In addition, lease incentives that the Company receives are treated as a reduction of rent expense over the term of the related agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;a. Collaboration Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company earns collaboration revenue in connection with collaboration agreements to develop and commercialize product candidates and utilize the Company&amp;#8217;s technology platforms.&amp;#160;&amp;#160;The terms of these agreements typically include non-refundable up-front licensing payments, research progress (milestone) payments, and payments for development activities.&amp;#160;&amp;#160;Non-refundable up-front license payments, where continuing involvement is required of the Company, are deferred and recognized over the related performance period.&amp;#160;&amp;#160;The Company estimates its performance period based on the specific terms of each agreement, and adjusts the performance periods, if appropriate, based on the applicable facts and circumstances.&amp;#160;&amp;#160;&amp;#160;Although the Company did not enter into, or materially modify, any collaboration arrangements with multiple-deliverables during the year ended December 31, 2011, any future arrangements with multiple deliverables will be divided into separate units of accounting if the deliverables in the arrangement meet certain criteria, including whether the delivered item or items has value to the collaborator on a standalone basis.&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold"&gt;&amp;#160;&lt;/font&gt;Payments which are based on achieving a specific performance milestone, involving a degree of risk, are recognized as revenue when the milestone is achieved and the related payment is due and non-refundable, provided there is no future service obligation associated with that milestone.&amp;#160; Substantive performance milestones typically consist of significant achievements in the development life-cycle of the related product candidate, such as completion of clinical trials, filing for approval with regulatory agencies, and receipt of approvals by regulatory agencies.&amp;#160;&amp;#160;In determining whether a payment is deemed to be a substantive performance milestone, the Company takes into consideration (i) the enhancement in value to the related development product candidate, (ii) the Company&amp;#8217;s performance and relative level of effort required to achieve the milestone, (iii) whether the milestone relates solely to past performance, and (iv) whether the milestone payment is considered reasonable relative to all of the deliverables and payment terms.&amp;#160; Payments for achieving milestones which are not considered substantive are deferred and recognized over the related performance period.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;a id="p25-2" name="p25-2"&gt;&lt;!--EFPlaceholder--&gt;&lt;/a&gt;&lt;a id="p25-2-a" name="p25-2-a"&gt;&lt;!--EFPlaceholder--&gt;&lt;/a&gt;&lt;a id="p25-2-a-1" name="p25-2-a-1"&gt;&lt;!--EFPlaceholder--&gt;&lt;/a&gt;&lt;a id="p25-2-a-2" name="p25-2-a-2"&gt;&lt;!--EFPlaceholder--&gt;&lt;/a&gt;&lt;a id="p25-2-b" name="p25-2-b"&gt;&lt;!--EFPlaceholder--&gt;&lt;/a&gt;&lt;a id="p25-2-c" name="p25-2-c"&gt;&lt;!--EFPlaceholder--&gt;&lt;/a&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company enters into collaboration agreements that include varying arrangements regarding which parties perform and bear the costs of research and development activities.&amp;#160;&amp;#160;The Company may&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;&amp;#160;&lt;/font&gt;share the costs of research and development activities with a collaborator, such as in the Company&amp;#8217;s EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-WEIGHT: bold"&gt;&amp;#210;&lt;/font&gt; collaboration with Bayer HealthCare LLC, or the Company may be reimbursed for all or a significant portion of the costs of the Company&amp;#8217;s research and development activities, such as in the Company&amp;#8217;s ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-WEIGHT: bold"&gt;&amp;#174;&lt;/font&gt; (aflibercept) and antibody collaborations with Sanofi.&amp;#160;&amp;#160;The Company records its internal and third-party development costs associated with these collaborations as research and development expenses.&amp;#160;&amp;#160;When the Company is entitled to reimbursement of all or a portion of the research and development expenses that it incurs under a collaboration, the Company records those reimbursable amounts as collaboration revenue proportionately as the Company recognizes its expenses.&amp;#160;&amp;#160;If the collaboration is a cost-sharing arrangement in which both the Company and its collaborator perform development work and share costs, in periods when the Company&amp;#8217;s collaborator incurs development expenses that benefit the collaboration and Regeneron, the Company also recognizes, as additional research and development expense, the portion of the collaborator&amp;#8217;s development expenses that the Company is obligated to reimburse.&amp;#160;&amp;#160;In certain cases, the Company may also share the costs of pre-launch commercialization activities with its collaborators.&amp;#160;&amp;#160;The Company records its share of these costs as a reduction of collaboration revenue.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In connection with non-refundable licensing payments, the Company&amp;#8217;s performance period estimates are principally based on projections of the scope, progress, and results of its research and development activities.&amp;#160;&amp;#160;Due to the variability in the scope of activities and length of time necessary to develop a drug product, changes to development plans as programs progress, and uncertainty in the ultimate requirements to obtain governmental approval for commercialization, revisions to performance period estimates are likely to occur periodically, and could result in material changes to the amount of revenue recognized each year in the future.&amp;#160;&amp;#160;In addition, estimated performance periods may change if development programs encounter delays, or the Company and its collaborators decide to expand or contract the clinical plans for a drug candidate in various disease indications.&amp;#160;&amp;#160;Also, if a collaborator terminates an agreement in accordance with the terms of the agreement, the Company would recognize any unamortized remainder of an up-front or previously deferred payment at the time of the termination.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;b. &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;VelocImmune&lt;/font&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174; &lt;/font&gt;Technology Licensing&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company enters into non-exclusive license agreements with third parties that allow the third party to utilize the Company&amp;#8217;s &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;VelocImmune&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; technology in its internal research programs.&amp;#160;&amp;#160;The terms of these agreements include up-front payments and entitle the Company to receive royalties on any future sales of products discovered by the third party using the Company&amp;#8217;s &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;VelocImmune&lt;/font&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;&amp;#160;&lt;/font&gt;technology.&amp;#160;&amp;#160;Up-front payments under these agreements, where continuing involvement is required of the Company, are deferred and recognized ratably over their respective license periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;c. Product Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;Product sales consist of U.S. sales of the Company&amp;#8217;s two marketed products, EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; and ARCALYST&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt;.&amp;#160;&amp;#160;Revenue from product sales is recognized when persuasive evidence of an arrangement exists, title to product and associated risk of loss have passed to the customer, the price is fixed or determinable, collection from the customer is reasonably assured, the Company has no further performance obligations, and returns can be reasonably estimated.&amp;#160;&amp;#160;The Company&amp;#8217;s written contracts with its customers stipulate product is shipped freight on board destination (FOB destination).&amp;#160;&amp;#160;The Company records revenue from product sales upon delivery to its customers.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;The Company sells EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#160;&lt;/font&gt;in the United States to three distributors and several specialty pharmacies.&amp;#160;&amp;#160;The Company sells ARCALYST&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; in the United States to two specialty pharmacies.&amp;#160;&amp;#160;Under these distribution models, the distributors and specialty pharmacies generally take physical delivery of product.&amp;#160;&amp;#160;For EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt;, the distributors and specialty pharmacies generally sell the product directly to healthcare providers; whereas for ARCALYST&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt;, the specialty pharmacies sell the product directly to patients.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;Revenue from product sales are recorded net of applicable provisions for prompt pay discounts, rebates and chargebacks under governmental programs (including Medicaid), product returns, distribution-related fees, and other sales-related deductions.&amp;#160;&amp;#160;Calculating these provisions involves estimates and judgments.&amp;#160;&amp;#160;The Company reviews its estimates of rebates, chargebacks, and other applicable provisions each period and records any necessary adjustments in the current period&amp;#8217;s net product sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Prompt Pay Discounts: &lt;/font&gt;No prompt pay discounts are currently offered to the Company&amp;#8217;s customers on sales of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt;.&amp;#160;&amp;#160;In connection with sales of ARCALYST&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt;, the Company offers discounts to its customers for prompt payments.&amp;#160;&amp;#160;The Company estimates these discounts based on customer terms and historical experience, and expects that its customers will always take advantage of this discount.&amp;#160;&amp;#160;Therefore, the Company accrues 100% of the prompt pay discount that is based on the gross amount of each ARCALYST&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#160;&lt;/font&gt;invoice, at the time of sale.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;The Company&amp;#8217;s accrual for prompt pay discounts was not material at December 31, 2011 and 2010.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Government Rebates and Chargebacks:&amp;#160;&amp;#160;&lt;/font&gt;The Company estimates reductions to product sales for Medicaid and Veterans&amp;#8217; Administration (VA) programs, and for certain other qualifying federal and state government programs.&amp;#160;&amp;#160;Based upon the Company&amp;#8217;s contracts with government agencies, statutorily-defined discounts applicable to government-funded programs, historical experience, and, in the case of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt;, estimated payer mix based on third-party market research data, the Company estimates and records an allowance for rebates and chargebacks.&amp;#160;&amp;#160;The Company&amp;#8217;s liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, and invoices received for claims from prior quarters that have not been paid.&amp;#160;&amp;#160;The Company&amp;#8217;s reserves related to discounted pricing offered to VA,&amp;#160;&amp;#160;Public Health Services (PHS), and other institutions (collectively, &amp;#8220;qualified healthcare providers&amp;#8221;) represent the Company&amp;#8217;s estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices the Company charges to its customers (i.e., distributors and specialty pharmacies).&amp;#160;&amp;#160;The Company&amp;#8217;s customers charge the Company for the difference between what they pay for the products and the ultimate selling price to the qualified healthcare providers.&amp;#160;&amp;#160;The Company&amp;#8217;s reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;The Company&amp;#8217;s government rebate and chargeback accruals were $0.6 million at December 31, 2011, which was based on a percentage of gross sales.&amp;#160;&amp;#160;Government rebate and chargeback accruals were not material at December 31, 2010.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Product Returns:&amp;#160;&amp;#160;&lt;/font&gt;Consistent with industry practice, the Company offers its customers a limited right to return product purchased directly from the Company, which is principally based upon the product&amp;#8217;s expiration date.&amp;#160;&amp;#160;The Company will accept returns for three months prior to and up to six months after the product expiration date.&amp;#160;&amp;#160;Product returned is generally not resalable given the nature of the Company&amp;#8217;s products and method of administration.&amp;#160;&amp;#160;The Company develops estimates for product returns based upon historical experience, inventory levels in the distribution channel, and other relevant factors.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;The Company has developed estimates for EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; product returns, based on several factors, including (i) the Company&amp;#8217;s historical experience to date, and the Company&amp;#8217;s expectation, that its customers will not stock significant supplies of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; due to contractual limitations and other mitigating circumstances, (ii) historical industry information regarding product return rates for similar specialty products, and (iii) the shelf life of the product.&amp;#160;&amp;#160;Estimates for ARCALYST&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; product returns have been developed based primarily on historical returns experience; to date, actual ARCALYST&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; product returns have been negligible.&amp;#160;&amp;#160;The Company monitors product supply levels in the distribution channel, as well as sales by its customers of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; to healthcare providers and ARCALYST&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; to patients using product-specific data provided by its customers.&amp;#160;&amp;#160;If necessary, the Company&amp;#8217;s estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;The Company&amp;#8217;s product returns accruals were not material at December 31, 2011 and 2010.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Distribution-Related Fees:&amp;#160;&amp;#160;&lt;/font&gt;The Company has written contracts with its customers that include terms for distribution-related fees.&amp;#160;&amp;#160;The Company estimates and records distribution and related fees due to its customers based on a percentage of gross sales.&amp;#160;&amp;#160;The Company&amp;#8217;s accrual for distribution-related fees was $1.5 million at December 31, 2011.&amp;#160;&amp;#160;&amp;#160;The Company&amp;#8217;s accrual for distribution-related fees at December 31, 2010 was not material.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;br /&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Investment Income&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Interest income, which is included in investment income, is recognized as earned.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, materials, supplies, depreciation on and maintenance of research equipment, costs related to research collaboration and licensing agreements, the cost of services provided by outside contractors, including services related to the Company&amp;#8217;s clinical trials, clinical trial expenses, the full cost of manufacturing drug for use in research, preclinical development, and clinical trials, amounts that the Company is obligated to reimburse to collaborators for research and development expenses that they incur, and the allocable portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, and general support services.&amp;#160;&amp;#160;All costs associated with research and development are expensed.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors.&amp;#160;&amp;#160;The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as contract research organizations (&amp;#8220;CROs&amp;#8221;), independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies.&amp;#160;&amp;#160;For each clinical trial that the Company conducts, certain clinical trial costs are expensed immediately, while others are expensed over time based on the expected total number of patients in the trial, the rate at which patients enter the trial, and/or the period over which clinical investigators or CROs are expected to provide services.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Clinical activities which relate principally to clinical sites and other administrative functions to manage the Company&amp;#8217;s clinical trials are performed primarily by CROs.&amp;#160;&amp;#160;CROs typically perform most of the start-up activities for the Company&amp;#8217;s trials, including document preparation, site identification, screening and preparation, pre-study visits, training, and program management.&amp;#160;&amp;#160;On a budgeted basis, these start-up costs are typically&amp;#160;10% to&amp;#160;20% of the total contract value.&amp;#160;&amp;#160;On an actual basis, this percentage range can be significantly wider, as many of the Company&amp;#8217;s contracts with CROs are either expanded or reduced in scope compared to the original budget, while start-up costs for the particular trial may not change materially.&amp;#160;&amp;#160;These start-up costs usually occur within a few months after the contract has been executed and are event driven in nature. The remaining activities and related costs, such as patient monitoring and administration, generally occur ratably throughout the life of the individual contract or study. In the event of early termination of a clinical trial, the Company accrues and recognizes expenses in an amount based on its estimate of the remaining non-cancelable obligations associated with the winding down of the clinical trial and/or penalties.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;For clinical study sites, where payments are made periodically on a per-patient basis to the institutions performing the clinical study, the Company accrues expense on an estimated cost-per-patient basis, based on subject enrollment and activity in each quarter.&amp;#160;&amp;#160;The amount of clinical study expense recognized in a quarter may vary from period to period based on the duration and progress of the study, the activities to be performed by the sites each quarter, the required level of patient enrollment, the rate at which patients actually enroll in and drop-out of the clinical study, and the number of sites involved in the study.&amp;#160;&amp;#160;Clinical trials that bear the greatest risk of change in estimates are typically those that have a significant number of sites, require a large number of patients, have complex patient screening requirements, and span multiple years.&amp;#160;&amp;#160;During the course of a trial, the Company adjusts its rate of clinical expense recognition if actual results differ from the Company&amp;#8217;s estimates.&amp;#160;&amp;#160;The Company&amp;#8217;s estimates and assumptions for clinical expense recognition could differ significantly from its actual results, which could cause material increases or decreases in research and development expenses in future periods when the actual results become known.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;br /&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Stock-based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company recognizes stock-based compensation expense for grants of stock option awards and restricted stock under the Company&amp;#8217;s Long-Term Incentive Plan to employees and non-employee members of the Company&amp;#8217;s board of directors based on the grant-date fair value of those awards.&amp;#160;&amp;#160;The grant-date fair value of an award is generally recognized as compensation expense over the award&amp;#8217;s requisite service period.&amp;#160;&amp;#160;In addition, the Company has granted performance-based stock option awards which vest based upon the optionee satisfying certain performance and service conditions as defined in the agreements.&amp;#160;&amp;#160;Potential compensation cost, measured on the grant date, related to these performance options will be recognized only if, and when, the Company estimates that these options will vest, which is based on whether the Company consider the options&amp;#8217; performance conditions to be probable of attainment.&amp;#160;&amp;#160;The Company&amp;#8217;s estimates of the number of performance-based options that will vest will be revised, if necessary, in subsequent periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company uses the Black-Scholes model to compute the estimated fair value of stock option awards.&amp;#160;&amp;#160;Using this model, fair value is calculated based on assumptions with respect to (i) expected volatility of the Company&amp;#8217;s Common Stock price, (ii) the periods of time over which employees and members of the board of directors are expected to hold their options prior to exercise (expected lives), (iii) expected dividend yield on the Common Stock, and (iv) risk-free interest rates.&amp;#160;&amp;#160;Stock-based compensation expense also includes an estimate, which is made at the time of grant, of the number of awards that are expected to be forfeited.&amp;#160;&amp;#160;This estimate is revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns.&amp;#160;&amp;#160;Under this method, deferred tax liabilities and assets are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (&amp;#8220;temporary differences&amp;#8221;) at enacted tax rates in effect for the years in which the differences are expected to reverse.&amp;#160;&amp;#160;A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets will not be realized.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Uncertain tax positions are accounted for in accordance with FASB authoritative guidance, which prescribes a comprehensive model for the manner in which a company should recognize, measure, present, and disclose in its financial statements all material uncertain tax positions that the company has taken or expects to take on a tax return.&amp;#160;&amp;#160;Those positions, for which management's assessment is that there is more than a 50% probability of sustaining the position upon challenge by a taxing authority based upon its technical merits, are subjected to certain measurement criteria.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company&amp;#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Comprehensive Income (Loss)&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Comprehensive income (loss) of the Company includes net income (loss) adjusted for the change in net unrealized gain or loss on marketable securities, net of any tax effect.&amp;#160;&amp;#160;Comprehensive income (loss) for the years ended December 31, 2011, 2010, and 2009 have been included in the Statements of Stockholders&amp;#8217; Equity.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;Financial instruments which potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents, marketable securities (see Note 6), and accounts receivable.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Per Share Data&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;Net income (loss) per share, basic and diluted, is computed on the basis of the net income (loss) for the period divided by the weighted average number of shares of Common Stock and Class A Stock outstanding during the period.&amp;#160;&amp;#160;Basic net income (loss) per share excludes restricted stock awards until vested.&amp;#160;&amp;#160;Diluted net income per share is based upon the weighted average number of shares of Common Stock and Class A Stock outstanding, and of common stock equivalents outstanding when dilutive.&amp;#160;&amp;#160;Common stock equivalents include: (i) outstanding stock options and restricted stock awards under the Company&amp;#8217;s Long-Term Incentive Plans, which are included under the &amp;#8220;treasury stock method&amp;#8221; when dilutive, (ii) Common Stock to be issued upon the assumed conversion of the Company&amp;#8217;s convertible senior notes, which are included under the &amp;#8220;if-converted method&amp;#8221; when dilutive, and (iii) Common Stock to be issued upon the exercise of outstanding warrants, which are included under the &amp;#8220;treasury stock method&amp;#8221; when dilutive.&amp;#160;&amp;#160;The computation of diluted net loss per share for the years ended December 31, 2011, 2010, and 2009 does not include common stock equivalents, since such inclusion would be antidilutive.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Risks and Uncertainties&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Developing and commercializing new medicines entails significant risk and expense.&amp;#160;&amp;#160;Before revenues from the commercialization of the Company&amp;#8217;s current or future product candidates can be realized, the Company (or its collaborators) must overcome a number of hurdles which include successfully completing research and development and obtaining regulatory approval from the FDA and regulatory authorities in other countries.&amp;#160;&amp;#160;In addition, the biotechnology and pharmaceutical industries are rapidly evolving and highly competitive, and new developments may render the Company&amp;#8217;s products and technologies uncompetitive or obsolete.&amp;#160;&amp;#160;The Company may be subject to legal claims by third parties seeking to enforce patents to limit or prohibit the Company from marketing or selling its products.&amp;#160;&amp;#160;The Company is also dependent upon the services of its employees, consultants, collaborators, and certain third-party suppliers, including single-source unaffiliated third-party suppliers of certain raw materials and equipment.&amp;#160;&amp;#160;Regeneron, as licensee, licenses certain technologies that are important to the Company&amp;#8217;s business which impose various obligations on the Company.&amp;#160;&amp;#160;If Regeneron fails to comply with these requirements, licensors may have the right to terminate the Company&amp;#8217;s licenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company has generally incurred net losses and negative cash flows from operations since its inception.&amp;#160;&amp;#160;The Company received regulatory approval from the FDA for ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174; &lt;/font&gt;for the treatment of CAPS in February 2008 and EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; for the treatment of wet AMD in November 2011; however, the Company has not generated significant sales or profits to date from these two drug products.&amp;#160;&amp;#160;Revenues to date have principally been limited to (i) up-front, license, milestone, and reimbursement payments from the Company&amp;#8217;s collaborators and other entities related to the Company&amp;#8217;s development activities and technology platforms, (ii) ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; and EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; product sales, (iii) payments for past contract manufacturing activities, and (iv) investment income.&amp;#160;&amp;#160;Collaboration revenue in 2011 was earned from Sanofi and Bayer HealthCare under collaboration agreements (see Note 3 for the terms of these agreements).&amp;#160;&amp;#160;These collaboration agreements contain early termination provisions that are exercisable by Sanofi or Bayer HealthCare, as applicable.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.&amp;#160;&amp;#160;Actual results could differ from those estimates.&amp;#160;&amp;#160;Estimates which could have a significant impact on the Company&amp;#8217;s financial statements include:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Product rebates, chargebacks, and returns in connection with the recognition of product sales revenue.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Periods over which payments, including non-refundable up-front, license, and milestone payments, are recognized as revenue in connection with collaboration and other agreements to develop and commercialize product candidates and utilize the Company&amp;#8217;s technology platforms.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Periods over which certain clinical trial costs, including costs for clinical activities performed by contract research organizations, are recognized as research and development expenses.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In connection with the recognition of expense, using a blended royalty rate, related to the Company&amp;#8217;s non-exclusive license with Genentech, Inc., the Company&amp;#8217;s estimate of cumulative EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; sales through May 7, 2016 (see Note 12b).&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In connection with stock option awards, (i) the fair value of stock options on their date of grant using the Black-Scholes option-pricing model, based on assumptions with respect to (a) expected volatility of the Company&amp;#8217;s Common Stock price, (b) the periods of time for which employees and members of the Company&amp;#8217;s board of directors are expected to hold their options prior to exercise (expected lives), (c) expected dividend yield on the Company&amp;#8217;s Common Stock, and (d) risk-free interest rates, which are based on quoted U.S. Treasury rates for securities with maturities approximating the options&amp;#8217; expected lives; (ii) the number of stock option awards that are expected to be forfeited; and (iii) with respect to performance-based stock option awards, if and when the options&amp;#8217; performance conditions are considered to be probable of attainment.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company&amp;#8217;s determination of whether marketable securities are other-than-temporarily impaired.&amp;#160;&amp;#160;The Company conducts a review of its portfolio of marketable securities, using both quantitative and qualitative factors, to determine, for securities whose current fair value is less than their cost, whether the decline in fair value below cost is other-than-temporary.&amp;#160;&amp;#160;In making this determination, the Company considers factors such as the length of time and the extent to which fair value has been less than cost, financial condition and near-term prospects of the issuer, recommendations of investment advisors, and forecasts of economic, market, or industry trends.&amp;#160;&amp;#160;This review process also includes an evaluation of the Company&amp;#8217;s ability and intent to hold individual securities until they mature or their full value can be recovered.&amp;#160;&amp;#160;This review is subjective and requires a high degree of judgment.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Useful lives of property, plant, and equipment.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value, which is written-down, as appropriate.&amp;#160;&amp;#160;In addition, capitalization of inventory costs associated with the Company&amp;#8217;s products prior to regulatory approval when, based on management&amp;#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The extent to which deferred tax assets and liabilities are offset by a valuation allowance.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In addition, the Company&amp;#8217;s share of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-WEIGHT: bold"&gt;&amp;#210;&lt;/font&gt; development expenses incurred by Bayer HealthCare, including the Company&amp;#8217;s share of Bayer HealthCare&amp;#8217;s estimated EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-WEIGHT: bold"&gt;&amp;#210;&lt;/font&gt; development expenses for the most recent fiscal quarter, are included in research and development expenses.&amp;#160;&amp;#160;The Bayer HealthCare estimate for the most recent fiscal quarter is adjusted in the subsequent quarter to reflect actual expenses for the quarter.&amp;#160;&amp;#160;Also, the Company&amp;#8217;s share of ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; pre-launch commercialization expenses incurred by Sanofi, including the Company&amp;#8217;s share of Sanofi&amp;#8217;s estimated ZALTRAP&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; pre-launch commercialization expenses for the most recent fiscal quarter, are included as a reduction of Sanofi collaboration revenue.&amp;#160;&amp;#160;The Sanofi estimate for the most recent fiscal quarter is adjusted in the subsequent quarter to reflect actual expenses for the quarter.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Impact of Recently Issued Accounting Standards&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Multiple-deliverable revenue arrangements&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 1pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;During the first quarter of 2011 the Company adopted amended authoritative guidance issued by the FASB on multiple-deliverable revenue arrangements.&amp;#160;&amp;#160;The amended guidance provides greater ability to separate and allocate consideration to be received in a multiple-deliverable revenue arrangement by requiring the use of estimated selling prices to allocate the consideration, thereby eliminating the use of the residual method of allocation.&amp;#160;&amp;#160;The amended guidance also requires expanded qualitative and quantitative disclosures surrounding multiple-deliverable revenue arrangements.&amp;#160;&amp;#160;The Company is applying this amended guidance prospectively for new or materially modified arrangements, of which there were none during the year ended December 31, 2011; therefore, the adoption of this guidance did not have an impact on the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Milestone method of revenue recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;During the first quarter of 2011, the Company adopted amended authoritative guidance issued by the FASB codifying the milestone method of revenue recognition as an acceptable revenue recognition model when a milestone is deemed to be substantive.&amp;#160;&amp;#160;The Company earns substantive performance milestone payments in connection with its collaboration agreements to develop and commercialize product candidates with Sanofi and Bayer HealthCare.&amp;#160;&amp;#160;Descriptions of these collaboration agreements, including various financial terms and conditions, are provided in &lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;Note 3&lt;/font&gt;.&amp;#160;&amp;#160;Since the Company has historically accounted for milestones under the milestone method, the adoption of this guidance did not have a material impact on the Company&amp;#8217;s financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Fees paid to the federal government by pharmaceutical manufacturers&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In December 2010, the FASB provided authoritative guidance on how pharmaceutical manufacturers should recognize and classify in their income statement annual fees mandated by the Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act.&amp;#160;&amp;#160;This guidance became effective for calendar years beginning after December 31, 2010.&amp;#160;&amp;#160;The adoption of this guidance did not have an impact on the Company&amp;#8217;s financial statements for the year ended December 31, 2011, since (i) ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; for the treatment of CAPS, has been approved as an orphan drug and orphan drugs are not subject to this annual fee and (ii) since EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; received regulatory approval from the FDA, and was launched, in November 2011.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Presentation of comprehensive income&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In June 2011, the FASB amended its authoritative guidance on the presentation of comprehensive income.&amp;#160;&amp;#160;Under the amendment, an entity will have the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements.&amp;#160;&amp;#160;This amendment, therefore, eliminates the currently available option to present the components of other comprehensive income as part of the statement of changes in stockholders' equity. The amendment does not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income.&amp;#160;&amp;#160;The Company will adopt this amended guidance for the fiscal year beginning January 1, 2012.&amp;#160;&amp;#160;As this guidance relates to presentation only, the adoption of this guidance will not have any other effect on the Company's financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Reclassifications&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Certain reclassifications have been made to prior period amounts to conform with the current period&amp;#8217;s presentation.&lt;/font&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <!--Cash and Cash Equivalents-->
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;For purposes of the statement of cash flows and the balance sheet, the Company considers all highly liquid debt instruments with a maturity of three months or less when purchased to be cash equivalents.&amp;#160;&amp;#160;The carrying amount reported in the balance sheet for cash and cash equivalents approximates its fair value.&lt;/font&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <!--Weighted-Average Exercise Prices and Weighted-Average Grant-Date Fair Values of Options Issued-->
  <regn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePricesAndWeightedAverageGrantDateFairValueTableTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The fair value of each option granted under the 2000 Incentive Plan during 2011, 2010, and 2009 was estimated on the date of grant using the Black-Scholes option-pricing model.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="15%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Number of &lt;font style="DISPLAY: inline"&gt;Options Granted&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Weighted-Average Exercise &lt;font style="DISPLAY: inline"&gt;Price&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Weighted-Average Fair &lt;font style="DISPLAY: inline"&gt;Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;2011:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Exercise price equal to Market Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;4,286,640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$51.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$23.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;2010:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Exercise price equal to Market Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;4,319,856&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$29.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$13.36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;2009:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;Exercise price equal to Market Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;3,490,560&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$20.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$10.89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</regn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePricesAndWeightedAverageGrantDateFairValueTableTextBlock>
  <!--Income tax expense (benefit) resulting from provision in American Recovery and Reinvestment Act of 2009 + Income tax expense (benefit) resulting from provision in American Recovery and Reinvestment Act of 2009-->
  <regn:IncomeTaxExpenseBenefitResultingFromProvisionInAmericanRecoveryAndReinvestmentActOf2009 contextRef="c00124" unitRef="u000" decimals="-5">-700000</regn:IncomeTaxExpenseBenefitResultingFromProvisionInAmericanRecoveryAndReinvestmentActOf2009>
  <!--Income tax expense (benefit) resulting from provision in American Recovery and Reinvestment Act of 2009 + Income tax expense (benefit) resulting from provision in American Recovery and Reinvestment Act of 2009-->
  <regn:IncomeTaxExpenseBenefitResultingFromProvisionInAmericanRecoveryAndReinvestmentActOf2009 contextRef="c00195" unitRef="u000" decimals="-5">-700000</regn:IncomeTaxExpenseBenefitResultingFromProvisionInAmericanRecoveryAndReinvestmentActOf2009>
  <!--Unrecognized stock-based compensation cost, net of estimated forfeitures- Non-Performance Based Stock Options [Member]-->
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c00055" unitRef="u000" decimals="-5">93600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <!--Unrecognized stock-based compensation cost, net of estimated forfeitures- Performance-Based Stock Options [Member]-->
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c00056" unitRef="u000" decimals="-5">17400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <!--Unrecognized stock-based compensation cost, net of estimated forfeitures- Restricted Stock [Member]-->
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c00057" unitRef="u000" decimals="-5">9800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <!--Number of shares of Common Stock reserved for future issuance (in shares)- Long-Term Incentive Plan 2000 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="c00053" unitRef="u001" decimals="0">41307016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <!--2014- Facilities Buildings A and B [Member]-->
  <regn:FacilityLeasesFutureMinimumPaymentsDueDueInThreeYears contextRef="c00048" unitRef="u000" decimals="-3">13343000</regn:FacilityLeasesFutureMinimumPaymentsDueDueInThreeYears>
  <!--2014- Facilities Building C [Member]-->
  <regn:FacilityLeasesFutureMinimumPaymentsDueDueInThreeYears contextRef="c00049" unitRef="u000" decimals="-3">4490000</regn:FacilityLeasesFutureMinimumPaymentsDueDueInThreeYears>
  <!--2014-->
  <regn:FacilityLeasesFutureMinimumPaymentsDueDueInThreeYears contextRef="c00001" unitRef="u000" decimals="-3">17833000</regn:FacilityLeasesFutureMinimumPaymentsDueDueInThreeYears>
  <!--Letter of credit amount outstanding in connection with lease- Tarrytown Lease [Member] + Letter of credit amount outstanding in connection with lease- Tarrytown Lease [Member]-->
  <us-gaap:LettersOfCreditOutstandingAmount contextRef="c00047" unitRef="u000" decimals="-5">3400000</us-gaap:LettersOfCreditOutstandingAmount>
  <!--Letter of credit amount outstanding in connection with lease- Tarrytown Lease [Member] + Letter of credit amount outstanding in connection with lease- Tarrytown Lease [Member]-->
  <us-gaap:LettersOfCreditOutstandingAmount contextRef="c00101" unitRef="u000" decimals="-5">3400000</us-gaap:LettersOfCreditOutstandingAmount>
  <!--Description of leasing arrangement- Tarrytown Lease [Member]-->
  <us-gaap:DescriptionOfLesseeLeasingArrangementsOperatingLeases contextRef="c00148">expire in June 2024 and contains three renewal options to extend the term of the lease by five years each, escalations at 2.5% per annum</us-gaap:DescriptionOfLesseeLeasingArrangementsOperatingLeases>
  <!--2013-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="c00001" unitRef="u000" decimals="-3">7562000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <!--2013- Equipment [Member]-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="c00020" unitRef="u000" decimals="-3">258000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <!--2013- Building [Member]-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="c00046" unitRef="u000" decimals="-3">7304000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <!--Weighted average number, in thousands (in shares)- Stock Options [Member] + Weighted average number, in thousands (in shares)- Stock Options [Member] + Weighted average number, in thousands (in shares)- Stock Options [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c00142" unitRef="u001" decimals="-3">20942000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Weighted average number, in thousands (in shares)- Stock Options [Member] + Weighted average number, in thousands (in shares)- Stock Options [Member] + Weighted average number, in thousands (in shares)- Stock Options [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c00178" unitRef="u001" decimals="-3">21428000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Weighted average number, in thousands (in shares)- Stock Options [Member] + Weighted average number, in thousands (in shares)- Stock Options [Member] + Weighted average number, in thousands (in shares)- Stock Options [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c00209" unitRef="u001" decimals="-3">20040000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Weighted average number, in thousands (in shares)- Restricted Stock [Member] + Weighted average number, in thousands (in shares)- Restricted Stock [Member] + Weighted average number, in thousands (in shares)- Restricted Stock [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c00143" unitRef="u001" decimals="-3">846000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Weighted average number, in thousands (in shares)- Restricted Stock [Member] + Weighted average number, in thousands (in shares)- Restricted Stock [Member] + Weighted average number, in thousands (in shares)- Restricted Stock [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c00179" unitRef="u001" decimals="-3">526000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Weighted average number, in thousands (in shares)- Restricted Stock [Member] + Weighted average number, in thousands (in shares)- Restricted Stock [Member] + Weighted average number, in thousands (in shares)- Restricted Stock [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c00210" unitRef="u001" decimals="-3">500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Weighted average number, in thousands (in shares)- Convertible Debt Securities [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c00144" unitRef="u001" decimals="-3">939000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Weighted average number, in thousands (in shares)- Warrants [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c00145" unitRef="u001" decimals="-3">939000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Capitalized interest costs-->
  <us-gaap:InterestCostsIncurredCapitalized contextRef="c00164" unitRef="u000" decimals="-5">6400000</us-gaap:InterestCostsIncurredCapitalized>
  <!--Property, plant and equipment, gross- Land [Member] + Property, plant and equipment, gross- Land [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c00015" unitRef="u000" decimals="-3">2117000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, plant and equipment, gross- Land [Member] + Property, plant and equipment, gross- Land [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c00072" unitRef="u000" decimals="-3">2117000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, plant and equipment, gross- Building and Building Improvements [Member] + Property, plant and equipment, gross- Building and Building Improvements [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c00016" unitRef="u000" decimals="-3">322753000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, plant and equipment, gross- Building and Building Improvements [Member] + Property, plant and equipment, gross- Building and Building Improvements [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c00073" unitRef="u000" decimals="-3">242035000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, plant and equipment, gross- Leasehold Improvements [Member] + Property, plant and equipment, gross- Leasehold Improvements [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c00017" unitRef="u000" decimals="-3">4479000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, plant and equipment, gross- Leasehold Improvements [Member] + Property, plant and equipment, gross- Leasehold Improvements [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c00074" unitRef="u000" decimals="-3">4063000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, plant and equipment, gross- Construction-in-Progress [Member] + Property, plant and equipment, gross- Construction-in-Progress [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c00018" unitRef="u000" decimals="-3">10880000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, plant and equipment, gross- Construction-in-Progress [Member] + Property, plant and equipment, gross- Construction-in-Progress [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c00075" unitRef="u000" decimals="-3">70356000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, plant and equipment, gross- Furniture, Computer and Office Equipment, and Other [Member] + Property, plant and equipment, gross- Furniture, Computer and Office Equipment, and Other [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c00019" unitRef="u000" decimals="-3">29468000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, plant and equipment, gross- Furniture, Computer and Office Equipment, and Other [Member] + Property, plant and equipment, gross- Furniture, Computer and Office Equipment, and Other [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c00076" unitRef="u000" decimals="-3">22235000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, plant and equipment, gross + Property, plant and equipment, gross-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c00001" unitRef="u000" decimals="-3">526094000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, plant and equipment, gross + Property, plant and equipment, gross-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c00060" unitRef="u000" decimals="-3">478757000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, plant and equipment, gross- Equipment [Member] + Property, plant and equipment, gross- Equipment [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c00020" unitRef="u000" decimals="-3">156397000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, plant and equipment, gross- Equipment [Member] + Property, plant and equipment, gross- Equipment [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c00077" unitRef="u000" decimals="-3">137951000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, plant and equipment, gross- Leased Equipment Under Capital Leases [Member] + Property, plant and equipment, gross- Leased Equipment Under Capital Leases [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c00021" unitRef="u000" decimals="-5">3600000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, plant and equipment, gross- Leased Equipment Under Capital Leases [Member] + Property, plant and equipment, gross- Leased Equipment Under Capital Leases [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c00078" unitRef="u000" decimals="-5">2800000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Non-exclusive license agreement term (in years)- License Agreement with Astellas Pharma Inc [Member]-->
  <regn:NonExclusiveLicenseAgreementTerm contextRef="c00247">6Y</regn:NonExclusiveLicenseAgreementTerm>
  <!--Non-exclusive license agreement term (in years)- License Agreement with AstraZeneca UK Limited [Member]-->
  <regn:NonExclusiveLicenseAgreementTerm contextRef="c00253">6Y</regn:NonExclusiveLicenseAgreementTerm>
  <!--Share of losses outside the United States, for Company (in hundredths)- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:ShareOfLossesOutsideUnitedStatesForCompany contextRef="c00135" unitRef="u004" decimals="2">0.45</regn:ShareOfLossesOutsideUnitedStatesForCompany>
  <!--Percentage of start-up costs of total contract value, maximum (in hundredths)-->
  <regn:PercentageOfStartUpCostsOfTotalContractValueMaximum contextRef="c00124" unitRef="u004" decimals="2">0.20</regn:PercentageOfStartUpCostsOfTotalContractValueMaximum>
  <!--Conversion of Class A Stock to Common Stock - Class A Stock Shares- Class A Stock [Member] + Conversion of Class A Stock to Common Stock - Class A Stock Shares- Class A Stock [Member] + Conversion of Class A Stock to Common Stock - Class A Stock Shares- Class A Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c00198" unitRef="u001" decimals="-3">-4000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <!--Conversion of Class A Stock to Common Stock - Class A Stock Shares- Class A Stock [Member] + Conversion of Class A Stock to Common Stock - Class A Stock Shares- Class A Stock [Member] + Conversion of Class A Stock to Common Stock - Class A Stock Shares- Class A Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c00167" unitRef="u001" decimals="-3">-63000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <!--Conversion of Class A Stock to Common Stock - Class A Stock Shares- Class A Stock [Member] + Conversion of Class A Stock to Common Stock - Class A Stock Shares- Class A Stock [Member] + Conversion of Class A Stock to Common Stock - Class A Stock Shares- Class A Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c00127" unitRef="u001" decimals="-3">-73000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <!--Conversion of Class A Stock to Common Stock - Common Stock Shares- Common Stock [Member] + Conversion of Class A Stock to Common Stock - Common Stock Shares- Common Stock [Member] + Conversion of Class A Stock to Common Stock - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c00196" unitRef="u001" decimals="-3">4000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <!--Conversion of Class A Stock to Common Stock - Common Stock Shares- Common Stock [Member] + Conversion of Class A Stock to Common Stock - Common Stock Shares- Common Stock [Member] + Conversion of Class A Stock to Common Stock - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c00165" unitRef="u001" decimals="-3">63000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <!--Conversion of Class A Stock to Common Stock - Common Stock Shares- Common Stock [Member] + Conversion of Class A Stock to Common Stock - Common Stock Shares- Common Stock [Member] + Conversion of Class A Stock to Common Stock - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c00125" unitRef="u001" decimals="-3">73000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <!--Balance, December 31, 2008 - Class A Stock Shares- Class A Stock [Member] + Balance, December 31, 2009 - Class A Stock Shares- Class A Stock [Member] + Balance, December 31, 2010 - Class A Stock Shares- Class A Stock [Member] + Balance, December 31, 2011 - Class A Stock Shares- Class A Stock [Member]-->
  <us-gaap:SharesOutstanding contextRef="c00222" unitRef="u001" decimals="-3">2249000</us-gaap:SharesOutstanding>
  <!--Balance, December 31, 2008 - Class A Stock Shares- Class A Stock [Member] + Balance, December 31, 2009 - Class A Stock Shares- Class A Stock [Member] + Balance, December 31, 2010 - Class A Stock Shares- Class A Stock [Member] + Balance, December 31, 2011 - Class A Stock Shares- Class A Stock [Member]-->
  <us-gaap:SharesOutstanding contextRef="c00107" unitRef="u001" decimals="-3">2245000</us-gaap:SharesOutstanding>
  <!--Balance, December 31, 2008 - Class A Stock Shares- Class A Stock [Member] + Balance, December 31, 2009 - Class A Stock Shares- Class A Stock [Member] + Balance, December 31, 2010 - Class A Stock Shares- Class A Stock [Member] + Balance, December 31, 2011 - Class A Stock Shares- Class A Stock [Member]-->
  <us-gaap:SharesOutstanding contextRef="c00062" unitRef="u001" decimals="-3">2182000</us-gaap:SharesOutstanding>
  <!--Balance, December 31, 2008 - Class A Stock Shares- Class A Stock [Member] + Balance, December 31, 2009 - Class A Stock Shares- Class A Stock [Member] + Balance, December 31, 2010 - Class A Stock Shares- Class A Stock [Member] + Balance, December 31, 2011 - Class A Stock Shares- Class A Stock [Member]-->
  <us-gaap:SharesOutstanding contextRef="c00003" unitRef="u001" decimals="-3">2109000</us-gaap:SharesOutstanding>
  <!--Balance, December 31, 2008 - Common Stock Shares- Common Stock [Member] + Balance, December 31, 2009 - Common Stock Shares- Common Stock [Member] + Balance, December 31, 2010 - Common Stock Shares- Common Stock [Member] + Balance, December 31, 2011 - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:SharesOutstanding contextRef="c00223" unitRef="u001" decimals="-3">77642000</us-gaap:SharesOutstanding>
  <!--Balance, December 31, 2008 - Common Stock Shares- Common Stock [Member] + Balance, December 31, 2009 - Common Stock Shares- Common Stock [Member] + Balance, December 31, 2010 - Common Stock Shares- Common Stock [Member] + Balance, December 31, 2011 - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:SharesOutstanding contextRef="c00108" unitRef="u001" decimals="-3">78861000</us-gaap:SharesOutstanding>
  <!--Balance, December 31, 2008 - Common Stock Shares- Common Stock [Member] + Balance, December 31, 2009 - Common Stock Shares- Common Stock [Member] + Balance, December 31, 2010 - Common Stock Shares- Common Stock [Member] + Balance, December 31, 2011 - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:SharesOutstanding contextRef="c00063" unitRef="u001" decimals="-3">87238000</us-gaap:SharesOutstanding>
  <!--Balance, December 31, 2008 - Common Stock Shares- Common Stock [Member] + Balance, December 31, 2009 - Common Stock Shares- Common Stock [Member] + Balance, December 31, 2010 - Common Stock Shares- Common Stock [Member] + Balance, December 31, 2011 - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:SharesOutstanding contextRef="c00004" unitRef="u001" decimals="-3">90692000</us-gaap:SharesOutstanding>
  <!--Class A Stock, shares outstanding- Class A Stock [Member]-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c00002" unitRef="u001" decimals="0">2109512</us-gaap:CommonStockSharesOutstanding>
  <!--Class A Stock, shares outstanding- Class A Stock [Member]-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c00061" unitRef="u001" decimals="0">2182036</us-gaap:CommonStockSharesOutstanding>
  <!--Common Stock, shares outstanding-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c00001" unitRef="u001" decimals="0">90692071</us-gaap:CommonStockSharesOutstanding>
  <!--Common Stock, shares outstanding-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c00060" unitRef="u001" decimals="0">87238301</us-gaap:CommonStockSharesOutstanding>
  <!--Marketable securities-->
  <us-gaap:MarketableSecuritiesCurrent contextRef="c00001" unitRef="u000" decimals="-3">43332000</us-gaap:MarketableSecuritiesCurrent>
  <!--Marketable securities-->
  <us-gaap:MarketableSecuritiesCurrent contextRef="c00060" unitRef="u000" decimals="-3">136796000</us-gaap:MarketableSecuritiesCurrent>
  <!--Commitments and Contingencies-->
  <us-gaap:CommitmentsDisclosureTextBlock contextRef="c00124">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;12.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;a. Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Descriptions of Lease Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company leases laboratory and office facilities in Tarrytown, New York, under a December 2006 lease agreement, as amended (the &amp;#8220;Tarrytown Lease&amp;#8221;).&amp;#160;&amp;#160;The facilities leased by the Company under the Tarrytown Lease include (i) space in previously existing buildings, (ii) newly constructed space in two new buildings (&amp;#8220;Buildings A and B&amp;#8221;) that was completed in the third quarter of 2009 and, (iii) under a December 2009 amendment to the Tarrytown Lease, additional newly constructed space in a third new building (&amp;#8220;Building C&amp;#8221;) that was completed in the first quarter of 2011.&amp;#160;&amp;#160;The Tarrytown Lease will expire in June 2024 and contains three renewal options to extend the term of the lease by five years each, escalations at 2.5% per annum, and early termination options for various portions of the space exclusive of the newly constructed space in Buildings A and B.&amp;#160;&amp;#160;&amp;#160;The Tarrytown Lease provides for monthly payments over its term and additional charges for utilities, taxes, and operating expenses.&amp;#160;&amp;#160;Certain premises under the Tarrytown Lease are accounted for as operating leases.&amp;#160;&amp;#160;However, for Buildings A, B, and C that the Company is leasing, the Company is deemed, in substance, to be the owner of the landlord&amp;#8217;s buildings in accordance with the application of FASB authoritative guidance, and the landlord&amp;#8217;s costs of constructing these new facilities are required to be capitalized on the Company&amp;#8217;s books as a non-cash transaction, offset by a corresponding lease obligation on the Company&amp;#8217;s balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In connection with the Tarrytown Lease, the Company issued a&lt;a id="exp1" name="exp1"&gt;&lt;!--EFPlaceholder--&gt;&lt;/a&gt; letter of credit in the amount of $3.4 million and collateralized the letter of credit with cash and marketable debt securities totaling $3.6 million at both December 31, 2011 and 2010.&amp;#160;&amp;#160;Such collateral has been classified as restricted cash and marketable securities.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In October 2008, the Company entered into a sublease with Sanofi U.S. for office space in Bridgewater, New Jersey.&amp;#160;&amp;#160;The lease commenced in January 2009 and expired in July 2011.&amp;#160;&amp;#160;In July 2011, the Company entered into an operating lease for office space in Liberty Corner, New Jersey, which expires in January 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company also leases certain equipment under operating and capital leases which expire at various times through 2014.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;br /&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Commitments under Operating Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The estimated future minimum noncancelable lease commitments under operating leases were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="29%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;December 31,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Facilities&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Equipment&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;Total&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$6,072&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 23pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$1,188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$7,260&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,304&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 23pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;258&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,428&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 23pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,463&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,583&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,583&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;59,631&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 23pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;___&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;59,631&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$95,756&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 23pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$1,481&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$97,237&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Rent expense under operating leases was:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="29%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Year Ending December 31,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Facilities&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;Equipment&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Total&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$7,191&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 18.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$599&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 18.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$7,790&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,301&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 18.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;335&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 18.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2009&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7,722&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 18.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 18.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;8,117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In addition to its rent expense under operating leases, and payments under facility lease obligations (see below), for various facilities, the Company paid rental charges for utilities, real estate taxes, and operating expenses of $9.3 million, $10.3 million, and $8.4 million for the years ended December 31, 2011, 2010, and 2009, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Commitments under Capital Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In 2011 and 2010, the Company entered into capital leases in connection with acquisitions of new equipment.&amp;#160;&amp;#160;The lease obligations are collateralized with marketable debt securities totaling $3.3 million and $3.5 at December 31, 2011 and 2010, respectively; such collateral has been classified as restricted cash and marketable securities at December 31, 2011 and 2010.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The estimated future minimum noncancelable lease commitments under capital leases were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="29%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;December 31,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Equipment&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$1,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;1,254&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;130&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Total minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2,778&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Less: amount representing interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;(272)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$2,506&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;At the end of the lease term, the Company is required to purchase the leased equipment for a nominal amount defined in the lease agreement.&amp;#160;&amp;#160;At December 31, 2011 and 2010, capital lease obligations totaled $2.5 million and $2.8 million, respectively, and were included in other liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Facility Lease Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;As described above, in connection with the application of FASB authoritative guidance to the Company&amp;#8217;s lease of office and laboratory facilities in Buildings A, B, and C, the Company capitalized the landlord&amp;#8217;s costs of constructing the new facilities and recognized a corresponding facility lease obligation.&amp;#160;&amp;#160;The Company also recognized, as additional facility lease obligation, reimbursements from the Company&amp;#8217;s landlord for tenant improvement costs that the Company incurred since, under FASB authoritative guidance, such payments that the Company receives from its landlord are deemed to be a financing obligation.&amp;#160;&amp;#160;Monthly lease payments on these facilities are allocated between the land element of the lease (which is accounted for as an operating lease) and the facility lease obligation, based on the estimated relative fair values of the land and buildings.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;As of December 31, 2010, the Company had capitalized the landlord&amp;#8217;s costs of constructing Buildings A and B, which totaled $58.4 million, and of constructing Building C, which totaled $27.8 million.&amp;#160;&amp;#160;Reimbursements from the Company&amp;#8217;s landlord for Buildings A and B tenant improvement costs totaled $56.9 million and were received by the Company during 2010 and 2009.&amp;#160;&amp;#160;Reimbursements for Building C tenant improvement costs totaled $14.2 million and were received by the Company during 2010.&amp;#160;&amp;#160;With respect to Buildings A and B, monthly lease payments commenced in August 2009, the buildings were placed in service by the Company in September 2009, and the imputed interest rate applicable to the Company&amp;#8217;s facility lease obligation is approximately 11%.&amp;#160;&amp;#160;With respect to Building C, monthly lease payments commenced in January 2011, the building was placed in service by the Company in February 2011, and the imputed interest rate applicable to the Company&amp;#8217;s facility lease obligation is approximately 9%.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In 2011, the Company recognized $15.6 million of interest expense in connection with the Buildings A and B and the Building C facility lease obligations.&amp;#160;&amp;#160;In 2010 and 2009, the Company recognized $9.1 million and $2.3 million, respectively, of interest expense in connection with the Buildings A and B facility lease obligation.&amp;#160;&amp;#160;At December 31, 2011 and 2010, the Buildings A and B facility lease obligation balance was $113.0 million and $113.7 million, respectively, and the Building C facility lease obligation balance was $47.5 million and $46.4 million, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The estimated future minimum noncancelable commitments under these facility lease obligations, as of December 31, 2011, were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="29%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;December 31,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="15%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Buildings A and B&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Building C&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Total&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$12,847&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$2,825&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$15,672&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;13,092&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;4,370&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;17,462&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;13,343&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;4,490&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;17,833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;13,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;4,614&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;18,214&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;13,864&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;4,740&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;18,604&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;113,040&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;39,899&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;152,939&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="15%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$179,786&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$60,938&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="14%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$240,724&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;b. Research Collaboration and Licensing Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;As part of the Company's research and development efforts, the Company enters into research collaboration and licensing agreements with related and unrelated companies, scientific collaborators, universities, and consultants.&amp;#160;&amp;#160;These agreements contain varying terms and provisions which include fees and milestones to be paid by the Company, services to be provided, and ownership rights to certain proprietary technology developed under the agreements.&amp;#160;&amp;#160;Some of the agreements contain provisions which require the Company to pay royalties, as defined, at rates that range from 0.25% to 16.5%, in the event the Company sells or licenses any proprietary products developed under the respective agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In December 2011, the Company and Genentech, Inc., a member of the Roche Group, entered into a Non-Exclusive License and Partial Settlement Agreement (the &amp;#8220;Genentech Agreement&amp;#8221;) relating to ophthalmic sales of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; in the United States.&amp;#160;&amp;#160;&amp;#160;Pursuant to the Genentech Agreement, the Company received a non-exclusive license to certain patents relating to VEGF receptor proteins, known as the Davis-Smyth patents, and other technology patents.&amp;#160;&amp;#160;The Davis-Smyth patents are the subject of patent litigation between the Company and Genentech now pending in the United States District Court, Southern District of New York.&amp;#160;&amp;#160;Patent litigation is continuing with respect to matters not covered by the Genentech Agreement (see Note 18).&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Under the terms of the Genentech Agreement, the Company agreed to make payments to Genentech based on U.S. sales of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; commencing upon FDA approval of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; in November 2011 through May 7, 2016.&amp;#160;&amp;#160;The Company will be required to make a one-time, non-refundable $60 million payment upon cumulative U.S. sales of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; reaching $400 million.&amp;#160;&amp;#160;In addition, the Company agreed to pay royalties of 4.75% on cumulative U.S. sales of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; between $400 million and $3 billion and 5.5% on any cumulative U.S sales of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; over $3 billion.&amp;#160;&amp;#160;As the Company records net product sales of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt;, the Company is recognizing expense in connection with the Genentech Agreement using a blended mid-single digit royalty rate that reflects both the $60 million payment and the royalties payable on cumulative sales and that is based upon the Company&amp;#8217;s estimate of cumulative EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; sales through May 7, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company recognizes royalty expense based on net product sales of EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; and ARCALYST&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#160;&lt;/font&gt;under various licensing agreements, including, for EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt;, the Genentech Agreement described above.&amp;#160;&amp;#160;For the years ended December 31, 2011, 2010, and 2009, royalties on net product sales totaled $3.2 million, $1.7 million, and $1.5 million, respectively, and are included in cost of goods sold.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;br /&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In July 2008, the Company and Cellectis S.A. (&amp;#8220;Cellectis&amp;#8221;) entered into an Amended and Restated Non-Exclusive License Agreement (the &amp;#8220;Cellectis Agreement&amp;#8221;).&amp;#160;&amp;#160;The Cellectis Agreement resolved a dispute between the parties related to the interpretation of a license agreement entered into by the parties in December 2003 pursuant to which the Company licensed certain patents and patent applications from Cellectis.&amp;#160;&amp;#160;Pursuant to the Cellectis Agreement, in July 2008, the Company made a non-refundable $12.5 million payment to Cellectis (the &amp;#8220;Cellectis Payment&amp;#8221;) and agreed to pay Cellectis a low single-digit royalty based on revenue received by the Company from any future licenses or sales of the Company&amp;#8217;s &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;VelociGene&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; or &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;VelocImmune&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; products and services.&amp;#160;&amp;#160;No royalties are payable to Cellectis with respect to the Company&amp;#8217;s &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;VelocImmune&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; license agreements with AstraZeneca and Astellas or the Company&amp;#8217;s antibody collaboration with Sanofi.&amp;#160;&amp;#160;Moreover, no royalties are payable to Cellectis on any revenue from commercial sales of antibodies from the Company&amp;#8217;s &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;VelocImmune&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; technology.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company began amortizing the Cellectis Payment in the second quarter of 2008 in proportion to past and future anticipated revenues under the Company&amp;#8217;s license agreements with AstraZeneca and Astellas and the Discovery and Preclinical Development Agreement under the Company&amp;#8217;s antibody collaboration with Sanofi (as amended in November 2009).&amp;#160;&amp;#160;In 2011, 2010, and 2009, the Company recognized $1.0 million, $0.9 million, and $2.3 million, respectively, of expense in connection with the Cellectis Payment.&amp;#160;&amp;#160;At December 31, 2011 and 2010, the unamortized balance of the Cellectis Payment, which was included in other assets, was $5.7 million and $6.6 million, respectively.&amp;#160;&amp;#160;The Company estimates that it will recognize expense of $1.0 million in each of 2012 and 2013, and $0.9 million in each of 2014, 2015 and 2016, in connection with the Cellectis Payment.&lt;/font&gt;&lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
  <!--Product Revenue-->
  <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="c00124">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;5.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Product Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In November 2011, the Company received marketing approval from the FDA for EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; for the treatment of wet AMD.&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;In accordance with the Company&amp;#8217;s revenue recognition policy described in Note 2, the Company recorded &lt;/font&gt;EYLEA&lt;font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#210;&lt;/font&gt; net product sales of $24.8 million for the year ended December 31, 2011.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In February 2008, the Company received marketing approval from the FDA for ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; Injection for Subcutaneous Use for the treatment of CAPS.&amp;#160;&amp;#160;ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; net product sales totaled $19.9 million, $25.3 million, and $18.4 million for the years ended December 31, 2011, 2010, and 2009, respectively.&amp;#160;&amp;#160;The Company had limited historical return experience for ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; beginning with initial sales in 2008 through the end of 2009; therefore, ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; net product sales were deferred until the right of return no longer existed and rebates could be reasonably estimated.&amp;#160;&amp;#160;Effective in the first quarter of 2010, the Company determined that it had accumulated sufficient historical data to reasonably estimate both product returns and rebates of ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt;.&amp;#160;&amp;#160;As a result, ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174; &lt;/font&gt;net product sales during 2010 included $20.5 million of net product sales made during this period and $4.8 million of previously deferred net product sales.&amp;#160;&amp;#160;The effect of recognizing the previously deferred ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; net product sales revenue was to lower the Company&amp;#8217;s net loss per share by $0.06 in 2010.&lt;/font&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
  <!--Maximum number of product candidates for which milestone payments may be received relating to marketing approvals in Japan- Collaboration Agreement with Sanofi [Member]-->
  <regn:MaximumNumberOfProductCandidatesForWhichSubstantiveMilestonePaymentsMayBeReceivedInJapan contextRef="c00160" unitRef="u006" decimals="0">5</regn:MaximumNumberOfProductCandidatesForWhichSubstantiveMilestonePaymentsMayBeReceivedInJapan>
  <!--Maximum amount of milestone payments that may be received relating to marketing approvals- Collaboration Agreement with Sanofi [Member]-->
  <regn:MaximumAmountOfSubstantiveMilestonePaymentsThatMayBeReceivedRelatingToMarketingApprovals contextRef="c00160" unitRef="u000" decimals="-6">400000000</regn:MaximumAmountOfSubstantiveMilestonePaymentsThatMayBeReceivedRelatingToMarketingApprovals>
  <!--Gross decreases due to settlements and lapse of statute of limitations-->
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c00124" unitRef="u000" decimals="-3">9415000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
  <!--Other + Other-->
  <us-gaap:DeferredTaxAssetsOther contextRef="c00001" unitRef="u000" decimals="-3">15956000</us-gaap:DeferredTaxAssetsOther>
  <!--Other + Other-->
  <us-gaap:DeferredTaxAssetsOther contextRef="c00060" unitRef="u000" decimals="-3">10863000</us-gaap:DeferredTaxAssetsOther>
  <!--Granted, weighted-average grant date fair value (in dollars per share)- Restricted Stock [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="c00156" unitRef="u002" decimals="2">58.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <!--Outstanding, beginning of period, weighted-average grant date fair value (in dollars per share)- Restricted Stock [Member] + Outstanding, beginning of period, weighted-average grant date fair value (in dollars per share)- Restricted Stock [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c00106" unitRef="u002" decimals="2">25.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <!--Outstanding, beginning of period, weighted-average grant date fair value (in dollars per share)- Restricted Stock [Member] + Outstanding, beginning of period, weighted-average grant date fair value (in dollars per share)- Restricted Stock [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c00057" unitRef="u002" decimals="2">25.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <!--Total intrinsic value of stock options exercised- Stock Options [Member] + Total intrinsic value of stock options exercised- Stock Options [Member] + Total intrinsic value of stock options exercised- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c00152" unitRef="u000" decimals="-5">49200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <!--Total intrinsic value of stock options exercised- Stock Options [Member] + Total intrinsic value of stock options exercised- Stock Options [Member] + Total intrinsic value of stock options exercised- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c00187" unitRef="u000" decimals="-5">21400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <!--Total intrinsic value of stock options exercised- Stock Options [Member] + Total intrinsic value of stock options exercised- Stock Options [Member] + Total intrinsic value of stock options exercised- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c00217" unitRef="u000" decimals="-5">13200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <!--Exercisable, end of period, intrinsic value- Stock Options [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c00054" unitRef="u000" decimals="-3">451478000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <!--Vested and expected to vest, end of period, weighted-average remaining contractual term (in years)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm contextRef="c00152" unitRef="u006" decimals="2">6.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm>
  <!--Number of shares available for future grants (in shares)- Long-Term Incentive Plan 2000 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="c00053" unitRef="u001" decimals="0">10244318</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <!--Period within vesting date that awards may be received (in days)- Phantom Stock [Member]-->
  <regn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFromVestingDateAwardsMayBeReceived contextRef="c00153">30D</regn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFromVestingDateAwardsMayBeReceived>
  <!--Common Stock, conversion features- Class A Stock [Member]-->
  <us-gaap:CommonStockConversionFeatures contextRef="c00151">share-for-share basis</us-gaap:CommonStockConversionFeatures>
  <!--Thereafter- Facilities Buildings A and B [Member]-->
  <regn:FacilityLeasesFutureMinimumPaymentsDueDueThereafter contextRef="c00048" unitRef="u000" decimals="-3">113040000</regn:FacilityLeasesFutureMinimumPaymentsDueDueThereafter>
  <!--Thereafter- Facilities Building C [Member]-->
  <regn:FacilityLeasesFutureMinimumPaymentsDueDueThereafter contextRef="c00049" unitRef="u000" decimals="-3">39899000</regn:FacilityLeasesFutureMinimumPaymentsDueDueThereafter>
  <!--Thereafter-->
  <regn:FacilityLeasesFutureMinimumPaymentsDueDueThereafter contextRef="c00001" unitRef="u000" decimals="-3">152939000</regn:FacilityLeasesFutureMinimumPaymentsDueDueThereafter>
  <!--2013- Equipment [Member]-->
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears contextRef="c00020" unitRef="u000" decimals="-3">1254000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears>
  <!--Number of new buildings leased- Tarrytown Lease [Member]-->
  <regn:NumberOfNewBuildingsLeased contextRef="c00148" unitRef="u006" decimals="0">2</regn:NumberOfNewBuildingsLeased>
  <!--U.S. government guaranteed collateralized mortgage obligations- Unrestricted [Member] + U.S. government guaranteed collateralized mortgage obligations- Unrestricted [Member]-->
  <regn:USGovernmentGuaranteedCollateralizedMortgageObligationsFairValueDisclosure contextRef="c00034" unitRef="u000" decimals="-3">622000</regn:USGovernmentGuaranteedCollateralizedMortgageObligationsFairValueDisclosure>
  <!--U.S. government guaranteed collateralized mortgage obligations- Unrestricted [Member] + U.S. government guaranteed collateralized mortgage obligations- Unrestricted [Member]-->
  <regn:USGovernmentGuaranteedCollateralizedMortgageObligationsFairValueDisclosure contextRef="c00090" unitRef="u000" decimals="-3">2131000</regn:USGovernmentGuaranteedCollateralizedMortgageObligationsFairValueDisclosure>
  <!--U.S. government guaranteed collateralized mortgage obligations- Unrestricted [Member]- Fair Value, Inputs, Level 2 [Member] + U.S. government guaranteed collateralized mortgage obligations- Unrestricted [Member]- Fair Value, Inputs, Level 2 [Member]-->
  <regn:USGovernmentGuaranteedCollateralizedMortgageObligationsFairValueDisclosure contextRef="c00041" unitRef="u000" decimals="-3">622000</regn:USGovernmentGuaranteedCollateralizedMortgageObligationsFairValueDisclosure>
  <!--U.S. government guaranteed collateralized mortgage obligations- Unrestricted [Member]- Fair Value, Inputs, Level 2 [Member] + U.S. government guaranteed collateralized mortgage obligations- Unrestricted [Member]- Fair Value, Inputs, Level 2 [Member]-->
  <regn:USGovernmentGuaranteedCollateralizedMortgageObligationsFairValueDisclosure contextRef="c00096" unitRef="u000" decimals="-3">2131000</regn:USGovernmentGuaranteedCollateralizedMortgageObligationsFairValueDisclosure>
  <!--Unrealized Net - Total- Unrestricted [Member] + Unrealized Net - Total- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGainLoss contextRef="c00034" unitRef="u000" decimals="-3">272000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGainLoss>
  <!--Unrealized Net - Total- Unrestricted [Member] + Unrealized Net - Total- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGainLoss contextRef="c00090" unitRef="u000" decimals="-3">-1331000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGainLoss>
  <!--Unrealized Net - Total- Restricted [Member] + Unrealized Net - Total- Restricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGainLoss contextRef="c00036" unitRef="u000" decimals="-3">21000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGainLoss>
  <!--Unrealized Net - Total- Restricted [Member] + Unrealized Net - Total- Restricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGainLoss contextRef="c00092" unitRef="u000" decimals="-3">-18000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGainLoss>
  <!--Unrealized Net - Total- Debt Securities [Member] + Unrealized Net - Total- Debt Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGainLoss contextRef="c00037" unitRef="u000" decimals="-3">293000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGainLoss>
  <!--Unrealized Net - Total- Debt Securities [Member] + Unrealized Net - Total- Debt Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGainLoss contextRef="c00093" unitRef="u000" decimals="-3">-1349000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGainLoss>
  <!--Cost basis of equity securities- Equity Securities [Member] + Cost basis of equity securities- Equity Securities [Member]-->
  <us-gaap:AvailableForSaleEquitySecuritiesAmortizedCostBasis contextRef="c00028" unitRef="u000" decimals="-5">4000000</us-gaap:AvailableForSaleEquitySecuritiesAmortizedCostBasis>
  <!--Cost basis of equity securities- Equity Securities [Member] + Cost basis of equity securities- Equity Securities [Member]-->
  <us-gaap:AvailableForSaleEquitySecuritiesAmortizedCostBasis contextRef="c00084" unitRef="u000" decimals="-5">4000000</us-gaap:AvailableForSaleEquitySecuritiesAmortizedCostBasis>
  <!--Work in process + Work in process-->
  <us-gaap:InventoryWorkInProcess contextRef="c00001" unitRef="u000" decimals="-3">10806000</us-gaap:InventoryWorkInProcess>
  <!--Work in process + Work in process-->
  <us-gaap:InventoryWorkInProcess contextRef="c00060" unitRef="u000" decimals="-3">699000</us-gaap:InventoryWorkInProcess>
  <!--Government Rebate and Chargeback Accruals-->
  <regn:GovernmentRebateAndChargebackAccruals contextRef="c00001" unitRef="u000" decimals="-5">600000</regn:GovernmentRebateAndChargebackAccruals>
  <!--Additional funding to optimize certain existing technology- Grant from National Institutes of Health [Member]-->
  <regn:AdditionalFundingToOptimizeCertainExistingTechnology contextRef="c00246" unitRef="u000" decimals="-5">1500000</regn:AdditionalFundingToOptimizeCertainExistingTechnology>
  <!--Increase (decrease) in collaboration revenue recognized based on shortened (extended) performance period- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:IncreaseDecreaseInCollaborationRevenueRecognizedBasedOnShortenedExtendedPerformancePeriod contextRef="c00135" unitRef="u000" decimals="-5">-5300000</regn:IncreaseDecreaseInCollaborationRevenueRecognizedBasedOnShortenedExtendedPerformancePeriod>
  <!--Amount of funding to expand manufacturing capacity that has been received or is receivable- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:AmountOfFundingToExpandManufacturingCapacityThatHasBeenReceivedOrIsReceivable contextRef="c00011" unitRef="u000" decimals="-5">28200000</regn:AmountOfFundingToExpandManufacturingCapacityThatHasBeenReceivedOrIsReceivable>
  <!--Amount of funding of agreed-upon cost incurred to expand manufacturing capacity- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:AmountOfFundingOfAgreedUponCostIncurredToExpandManufacturingCapacity contextRef="c00135" unitRef="u000" decimals="-6">30000000</regn:AmountOfFundingOfAgreedUponCostIncurredToExpandManufacturingCapacity>
  <!--Share of losses outside the United States, for collaborating party (in hundredths)- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:ShareOfLossesOutsideUnitedStatesForCollaboratingParty contextRef="c00135" unitRef="u004" decimals="2">0.55</regn:ShareOfLossesOutsideUnitedStatesForCollaboratingParty>
  <!--Excess share of profit not required to to be applied to reimburse development cost (in hundredths)- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:ExcessShareOfProfitNotRequiredToToBeAppliedToReimburseDevelopmentCost contextRef="c00135" unitRef="u004" decimals="2">0.10</regn:ExcessShareOfProfitNotRequiredToToBeAppliedToReimburseDevelopmentCost>
  <!--Proceeds in connection with issuance of warrants-->
  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c00124" unitRef="u000" decimals="-3">93800000</us-gaap:ProceedsFromIssuanceOfWarrants>
  <!--Proceeds in connection with issuance of warrants-->
  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c00164" unitRef="u000" decimals="-3">0</us-gaap:ProceedsFromIssuanceOfWarrants>
  <!--Proceeds in connection with issuance of warrants-->
  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c00195" unitRef="u000" decimals="-3">0</us-gaap:ProceedsFromIssuanceOfWarrants>
  <!--Capital expenditures-->
  <us-gaap:PaymentsToAcquireProductiveAssets contextRef="c00124" unitRef="u000" decimals="-3">57217000</us-gaap:PaymentsToAcquireProductiveAssets>
  <!--Capital expenditures-->
  <us-gaap:PaymentsToAcquireProductiveAssets contextRef="c00164" unitRef="u000" decimals="-3">99689000</us-gaap:PaymentsToAcquireProductiveAssets>
  <!--Capital expenditures-->
  <us-gaap:PaymentsToAcquireProductiveAssets contextRef="c00195" unitRef="u000" decimals="-3">97318000</us-gaap:PaymentsToAcquireProductiveAssets>
  <!--Issuance of warrants in connection with issuance of convertible senior notes - Total Stockholders' Equity-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c00124" unitRef="u000" decimals="-3">93800000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <!--Issuance of warrants in connection with issuance of convertible senior notes - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c00126" unitRef="u000" decimals="-3">93800000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <!--Weighted average shares outstanding, basic and diluted-->
  <regn:WeightedAverageSharesOutstandingBasicAndDiluted contextRef="c00124" unitRef="u001" decimals="-3">90610000</regn:WeightedAverageSharesOutstandingBasicAndDiluted>
  <!--Weighted average shares outstanding, basic and diluted-->
  <regn:WeightedAverageSharesOutstandingBasicAndDiluted contextRef="c00164" unitRef="u001" decimals="-3">82926000</regn:WeightedAverageSharesOutstandingBasicAndDiluted>
  <!--Weighted average shares outstanding, basic and diluted-->
  <regn:WeightedAverageSharesOutstandingBasicAndDiluted contextRef="c00195" unitRef="u001" decimals="-3">79782000</regn:WeightedAverageSharesOutstandingBasicAndDiluted>
  <!--Income tax benefit-->
  <us-gaap:IncomeTaxExpenseBenefit contextRef="c00124" unitRef="u000" decimals="-3">-1132000</us-gaap:IncomeTaxExpenseBenefit>
  <!--Income tax benefit-->
  <us-gaap:IncomeTaxExpenseBenefit contextRef="c00164" unitRef="u000" decimals="-3">0</us-gaap:IncomeTaxExpenseBenefit>
  <!--Income tax benefit-->
  <us-gaap:IncomeTaxExpenseBenefit contextRef="c00195" unitRef="u000" decimals="-3">-4122000</us-gaap:IncomeTaxExpenseBenefit>
  <!--Net product sales-->
  <us-gaap:SalesRevenueGoodsNet contextRef="c00124" unitRef="u000" decimals="-3">44686000</us-gaap:SalesRevenueGoodsNet>
  <!--Net product sales-->
  <us-gaap:SalesRevenueGoodsNet contextRef="c00164" unitRef="u000" decimals="-3">25254000</us-gaap:SalesRevenueGoodsNet>
  <!--Net product sales-->
  <us-gaap:SalesRevenueGoodsNet contextRef="c00195" unitRef="u000" decimals="-3">18364000</us-gaap:SalesRevenueGoodsNet>
  <!--Net product sales- EYLEA Net Product Sales [Member]- Product Concentration Risk [Member]-->
  <us-gaap:SalesRevenueGoodsNet contextRef="c00140" unitRef="u000" decimals="-5">24800000</us-gaap:SalesRevenueGoodsNet>
  <!--Net product sales- Arcalyst Net Product Sales Member- Product Concentration Risk [Member] + Net product sales- Arcalyst Net Product Sales Member- Product Concentration Risk [Member] + Net product sales- Arcalyst Net Product Sales Member- Product Concentration Risk [Member]-->
  <us-gaap:SalesRevenueGoodsNet contextRef="c00141" unitRef="u000" decimals="-5">19900000</us-gaap:SalesRevenueGoodsNet>
  <!--Net product sales- Arcalyst Net Product Sales Member- Product Concentration Risk [Member] + Net product sales- Arcalyst Net Product Sales Member- Product Concentration Risk [Member] + Net product sales- Arcalyst Net Product Sales Member- Product Concentration Risk [Member]-->
  <us-gaap:SalesRevenueGoodsNet contextRef="c00177" unitRef="u000" decimals="-5">25300000</us-gaap:SalesRevenueGoodsNet>
  <!--Net product sales- Arcalyst Net Product Sales Member- Product Concentration Risk [Member] + Net product sales- Arcalyst Net Product Sales Member- Product Concentration Risk [Member] + Net product sales- Arcalyst Net Product Sales Member- Product Concentration Risk [Member]-->
  <us-gaap:SalesRevenueGoodsNet contextRef="c00208" unitRef="u000" decimals="-5">18400000</us-gaap:SalesRevenueGoodsNet>
  <!--Entity Filer Category-->
  <dei:EntityFilerCategory contextRef="c00124">Large Accelerated Filer</dei:EntityFilerCategory>
  <!--Entity Central Index Key-->
  <dei:EntityCentralIndexKey contextRef="c00124">0000872589</dei:EntityCentralIndexKey>
  <!--Entity Current Reporting Status-->
  <dei:EntityCurrentReportingStatus contextRef="c00124">Yes</dei:EntityCurrentReportingStatus>
  <!--Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution (in shares)- Common Stock [Member] + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution (in shares)- Common Stock [Member] + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution (in shares)- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan contextRef="c00196" unitRef="u001" decimals="-3">81000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
  <!--Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution (in shares)- Common Stock [Member] + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution (in shares)- Common Stock [Member] + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution (in shares)- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan contextRef="c00165" unitRef="u001" decimals="-3">111000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
  <!--Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution (in shares)- Common Stock [Member] + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution (in shares)- Common Stock [Member] + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution (in shares)- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan contextRef="c00125" unitRef="u001" decimals="-3">92000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
  <!--Common Stock contributed to the Savings Plan (in shares) + Common Stock contributed to the Savings Plan (in shares)-->
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan contextRef="c00116" unitRef="u001" decimals="-3">64000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
  <!--Common Stock contributed to the Savings Plan (in shares) + Common Stock contributed to the Savings Plan (in shares)-->
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan contextRef="c00117" unitRef="u001" decimals="-3">92000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
  <!--Convertible Debt-->
  <us-gaap:DebtDisclosureTextBlock contextRef="c00124">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;11.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Convertible Debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In October 2011, the Company issued $400.0 million aggregate principal amount of 1.875% convertible senior notes (the &amp;#8220;Notes&amp;#8221;) in a private placement. &amp;#160;The net proceeds from the Notes offering were $391.1 million after deducting the initial purchaser&amp;#8217;s discount and issuance costs.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The Notes will pay interest semi-annually on April 1 and October 1, beginning April 1, 2012, and will mature on October 1, 2016 unless earlier converted or repurchased. &amp;#160;The Notes will be convertible, subject to certain conditions, into cash, shares of the Company&amp;#8217;s Common Stock, or a combination of cash and shares of Common Stock, at the Company's option. &amp;#160;The initial conversion rate for the Notes will be 11.9021 shares of Common Stock (subject to adjustment in certain circumstances) per $1,000 principal amount of the Notes, or a total of approximately 4,760,840 shares upon conversion, which is equal to an initial conversion price of approximately $84.02 per share.&amp;#160;&amp;#160;A holder of the Notes may surrender their Notes at their option any time prior to the close of business on the business day immediately preceding July 1, 2016, only under the following circumstances: &lt;/font&gt;(i) during any calendar quarter commencing after the calendar quarter ending on December 31, 2011 (and only during such calendar quarter), if the last reported sale price of the Company&amp;#8217;s Common Stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (ii) during the five business day period after any ten consecutive trading day period (the &amp;#8220;measurement period&amp;#8221;) in which the trading price, as defined, of the Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company&amp;#8217;s Common Stock and the conversion rate on each such trading day; (iii) if the Company elects to issue to all or substantially all holders of its Common Stock any rights, options or warrants (other than pursuant to a rights plan) entitling them for a period of not more than 60 calendar days after the record date for such issuance, to subscribe for or purchase shares of the Company&amp;#8217;s Common Stock, at a price per share less than the average of the last reported sales prices of the Company&amp;#8217;s Common Stock for the ten consecutive day period ending on, and including, the trading day immediately preceding the declaration date for such issuance; (iv) upon specified distributions to the Company&amp;#8217;s shareholders; or (v) upon the occurrence of specified corporate transactions, such as a fundamental change (i.e., a change in control), or the Company&amp;#8217;s Common Stock ceasing to be listed on at least one U.S. national securities exchange.&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;&amp;#160;&lt;/font&gt;On or after July 1, 2016, holders may convert their Notes at the conversion rate at any time prior to the close of business on the second scheduled trading day immediately preceding the maturity date irrespective of the foregoing conditions.&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;&amp;#160;&lt;/font&gt;In the event that a fundamental change, as defined in the indenture under which the Notes have been issued, occurs prior to maturity of the Notes, the initial conversion rate may be increased to include additional shares upon conversion, or holders can require the Company to purchase from them all or a portion of their Notes for 100% of the principal value plus any accrued and unpaid interest.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The Company has reserved sufficient shares of its Common Stock to satisfy the conversion requirements related to the Notes.&amp;#160;&amp;#160;The Company may not redeem the Notes prior to their maturity date.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In accordance with accounting guidance for debt with conversion and other options, the Company accounted for the liability and equity components of the Notes separately.&amp;#160;&amp;#160;&amp;#160;The estimated fair value of the liability component at the date of issuance was $271.1 million, and was computed based on the fair value of similar debt instruments that do not include a conversion feature.&amp;#160;&amp;#160;The equity component of $120.9 million was recognized as a debt discount and represents the difference between the $392.0 million of gross proceeds from the issuance of the Notes and the $271.1 million estimated fair value of the liability component at the date of issuance.&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The debt discount is amortized over the expected life of a similar liability without the equity component.&amp;#160;&amp;#160;The Company determined this expected life to be equal to the term of the Notes, resulting in an amortization period ending October 1, 2016.&lt;/font&gt;&amp;#160;&amp;#160;The effective interest rate used to amortize the debt discount is approximately 10.2%, which was based on the Company&amp;#8217;s estimated non-convertible borrowing rate as of the date the Notes were issued.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Issuance costs of $0.9&amp;#160;million related to the issuance of the Notes were allocated to the liability and equity components in proportion to the allocation of the proceeds and accounted for as capitalized debt issuance costs and equity issuance costs, respectively.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The net carrying amount of the liability component of the Notes as of December 31, 2011 consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="46%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Total convertible senior notes &amp;#8211; par&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 16.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$400,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Unamortized discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 16.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;124,981&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 16.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$275,019&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Total interest expense associated with the Notes consisted of the following for the year ended December 31, 2011:&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="46%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Contractual coupon interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 16.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$1,455&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Amortization of discount and note issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 16.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;3,944&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 16.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;$5,399&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="16%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;As of December&amp;#160;31, 2011, the "if converted value" does not exceed the principal amount of the Notes since the closing sales price of the Company&amp;#8217;s Common Stock was less than the initial conversion price of the Notes.&amp;#160;&amp;#160;The fair value of the outstanding Notes was estimated to be $375.5&amp;#160;million as of December&amp;#160;31, 2011, and was determined based on quoted market rates.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In connection with the offering of the Notes, the Company entered into convertible note hedge (&amp;#8220;call option&amp;#8221;) and warrant transactions with multiple counterparties, including an affiliate of the initial purchaser.&amp;#160;&amp;#160;The convertible note hedge transactions cover, subject to customary anti-dilution adjustments, the number of shares of the Company's Common Stock that initially underlie the Notes, and are intended to reduce the potential dilutive impact of the conversion feature of the Notes.&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt; The convertible note hedge &lt;/font&gt;will terminate upon the earlier of the maturity date of the Notes or the first day the Notes are no longer outstanding.&amp;#160;&amp;#160;The Company paid $117.5 million for the convertible note hedge, which was recorded as a reduction to additional paid-in capital.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The warrant transactions have an initial strike price of approximately $103.41 per share, and may be settled in cash or shares of the Company&amp;#8217;s Common Stock, at the Company&amp;#8217;s option.&amp;#160;&amp;#160;The warrant transactions will have a dilutive effect to the extent that the market price per share of the Company's Common Stock exceeds the applicable strike price of the warrants.&amp;#160;&amp;#160;Proceeds received from the warrant transactions totaled $93.8&amp;#160;million and were recorded as additional paid-in capital.&amp;#160;&amp;#160;The warrants expire at various dates during 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The convertible note hedge and warrants are both considered indexed to the Company&amp;#8217;s Common Stock and classified as equity; therefore, the convertible note hedge and warrants are not accounted for as derivative instruments.&amp;#160;&amp;#160;The Company has reserved sufficient shares of its Common Stock to satisfy the potential settlement of the warrants&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <!--Property, Plant, and Equipment-->
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Property, Plant, and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Property, plant, and equipment are stated at cost, net of accumulated depreciation.&amp;#160;&amp;#160;Depreciation is provided on a straight-line basis over the estimated useful lives of the assets.&amp;#160;&amp;#160;Expenditures for maintenance and repairs which do not materially extend the useful lives of the assets are charged to expense as incurred.&amp;#160;&amp;#160;The cost and accumulated depreciation or amortization of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized in operations.&amp;#160;&amp;#160;The estimated useful lives of property, plant, and equipment are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 72pt"&gt;&lt;/font&gt;Building and improvements&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;10-40 years&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 72pt"&gt;&lt;/font&gt;Laboratory and other equipment&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3-10 years&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="MARGIN-LEFT: 72pt"&gt;&lt;/font&gt;Furniture and fixtures&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;5 years&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Leasehold improvements are amortized over the shorter of the estimated useful lives of the assets or the lease term, without assuming renewal features, if any, are exercised.&amp;#160;&amp;#160;Costs of construction of certain long-lived assets include capitalized interest which is amortized over the estimated useful life of the related asset.&lt;/font&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <!--Inventory-->
  <us-gaap:InventoryPolicyTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Inventories are stated at the lower of cost or estimated realizable value.&amp;#160;&amp;#160;The Company determines the cost of inventory using the first-in, first-out, or FIFO, method.&amp;#160;&amp;#160;The Company capitalizes inventory costs associated with the Company's products prior to regulatory approval when, based on management's judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development.&amp;#160;&amp;#160;The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value, and writes-down such inventories as appropriate. In addition, the Company's products are subject to strict quality control and monitoring which the Company performs throughout the manufacturing process.&amp;#160;&amp;#160;If certain batches or units of product no longer meet quality specifications or become obsolete due to expiration, the Company records a charge to cost of goods sold to write down such unmarketable inventory to its estimated realizable value.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <!--Transactions Involving Stock Option Awards-->
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c00124">&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Transactions involving stock option awards during 2011 under the 2000 Incentive Plan is summarized in the table below.&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="36%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;Stock Options:&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Number of &lt;font style="DISPLAY: inline"&gt;Shares&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;Exercise Price&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Weighted-Average Remaining Contractual Term (in &lt;font style="DISPLAY: inline"&gt;years)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#160;&lt;/div&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Intrinsic Value (in &lt;font style="DISPLAY: inline"&gt;thousands)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="36%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Outstanding at December 31, 2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;23,362,248&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$19.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="36%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;2011:&lt;/font&gt;&amp;#160;&amp;#160;&amp;#160;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;4,286,640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$51.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="36%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(247,898)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$28.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="36%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(551,456)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$13.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="36%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;font style="DISPLAY: inline"&gt;(4,523,173)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$18.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="36%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Outstanding at December 31, 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;22,326,361&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$26.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 18.55pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;6.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$663,376&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="36%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="36%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Vested and expected to vest at December 31, 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;21,755,141&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$26.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 18.55pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;6.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$653,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="36%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="36%" align="left"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Exercisable at December 31, 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;11,963,345&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$18.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 18.55pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;5.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%" align="right"&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;$451,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <!--Deferred tax assets (liabilities), net + Deferred tax assets (liabilities), net-->
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c00001" unitRef="u000" decimals="-3">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <!--Deferred tax assets (liabilities), net + Deferred tax assets (liabilities), net-->
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c00060" unitRef="u000" decimals="-3">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <!--Net deferred tax assets-->
  <regn:NetDeferredTaxAssetsLiabilitiesGross contextRef="c00001" unitRef="u000" decimals="-3">578542000</regn:NetDeferredTaxAssetsLiabilitiesGross>
  <!--Research and experimental and other tax credit carry-forwards + Research and experimental and other tax credit carry-forwards-->
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c00001" unitRef="u000" decimals="-3">67734000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <!--Research and experimental and other tax credit carry-forwards + Research and experimental and other tax credit carry-forwards-->
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c00060" unitRef="u000" decimals="-3">45588000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <!--Deferred revenue + Deferred revenue-->
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c00001" unitRef="u000" decimals="-3">120490000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <!--Deferred revenue + Deferred revenue-->
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c00060" unitRef="u000" decimals="-3">70443000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <!--Net operating loss carry-forward + Net operating loss carry-forward-->
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c00001" unitRef="u000" decimals="-3">282480000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <!--Net operating loss carry-forward + Net operating loss carry-forward-->
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c00060" unitRef="u000" decimals="-3">243893000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <!--Released, weighted-average grant date fair value (in dollars per share)- Restricted Stock [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="c00156" unitRef="u002" decimals="2">30.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <!--Estimated percentage of options issued that will vest (in hundredths)- Performance-Based Stock Options [Member] + Estimated percentage of options issued that will vest (in hundredths)- Performance-Based Stock Options [Member] + Estimated percentage of options issued that will vest (in hundredths)- Performance-Based Stock Options [Member] + Estimated percentage of options issued that will vest (in hundredths)- Performance-Based Stock Options [Member]-->
  <regn:EstimatedPercentageOfOptionsIssuedThatWillVest contextRef="c00155" unitRef="u004" decimals="2">0.50</regn:EstimatedPercentageOfOptionsIssuedThatWillVest>
  <!--Estimated percentage of options issued that will vest (in hundredths)- Performance-Based Stock Options [Member] + Estimated percentage of options issued that will vest (in hundredths)- Performance-Based Stock Options [Member] + Estimated percentage of options issued that will vest (in hundredths)- Performance-Based Stock Options [Member] + Estimated percentage of options issued that will vest (in hundredths)- Performance-Based Stock Options [Member]-->
  <regn:EstimatedPercentageOfOptionsIssuedThatWillVest contextRef="c00189" unitRef="u004" decimals="2">1.00</regn:EstimatedPercentageOfOptionsIssuedThatWillVest>
  <!--Estimated percentage of options issued that will vest (in hundredths)- Performance-Based Stock Options [Member] + Estimated percentage of options issued that will vest (in hundredths)- Performance-Based Stock Options [Member] + Estimated percentage of options issued that will vest (in hundredths)- Performance-Based Stock Options [Member] + Estimated percentage of options issued that will vest (in hundredths)- Performance-Based Stock Options [Member]-->
  <regn:EstimatedPercentageOfOptionsIssuedThatWillVest contextRef="c00219" unitRef="u004" decimals="2">1.00</regn:EstimatedPercentageOfOptionsIssuedThatWillVest>
  <!--Estimated percentage of options issued that will vest (in hundredths)- Performance-Based Stock Options [Member] + Estimated percentage of options issued that will vest (in hundredths)- Performance-Based Stock Options [Member] + Estimated percentage of options issued that will vest (in hundredths)- Performance-Based Stock Options [Member] + Estimated percentage of options issued that will vest (in hundredths)- Performance-Based Stock Options [Member]-->
  <regn:EstimatedPercentageOfOptionsIssuedThatWillVest contextRef="c00266" unitRef="u004" decimals="2">1.00</regn:EstimatedPercentageOfOptionsIssuedThatWillVest>
  <!--Weighted-Average Fair Value (in dollars per share)- Stock Options [Member] + Weighted-Average Fair Value (in dollars per share)- Stock Options [Member] + Weighted-Average Fair Value (in dollars per share)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="c00152" unitRef="u002" decimals="2">23.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <!--Weighted-Average Fair Value (in dollars per share)- Stock Options [Member] + Weighted-Average Fair Value (in dollars per share)- Stock Options [Member] + Weighted-Average Fair Value (in dollars per share)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="c00187" unitRef="u002" decimals="2">13.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <!--Weighted-Average Fair Value (in dollars per share)- Stock Options [Member] + Weighted-Average Fair Value (in dollars per share)- Stock Options [Member] + Weighted-Average Fair Value (in dollars per share)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="c00217" unitRef="u002" decimals="2">10.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <!--Vested and expected to vest, end of period, weighted-average exercise price (in dollars per share)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="c00054" unitRef="u002" decimals="2">26.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <!--Outstanding, beginning of period, weighted-average exercise price (in dollars per share)- Stock Options [Member] + Outstanding, beginning of period, weighted-average exercise price (in dollars per share)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c00105" unitRef="u002" decimals="2">19.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <!--Outstanding, beginning of period, weighted-average exercise price (in dollars per share)- Stock Options [Member] + Outstanding, beginning of period, weighted-average exercise price (in dollars per share)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c00054" unitRef="u002" decimals="2">26.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <!--Forfeited (in shares)- Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c00152" unitRef="u001" decimals="0">247898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <!--Percentage of outstanding shares of Common Stock related to prohibition on selling to beneficial owners (in hundredths)- Sanofi [Member]-->
  <regn:PercentageOfOutstandingSharesOfCommonStockRelatedToProhibitionOnSellingToBeneficialOwners contextRef="c00239" unitRef="u004" decimals="2">0.05</regn:PercentageOfOutstandingSharesOfCommonStockRelatedToProhibitionOnSellingToBeneficialOwners>
  <!--Amortization of advance payment- Cellectis Agreement [Member] + Amortization of advance payment- Cellectis Agreement [Member] + Amortization of advance payment- Cellectis Agreement [Member]-->
  <regn:AmortizationOfAdvancePayment contextRef="c00150" unitRef="u000" decimals="-5">1000000</regn:AmortizationOfAdvancePayment>
  <!--Amortization of advance payment- Cellectis Agreement [Member] + Amortization of advance payment- Cellectis Agreement [Member] + Amortization of advance payment- Cellectis Agreement [Member]-->
  <regn:AmortizationOfAdvancePayment contextRef="c00186" unitRef="u000" decimals="-5">900000</regn:AmortizationOfAdvancePayment>
  <!--Amortization of advance payment- Cellectis Agreement [Member] + Amortization of advance payment- Cellectis Agreement [Member] + Amortization of advance payment- Cellectis Agreement [Member]-->
  <regn:AmortizationOfAdvancePayment contextRef="c00216" unitRef="u000" decimals="-5">2300000</regn:AmortizationOfAdvancePayment>
  <!--Thereafter-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="c00001" unitRef="u000" decimals="-3">59631000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
  <!--Thereafter- Building [Member]-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="c00046" unitRef="u000" decimals="-3">59631000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
  <!--Effective interest rate used to amortize the discount on the liability component (in hundredths)- Convertible Debt [Member]-->
  <us-gaap:DebtInstrumentConvertibleEffectiveInterestRate contextRef="c00258" unitRef="u004" decimals="3">0.102</us-gaap:DebtInstrumentConvertibleEffectiveInterestRate>
  <!--Fair Value - Less than 12 Months- Unrestricted [Member]- U S Government Obligations [Member] + Fair Value - Less than 12 Months- Unrestricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="c00029" unitRef="u000" decimals="-3">103529000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
  <!--Fair Value - Less than 12 Months- Unrestricted [Member]- U S Government Obligations [Member] + Fair Value - Less than 12 Months- Unrestricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="c00085" unitRef="u000" decimals="-3">340444000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
  <!--Fair Value - Less than 12 Months- Unrestricted [Member]- U S Government Guaranteed Collateralized Mortgage Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="c00031" unitRef="u000" decimals="-3">623000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
  <!--Fair Value - Less than 12 Months- Unrestricted [Member]- Municipal Bonds [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="c00032" unitRef="u000" decimals="-3">4603000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
  <!--Fair Value - Less than 12 Months- Equity Securities [Member] + Fair Value - Less than 12 Months- Equity Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="c00028" unitRef="u000" decimals="-3">3019000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
  <!--Fair Value - Less than 12 Months- Equity Securities [Member] + Fair Value - Less than 12 Months- Equity Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="c00084" unitRef="u000" decimals="-3">3612000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
  <!--Fair Value - Less than 12 Months + Fair Value - Less than 12 Months-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="c00001" unitRef="u000" decimals="-3">111774000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
  <!--Fair Value - Less than 12 Months + Fair Value - Less than 12 Months-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="c00060" unitRef="u000" decimals="-3">369215000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
  <!--Fair Value - Less than 12 Months- Unrestricted [Member]- U S Government Guaranteed Corporate Bonds [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="c00086" unitRef="u000" decimals="-3">19005000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
  <!--Fair Value - Less than 12 Months- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="c00090" unitRef="u000" decimals="-3">363061000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
  <!--Fair Value - Less than 12 Months- Restricted [Member]- U S Government Obligations [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="c00091" unitRef="u000" decimals="-3">6154000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
  <!--Fair Value - Less than 12 Months- Restricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="c00092" unitRef="u000" decimals="-3">6154000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
  <!--Amortized Cost Basis - Total- Unrestricted [Member] + Amortized Cost Basis - Total- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost contextRef="c00034" unitRef="u000" decimals="-3">315926000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost>
  <!--Amortized Cost Basis - Total- Unrestricted [Member] + Amortized Cost Basis - Total- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost contextRef="c00090" unitRef="u000" decimals="-3">504568000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost>
  <!--Amortized Cost Basis - Total- Restricted [Member] + Amortized Cost Basis - Total- Restricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost contextRef="c00036" unitRef="u000" decimals="-3">5919000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost>
  <!--Amortized Cost Basis - Total- Restricted [Member] + Amortized Cost Basis - Total- Restricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost contextRef="c00092" unitRef="u000" decimals="-3">7057000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost>
  <!--Amortized Cost Basis - Total- Debt Securities [Member] + Amortized Cost Basis - Total- Debt Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost contextRef="c00037" unitRef="u000" decimals="-3">321845000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost>
  <!--Amortized Cost Basis - Total- Debt Securities [Member] + Amortized Cost Basis - Total- Debt Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost contextRef="c00093" unitRef="u000" decimals="-3">511625000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost>
  <!--Amortized Cost Basis - Maturities after five years through ten years- Unrestricted [Member]- Mortgage-Backed Securities [Member] + Amortized Cost Basis - Maturities after five years through ten years- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost contextRef="c00033" unitRef="u000" decimals="-3">164000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
  <!--Amortized Cost Basis - Maturities after five years through ten years- Unrestricted [Member]- Mortgage-Backed Securities [Member] + Amortized Cost Basis - Maturities after five years through ten years- Unrestricted [Member]- Mortgage-Backed Securities [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost contextRef="c00089" unitRef="u000" decimals="-3">284000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
  <!--Amortized Cost Basis - Maturities after five years through ten years- Unrestricted [Member] + Amortized Cost Basis - Maturities after five years through ten years- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost contextRef="c00034" unitRef="u000" decimals="-3">164000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
  <!--Amortized Cost Basis - Maturities after five years through ten years- Unrestricted [Member] + Amortized Cost Basis - Maturities after five years through ten years- Unrestricted [Member]-->
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost contextRef="c00090" unitRef="u000" decimals="-3">284000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
  <!--Facility lease obligation + Facility lease obligation-->
  <regn:FacilityLeaseObligationsIncurred contextRef="c00164" unitRef="u000" decimals="-5">200000</regn:FacilityLeaseObligationsIncurred>
  <!--Facility lease obligation + Facility lease obligation-->
  <regn:FacilityLeaseObligationsIncurred contextRef="c00195" unitRef="u000" decimals="-5">31700000</regn:FacilityLeaseObligationsIncurred>
  <!--Number of shares available for future grants under the Plan (in shares)- Executive Stock Purchase Plan [Member]-->
  <us-gaap:EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares contextRef="c00027" unitRef="u001" decimals="0">44246</us-gaap:EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares>
  <!--Maximum amount of milestone payments that may be received if certain sales are achieved- Collaboration Agreement with Sanofi [Member]- Antibody Collaboration [Member]-->
  <regn:MaximumAmountOfMilestonePaymentsThatMayBeReceivedIfCertainSalesAreAchieved contextRef="c00135" unitRef="u000" decimals="-6">250000000</regn:MaximumAmountOfMilestonePaymentsThatMayBeReceivedIfCertainSalesAreAchieved>
  <!--Payment in connection with purchase of convertible note hedges-->
  <us-gaap:PaymentsForHedgeFinancingActivities contextRef="c00124" unitRef="u000" decimals="-3">117500000</us-gaap:PaymentsForHedgeFinancingActivities>
  <!--Payment in connection with purchase of convertible note hedges-->
  <us-gaap:PaymentsForHedgeFinancingActivities contextRef="c00164" unitRef="u000" decimals="-3">0</us-gaap:PaymentsForHedgeFinancingActivities>
  <!--Payment in connection with purchase of convertible note hedges-->
  <us-gaap:PaymentsForHedgeFinancingActivities contextRef="c00195" unitRef="u000" decimals="-3">0</us-gaap:PaymentsForHedgeFinancingActivities>
  <!--(Decrease) increase in deferred revenue-->
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c00124" unitRef="u000" decimals="-3">-40329000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <!--(Decrease) increase in deferred revenue-->
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c00164" unitRef="u000" decimals="-3">158151000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <!--(Decrease) increase in deferred revenue-->
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c00195" unitRef="u000" decimals="-3">-27497000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <!--Issuance of restricted Common Stock under Long-Term Incentive Plan - Common Stock Shares- Common Stock [Member] + Issuance of restricted Common Stock under Long-Term Incentive Plan - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c00165" unitRef="u001" decimals="-3">345000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <!--Issuance of restricted Common Stock under Long-Term Incentive Plan - Common Stock Shares- Common Stock [Member] + Issuance of restricted Common Stock under Long-Term Incentive Plan - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c00125" unitRef="u001" decimals="-3">16000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <!--Stock-based compensation charges - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Stock-based compensation charges - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Stock-based compensation charges - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c00197" unitRef="u000" decimals="-3">31259000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <!--Stock-based compensation charges - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Stock-based compensation charges - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Stock-based compensation charges - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c00166" unitRef="u000" decimals="-3">39897000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <!--Stock-based compensation charges - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Stock-based compensation charges - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Stock-based compensation charges - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c00126" unitRef="u000" decimals="-3">56609000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <!--Stock-based compensation charges - Total Stockholders' Equity + Stock-based compensation charges - Total Stockholders' Equity + Stock-based compensation charges - Total Stockholders' Equity-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c00195" unitRef="u000" decimals="-3">31259000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <!--Stock-based compensation charges - Total Stockholders' Equity + Stock-based compensation charges - Total Stockholders' Equity + Stock-based compensation charges - Total Stockholders' Equity-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c00164" unitRef="u000" decimals="-3">39897000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <!--Stock-based compensation charges - Total Stockholders' Equity + Stock-based compensation charges - Total Stockholders' Equity + Stock-based compensation charges - Total Stockholders' Equity-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c00124" unitRef="u000" decimals="-3">56609000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <!--Class A Stock, shares authorized- Class A Stock [Member]-->
  <us-gaap:CommonStockSharesAuthorized contextRef="c00002" unitRef="u001" decimals="0">40000000</us-gaap:CommonStockSharesAuthorized>
  <!--Class A Stock, shares authorized- Class A Stock [Member]-->
  <us-gaap:CommonStockSharesAuthorized contextRef="c00061" unitRef="u001" decimals="0">40000000</us-gaap:CommonStockSharesAuthorized>
  <!--Common Stock, shares authorized-->
  <us-gaap:CommonStockSharesAuthorized contextRef="c00001" unitRef="u001" decimals="0">160000000</us-gaap:CommonStockSharesAuthorized>
  <!--Common Stock, shares authorized-->
  <us-gaap:CommonStockSharesAuthorized contextRef="c00060" unitRef="u001" decimals="0">160000000</us-gaap:CommonStockSharesAuthorized>
  <!--Amendment Flag-->
  <dei:AmendmentFlag contextRef="c00124">false</dei:AmendmentFlag>
  <!--Deferred revenue from Sanofi, current portion-->
  <regn:DeferredRevenueFromRelatedPartyCurrent contextRef="c00001" unitRef="u000" decimals="-3">20011000</regn:DeferredRevenueFromRelatedPartyCurrent>
  <!--Deferred revenue from Sanofi, current portion-->
  <regn:DeferredRevenueFromRelatedPartyCurrent contextRef="c00060" unitRef="u000" decimals="-3">19506000</regn:DeferredRevenueFromRelatedPartyCurrent>
  <!--Accounts receivable - trade, net-->
  <us-gaap:AccountsReceivableNetCurrent contextRef="c00001" unitRef="u000" decimals="-3">28254000</us-gaap:AccountsReceivableNetCurrent>
  <!--Accounts receivable - trade, net-->
  <us-gaap:AccountsReceivableNetCurrent contextRef="c00060" unitRef="u000" decimals="-3">2314000</us-gaap:AccountsReceivableNetCurrent>

</xbrl>
</XBRL>
